1	Comparison	O
2	with	O
3	alkaline	B
4	phosphatases	I
5	and	O
6	5	B
7	-	I
8	nucleotidase	I
9	.	O

1	Pharmacologic	O
2	aspects	O
3	of	O
4	neonatal	O
5	hyperbilirubinemia	O
6	.	O

1	When	O
2	CSF	O
3	[	O
4	HCO3	O
5	-]	O
6	is	O
7	shown	O
8	as	O
9	a	O
10	function	O
11	of	O
12	CSF	O
13	PCO2	O
14	the	O
15	data	O
16	of	O
17	K	O
18	-	O
19	depleted	O
20	rats	O
21	are	O
22	no	O
23	longer	O
24	displaced	O
25	when	O
26	compared	O
27	to	O
28	controls	O
29	but	O
30	still	O
31	have	O
32	a	O
33	significantly	O
34	greater	O
35	slope	O
36	(	O
37	1	O
38	.	O
39	21	O
40	+/-	O
41	0	O
42	.	O
43	23	O
44	vs	O
45	.	O

1	Flurazepam	O
2	thus	O
3	appears	O
4	to	O
5	be	O
6	an	O
7	effective	O
8	hypnotic	O
9	drug	O
10	with	O
11	the	O
12	optimum	O
13	dose	O
14	for	O
15	use	O
16	in	O
17	general	O
18	practice	O
19	being	O
20	15	O
21	mg	O
22	at	O
23	night	O
24	.	O

1	Beta	O
2	blocking	O
3	agents	O
4	.	O

1	When	O
2	extracorporeal	O
3	CO2	O
4	removal	O
5	approximated	O
6	CO2	O
7	production	O
8	(	O
9	VCO2	O
10	),	O
11	alveolar	O
12	ventilation	O
13	almost	O
14	ceased	O
15	.	O

1	Intravenous	O
2	administration	O
3	(	O
4	25	O
5	mg	O
6	/	O
7	kg	O
8	)	O
9	of	O
10	carbonic	B
11	anhydrase	I
12	inhibitors	O
13	(	O
14	acetazolamide	O
15	,	O
16	methazolamide	O
17	,	O
18	dichlorphenamide	O
19	,	O
20	sulthiame	O
21	)	O
22	induced	O
23	an	O
24	early	O
25	important	O
26	rise	O
27	of	O
28	cortical	O
29	p	O
30	O2	O
31	,	O
32	which	O
33	is	O
34	not	O
35	dependent	O
36	on	O
37	increase	O
38	of	O
39	p	O
40	O2	O
41	and	O
42	p	O
43	CO2	O
44	and	O
45	decrease	O
46	of	O
47	pH	O
48	in	O
49	arterial	O
50	blood	O
51	.	O

1	Teratological	O
2	study	O
3	of	O
4	etoperidone	O
5	in	O
6	the	O
7	rat	O
8	and	O
9	rabbit	O
10	.	O

1	Colorectal	O
2	polyps	O
3	should	O
4	be	O
5	removed	O
6	endoscopically	O
7	whenever	O
8	possible	O
9	.	O

1	The	O
2	variable	O
3	HMG	B
4	dosage	O
5	regimen	O
6	was	O
7	found	O
8	to	O
9	offer	O
10	no	O
11	advantages	O
12	when	O
13	compared	O
14	with	O
15	our	O
16	standard	O
17	daily	O
18	dosage	O
19	regimen	O
20	.	O

1	When	O
2	the	O
3	CO2	O
4	content	O
5	reached	O
6	9	O
7	Vol	O
8	%	O
9	the	O
10	animals	O
11	became	O
12	apathic	O
13	and	O
14	lost	O
15	body	O
16	weight	O
17	.	O

1	Serum	B
2	gamma	I
3	glutamyltransferase	I
4	in	O
5	the	O
6	diagnosis	O
7	of	O
8	liver	O
9	disease	O
10	in	O
11	cattle	O
12	.	O

1	By	O
2	contrast	O
3	,	O
4	secretory	B
5	HI	I
6	antibodies	I
7	were	O
8	not	O
9	demonstrated	O
10	at	O
11	the	O
12	onset	O
13	of	O
14	illness	O
15	in	O
16	any	O
17	of	O
18	the	O
19	patients	O
20	,	O
21	but	O
22	their	O
23	formation	O
24	started	O
25	early	O
26	and	O
27	the	O
28	antibodies	O
29	reached	O
30	maximal	O
31	levels	O
32	about	O
33	10	O
34	days	O
35	after	O
36	onset	O
37	of	O
38	illness	O
39	.	O

1	With	O
2	the	O
3	exception	O
4	of	O
5	virus	O
6	assay	O
7	and	O
8	quantitation	O
9	,	O
10	these	O
11	methods	O
12	are	O
13	simple	O
14	and	O
15	inexpensive	O
16	enough	O
17	to	O
18	be	O
19	done	O
20	in	O
21	typical	O
22	shellfish	O
23	microbiology	O
24	laboratories	O
25	.	O

1	Characteristics	O
2	of	O
3	lipase	B
4	activity	O
5	.	O

1	Takayasu	O
2	'	O
3	s	O
4	disease	O
5	:	O
6	association	O
7	with	O
8	HLA	B
9	-	I
10	B5	I
11	.	O

1	SGPT	B
2	,	O
3	SGOT	B
4	,	O
5	and	O
6	alkaline	B
7	phosphatase	I
8	concentrations	O
9	were	O
10	essentially	O
11	normal	O
12	in	O
13	all	O
14	subjects	O
15	.	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	(	O
5	GGTP	B
6	)	O
7	activity	O
8	in	O
9	the	O
10	seminal	O
11	fluid	O

1	Patients	O
2	with	O
3	Parkinson	O
4	'	O
5	s	O
6	disease	O
7	showed	O
8	a	O
9	relatively	O
10	high	O
11	incidence	O
12	to	O
13	psychoses	O
14	during	O
15	drug	O
16	treatment	O
17	(	O
18	51	O
19	.	O
20	47	O
21	%).	O

1	Selective	O
2	stimulation	O
3	of	O
4	central	O
5	alpha	B
6	-	I
7	autoreceptors	I
8	following	O
9	treatment	O
10	with	O
11	alpha	O
12	-	O
13	methyldopa	O
14	and	O
15	FLA	O
16	136	O
17	.	O

1	Anti	O
2	-	O
3	anxiety	O
4	action	O
5	of	O
6	diazepam	O
7	after	O
8	intra	O
9	-	O
10	amygdaloid	O
11	application	O
12	in	O
13	the	O
14	rat	O
15	.	O

1	Abstracts	O
2	.	O

1	Removal	O
2	of	O
3	thick	O
4	,	O
5	permanently	O
6	altered	O
7	mucoas	O
8	is	O
9	recommended	O
10	even	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	squamous	O
16	epithelium	O
17	.	O

1	An	O
2	IgG	B
3	monoclonal	O
4	gammopathy	O
5	was	O
6	present	O
7	in	O
8	the	O
9	serum	O
10	of	O
11	4	O
12	patients	O
13	and	O
14	Bence	O
15	-	O
16	Joanes	O
17	proteinuria	O
18	was	O
19	found	O
20	in	O
21	1	O
22	patient	O
23	.	O

1	Studies	O
2	on	O
3	immunoglobulin	B
4	E	I
5	:	O
6	the	O
7	impact	O
8	of	O
9	a	O
10	sojourn	O
11	with	O
12	Professor	O
13	Dan	O
14	H	O
15	.	O

1	Peroxydase	B
2	reaction	O
3	stains	O
4	were	O
5	negative	O
6	,	O
7	chloroacetate	B
8	esterase	I
9	were	O
10	strongly	O
11	positive	O
12	.	O

1	Ten	O
2	out	O
3	-	O
4	patients	O
5	with	O
6	pustulosis	O
7	palmaris	O
8	et	O
9	plantaris	O
10	were	O
11	examined	O
12	with	O
13	direct	O
14	immunofluorescence	O
15	(	O
16	IF	O
17	)	O
18	technique	O
19	for	O
20	deposition	O
21	of	O
22	fibrinogen	B
23	,	O
24	fibrin	B
25	or	O
26	its	O
27	degradation	O
28	products	O
29	(	O
30	FR	B
31	-	I
32	antigen	I
33	)	O
34	in	O
35	affected	O
36	and	O
37	unaffected	O
38	skin	O
39	,	O
40	together	O
41	with	O
42	heparin	O
43	-	O
44	precipitable	O
45	fraction	O
46	(	O
47	HPF	O
48	),	O
49	cryoglobulin	B
50	and	O
51	total	O
52	plasma	O
53	fibrinogen	B
54	in	O
55	the	O
56	blood	O
57	.	O

1	Of	O
2	600	O
3	mediastinoscopies	O
4	carried	O
5	out	O
6	from	O
7	1966	O
8	to	O
9	1973	O
10	,	O
11	479	O
12	were	O
13	performed	O
14	to	O
15	assess	O
16	the	O
17	operability	O
18	of	O
19	a	O
20	pulmonary	O
21	carcinoma	O
22	.	O

1	A	O
2	mixture	O
3	of	O
4	human	B
5	albumin	I
6	5	O
7	%	O
8	and	O
9	hydroxy	O
10	-	O
11	ethyl	O
12	-	O
13	starch	O
14	was	O
15	used	O
16	as	O
17	a	O
18	solution	O
19	for	O
20	dilution	O
21	.	O

1	In	O
2	the	O
3	matched	O
4	control	O
5	group	O
6	the	O
7	acquisition	O
8	-	O
9	rate	O
10	of	O
11	both	O
12	symptomatic	O
13	and	O
14	asymptomatic	O
15	0acteriuria	O
16	was	O
17	over	O
18	12	O
19	%,	O
20	a	O
21	figure	O
22	similar	O
23	to	O
24	the	O
25	percentage	O
26	of	O
27	women	O
28	present	O
29	in	O
30	the	O
31	practice	O
32	population	O
33	during	O
34	one	O
35	year	O
36	with	O
37	transient	O
38	,	O
39	symptomatic	O
40	,	O
41	and	O
42	persistent	O
43	A	O
44	.	O
45	B	O
46	.	O

1	Late	O
2	complications	O
3	of	O
4	catheterisation	O
5	for	O
6	intravenous	O
7	nutrition	O
8	.	O

1	Prenatal	O
2	diagnosis	O
3	of	O
4	galactosaemia	O
5	.	O

1	Sings	O
2	which	O
3	are	O
4	indicative	O
5	of	O
6	metaplastic	O
7	erythropoiesis	O
8	are	O
9	absent	O
10	.	O

1	False	O
2	positive	O
3	amniotic	B
4	fluid	I
5	alpha	I
6	fetoprotein	I
7	levels	O
8	resulting	O
9	from	O
10	contamination	O
11	with	O
12	fetal	O
13	blood	O
14	:	O
15	results	O
16	of	O
17	an	O
18	experiment	O
19	.	O

1	Serum	O
2	-	O
3	ferritin	B
4	in	O
5	diagnosis	O
6	of	O
7	haemochromatosis	O
8	.	O

1	In	O
2	2	O
3	subjects	O
4	the	O
5	phytomitogen	O
6	reactivity	O
7	of	O
8	the	O
9	lymphocytes	O
10	was	O
11	improved	O
12	after	O
13	treatment	O
14	.	O

1	Patients	O
2	at	O
3	risk	O
4	of	O
5	hypothyroidism	O
6	.	O

1	Albumin	B
2	and	O
3	cyclic	O
4	AMP	O
5	levels	O
6	in	O
7	peritoneal	O
8	fluids	O
9	in	O
10	the	O
11	child	O

1	Preface	O
2	.	O

1	Thirty	O
2	-	O
3	five	O
4	strains	O
5	of	O
6	Legionnaires	O
7	'	O
8	disease	O
9	bacteria	O
10	were	O
11	shown	O
12	to	O
13	belong	O
14	in	O
15	four	O
16	distinct	O
17	serologic	O
18	groups	O
19	on	O
20	the	O
21	basis	O
22	of	O
23	findings	O
24	obtained	O
25	with	O
26	direct	O
27	fluorescent	O
28	antibody	O
29	testing	O
30	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	factor	B
6	IX	I
7	activity	O
8	is	O
9	decreased	O
10	in	O
11	coumarin	O
12	treatment	O
13	with	O
14	factor	B
15	IX	I
16	antigen	O
17	remaining	O
18	normal	O
19	.	O

1	The	O
2	concentration	O
3	of	O
4	alpha	B
5	2	I
6	-	I
7	macroglobulin	I
8	,	O
9	alpha	B
10	1	I
11	-	I
12	antitrypsin	I
13	,	O
14	plasminogen	B
15	,	O
16	C3	B
17	-	I
18	complement	I
19	,	O
20	fibrinogen	B
21	degradation	I
22	products	I
23	(	O
24	FDP	B
25	)	O
26	and	O
27	fibrinolytic	O
28	activity	O
29	,	O
30	were	O
31	studied	O
32	in	O
33	the	O
34	aqueous	O
35	humour	O
36	and	O
37	serum	O
38	from	O
39	nine	O
40	patients	O
41	with	O
42	Fuchs	O
43	'	O
44	endothelial	O
45	dystrophy	O
46	,	O
47	17	O
48	patients	O
49	with	O
50	uncomplicated	O
51	senile	O
52	cataract	O
53	and	O
54	in	O
55	the	O
56	secondary	O
57	aqueous	O
58	from	O
59	six	O
60	cataract	O
61	patients	O
62	.	O

1	Only	O
2	17	O
3	%	O
4	of	O
5	all	O
6	patients	O
7	admitted	O
8	it	O
9	at	O
10	all	O
11	times	O
12	.	O

1	Prazosin	O
2	alone	O
3	was	O
4	effective	O
5	in	O
6	volume	O
7	responsive	O
8	patients	O
9	at	O
10	a	O
11	dose	O
12	of	O
13	5	O
14	+/-	O
15	1	O
16	.	O
17	0	O
18	mg	O
19	daily	O
20	.	O

1	T4	O
2	and	O
3	FT4I	O
4	followed	O
5	parallel	O
6	courses	O
7	in	O
8	both	O
9	groups	O
10	;	O
11	during	O
12	the	O
13	first	O
14	45	O
15	days	O
16	,	O
17	however	O
18	,	O
19	the	O
20	values	O
21	were	O
22	significantly	O
23	lower	O
24	in	O
25	premature	O
26	infants	O
27	under	O
28	34	O
29	weeks	O
30	'	O
31	EGA	O
32	than	O
33	in	O
34	term	O
35	infants	O
36	(	O
37	P	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	A	O
2	three	O
3	-	O
4	phased	O
5	analysis	O
6	of	O
7	treatment	O
8	plans	O
9	for	O
10	45	O
11	patients	O
12	was	O
13	undertaken	O
14	.	O

1	Aspirin	O
2	intolerance	O
3	:	O
4	unaltered	O
5	susceptibility	O
6	of	O
7	platelet	B
8	cyclo	I
9	-	I
10	oxygenase	I
11	to	O
12	inhibition	O
13	by	O
14	aspirin	O
15	in	O
16	vitro	O
17	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	cynomolgus	O
6	monkeys	O
7	are	O
8	either	O
9	less	O
10	sensitive	O
11	or	O
12	respond	O
13	differently	O
14	than	O
15	rhesus	O
16	monkeys	O
17	to	O
18	some	O
19	of	O
20	the	O
21	pharmacological	O
22	effects	O
23	of	O
24	norcocaine	O
25	.	O

1	59	O
2	cases	O
3	of	O
4	surgically	O
5	resectable	O
6	cancers	O
7	(	O
8	T1	O
9	,	O
10	T2	O
11	,	O
12	T3	O
13	,	O
14	N0	O
15	,	O
16	N1	O
17	)	O
18	had	O
19	a	O
20	minimum	O
21	followup	O
22	of	O
23	two	O
24	years	O
25	(	O
26	average	O
27	4	O
28	years	O
29	+/-	O
30	3	O
31	months	O
32	).	O

1	The	O
2	effect	O
3	of	O
4	CBZ	O
5	and	O
6	DPH	O
7	can	O
8	be	O
9	explained	O
10	by	O
11	interference	O
12	with	O
13	thyroid	O
14	hormone	O
15	binding	O
16	to	O
17	TBG	B
18	combined	O
19	with	O
20	enzyme	O
21	-	O
22	induced	O
23	increased	O
24	metabolic	O
25	clearance	O
26	rate	O
27	of	O
28	thyroid	O
29	hormones	O
30	without	O
31	homeostatic	O
32	maintenance	O
33	of	O
34	premedication	O
35	levels	O
36	of	O
37	FT4	O
38	and	O
39	FT3	O
40	.	O

1	The	O
2	present	O
3	research	O
4	evaluated	O
5	the	O
6	possibility	O
7	that	O
8	polyethylene	O
9	glycol	O
10	400	O
11	(	O
12	PEG	O
13	400	O
14	)	O
15	might	O
16	be	O
17	efficacious	O
18	,	O
19	toxic	O
20	,	O
21	or	O
22	both	O
23	.	O

1	According	O
2	to	O
3	their	O
4	functional	O
5	properties	O
6	the	O
7	latter	O
8	neurons	O
9	were	O
10	subdivided	O
11	into	O
12	:	O
13	(	O
14	a	O
15	)	O
16	neurons	O
17	responding	O
18	to	O
19	stimuli	O
20	near	O
21	the	O
22	eyes	O
23	;	O
24	(	O
25	b	O
26	)	O
27	neurons	O
28	triggered	O
29	by	O
30	complex	O
31	visual	O
32	stimuli	O
33	;	O
34	(	O
35	c	O
36	)	O
37	neurons	O
38	inhibited	O
39	by	O
40	visual	O
41	stimuli	O
42	.	O

1	Pentobarbital	O
2	(	O
3	1	O
4	,	O
5	3	O
6	,	O
7	10	O
8	,	O
9	and	O
10	17	O
11	.	O
12	5	O
13	mg	O
14	/	O
15	kg	O
16	)	O
17	was	O
18	also	O
19	tested	O
20	in	O
21	combination	O
22	with	O
23	rate	O
24	-	O
25	decreasing	O
26	doses	O
27	of	O
28	normeperidine	O
29	(	O
30	17	O
31	.	O
32	5	O
33	mg	O
34	/	O
35	kg	O
36	),	O
37	anileridine	O
38	(	O
39	10	O
40	mg	O
41	/	O
42	kg	O
43	),	O
44	alphaprodine	O
45	(	O
46	10	O
47	mg	O
48	/	O
49	kg	O
50	),	O
51	and	O
52	fentanyl	O
53	(	O
54	0	O
55	.	O
56	3	O
57	mg	O
58	/	O
59	kg	O
60	).	O

1	Pb	O
2	foil	O
3	(	O
4	0	O
5	.	O
6	55	O
7	gcm	O
8	-	O
9	2	O
10	)	O
11	provided	O
12	the	O
13	best	O
14	overall	O
15	improvement	O
16	.	O

1	An	O
2	anatomical	O
3	and	O
4	histochemical	O
5	study	O
6	has	O
7	been	O
8	undertaken	O
9	and	O
10	as	O
11	a	O
12	result	O
13	emphasis	O
14	is	O
15	given	O
16	to	O
17	recent	O
18	hypotheses	O
19	that	O
20	suggest	O
21	there	O
22	are	O
23	similarities	O
24	with	O
25	Type	O
26	IV	O
27	glycogen	O
28	storage	O
29	disease	O
30	(	O
31	Andersen	O
32	'	O
33	s	O
34	disease	O
35	)	O
36	which	O
37	,	O
38	although	O
39	clinically	O
40	distinct	O
41	,	O
42	has	O
43	the	O
44	same	O
45	enzyme	O
46	defect	O
47	.	O

1	All	O
2	groups	O
3	were	O
4	tested	O
5	in	O
6	a	O
7	Hebb	O
8	-	O
9	Williams	O
10	maze	O
11	at	O
12	100	O
13	approximately	O
14	10	O
15	days	O
16	of	O
17	age	O
18	.	O

1	Erythromycin	O
2	and	O
3	clindamycin	O
4	resistance	O
5	in	O
6	Corynebacterium	O
7	diphtheriae	O
8	from	O
9	skin	O
10	lesions	O
11	.	O

1	Imposed	O
2	angular	O
3	displacements	O
4	of	O
5	monkey	O
6	'	O
7	s	O
8	wrist	O
9	produce	O
10	three	O
11	major	O
12	peaks	O
13	of	O
14	activity	O
15	(	O
16	terms	O
17	M1	O
18	,	O
19	M2	O
20	,	O
21	and	O
22	M3	O
23	peaks	O
24	)	O
25	in	O
26	the	O
27	averaged	O
28	gross	O
29	EMG	O
30	activity	O
31	ot	O
32	the	O
33	stretched	O
34	muscles	O
35	.	O

1	Hemolytic	O
2	disease	O
3	of	O
4	African	O
5	newborn	O
6	.	O

1	In	O
2	this	O
3	animal	O
4	,	O
5	infected	O
6	with	O
7	what	O
8	was	O
9	judged	O
10	previously	O
11	to	O
12	be	O
13	the	O
14	less	O
15	virulent	O
16	of	O
17	the	O
18	two	O
19	T	O
20	.	O
21	cruzi	O
22	stocks	O
23	used	O
24	('	O
25	strain	O
26	7	O
27	'),	O
28	there	O
29	was	O
30	severe	O
31	myocarditis	O
32	,	O
33	with	O
34	myofibre	O
35	degeneration	O
36	,	O
37	and	O
38	lesions	O
39	of	O
40	the	O
41	oesophagus	O
42	.	O

1	The	O
2	majority	O
3	of	O
4	MRF	O
5	units	O
6	were	O
7	behaviorally	O
8	incongruent	O
9	;	O
10	in	O
11	the	O
12	most	O
13	frequently	O
14	observed	O
15	case	O
16	,	O
17	their	O
18	activity	O
19	failed	O
20	to	O
21	change	O
22	reliably	O
23	when	O
24	behavior	O
25	habituated	O
26	.	O

1	Variability	O
2	within	O
3	Down	O
4	'	O
5	s	O
6	syndrome	O
7	(	O
8	trisomy	O
9	-	O
10	21	O
11	):	O
12	empirically	O
13	observed	O
14	sex	O
15	differences	O
16	in	O
17	IQs	O
18	.	O

1	VII	O
2	.	O

1	Several	O
2	demographic	O
3	indices	O
4	of	O
5	isolated	O
6	populations	O
7	in	O
8	Uzbekistan	O

1	2	O
2	.--	O
3	concepts	O
4	of	O
5	higher	O
6	nervous	O
7	function	O
8	in	O
9	the	O
10	USSR	O
11	.	O

1	The	O
2	maintenance	O
3	of	O
4	increased	O
5	myocardial	O
6	capillary	O
7	density	O
8	required	O
9	a	O
10	similar	O
11	amount	O
12	of	O
13	exercise	O
14	,	O
15	and	O
16	at	O
17	least	O
18	1	O
19	h	O
20	of	O
21	exercise	O
22	once	O
23	a	O
24	week	O
25	was	O
26	necessary	O
27	to	O
28	maintain	O
29	the	O
30	enlargement	O
31	of	O
32	ECA	O
33	.	O
34	20	O

1	These	O
2	observations	O
3	have	O
4	led	O
5	us	O
6	to	O
7	conclude	O
8	that	O
9	an	O
10	elevated	O
11	VIII	O
12	-	O
13	ratio	O
14	is	O
15	a	O
16	very	O
17	sensitive	O
18	indicator	O
19	of	O
20	intravascular	O
21	coagulation	O
22	.	O

1	Eight	O
2	hours	O
3	after	O
4	the	O
5	administration	O
6	of	O
7	colchicine	O
8	,	O
9	the	O
10	serum	B
11	ceruloplasmin	I
12	level	O
13	began	O
14	to	O
15	rise	O
16	again	O
17	in	O
18	female	O
19	rats	O
20	,	O
21	but	O
22	not	O
23	in	O
24	male	O
25	rats	O
26	.	O

1	Radioimmunoassays	O
2	of	O
3	pregnenolone	O
4	,	O
5	progesterone	O
6	,	O
7	dehydroepiandrosterone	O
8	(	O
9	DHA	O
10	)	O
11	16	O
12	alpha	O
13	-	O
14	hydroxy	O
15	-	O
16	DHA	O
17	,	O
18	estriol	O
19	,	O
20	and	O
21	cortisol	O
22	were	O
23	performed	O
24	on	O
25	a	O
26	total	O
27	of	O
28	0	O
29	;	O
30	1	O
31	ml	O
32	;	O
33	of	O
34	fetal	O
35	plasma	O
36	,	O
37	collected	O
38	during	O
39	the	O
40	course	O
41	of	O
42	normal	O
43	vaginal	O
44	delivery	O
45	.	O

1	In	O
2	only	O
3	two	O
4	patients	O
5	were	O
6	we	O
7	able	O
8	to	O
9	demonstrate	O
10	changes	O
11	suggestive	O
12	of	O
13	pulmonary	O
14	metastases	O
15	any	O
16	earlier	O
17	with	O
18	a	O
19	99mTc	O
20	-	O
21	EHDP	O
22	scan	O
23	than	O
24	with	O
25	chest	O
26	radiographs	O
27	and	O
28	one	O
29	of	O
30	these	O
31	resolved	O
32	spontaneously	O
33	.	O

1	The	O
2	majority	O
3	of	O
4	tumors	O
5	occurred	O
6	in	O
7	the	O
8	nasal	O
9	cavities	O
10	,	O
11	although	O
12	significant	O
13	incidences	O
14	were	O
15	also	O
16	found	O
17	in	O
18	the	O
19	larynx	O
20	,	O
21	trachea	O
22	and	O
23	stem	O
24	bronchi	O
25	.	O

1	Prediction	O
2	of	O
3	the	O
4	times	O
5	of	O
6	sandfly	O
7	development	O

1	Native	O
2	human	B
3	fibrinogen	I
4	was	O
5	brought	O
6	to	O
7	coagulation	O
8	by	O
9	adding	O
10	thrombin	B
11	.	O

1	No	O
2	post	O
3	-	O
4	operative	O
5	haemorrhages	O
6	from	O
7	the	O
8	prostheses	O
9	were	O
10	observed	O
11	.	O

1	The	O
2	Southern	O
3	technique	O
4	allowed	O
5	a	O
6	further	O
7	localization	O
8	of	O
9	the	O
10	region	O
11	of	O
12	most	O
13	extensive	O
14	transcription	O
15	to	O
16	a	O
17	1	O
18	.	O
19	8	O
20	kb	O
21	HindIII	B
22	-	O
23	EcoRI	B
24	fragment	O
25	.	O

1	Accepting	O
2	arbitrarily	O
3	chosen	O
4	limits	O
5	of	O
6	maximized	O
7	errors	O
8	of	O
9	+/-	O
10	10	O
11	%,	O
12	it	O
13	could	O
14	be	O
15	shown	O
16	that	O
17	the	O
18	system	O
19	did	O
20	not	O
21	work	O
22	acceptably	O
23	when	O
24	the	O
25	mean	O
26	carbon	O
27	dioxide	O
28	concentration	O
29	was	O
30	below	O
31	1	O
32	.	O
33	5	O
34	vol	O
35	.%	O
36	within	O
37	the	O
38	fresh	O
39	gas	O
40	flow	O
41	rates	O
42	(	O
43	2	O
44	.	O
45	2	O
46	--	O
47	7	O
48	.	O
49	7	O
50	1	O
51	min	O
52	-	O
53	1	O
54	)	O
55	and	O
56	the	O
57	range	O
58	of	O
59	minute	O
60	ventilation	O
61	(	O
62	4	O
63	--	O
64	10	O
65	1	O
66	min	O
67	-	O
68	1	O
69	)	O
70	employed	O
71	.	O

1	SV	O
2	increased	O
3	less	O
4	in	O
5	SHR	O
6	,	O
7	mainly	O
8	reflecting	O
9	the	O
10	reduced	O
11	diastolic	O
12	compliance	O
13	of	O
14	the	O
15	hypertrophied	O
16	SHR	O
17	left	O
18	ventricle	O
19	and	O
20	the	O
21	consequent	O
22	rightward	O
23	shift	O
24	of	O
25	its	O
26	Frank	O
27	-	O
28	Starling	O
29	curve	O
30	.	O

1	The	O
2	carcass	O
3	of	O
4	a	O
5	great	O
6	horned	O
7	owl	O
8	(	O
9	Bubo	O
10	virginianus	O
11	),	O
12	which	O
13	had	O
14	been	O
15	found	O
16	moribund	O
17	in	O
18	southern	O
19	Ontario	O
20	,	O
21	was	O
22	presented	O
23	for	O
24	necropsy	O
25	.	O

1	The	O
2	inner	O
3	ears	O
4	were	O
5	exposed	O
6	by	O
7	microdissection	O
8	,	O
9	and	O
10	the	O
11	vestibular	O
12	sensory	O
13	regions	O
14	were	O
15	either	O
16	sectioned	O
17	and	O
18	studied	O
19	with	O
20	light	O
21	or	O
22	electron	O
23	microscopy	O
24	,	O
25	or	O
26	prepared	O
27	and	O
28	studied	O
29	with	O
30	the	O
31	surface	O
32	specimen	O
33	technique	O
34	.	O

1	Patulin	O
2	is	O
3	extracted	O
4	from	O
5	apple	O
6	butter	O
7	samples	O
8	with	O
9	ethyl	O
10	acetate	O
11	and	O
12	the	O
13	extract	O
14	is	O
15	cleaned	O
16	up	O
17	on	O
18	a	O
19	silica	O
20	gel	O
21	column	O
22	,	O
23	using	O
24	benzene	O
25	-	O
26	ethyl	O
27	acetate	O
28	(	O
29	75	O
30	+	O
31	25	O
32	)	O
33	as	O
34	the	O
35	eluant	O
36	.	O

1	Steroid	O
2	glucuronides	O
3	in	O
4	amniotic	O
5	fluid	O
6	at	O
7	term	O
8	.	O

1	The	O
2	matrix	O
3	surrounding	O
4	the	O
5	clusters	O
6	either	O
7	showed	O
8	a	O
9	normal	O
10	morphology	O
11	or	O
12	a	O
13	homogeneous	O
14	appearance	O
15	,	O
16	within	O
17	which	O
18	faint	O
19	cross	O
20	striations	O
21	but	O
22	no	O
23	distinctly	O
24	fibrillar	O
25	outlines	O
26	could	O
27	be	O
28	identified	O
29	.	O

1	Riboflavin	O
2	did	O
3	not	O
4	affect	O
5	the	O
6	percentage	O
7	of	O
8	aflatoxin	O
9	-	O
10	treated	O
11	animals	O
12	with	O
13	abnormal	O
14	urinary	O
15	excretion	O
16	patterns	O
17	,	O
18	but	O
19	did	O
20	increase	O
21	the	O
22	magnitude	O
23	of	O
24	the	O
25	disturbances	O
26	in	O
27	elimination	O
28	of	O
29	kynurenic	O
30	and	O
31	xanthurenic	O
32	acids	O
33	.	O

1	Polyglactin	O
2	910	O
3	suture	O
4	absorption	O
5	and	O
6	the	O
7	role	O
8	of	O
9	cellular	O
10	enzymes	O
11	.	O

1	The	O
2	incidence	O
3	of	O
4	DNCB	O
5	reactions	O
6	was	O
7	78	O
8	per	O
9	cent	O
10	for	O
11	Stage	O
12	I	O
13	and	O
14	II	O
15	cancers	O
16	(	O
17	37	O
18	patinets	O
19	),	O
20	73	O
21	per	O
22	cent	O
23	for	O
24	resectable	O
25	Stage	O
26	III	O
27	cancer	O
28	(	O
29	22	O
30	patients	O
31	),	O
32	and	O
33	66	O
34	per	O
35	cent	O
36	in	O
37	patients	O
38	with	O
39	unresectable	O
40	or	O
41	inoperable	O
42	Stage	O
43	III	O
44	cancer	O
45	.	O

1	Studies	O
2	of	O
3	lipoproteins	O
4	should	O
5	,	O
6	however	O
7	,	O
8	be	O
9	made	O
10	in	O
11	children	O
12	from	O
13	families	O
14	known	O
15	to	O
16	have	O
17	FH	O
18	or	O
19	early	O
20	coronary	O
21	heart	O
22	disease	O
23	.	O

1	Sixteen	O
2	other	O
3	normal	O
4	subjects	O
5	with	O
6	2	O
7	g	O
8	of	O
9	Metyrapone	O
10	are	O
11	best	O
12	responses	O
13	.	O

1	EEG	O
2	theta	O
3	waves	O
4	and	O
5	psychological	O
6	phenomena	O
7	:	O
8	a	O
9	review	O
10	and	O
11	analysis	O
12	.	O

1	REM	O
2	dream	O
3	content	O
4	was	O
5	scored	O
6	for	O
7	categories	O
8	suggesting	O
9	the	O
10	predominant	O
11	influence	O
12	of	O
13	the	O
14	left	O
15	hemisphere	O
16	,	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	good	O
22	ego	O
23	functioning	O
24	,	O
25	verbalization	O
26	,	O
27	or	O
28	the	O
29	right	O
30	hemisphere	O
31	,	O
32	e	O
33	.	O
34	g	O
35	.,	O
36	music	O
37	,	O
38	spatial	O
39	salience	O
40	,	O
41	bizarreness	O
42	.	O

1	Innervation	O
2	of	O
3	the	O
4	ventral	O
5	diaphragm	O
6	of	O
7	the	O
8	locust	O
9	(	O
10	Locusta	O
11	migratoria	O
12	).	O

1	Ectopic	O
2	ACTH	B
3	syndrome	O
4	and	O
5	medullary	O
6	thyroid	O
7	carcinoma	O
8	.	O

1	A	O
2	striking	O
3	finding	O
4	in	O
5	all	O
6	of	O
7	the	O
8	studies	O
9	was	O
10	a	O
11	positive	O
12	correlation	O
13	between	O
14	PI	O
15	ACTH	B
16	and	O
17	MSH	B
18	contents	O
19	.	O

1	Chronic	O
2	hypophosphatemia	O
3	is	O
4	the	O
5	most	O
6	common	O
7	type	O
8	of	O
9	"	O
10	resistant	O
11	"	O
12	rickets	O
13	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	serum	B
7	LH	I
8	and	O
9	chronological	O
10	or	O
11	bone	O
12	age	O
13	in	O
14	this	O
15	age	O
16	group	O
17	,	O
18	which	O
19	suggests	O
20	that	O
21	the	O
22	correlation	O
23	found	O
24	is	O
25	not	O
26	due	O
27	to	O
28	age	O
29	-	O
30	related	O
31	parallel	O
32	phenomena	O
33	.	O

1	Molecular	O
2	neurochemistry	O
3	of	O
4	addictive	O
5	drugs	O
6	.	O

1	Efforts	O
2	were	O
3	made	O
4	to	O
5	determine	O
6	the	O
7	amount	O
8	of	O
9	time	O
10	required	O
11	for	O
12	kidney	O
13	lesions	O
14	to	O
15	develop	O
16	and	O
17	,	O
18	if	O
19	possible	O
20	,	O
21	to	O
22	delineate	O
23	the	O
24	potential	O
25	site	O
26	of	O
27	action	O
28	of	O
29	PBB	O
30	.	O

1	Effect	O
2	of	O
3	succimer	O
4	on	O
5	the	O
6	intensity	O
7	of	O
8	tricarboxylic	B
9	acid	I
10	dehydrogenase	I
11	reactions	O
12	in	O
13	the	O
14	brain	O
15	of	O
16	rats	O
17	poisoned	O
18	with	O
19	mercuric	O
20	chloride	O

1	Distribution	O
2	and	O
3	correlations	O
4	of	O
5	serum	O
6	uric	O
7	-	O
8	acid	O
9	in	O
10	two	O
11	French	O
12	adult	O
13	populations	O
14	:	O
15	13	O
16	,	O
17	885	O
18	men	O
19	and	O
20	6	O
21	,	O
22	861	O
23	women	O

1	The	O
2	incidence	O
3	of	O
4	hepatitis	B
5	B	I
6	antigen	I
7	following	O
8	transfusion	O
9	was	O
10	about	O
11	2	O
12	.	O
13	8	O
14	per	O
15	cent	O
16	.	O

1	Technetium	O
2	-	O
3	99m	O
4	stannous	O
5	pyrophosphate	O
6	myocardial	O
7	scintigrams	O
8	were	O
9	obtained	O
10	in	O
11	138	O
12	clinically	O
13	stable	O
14	patients	O
15	32	O
16	.	O
17	7	O
18	+/-	O
19	47	O
20	.	O
21	3	O
22	weeks	O
23	(	O
24	range	O
25	6	O
26	to	O
27	260	O
28	)	O
29	after	O
30	acute	O
31	myocardial	O
32	infarction	O
33	.	O

1	A	O
2	similar	O
3	phenomenon	O
4	has	O
5	been	O
6	reported	O
7	in	O
8	a	O
9	few	O
10	humans	O
11	.	O

1	The	O
2	decline	O
3	in	O
4	the	O
5	activity	O
6	of	O
7	cytochrome	B
8	oxidase	I
9	,	O
10	peroxidase	B
11	and	O
12	in	O
13	the	O
14	lipid	O
15	content	O
16	of	O
17	peripheral	O
18	neutrophils	O
19	was	O
20	followed	O
21	by	O
22	a	O
23	decrease	O
24	in	O
25	the	O
26	phagocytic	O
27	activity	O
28	.	O

1	Treatment	O
2	of	O
3	2	O
4	patients	O
5	with	O
6	pseudohypoparathyroidism	O
7	type	O
8	I	O
9	with	O
10	vitamin	O
11	-	O
12	D	O
13	-	O
14	3	O
15	and	O
16	1	O
17	alpha	O
18	-	O
19	Hydroxycholecalciferol	O
20	consecutively	O
21	resulted	O
22	in	O
23	a	O
24	nonuniform	O
25	response	O
26	with	O
27	regard	O
28	to	O
29	the	O
30	normalisation	O
31	of	O
32	serum	O
33	-	O
34	calcium	O
35	.	O

1	Workers	O
2	with	O
3	"	O
4	sensitivity	O
5	"	O
6	to	O
7	toluene	O
8	diisocyanate	O
9	(	O
10	TDI	O
11	)	O
12	studied	O
13	in	O
14	depth	O
15	in	O
16	an	O
17	attempt	O
18	to	O
19	determine	O
20	mechanisms	O
21	of	O
22	bronchial	O
23	hyperreactivity	O
24	.	O

1	Total	O
2	VO2	O
3	was	O
4	decreased	O
5	in	O
6	both	O
7	groups	O
8	during	O
9	severe	O
10	hypoxia	O
11	but	O
12	limb	O
13	VO2	O
14	was	O
15	maintained	O
16	in	O
17	the	O
18	beta	O
19	-	O
20	block	O
21	group	O
22	.	O
23	beta	O
24	-	O
25	Block	O
26	prevented	O
27	the	O
28	fall	O
29	in	O
30	total	O
31	and	O
32	limb	O
33	peripheral	O
34	resistance	O
35	seen	O
36	in	O
37	severe	O
38	hypoxia	O
39	but	O
40	did	O
41	not	O
42	alter	O
43	the	O
44	consistently	O
45	more	O
46	efficient	O
47	utilization	O
48	of	O
49	total	O
50	O2	O
51	delivery	O
52	shown	O
53	by	O
54	the	O
55	limb	O
56	in	O
57	comparison	O
58	to	O
59	the	O
60	whole	O
61	body	O
62	by	O
63	higher	O
64	O2	O
65	extraction	O
66	ratios	O
67	and	O
68	lower	O
69	venous	O
70	O2	O
71	pressure	O
72	.	O
73	beta	B
74	-	I
75	Vasodilator	I
76	receptors	I
77	evidently	O
78	played	O
79	an	O
80	active	O
81	part	O
82	in	O
83	the	O
84	vasodilatation	O
85	seen	O
86	during	O
87	severe	O
88	hypoxia	O
89	.	O

1	Phenobarbital	O
2	-	O
3	induced	O
4	alterations	O
5	in	O
6	the	O
7	metabolism	O
8	of	O
9	[	O
10	3H	O
11	]	O
12	vitamin	O
13	D3	O
14	by	O
15	the	O
16	perfused	O
17	rachitic	O
18	rat	O
19	liver	O
20	in	O
21	vitro	O
22	.	O

1	Modulation	O
2	of	O
3	25	B
4	-	I
5	hydroxyvitamin	I
6	D3	I
7	-	I
8	24	I
9	-	I
10	hydroxylase	I
11	by	O
12	aminophylline	O
13	:	O
14	a	O
15	cytochrome	B
16	P	I
17	-	I
18	450	I
19	monooxygenase	I
20	system	O
21	.	O

1	In	O
2	both	O
3	these	O
4	respects	O
5	,	O
6	however	O
7	,	O
8	the	O
9	DBP	B
10	mRNA	I
11	resembles	O
12	the	O
13	late	O
14	messengers	O
15	of	O
16	SV40	O
17	and	O
18	polyoma	O
19	viruses	O
20	.	O

1	Effect	O
2	of	O
3	corticosteroid	O
4	-	O
5	containing	O
6	antirheumatic	O
7	combination	O
8	drugs	O
9	on	O
10	endogenous	O
11	ACTH	B
12	and	O
13	cortisol	O
14	production	O
15	.	O

1	Serum	B
2	ACTH	I
3	did	O
4	not	O
5	respond	O
6	to	O
7	insulin	B
8	and	O
9	metyrapone	O
10	.	O

1	Anatomy	O
2	of	O
3	the	O
4	RNA	O
5	and	O
6	gene	O
7	products	O
8	of	O
9	MC29	O
10	and	O
11	MH2	O
12	,	O
13	two	O
14	defective	O
15	avian	O
16	tumor	O
17	viruses	O
18	causing	O
19	acute	O
20	leukemia	O
21	and	O
22	carcinoma	O
23	:	O
24	evidence	O
25	for	O
26	a	O
27	new	O
28	class	O
29	of	O
30	transforming	O
31	genes	O
32	.	O

1	Bertioga	O
2	(	O
3	Guama	O
4	group	O
5	)	O
6	and	O
7	Anhembi	O
8	(	O
9	Bunyamwera	O
10	group	O
11	),	O
12	two	O
13	new	O
14	arboviruses	O
15	isolated	O
16	in	O
17	Sao	O
18	Paulo	O
19	,	O
20	Brazil	O
21	.	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	activity	O
5	was	O
6	increased	O
7	up	O
8	to	O
9	15	O
10	times	O
11	above	O
12	the	O
13	upper	O
14	normal	O
15	limit	O
16	in	O
17	children	O
18	,	O
19	who	O
20	received	O
21	aminopyrine	O
22	for	O
23	two	O
24	weeks	O
25	or	O
26	longer	O
27	.	O

1	XXI	O
2	.	O

1	A	O
2	gas	O
3	-	O
4	liquid	O
5	chromatographic	O
6	method	O
7	for	O
8	the	O
9	determination	O
10	of	O
11	p	O
12	-	O
13	chlorophenoxyisobutyric	O
14	(	O
15	CPIB	O
16	)	O
17	acid	O
18	in	O
19	blood	O
20	plasma	O
21	is	O
22	described	O
23	.	O

1	Dopamine	B
2	receptor	I
3	blockade	O
4	and	O
5	the	O
6	neuroleptics	O
7	,	O
8	a	O
9	crystallographic	O
10	study	O
11	.	O

1	V	O
2	.	O

1	A	O
2	rapid	O
3	fluorimetric	O
4	procedure	O
5	for	O
6	the	O
7	determination	O
8	of	O
9	the	O
10	fungicide	O
11	5	O
12	-	O
13	fluorocytosine	O
14	in	O
15	serum	O
16	is	O
17	described	O
18	.	O

1	The	O
2	'	O
3	field	O
4	of	O
5	stress	O
6	'	O
7	of	O
8	the	O
9	supervisory	O
10	nurse	O

1	How	O
2	do	O
3	graduates	O
4	of	O
5	different	O
6	types	O
7	of	O
8	programs	O
9	perform	O
10	on	O
11	state	O
12	boards	O
13	?	O

1	Similarly	O
2	,	O
3	maternal	B
4	serum	I
5	somatomedin	I
6	A	I
7	was	O
8	significantly	O
9	reduced	O
10	in	O
11	rats	O
12	nursing	O
13	large	O
14	litters	O
15	.	O

1	The	O
2	sequences	O
3	following	O
4	the	O
5	X	O
6	.	O
7	borealis	O
8	oocyte	O
9	and	O
10	somatic	O
11	5S	B
12	genes	I
13	are	O
14	identical	O
15	in	O
16	12	O
17	of	O
18	the	O
19	first	O
20	14	O
21	residues	O
22	and	O
23	contain	O
24	two	O
25	or	O
26	more	O
27	T	O
28	clusters	O
29	,	O
30	as	O
31	does	O
32	the	O
33	corresponding	O
34	region	O
35	of	O
36	X	B
37	.	I
38	laevis	I
39	oocyte	I
40	5S	I
41	DNA	I
42	.	O

1	This	O
2	mechanism	O
3	is	O
4	not	O
5	due	O
6	to	O
7	the	O
8	observed	O
9	grain	O
10	boundary	O
11	precipitates	O
12	.	O

1	This	O
2	report	O
3	has	O
4	reviewed	O
5	some	O
6	of	O
7	the	O
8	reasons	O
9	for	O
10	treatment	O
11	failures	O
12	and	O
13	has	O
14	presented	O
15	a	O
16	philosophy	O
17	for	O
18	their	O
19	management	O
20	.	O

1	Diagnosis	O
2	and	O
3	treatment	O
4	planning	O
5	in	O
6	Class	O
7	II	O
8	,	O
9	division	O
10	2	O

1	Because	O
2	of	O
3	serious	O
4	infections	O
5	(	O
6	fever	O
7	larger	O
8	than	O
9	or	O
10	equal	O
11	to	O
12	101	O
13	degrees	O
14	F	O
15	.	O
16	granulocytes	O
17	less	O
18	than	O
19	1	O
20	,	O
21	000	O
22	/	O
23	mm	O
24	,	O
25	3	O
26	and	O
27	hospitalization	O
28	)	O
29	and	O
30	1	O
31	drug	O
32	death	O
33	in	O
34	the	O
35	first	O
36	4	O
37	patients	O
38	,	O
39	oral	O
40	calcium	O
41	leucovorin	O
42	,	O
43	20	O
44	to	O
45	30	O
46	mg	O
47	/	O
48	m2	O
49	orally	O
50	,	O
51	was	O
52	given	O
53	2	O
54	days	O
55	after	O
56	methotrexate	O
57	in	O
58	subsequent	O
59	treatment	O
60	cycles	O
61	.	O

1	It	O
2	seems	O
3	that	O
4	the	O
5	way	O
6	in	O
7	which	O
8	drugs	O
9	modify	O
10	a	O
11	patient	O
12	'	O
13	s	O
14	serum	O
15	chemistry	O
16	may	O
17	be	O
18	used	O
19	to	O
20	assess	O
21	the	O
22	efficacy	O
23	with	O
24	which	O
25	they	O
26	control	O
27	the	O
28	inflammatory	O
29	process	O
30	.	O

1	Here	O
2	the	O
3	conventional	O
4	tests	O
5	clearly	O
6	pointed	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	retrocochlear	O
12	disease	O
13	.	O

1	The	O
2	end	O
3	-	O
4	stage	O
5	or	O
6	involutional	O
7	phase	O
8	of	O
9	proliferative	O
10	diabetic	O
11	retinopathy	O
12	may	O
13	result	O
14	in	O
15	stabilization	O
16	of	O
17	vision	O
18	for	O
19	long	O
20	periods	O
21	of	O
22	time	O
23	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	serum	B
6	alpha1AT	I
7	quantitation	O
8	,	O
9	newborn	O
10	infants	O
11	may	O
12	be	O
13	separated	O
14	into	O
15	two	O
16	groups	O
17	,	O
18	characterized	O
19	respectively	O
20	by	O
21	concentrations	O
22	above	O
23	or	O
24	below	O
25	150	O
26	mg	O
27	%.	O

1	In	O
2	patients	O
3	who	O
4	were	O
5	not	O
6	vented	O
7	,	O
8	there	O
9	was	O
10	overall	O
11	significant	O
12	depression	O
13	of	O
14	function	O
15	(	O
16	67	O
17	+/-	O
18	5	O
19	%	O
20	of	O
21	control	O
22	;	O
23	range	O
24	,	O
25	91	O
26	--	O
27	45	O
28	%,	O
29	p	O
30	less	O
31	than	O
32	0	O
33	.	O
34	01	O
35	).	O

1	Changes	O
2	in	O
3	body	O
4	weight	O
5	and	O
6	agonistic	O
7	behavior	O
8	were	O
9	also	O
10	recorded	O
11	.	O

1	The	O
2	uterine	O
3	response	O
4	to	O
5	prostaglandin	O
6	E2	O
7	(	O
8	PGE2	O
9	)	O
10	and	O
11	prostaglandin	O
12	F2alpha	O
13	(	O
14	administered	O
15	by	O
16	intravenous	O
17	and	O
18	intrauterine	O
19	routes	O
20	)	O
21	was	O
22	evaluated	O
23	during	O
24	different	O
25	phases	O
26	of	O
27	the	O
28	menstrual	O
29	cycle	O
30	in	O
31	five	O
32	functionally	O
33	infertile	O
34	women	O
35	.	O

1	A	O
2	total	O
3	of	O
4	26	O
5	BCG	O
6	strains	O
7	,	O
8	out	O
9	of	O
10	them	O
11	10	O
12	Czechoslovak	O
13	strains	O
14	(	O
15	2	O
16	lyophilized	O
17	cultures	O
18	of	O
19	BCG	O
20	of	O
21	different	O
22	batch	O
23	,	O
24	6	O
25	strains	O
26	isolated	O
27	from	O
28	abscesses	O
29	of	O
30	children	O
31	after	O
32	BCG	O
33	-	O
34	vaccination	O
35	and	O
36	2	O
37	strains	O
38	from	O
39	fatal	O
40	cases	O
41	after	O
42	BCG	O
43	-	O
44	vaccination	O
45	)	O
46	and	O
47	16	O
48	strains	O
49	obtained	O
50	from	O
51	foreign	O
52	laboratories	O
53	,	O
54	were	O
55	used	O
56	.	O

1	High	O
2	levels	O
3	of	O
4	serum	O
5	calcitonin	B
6	were	O
7	found	O
8	in	O
9	patients	O
10	with	O
11	chronic	O
12	renal	O
13	failure	O
14	.	O

1	Detection	O
2	of	O
3	anti	O
4	-	O
5	lymphocyte	O
6	antibodies	O
7	using	O
8	the	O
9	immunoperoxidase	B
10	antiglobulin	I
11	technic	O
12	.	O

1	The	O
2	response	O
3	of	O
4	serum	B
5	GH	I
6	to	O
7	arginine	O
8	infusion	O
9	was	O
10	normal	O
11	,	O
12	while	O
13	that	O
14	to	O
15	insulin	B
16	-	O
17	induced	O
18	hypoglycemia	O
19	was	O
20	poor	O
21	.	O

1	The	O
2	mortality	O
3	rate	O
4	and	O
5	histopathological	O
6	features	O
7	of	O
8	Nocardia	O
9	asteroides	O
10	and	O
11	Nocardia	O
12	brasiliensis	O
13	infections	O
14	in	O
15	congenitally	O
16	athymic	O
17	(	O
18	nude	O
19	)	O
20	mice	O
21	of	O
22	ICR	O
23	and	O
24	C3H	O
25	/	O
26	eB	O
27	origins	O
28	were	O
29	quite	O
30	different	O
31	from	O
32	what	O
33	we	O
34	found	O
35	for	O
36	Swiss	O
37	white	O
38	mice	O
39	and	O
40	other	O
41	inbred	O
42	mouse	O
43	strains	O
44	(	O
45	namely	O
46	,	O
47	C57	O
48	/	O
49	BL	O
50	/	O
51	6J	O
52	,	O
53	New	O
54	Zealand	O
55	Black	O
56	,	O
57	BALB	O
58	/	O
59	c	O
60	,	O
61	CBA	O
62	/	O
63	LAC	O
64	,	O
65	and	O
66	C3H	O
67	/	O
68	eB	O
69	).	O

1	Williams	O
2	,	O
3	2	O
4	August	O
5	1977	O
6	.	O

1	Use	O
2	of	O
3	radioactive	O
4	isotopes	O
5	in	O
6	the	O
7	chemistry	O
8	of	O
9	proteins	O

1	(	O
2	Emeritus	O
3	)	O
4	John	O
5	Henri	O
6	Roosegaarde	O
7	Bisschop	O

1	Disrupted	O
2	vaccines	O
3	and	O
4	whole	O
5	-	O
6	virus	O
7	vaccines	O
8	containing	O
9	type	B
10	B	I
11	antigen	I
12	only	O
13	did	O
14	not	O
15	cause	O
16	significant	O
17	reactivity	O
18	.	O

1	255	O
2	-	O
3	61	O
4	.	O

1	Antenatal	O
2	diagnosis	O
3	of	O
4	haematological	O
5	disorders	O
6	--'	O
7	1978	O
8	'.	O

1	Hepatic	O
2	oxygen	O
3	supply	O
4	and	O
5	selected	O
6	blood	O
7	parameters	O
8	were	O
9	recorded	O
10	in	O
11	fasted	O
12	male	O
13	rates	O
14	given	O
15	20	O
16	--	O
17	30	O
18	mg	O
19	/	O
20	kg	O
21	Escherichia	B
22	coli	I
23	endotoxin	I
24	intraperitoneally	O
25	.	O

1	Gonadal	O
2	dysfunction	O
3	in	O
4	patients	O
5	with	O
6	ataxia	O
7	telangiectasia	O
8	.	O

1	The	O
2	maximum	O
3	period	O
4	of	O
5	treatment	O
6	was	O
7	73	O
8	(	O
9	oral	O
10	),	O
11	73	O
12	(	O
13	intraperitoneal	O
14	)	O
15	or	O
16	75	O
17	(	O
18	dermal	O
19	)	O
20	weeks	O
21	.	O

1	A	O
2	study	O
3	of	O
4	the	O
5	comparative	O
6	efficacy	O
7	of	O
8	diflucortolone	O
9	valerate	O
10	0	O
11	.	O
12	3	O
13	%	O
14	ointment	O
15	and	O
16	clobetasol	O
17	propionate	O
18	0	O
19	.	O
20	05	O
21	%	O
22	ointment	O
23	.	O

1	Most	O
2	of	O
3	the	O
4	phenomena	O
5	of	O
6	azotaemic	O
7	osteodystrophy	O
8	are	O
9	encountered	O
10	in	O
11	simple	O
12	vitamin	O
13	D	O
14	deficiency	O
15	;	O
16	as	O
17	in	O
18	that	O
19	condition	O
20	,	O
21	deficiency	O
22	of	O
23	1	O
24	,	O
25	25	O
26	-	O
27	dihydroxycholecalciferol	O
28	may	O
29	be	O
30	of	O
31	primary	O
32	significance	O
33	in	O
34	causing	O
35	secondary	O
36	hyperparathyroidism	O
37	in	O
38	renal	O
39	failure	O
40	.	O

1	Basal	O
2	FSH	B
3	and	O
4	LH	B
5	levels	O
6	were	O
7	significantly	O
8	lower	O
9	in	O
10	addicts	O
11	;	O
12	after	O
13	GnRH	B
14	stimulation	O
15	the	O
16	addicts	O
17	'	O
18	FSH	B
19	and	O
20	LH	B
21	values	O
22	increased	O
23	but	O
24	not	O
25	significantly	O
26	compared	O
27	to	O
28	controls	O
29	.	O

1	Adriamycin	O
2	:	O
3	comparison	O
4	of	O
5	a	O
6	5	O
7	-	O
8	week	O
9	schedule	O
10	with	O
11	a	O
12	3	O
13	-	O
14	week	O
15	schedule	O
16	in	O
17	the	O
18	treatment	O
19	of	O
20	breast	O
21	cancer	O
22	.	O

1	Follow	O
2	-	O
3	up	O
4	controls	O
5	of	O
6	luteinizing	B
7	hormone	I
8	(	O
9	LH	B
10	),	O
11	follicle	B
12	stimulating	I
13	hormone	I
14	(	O
15	FSH	B
16	),	O
17	prolactin	B
18	(	O
19	HPRL	B
20	),	O
21	oestradiol	O
22	(	O
23	E2	O
24	),	O
25	progesterone	O
26	(	O
27	P	O
28	)	O
29	and	O
30	testosterone	O
31	(	O
32	T	O
33	)	O
34	in	O
35	the	O
36	catabolic	O
37	and	O
38	healing	O
39	phase	O
40	of	O
41	burn	O
42	disease	O
43	.	O

1	Renin	B
2	studies	O
3	performed	O
4	in	O
5	34	O
6	hypertensive	O
7	patients	O
8	and	O
9	in	O
10	a	O
11	control	O
12	group	O
13	of	O
14	11	O
15	recipients	O
16	showed	O
17	that	O
18	elevation	O
19	of	O
20	plasma	B
21	renin	I
22	activity	O
23	and	O
24	of	O
25	plasma	O
26	aldosterone	O
27	level	O
28	is	O
29	frequent	O
30	but	O
31	difficult	O
32	to	O
33	interpret	O
34	,	O
35	particularly	O
36	when	O
37	a	O
38	renal	O
39	artery	O
40	stenosis	O
41	is	O
42	observed	O
43	.	O

1	A	O
2	randomized	O
3	clinical	O
4	trial	O
5	in	O
6	sixty	O
7	-	O
8	two	O
9	adult	O
10	patients	O
11	suffering	O
12	from	O
13	typhoid	O
14	fever	O
15	,	O
16	proved	O
17	by	O
18	blood	O
19	and	O
20	marrow	O
21	culture	O
22	,	O
23	showed	O
24	that	O
25	amoxycillin	O
26	in	O
27	a	O
28	dosage	O
29	schedule	O
30	of	O
31	1	O
32	g	O
33	8	O
34	-	O
35	hourly	O
36	orally	O
37	for	O
38	fourteen	O
39	days	O
40	was	O
41	better	O
42	than	O
43	chloramphenicol	O
44	with	O
45	regard	O
46	to	O
47	clinical	O
48	and	O
49	temperature	O
50	response	O
51	and	O
52	in	O
53	respect	O
54	of	O
55	carriers	O
56	and	O
57	relapse	O
58	rates	O
59	.	O

1	202	O
2	-	O
3	8	O
4	.	O

1	Bone	O
2	marrow	O
3	transplantation	O
4	-	O
5	1979	O
6	.	O

1	In	O
2	this	O
3	article	O
4	,	O
5	the	O
6	clinical	O
7	actions	O
8	of	O
9	the	O
10	principal	O
11	dopamine	B
12	receptor	I
13	stimulating	O
14	agents	O
15	(	O
16	apomorphine	O
17	and	O
18	its	O
19	derivatives	O
20	;	O
21	piribedil	O
22	,	O
23	rye	O
24	-	O
25	ergot	O
26	derivatives	O
27	)	O
28	are	O
29	discussed	O
30	on	O
31	the	O
32	basis	O
33	of	O
34	their	O
35	biochemical	O
36	and	O
37	pharmacological	O
38	properties	O
39	.	O

1	The	O
2	unilateral	O
3	vestibular	O
4	hypofunction	O
5	.	O

1	Thus	O
2	,	O
3	the	O
4	inhibition	O
5	of	O
6	pepsin	B
7	in	O
8	human	O
9	gastric	O
10	juice	O
11	does	O
12	not	O
13	appear	O
14	to	O
15	have	O
16	a	O
17	major	O
18	influence	O
19	on	O
20	the	O
21	healing	O
22	of	O
23	duodenal	O
24	ulcer	O
25	.	O

1	The	O
2	IDF	O
3	standard	O
4	method	O
5	for	O
6	the	O
7	detection	O
8	of	O
9	penicillin	O
10	in	O
11	milk	O
12	is	O
13	not	O
14	suitable	O
15	for	O
16	the	O
17	detection	O
18	of	O
19	sulphonamide	O
20	residues	O
21	in	O
22	milk	O
23	.	O

1	Capsular	O
2	antigens	O
3	of	O
4	Staphylococcus	O
5	aureus	O

1	The	O
2	course	O
3	of	O
4	endotoxin	O
5	fever	O
6	remained	O
7	uninfluenced	O
8	by	O
9	ALS	O
10	.	O

1	2	O
2	new	O
3	Algerian	O
4	cases	O

1	Seventy	O
2	-	O
3	one	O
4	percent	O
5	of	O
6	patients	O
7	treated	O
8	with	O
9	ticarcillin	O
10	alone	O
11	responded	O
12	favorably	O
13	.	O

1	Accurate	O
2	pathologic	O
3	staging	O
4	identifies	O
5	patients	O
6	who	O
7	are	O
8	potentially	O
9	curable	O
10	with	O
11	radiotherapy	O
12	.	O

1	Inherent	O
2	hematology	O
3	of	O
4	old	O
5	age	O

1	Neomycin	O
2	is	O
3	fairly	O
4	effective	O
5	against	O
6	staphylococci	O
7	,	O
8	less	O
9	effective	O
10	against	O
11	streptococci	O
12	,	O
13	and	O
14	fairly	O
15	effective	O
16	against	O
17	gram	O
18	-	O
19	negative	O
20	intestinal	O
21	organisms	O
22	.	O

1	It	O
2	was	O
3	concluded	O
4	,	O
5	that	O
6	on	O
7	a	O
8	given	O
9	section	O
10	,	O
11	75	O
12	,	O
13	7	O
14	per	O
15	cent	O
16	of	O
17	the	O
18	trabeculae	O
19	were	O
20	in	O
21	contact	O
22	with	O
23	vascular	O
24	cavities	O
25	.	O

1	2	O
2	.	O

1	Changes	O
2	in	O
3	tissue	O
4	PCO2	O
5	were	O
6	less	O
7	dramatic	O
8	and	O
9	did	O
10	not	O
11	vary	O
12	significantly	O
13	from	O
14	those	O
15	recorded	O
16	in	O
17	venous	O
18	blood	O
19	.	O

1	Ultrasonic	O
2	evaluation	O
3	of	O
4	renal	O
5	calculi	O
6	.	O

1	Recognition	O
2	of	O
3	emphysema	O
4	was	O
5	poor	O
6	when	O
7	radiographs	O
8	of	O
9	inadequate	O
10	quality	O
11	were	O
12	included	O
13	(	O
14	anteroposterior	O
15	films	O
16	or	O
17	films	O
18	from	O
19	patients	O
20	with	O
21	acute	O
22	or	O
23	chronic	O
24	lung	O
25	disease	O
26	).	O

1	Isolation	O
2	of	O
3	T	O
4	.	O
5	gambiense	O
6	strains	O
7	in	O
8	Zaire	O
9	and	O
10	their	O
11	adaptation	O
12	to	O
13	laboratory	O
14	animals	O

1	Pharmacokinetic	O
2	profile	O
3	of	O
4	clonazepam	O
5	in	O
6	rhesus	O
7	monkeys	O
8	.	O

1	Immunologic	O
2	mechanisms	O
3	in	O
4	chronic	O
5	brucellosis	O
6	in	O
7	humans	O
8	.	O

1	Intestinal	O
2	adaptation	O
3	(	O
4	first	O
5	of	O
6	two	O
7	parts	O
8	).	O

1	In	O
2	patients	O
3	who	O
4	had	O
5	received	O
6	no	O
7	previous	O
8	drug	O
9	treatment	O
10	,	O
11	log	O
12	baseline	O
13	plasma	B
14	renin	I
15	activity	O
16	and	O
17	change	O
18	in	O
19	mean	O
20	blood	O
21	pressure	O
22	after	O
23	SQ	O
24	20881	O
25	correlated	O
26	significantly	O
27	(	O
28	r	O
29	=	O
30	0	O
31	.	O
32	651	O
33	,	O
34	P	O
35	less	O
36	than	O
37	0	O
38	.	O
39	05	O
40	).	O

1	These	O
2	techniques	O
3	have	O
4	been	O
5	used	O
6	by	O
7	many	O
8	people	O
9	for	O
10	many	O
11	years	O
12	and	O
13	no	O
14	claim	O
15	is	O
16	being	O
17	made	O
18	for	O
19	any	O
20	innovation	O
21	in	O
22	this	O
23	regard	O
24	.	O

1	40	O
2	patients	O
3	with	O
4	chronic	O
5	osteomyelitis	O
6	were	O
7	treated	O
8	per	O
9	os	O
10	with	O
11	the	O
12	bactericidal	O
13	beta	O
14	-	O
15	lactam	O
16	-	O
17	antibiotic	O
18	cephalexin	O
19	during	O
20	3	O
21	to	O
22	60	O
23	weeks	O
24	.	O

1	A	O
2	total	O
3	of	O
4	57	O
5	patients	O
6	with	O
7	Hodgkin	O
8	'	O
9	s	O
10	disease	O
11	limited	O
12	to	O
13	above	O
14	the	O
15	diaphragm	O
16	(	O
17	Stages	O
18	I	O
19	and	O
20	II	O
21	,	O
22	A	O
23	and	O
24	B	O
25	)	O
26	were	O
27	treated	O
28	with	O
29	radiation	O
30	therapy	O
31	alone	O
32	at	O
33	the	O
34	University	O
35	of	O
36	Florida	O
37	between	O
38	1964	O
39	and	O
40	1974	O
41	.	O

1	Year	O
2	one	O
3	of	O
4	the	O
5	first	O
6	general	O
7	practitioner	O
8	medical	O
9	unit	O
10	in	O
11	the	O
12	greater	O
13	Glasgow	O
14	area	O
15	.	O

1	This	O
2	multiple	O
3	-	O
4	electrode	O
5	array	O
6	for	O
7	round	O
8	window	O
9	cochlear	O
10	implantation	O
11	is	O
12	a	O
13	robust	O
14	,	O
15	reliable	O
16	system	O
17	for	O
18	inserting	O
19	20	O
20	mm	O
21	along	O
22	the	O
23	scala	O
24	tympani	O
25	with	O
26	a	O
27	minimum	O
28	of	O
29	trauma	O
30	and	O
31	can	O
32	provide	O
33	for	O
34	bipolar	O
35	stimulation	O
36	.	O

1	As	O
2	authorized	O
3	by	O
4	the	O
5	World	O
6	Health	O
7	Organization	O
8	29th	O
9	Expert	O
10	Committee	O
11	on	O
12	Biological	O
13	Standardization	O
14	,	O
15	the	O
16	preparation	O
17	of	O
18	human	B
19	prolactin	I
20	in	O
21	ampoules	O
22	coded	O
23	75	O
24	/	O
25	504	O
26	has	O
27	been	O
28	established	O
29	as	O
30	the	O
31	International	O
32	Reference	O
33	Preparation	O
34	(	O
35	IRP	O
36	)	O
37	of	O
38	human	B
39	prolactin	I
40	for	O
41	immunoassay	O
42	.	O

1	i	O
2	.	O

1	Biliary	O
2	-	O
3	enteric	O
4	fistulas	O

1	Plasma	O
2	ion	O
3	changes	O
4	in	O
5	venous	O
6	blood	O
7	incubated	O
8	with	O
9	beta	B
10	receptor	I
11	blockers	O
12	and	O
13	subjected	O
14	to	O
15	tonometry	O
16	in	O
17	vitro	O
18	.	O

1	Such	O
2	marked	O
3	differences	O
4	are	O
5	found	O
6	occasionally	O
7	in	O
8	the	O
9	literature	O
10	:	O
11	heterophile	O
12	antibodies	O
13	against	O
14	bovine	B
15	gammaglobulin	I
16	are	O
17	regarded	O
18	as	O
19	responsible	O
20	for	O
21	the	O
22	interference	O
23	in	O
24	the	O
25	Sephadex	O
26	system	O
27	of	O
28	RIST	O
29	.	O

1	"	O
2	Let	O
3	the	O
4	hundred	O
5	flowers	O
6	bloom	O
7	".	O

1	Various	O
2	treatment	O
3	modalities	O
4	are	O
5	reviewed	O
6	in	O
7	the	O
8	context	O
9	of	O
10	the	O
11	psychology	O
12	as	O
13	well	O
14	as	O
15	the	O
16	physiology	O
17	of	O
18	severe	O
19	intractable	O
20	pain	O
21	.	O

1	Lethal	O
2	Tachmalcor	O
3	(	O
4	4	O
5	-(	O
6	3	O
7	'-	O
8	diethylamino	O
9	-	O
10	2	O
11	'-	O
12	hydroxypropyl	O
13	)-	O
14	ajmaline	O
15	)	O
16	poisoning	O
17	in	O
18	childhood	O

1	Ophthalmosonographic	O
2	evaluation	O
3	of	O
4	blood	O
5	flow	O
6	velocity	O
7	in	O
8	arteriocavernous	O
9	fistula	O

1	Serum	O
2	ferritin	B
3	concentration	O
4	and	O
5	bone	O
6	marrow	O
7	iron	O
8	stores	O
9	.	O

1	The	O
2	systolic	O
3	pressure	O
4	gradient	O
5	(	O
6	SPG	O
7	)	O
8	between	O
9	the	O
10	left	O
11	ventricle	O
12	(	O
13	LV	O
14	)	O
15	and	O
16	left	O
17	atrium	O
18	(	O
19	LA	O
20	)	O
21	was	O
22	obtained	O
23	from	O
24	high	O
25	-	O
26	fidelity	O
27	pressure	O
28	transducers	O
29	.	O

1	A	O
2	prospective	O
3	trail	O
4	comparing	O
5	hysterectomy	O
6	,	O
7	hysterectomy	O
8	plus	O
9	vaginal	O
10	radium	O
11	,	O
12	and	O
13	uterine	O
14	radium	O
15	plus	O
16	hysterectomy	O
17	in	O
18	stage	O
19	I	O
20	endometrial	O
21	carcinoma	O
22	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	patient	O
7	'	O
8	s	O
9	report	O
10	of	O
11	one	O
12	inaccurate	O
13	Clinitemp	O
14	,	O
15	we	O
16	undertook	O
17	to	O
18	investigate	O
19	the	O
20	accuracy	O
21	of	O
22	this	O
23	thermometer	O
24	.	O

1	Cryoglobulinemia	O
2	in	O
3	Raynaud	O
4	'	O
5	s	O
6	syndrome	O

1	Data	O
2	were	O
3	processed	O
4	with	O
5	a	O
6	semi	O
7	-	O
8	automatic	O
9	computer	O
10	program	O
11	which	O
12	develops	O
13	an	O
14	averaged	O
15	-	O
16	volume	O
17	curve	O
18	from	O
19	an	O
20	assigned	O
21	LV	O
22	region	O
23	-	O
24	of	O
25	-	O
26	interest	O
27	.	O

1	The	O
2	preferential	O
3	serum	B
4	IgA	I
5	response	O
6	observed	O
7	in	O
8	the	O
9	patient	O
10	population	O
11	suggests	O
12	that	O
13	bronchial	O
14	associated	O
15	lymphoid	O
16	tissue	O
17	in	O
18	the	O
19	diseased	O
20	lung	O
21	is	O
22	an	O
23	important	O
24	source	O
25	of	O
26	circulating	O
27	IgA	B
28	.	O

1	Ultimate	O
2	strengthes	O
3	seem	O
4	to	O
5	be	O
6	reached	O
7	for	O
8	cast	O
9	cobalt	O
10	alloys	O
11	,	O
12	whereas	O
13	titanium	O
14	alloys	O
15	,	O
16	such	O
17	as	O
18	Ta	O
19	6	O
20	V	O
21	,	O
22	present	O
23	very	O
24	high	O
25	fatigue	O
26	limit	O
27	under	O
28	corrosion	O
29	.	O

1	The	O
2	effects	O
3	of	O
4	intracisternal	O
5	injection	O
6	(	O
7	i	O
8	.	O
9	c	O
10	.	O
11	i	O
12	.)	O
13	of	O
14	clonidine	O
15	(	O
16	1	O
17	microgram	O
18	kg	O
19	-	O
20	1	O
21	)	O
22	on	O
23	blood	O
24	pressure	O
25	and	O
26	heart	O
27	rate	O
28	were	O
29	studied	O
30	in	O
31	conscious	O
32	rabbits	O
33	with	O
34	an	O
35	implanted	O
36	catheter	O
37	in	O
38	the	O
39	cisterna	O
40	magna	O
41	.	O

1	Platelet	O
2	number	O
3	and	O
4	life	O
5	span	O
6	were	O
7	determined	O
8	in	O
9	the	O
10	last	O
11	trimester	O
12	of	O
13	pregnancy	O
14	in	O
15	22	O
16	women	O
17	who	O
18	were	O
19	delivered	O
20	of	O
21	small	O
22	-	O
23	for	O
24	-	O
25	gestational	O
26	age	O
27	(	O
28	SGA	O
29	)	O
30	infants	O
31	and	O
32	in	O
33	21	O
34	women	O
35	with	O
36	infants	O
37	having	O
38	normal	O
39	birth	O
40	weights	O
41	.	O

1	Serial	O
2	measurements	O
3	of	O
4	total	O
5	serum	O
6	IgE	B
7	appears	O
8	to	O
9	be	O
10	a	O
11	useful	O
12	index	O
13	of	O
14	disease	O
15	activity	O
16	in	O
17	ABPA	O
18	.	O

1	In	O
2	the	O
3	8	O
4	patients	O
5	the	O
6	difference	O
7	betweent	O
8	he	O
9	mean	O
10	diastolic	O
11	values	O
12	of	O
13	delta	O
14	PU	O
15	and	O
16	delta	O
17	PM	O
18	was	O
19	-	O
20	0	O
21	.	O
22	54	O
23	+/-	O
24	1	O
25	.	O
26	0	O
27	(	O
28	SD	O
29	)	O
30	mmHg	O
31	.	O

1	A	O
2	rise	O
3	of	O
4	hemoglobin	B
5	concentration	O
6	accompanied	O
7	by	O
8	an	O
9	increase	O
10	of	O
11	the	O
12	total	O
13	iron	O
14	in	O
15	the	O
16	blood	O
17	serum	O
18	of	O
19	white	O
20	mice	O
21	was	O
22	found	O
23	under	O
24	oxygen	O
25	pressure	O
26	of	O
27	4	O
28	atm	O
29	for	O
30	an	O
31	hour	O
32	(	O
33	preconvulsive	O
34	state	O
35	)	O
36	and	O
37	6	O
38	atm	O
39	(	O
40	convulsive	O
41	state	O
42	).	O

1	Nernst	O
2	--	O
3	Planck	O
4	analog	O
5	equations	O
6	and	O
7	stationary	O
8	state	O
9	membrane	O
10	electric	O
11	potentials	O
12	.	O

1	Effects	O
2	of	O
3	methylene	O
4	chloride	O
5	,	O
6	trichloroethane	O
7	,	O
8	trichloroethylene	O
9	,	O
10	tetrachloroethylene	O
11	and	O
12	toluene	O
13	on	O
14	the	O
15	development	O
16	of	O
17	chick	O
18	embryos	O
19	.	O

1	Effect	O
2	of	O
3	intraventricular	O
4	administration	O
5	of	O
6	streptolysin	B
7	O	I
8	on	O
9	the	O
10	electroencephalogram	O
11	of	O
12	rabbits	O
13	.	O

1	In	O
2	this	O
3	situation	O
4	the	O
5	convlusion	O
6	threshold	O
7	for	O
8	the	O
9	8	O
10	substances	O
11	is	O
12	as	O
13	follows	O
14	:	O
15	pethidine	O
16	20	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	I	O
23	.	O
24	V	O
25	.,	O
26	piritramide	O
27	30	O
28	,	O
29	morphine	O
30	180	O
31	,	O
32	phenoperidine	O
33	4	O
34	,	O
35	R	O
36	39	O
37	209	O
38	5	O
39	,	O
40	fentanyl	O
41	4	O
42	,	O
43	sufentanil	O
44	4	O
45	and	O
46	R	O
47	34	O
48	995	O
49	10	O
50	mg	O
51	.	O
52	kg	O
53	-	O
54	1	O
55	I	O
56	.	O
57	V	O
58	.	O

1	The	O
2	biochemistry	O
3	of	O
4	amniotic	O
5	fluid	O
6	with	O
7	poor	O
8	fetal	O
9	growth	O
10	.	O

1	Roentgenographically	O
2	,	O
3	the	O
4	lesion	O
5	was	O
6	usually	O
7	a	O
8	well	O
9	-	O
10	defined	O
11	and	O
12	benign	O
13	appearing	O
14	one	O
15	,	O
16	either	O
17	purely	O
18	lytic	O
19	(	O
20	3	O
21	cases	O
22	)	O
23	or	O
24	with	O
25	central	O
26	radiodensity	O
27	(	O
28	2	O
29	cases	O
30	).	O

1	Effects	O
2	of	O
3	chronic	O
4	descending	O
5	tractotomy	O
6	on	O
7	the	O
8	response	O
9	patterns	O
10	of	O
11	neurons	O
12	in	O
13	the	O
14	trigeminal	O
15	nuclei	O
16	principalis	O
17	and	O
18	oralis	O
19	.	O

1	Efficacy	O
2	of	O
3	a	O
4	three	O
5	-	O
6	versus	O
7	a	O
8	five	O
9	-	O
10	week	O
11	alcohol	O
12	treatment	O
13	program	O
14	.	O

1	Resistance	O
2	to	O
3	the	O
4	simulated	O
5	physiologic	O
6	environment	O
7	was	O
8	tested	O
9	by	O
10	measured	O
11	retention	O
12	of	O
13	mechanical	O
14	properties	O
15	after	O
16	immersion	O
17	times	O
18	in	O
19	pseudo	O
20	-	O
21	extracellular	O
22	fluid	O
23	(	O
24	PECF	O
25	)	O
26	at	O
27	37	O
28	degrees	O
29	C	O
30	for	O
31	as	O
32	long	O
33	as	O
34	three	O
35	years	O
36	.	O

1	Isolated	O
2	calcaneal	O
3	tuberculous	O
4	osteomyelitis	O
5	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	opiate	B
6	receptors	I
7	bordering	O
8	the	O
9	fourth	O
10	cerebral	O
11	ventricle	O
12	mediate	O
13	the	O
14	cardiovascular	O
15	and	O
16	hypnotic	O
17	action	O
18	of	O
19	fentanyl	O
20	.	O

1	In	O
2	case	O
3	of	O
4	a	O
5	pathologically	O
6	convoluted	O
7	internal	O
8	carotid	O
9	the	O
10	common	O
11	carotid	O
12	artery	O
13	was	O
14	resected	O
15	with	O
16	an	O
17	end	O
18	-	O
19	to	O
20	-	O
21	end	O
22	anastomosis	O
23	.	O

1	This	O
2	expression	O
3	assumes	O
4	:	O
5	(	O
6	1	O
7	)	O
8	a	O
9	laminar	O
10	flow	O
11	regimen	O
12	during	O
13	expiration	O
14	,	O
15	and	O
16	(	O
17	2	O
18	)	O
19	a	O
20	constant	O
21	CT	O
22	value	O
23	over	O
24	the	O
25	range	O
26	of	O
27	VT	O
28	.	O

1	These	O
2	data	O
3	confirm	O
4	the	O
5	existence	O
6	of	O
7	hyperlipemic	O
8	abdominal	O
9	crisis	O
10	as	O
11	a	O
12	distinct	O
13	entity	O
14	and	O
15	testify	O
16	to	O
17	the	O
18	importance	O
19	of	O
20	recognizing	O
21	this	O
22	syndrome	O
23	in	O
24	order	O
25	to	O
26	avoid	O
27	the	O
28	occurrence	O
29	of	O
30	acute	O
31	pancreatitis	O
32	and	O
33	the	O
34	performance	O
35	of	O
36	unnecessary	O
37	and	O
38	potentially	O
39	harmful	O
40	surgery	O
41	.	O

1	In	O
2	addition	O
3	a	O
4	significant	O
5	Treatment	O
6	X	O
7	Strain	O
8	interaction	O
9	was	O
10	due	O
11	to	O
12	the	O
13	larger	O
14	defecation	O
15	numbers	O
16	displayed	O
17	by	O
18	the	O
19	taurine	O
20	-	O
21	injected	O
22	MR	O
23	rats	O
24	relative	O
25	to	O
26	the	O
27	saline	O
28	-	O
29	injected	O
30	MR	O
31	rats	O
32	.	O

1	Their	O
2	conduction	O
3	velocity	O
4	ranged	O
5	from	O
6	0	O
7	.	O
8	23	O
9	to	O
10	0	O
11	.	O
12	98	O
13	m	O
14	/	O
15	sec	O
16	(	O
17	group	O
18	C	O
19	).	O

1	The	O
2	failures	O
3	frequently	O
4	were	O
5	related	O
6	to	O
7	patient	O
8	intolerance	O
9	or	O
10	poor	O
11	mechanical	O
12	fit	O
13	and	O
14	occurred	O
15	in	O
16	the	O
17	first	O
18	few	O
19	days	O
20	or	O
21	first	O
22	few	O
23	months	O
24	after	O
25	insertion	O
26	.	O

1	The	O
2	major	O
3	urinary	O
4	metabolites	O
5	were	O
6	3	O
7	-(	O
8	3	O
9	-	O
10	carboxyphenyl	O
11	)-	O
12	5	O
13	-	O
14	hydroxymethyl	O
15	-	O
16	2	O
17	-	O
18	oxazolidinone	O
19	and	O
20	a	O
21	glucuronide	O
22	of	O
23	toloxatone	O
24	.	O

1	These	O
2	characteristics	O
3	indicated	O
4	the	O
5	pronounced	O
6	activity	O
7	of	O
8	collagenous	O
9	fiber	O
10	synthesis	O
11	and	O
12	the	O
13	matrix	O
14	of	O
15	the	O
16	osteoid	O
17	tissue	O
18	.	O

1	The	O
2	ventilation	O
3	did	O
4	not	O
5	increase	O
6	when	O
7	PACO2	O
8	was	O
9	increased	O
10	.	O

1	Carbohydrate	O
2	metabolism	O
3	and	O
4	the	O
5	semen	O
6	profile	O
7	:	O
8	glucose	O
9	,	O
10	insulin	B
11	,	O
12	and	O
13	sperm	O
14	studies	O
15	.	O

1	It	O
2	has	O
3	come	O
4	out	O
5	that	O
6	CAEC	O
7	is	O
8	between	O
9	CC	O
10	and	O
11	CIEC	O
12	and	O
13	that	O
14	attacks	O
15	of	O
16	biliary	O
17	fever	O
18	and	O
19	high	O
20	levels	O
21	of	O
22	alkaline	B
23	phosphatase	I
24	and	O
25	transaminases	O
26	in	O
27	the	O
28	serum	O
29	are	O
30	the	O
31	helpful	O
32	findings	O
33	for	O
34	preoperative	O
35	diagnosis	O
36	.	O

1	The	O
2	sub	O
3	-	O
4	acute	O
5	inhalation	O
6	toxicity	O
7	of	O
8	furfural	O
9	was	O
10	studied	O
11	in	O
12	Syrian	O
13	golden	O
14	hamsters	O
15	.	O

1	Changes	O
2	of	O
3	thirtynine	O
4	serum	O
5	protein	O
6	components	O
7	following	O
8	surgical	O
9	stress	O
10	.	O

1	These	O
2	differences	O
3	are	O
4	smaller	O
5	than	O
6	those	O
7	described	O
8	in	O
9	standard	O
10	textbooks	O
11	.	O

1	A	O
2	study	O
3	of	O
4	the	O
5	E	O
6	.	O
7	O	O
8	.	O
9	R	O
10	.	O
11	T	O
12	.	O
13	C	O
14	.	O

1	The	O
2	present	O
3	study	O
4	examined	O
5	the	O
6	dependence	O
7	of	O
8	difference	O
9	tone	O
10	level	O
11	[	O
12	L	O
13	(	O
14	f2	O
15	-	O
16	f1	O
17	)]	O
18	on	O
19	the	O
20	following	O
21	parameters	O
22	of	O
23	the	O
24	two	O
25	-	O
26	tone	O
27	input	O
28	:	O
29	f1	O
30	,	O
31	f2	O
32	/	O
33	f1	O
34	(	O
35	f2	O
36	greater	O
37	than	O
38	f1	O
39	),	O
40	L1	O
41	,	O
42	L2	O
43	,	O
44	and	O
45	L1	O
46	=	O
47	L2	O
48	.	O

1	An	O
2	intravenous	O
3	preparation	O
4	of	O
5	doxycycline	O
6	(	O
7	DOTC	O
8	,	O
9	Vibramycin	O
10	'	O
11	Pfizer	O
12	'),	O
13	a	O
14	long	O
15	-	O
16	lasting	O
17	tetracycline	O
18	,	O
19	was	O
20	administered	O
21	mainly	O
22	by	O
23	drip	O
24	infusion	O
25	for	O
26	a	O
27	series	O
28	of	O
29	study	O
30	in	O
31	the	O
32	pediatrics	O
33	field	O
34	,	O
35	and	O
36	the	O
37	results	O
38	were	O
39	as	O
40	follows	O
41	:	O
42	1	O
43	)	O
44	DOTC	O
45	(	O
46	100	O
47	mg	O
48	)	O
49	was	O
50	dissolved	O
51	in	O
52	a	O
53	100	O
54	ml	O
55	of	O
56	glucose	O
57	solution	O
58	and	O
59	2	O
60	--	O
61	3	O
62	mg	O
63	/	O
64	kg	O
65	was	O
66	administered	O
67	intravenously	O
68	.	O

1	5	O
2	)	O
3	Before	O
4	and	O
5	ten	O
6	days	O
7	after	O
8	DOTC	O
9	infusion	O
10	,	O
11	laboratory	O
12	tests	O
13	for	O
14	liver	O
15	and	O
16	renal	O
17	functions	O
18	and	O
19	blood	O
20	were	O
21	performed	O
22	.	O

1	Structural	O
2	characteristics	O
3	of	O
4	the	O
5	erythrocyte	O
6	membrane	O
7	,	O
8	peroxidation	O
9	processes	O
10	and	O
11	antioxidant	O
12	function	O
13	in	O
14	children	O
15	with	O
16	diffuse	O
17	glomerulonephritis	O

1	The	O
2	enteric	O
3	route	O
4	is	O
5	the	O
6	principal	O
7	mode	O
8	of	O
9	transmission	O
10	for	O
11	hepatitis	O
12	A	O
13	,	O
14	but	O
15	maximal	O
16	levels	O
17	of	O
18	hepatitis	O
19	A	O
20	virus	O
21	excretion	O
22	occur	O
23	before	O
24	the	O
25	onset	O
26	of	O
27	jaundice	O
28	.	O

1	All	O
2	13	O
3	patients	O
4	showed	O
5	endoscopic	O
6	evidence	O
7	of	O
8	oesophagitis	O
9	,	O
10	moderate	O
11	in	O
12	4	O
13	and	O
14	severe	O
15	in	O
16	9	O
17	.	O

1	Urinary	O
2	excretion	O
3	of	O
4	oestrone	O
5	,	O
6	oestradiol	O
7	-	O
8	17	O
9	beta	O
10	and	O
11	oestriol	O
12	in	O
13	pregnancies	O
14	complicated	O
15	by	O
16	steroid	B
17	sulphatase	I
18	deficiency	O
19	.	O

1	Both	O
2	reduced	O
3	spontaneous	O
4	locomotor	O
5	activity	O
6	in	O
7	mice	O
8	,	O
9	protected	O
10	them	O
11	from	O
12	death	O
13	from	O
14	amphetamine	O
15	induced	O
16	toxicity	O
17	,	O
18	prolonged	O
19	hexobarbitone	O
20	sleeping	O
21	time	O
22	and	O
23	caused	O
24	a	O
25	depletion	O
26	of	O
27	catecholamines	O
28	from	O
29	various	O
30	organs	O
31	of	O
32	the	O
33	rat	O
34	.	O

1	On	O
2	the	O
3	role	O
4	of	O
5	transferrin	B
6	in	O
7	the	O
8	uptake	O
9	of	O
10	gallium	O
11	by	O
12	tumor	O
13	cells	O
14	.	O

1	Irradiation	O
2	of	O
3	human	O
4	blood	O
5	platelets	O
6	with	O
7	UV	O
8	-	O
9	A	O
10	in	O
11	vitro	O
12	impairs	O
13	their	O
14	ability	O
15	to	O
16	aggregate	O
17	after	O
18	challenge	O
19	with	O
20	collagen	B
21	.	O

1	With	O
2	certain	O
3	exceptions	O
4	the	O
5	method	O
6	was	O
7	considered	O
8	suitable	O
9	in	O
10	the	O
11	routine	O
12	intravenous	O
13	cholangiography	O
14	.	O

1	Following	O
2	the	O
3	satisfactory	O
4	results	O
5	and	O
6	taking	O
7	into	O
8	account	O
9	that	O
10	the	O
11	complications	O
12	had	O
13	reduced	O
14	to	O
15	a	O
16	very	O
17	low	O
18	rate	O
19	(	O
20	in	O
21	2	O
22	cases	O
23	lead	O
24	tip	O
25	displacement	O
26	and	O
27	pouch	O
28	haematoma	O
29	occurred	O
30	respectively	O
31	),	O
32	the	O
33	Authors	O
34	consider	O
35	the	O
36	adopted	O
37	method	O
38	an	O
39	useful	O
40	approach	O
41	for	O
42	PMK	O
43	implantation	O
44	particularly	O
45	when	O
46	the	O
47	use	O
48	of	O
49	the	O
50	vena	O
51	cephalica	O
52	is	O
53	deemed	O
54	impossible	O
55	.	O

1	When	O
2	two	O
3	determinations	O
4	were	O
5	performed	O
6	on	O
7	12	O
8	samples	O
9	of	O
10	plasma	O
11	taken	O
12	from	O
13	normal	O
14	adults	O
15	in	O
16	October	O
17	,	O
18	the	O
19	values	O
20	were	O
21	22	O
22	.	O
23	6	O
24	+/-	O
25	4	O
26	.	O
27	8	O
28	and	O
29	21	O
30	.	O
31	0	O
32	+/-	O
33	3	O
34	.	O
35	6	O
36	(	O
37	mean	O
38	+/-	O
39	SD	O
40	)	O
41	ng	O
42	/	O
43	ml	O
44	,	O
45	respectively	O
46	.	O

1	The	O
2	six	O
3	commonest	O
4	causes	O
5	of	O
6	death	O
7	varied	O
8	in	O
9	the	O
10	three	O
11	ethnic	O
12	groups	O
13	.	O

1	Although	O
2	Grice	O
3	'	O
4	s	O
5	operation	O
6	has	O
7	been	O
8	used	O
9	all	O
10	over	O
11	the	O
12	world	O
13	,	O
14	no	O
15	systematic	O
16	account	O
17	of	O
18	it	O
19	has	O
20	been	O
21	found	O
22	in	O
23	the	O
24	literature	O
25	(	O
26	including	O
27	publications	O
28	dealing	O
29	with	O
30	technique	O
31	),	O
32	which	O
33	presents	O
34	it	O
35	in	O
36	terms	O
37	related	O
38	to	O
39	the	O
40	basic	O
41	"	O
42	classical	O
43	"	O
44	principles	O
45	on	O
46	which	O
47	the	O
48	operation	O
49	was	O
50	conceived	O
51	.	O

1	(	O
2	5	O
3	)	O
4	No	O
5	changes	O
6	were	O
7	observed	O
8	in	O
9	the	O
10	gastric	O
11	venous	O
12	blood	O
13	flow	O
14	by	O
15	continuous	O
16	intravenous	O
17	injection	O
18	of	O
19	cimetidine	O
20	,	O
21	but	O
22	by	O
23	rapid	O
24	injection	O
25	both	O
26	the	O
27	flow	O
28	was	O
29	augmented	O
30	and	O
31	the	O
32	systemic	O
33	blood	O
34	pressure	O
35	decreased	O
36	transiently	O
37	.	O

1	Study	O
2	on	O
3	re	O
4	-	O
5	establishment	O
6	of	O
7	ovulation	O
8	after	O
9	termination	O
10	of	O
11	sex	O
12	-	O
13	steroidal	O
14	treatment	O
15	--	O
16	compared	O
17	with	O
18	re	O
19	-	O
20	appearance	O
21	of	O
22	ovulation	O
23	after	O
24	abortion	O
25	and	O
26	premature	O
27	delivery	O
28	.	O

1	Pharmacokinetics	O
2	of	O
3	Carbamazepine	O
4	in	O
5	man	O
6	:	O
7	a	O
8	review	O
9	.	O

1	Of	O
2	the	O
3	compounds	O
4	tested	O
5	,	O
6	alpha	O
7	-(	O
8	3	O
9	-	O
10	methyl	O
11	-	O
12	2	O
13	-	O
14	quinoxalinyl	O
15	)-	O
16	N	O
17	-	O
18	methylnitrone	O
19	1	O
20	,	O
21	4	O
22	-	O
23	dioxide	O
24	(	O
25	2	O
26	)	O
27	was	O
28	the	O
29	most	O
30	active	O
31	agent	O
32	in	O
33	vivo	O
34	against	O
35	the	O
36	gram	O
37	-	O
38	negative	O
39	and	O
40	the	O
41	gram	O
42	-	O
43	positive	O
44	organisms	O
45	.	O

1	Changes	O
2	in	O
3	ionic	O
4	content	O
5	of	O
6	the	O
7	mucous	O
8	suggest	O
9	that	O
10	cholinergic	O
11	mechanisms	O
12	affect	O
13	pressure	O
14	in	O
15	the	O
16	excretory	O
17	duct	O
18	of	O
19	the	O
20	gland	O
21	.	O

1	Calves	O
2	fed	O
3	MCT	O
4	-	O
5	milk	O
6	had	O
7	significantly	O
8	lower	O
9	blood	O
10	cholesterol	O
11	than	O
12	calves	O
13	fed	O
14	T	O
15	-	O
16	or	O
17	SBO	O
18	-	O
19	milk	O
20	.	O

1	Delayed	O
2	mortality	O
3	of	O
4	mice	O
5	following	O
6	inhalation	O
7	of	O
8	acute	O
9	doses	O
10	of	O
11	CH2O	O
12	,	O
13	SO2Cl2	O
14	,	O
15	and	O
16	Br2	O
17	.	O

1	Guinea	O
2	pigs	O
3	weighing	O
4	300	O
5	approximately	O
6	350	O
7	g	O
8	were	O
9	used	O
10	.	O

1	Under	O
2	halothane	O
3	anesthesia	O
4	,	O
5	the	O
6	flow	O
7	pneumocardiogram	O
8	(	O
9	PnCG	O
10	)	O
11	and	O
12	its	O
13	time	O
14	derivative	O
15	(	O
16	acceleration	O
17	pneumocardiogram	O
18	or	O
19	dPn	O
20	/	O
21	dt	O
22	)	O
23	were	O
24	transduced	O
25	during	O
26	apnea	O
27	by	O
28	a	O
29	small	O
30	high	O
31	-	O
32	gain	O
33	pneumotachograph	O
34	.	O

1	Sensory	O
2	kindling	O
3	:	O
4	implications	O
5	for	O
6	development	O
7	of	O
8	sensory	O
9	prostheses	O
10	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	stereotypy	O
6	can	O
7	be	O
8	evoked	O
9	also	O
10	in	O
11	the	O
12	case	O
13	when	O
14	the	O
15	striatal	O
16	dopaminergic	O
17	tone	O
18	is	O
19	normal	O
20	or	O
21	even	O
22	below	O
23	normal	O
24	:	O
25	it	O
26	is	O
27	the	O
28	equilibrium	O
29	of	O
30	the	O
31	striatal	O
32	cholinergic	O
33	-	O
34	dopaminergic	O
35	systems	O
36	which	O
37	must	O
38	be	O
39	shifted	O
40	towards	O
41	dopamine	O
42	,	O
43	which	O
44	is	O
45	necessary	O
46	for	O
47	the	O
48	development	O
49	of	O
50	this	O
51	behavioral	O
52	manifestation	O
53	.	O

1	None	O
2	of	O
3	the	O
4	cystometrograms	O
5	showed	O
6	uninhibited	O
7	detrusor	O
8	contractions	O
9	.	O

1	In	O
2	the	O
3	duodenum	O
4	a	O
5	small	O
6	part	O
7	of	O
8	the	O
9	administered	O
10	dose	O
11	was	O
12	transformed	O
13	to	O
14	3H	O
15	-	O
16	alpha	O
17	-	O
18	acetyldigoxin	O
19	.	O

1	Functional	O
2	effects	O
3	following	O
4	subacute	O
5	administration	O
6	.	O

1	Treatment	O
2	of	O
3	Graves	O
4	'	O
5	disease	O
6	.	O

1	Although	O
2	it	O
3	has	O
4	been	O
5	shown	O
6	that	O
7	it	O
8	is	O
9	possible	O
10	to	O
11	use	O
12	orally	O
13	administered	O
14	testosterone	O
15	to	O
16	maintain	O
17	se	O
18	-	O
19	T	O
20	levels	O
21	in	O
22	the	O
23	normal	O
24	male	O
25	range	O
26	,	O
27	the	O
28	convenience	O
29	to	O
30	the	O
31	patient	O
32	must	O
33	be	O
34	balanced	O
35	against	O
36	the	O
37	cost	O
38	and	O
39	possible	O
40	side	O
41	effects	O
42	of	O
43	the	O
44	large	O
45	doses	O
46	required	O
47	.	O

1	Contrary	O
2	to	O
3	1	O
4	,	O
5	8	O
6	-	O
7	dihydroxy	O
8	-	O
9	9	O
10	-	O
11	anthrone	O
12	,	O
13	1	O
14	,	O
15	8	O
16	,	O
17	9	O
18	-	O
19	triacetoxyanthracene	O
20	and	O
21	1	O
22	,	O
23	8	O
24	-	O
25	diacetoxy	O
26	-	O
27	9	O
28	-	O
29	anthrone	O
30	are	O
31	effective	O
32	against	O
33	psoriatic	O
34	lesions	O
35	without	O
36	accompanying	O
37	inflammations	O
38	of	O
39	the	O
40	skin	O
41	.	O

1	Etiopathogenetic	O
2	and	O
3	therapeutic	O
4	problems	O
5	in	O
6	acute	O
7	orbital	O
8	inflammation	O

1	Nursing	O
2	of	O
3	patients	O
4	with	O
5	gynecological	O
6	diseases	O

1	We	O
2	measured	O
3	basal	O
4	plasma	O
5	prolactin	B
6	concentrations	O
7	(	O
8	in	O
9	samples	O
10	obtained	O
11	during	O
12	the	O
13	early	O
14	follicular	O
15	phase	O
16	)	O
17	in	O
18	25	O
19	normal	O
20	(	O
21	control	O
22	)	O
23	women	O
24	and	O
25	in	O
26	a	O
27	similar	O
28	group	O
29	of	O
30	40	O
31	patients	O
32	with	O
33	a	O
34	long	O
35	-	O
36	standing	O
37	history	O
38	of	O
39	infertility	O
40	.	O

1	Ovarian	O
2	allotransplantation	O
3	in	O
4	human	O
5	.	O

1	Allergic	O
2	reaction	O
3	to	O
4	Patent	O
5	Blue	O
6	Violet	O
7	during	O
8	lymphography	O
9	.	O

1	Screening	O
2	of	O
3	asthma	O
4	patients	O
5	by	O
6	determination	O
7	of	O
8	IgE	B
9	and	O
10	by	O
11	comprehension	O
12	of	O
13	spectrum	O
14	of	O
15	allergospecific	B
16	IgE	I
17	antibodies	I

1	The	O
2	induction	O
3	of	O
4	seizures	O
5	in	O
6	"	O
7	Papio	O
8	papio	O
9	"	O
10	following	O
11	allylglycine	O
12	alone	O
13	or	O
14	in	O
15	combination	O
16	with	O
17	intermittent	O
18	photic	O
19	stimulation	O

1	A	O
2	highly	O
3	significant	O
4	correlation	O
5	was	O
6	found	O
7	between	O
8	the	O
9	presence	O
10	of	O
11	fibrinolytic	O
12	degradation	O
13	products	O
14	(	O
15	FDP	O
16	)	O
17	and	O
18	the	O
19	incidence	O
20	of	O
21	nephropathy	O
22	and	O
23	renal	O
24	insufficiency	O
25	,	O
26	as	O
27	well	O
28	as	O
29	between	O
30	the	O
31	presence	O
32	of	O
33	fibrin	B
34	monomers	I
35	(	O
36	Godal	O
37	'	O
38	s	O
39	ethanol	O
40	-	O
41	gelification	O
42	test	O
43	)	O
44	and	O
45	the	O
46	evolutive	O
47	signs	O
48	of	O
49	the	O
50	primary	O
51	disease	O
52	(	O
53	fever	O
54	,	O
55	accelerated	O
56	ESR	O
57	).	O

1	One	O
2	-	O
3	third	O
4	of	O
5	the	O
6	men	O
7	with	O
8	azoospermia	O
9	and	O
10	with	O
11	sperm	O
12	density	O
13	of	O
14	less	O
15	than	O
16	10	O
17	million	O
18	had	O
19	marked	O
20	FSH	B
21	elevation	O
22	and	O
23	our	O
24	experience	O
25	confirms	O
26	the	O
27	work	O
28	of	O
29	others	O
30	that	O
31	this	O
32	indicates	O
33	a	O
34	poor	O
35	prognosis	O
36	.	O

1	In	O
2	girls	O
3	prolactin	B
4	levels	O
5	rise	O
6	at	O
7	stage	O
8	2	O
9	,	O
10	and	O
11	are	O
12	higher	O
13	after	O
14	menarche	O
15	;	O
16	in	O
17	boys	O
18	there	O
19	is	O
20	no	O
21	change	O
22	in	O
23	prolactin	B
24	levels	O
25	.	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	both	O
6	of	O
7	these	O
8	surgical	O
9	procedures	O
10	were	O
11	as	O
12	effective	O
13	as	O
14	pinealectomy	O
15	in	O
16	reversing	O
17	the	O
18	pineal	O
19	-	O
20	induced	O
21	alterations	O
22	in	O
23	the	O
24	reproductive	O
25	physiology	O
26	of	O
27	the	O
28	blind	O
29	-	O
30	anosmic	O
31	female	O
32	rat	O
33	.	O

1	2	O
2	cases	O
3	of	O
4	toxic	O
5	lymphomononucleosis	O

1	Such	O
2	an	O
3	hemoglobin	B
4	solution	O
5	was	O
6	shown	O
7	to	O
8	exhibit	O
9	a	O
10	high	O
11	affinity	O
12	for	O
13	oxygen	O
14	and	O
15	a	O
16	low	O
17	Bohr	O
18	effect	O
19	(	O
20	assessed	O
21	from	O
22	the	O
23	delta	O
24	log	O
25	Po2	O
26	/	O
27	delta	O
28	pH	O
29	ratio	O
30	).	O

1	A	O
2	one	O
3	-	O
4	week	O
5	ulcer	O
6	therapy	O
7	with	O
8	atropine	O
9	and	O
10	Vikalin	O
11	(	O
12	Roter	O
13	)	O
14	led	O
15	to	O
16	a	O
17	significant	O
18	(	O
19	p	O
20	less	O
21	than	O
22	0	O
23	.	O
24	01	O
25	)	O
26	reduction	O
27	of	O
28	the	O
29	nocturnal	O
30	proteolytic	O
31	activity	O
32	.	O

1	In	O
2	one	O
3	patient	O
4	with	O
5	severe	O
6	diarrhea	O
7	the	O
8	estriol	O
9	concentration	O
10	in	O
11	serum	O
12	was	O
13	low	O
14	until	O
15	the	O
16	intestinal	O
17	function	O
18	normalised	O
19	and	O
20	the	O
21	estriol	O
22	concentration	O
23	went	O
24	up	O
25	exactly	O
26	when	O
27	the	O
28	diarrhea	O
29	stopped	O
30	.	O

1	Serum	O
2	levels	O
3	of	O
4	IgG	B
5	and	O
6	IgM	B
7	were	O
8	also	O
9	raised	O
10	,	O
11	but	O
12	contrary	O
13	to	O
14	the	O
15	findings	O
16	of	O
17	other	O
18	observers	O
19	IgA	B
20	levels	O
21	were	O
22	normal	O
23	.	O

1	Experimental	O
2	ischemic	O
3	heart	O
4	disease	O
5	induced	O
6	by	O
7	thromboxane	O
8	A2	O
9	in	O
10	rabbits	O
11	.	O

1	Vitrectomy	O
2	in	O
3	ocular	O
4	traumatology	O

1	To	O
2	study	O
3	the	O
4	sensitivity	O
5	of	O
6	some	O
7	central	O
8	brain	O
9	structures	O
10	to	O
11	the	O
12	action	O
13	of	O
14	an	O
15	electromagnetic	O
16	field	O
17	of	O
18	decimeter	O
19	waves	O
20	(	O
21	EMF	O
22	of	O
23	DW	O
24	)	O
25	a	O
26	dynamic	O
27	investigation	O
28	of	O
29	single	O
30	unit	O
31	activity	O
32	was	O
33	undertaken	O
34	.	O

1	No	O
2	systematic	O
3	L	O
4	-	O
5	R	O
6	differences	O
7	were	O
8	observed	O
9	.	O

1	A	O
2	decrease	O
3	of	O
4	the	O
5	lysozyme	B
6	activity	O
7	coincided	O
8	with	O
9	the	O
10	clinical	O
11	improvement	O
12	of	O
13	the	O
14	bacterial	O
15	meningitis	O
16	.	O

1	This	O
2	implies	O
3	that	O
4	the	O
5	groups	O
6	do	O
7	not	O
8	just	O
9	differ	O
10	along	O
11	one	O
12	dimension	O
13	,	O
14	but	O
15	along	O
16	three	O
17	dimensions	O
18	.	O

1	Deep	O
2	tans	O
3	were	O
4	induced	O
5	over	O
6	the	O
7	backs	O
8	of	O
9	volunteers	O
10	with	O
11	repeated	O
12	exposure	O
13	to	O
14	longwave	O
15	ultraviolet	O
16	radiation	O
17	(	O
18	UV	O
19	-	O
20	A	O
21	).	O

1	1	O
2	The	O
3	effects	O
4	in	O
5	normal	O
6	subjects	O
7	of	O
8	a	O
9	single	O
10	oral	O
11	dose	O
12	of	O
13	Motival	O
14	(	O
15	one	O
16	tablet	O
17	,	O
18	containing	O
19	fluphenazine	O
20	0	O
21	.	O
22	5	O
23	mg	O
24	and	O
25	nortriptyline	O
26	10	O
27	mg	O
28	)	O
29	on	O
30	the	O
31	contingent	O
32	negative	O
33	variation	O
34	(	O
35	CNV	O
36	),	O
37	reaction	O
38	time	O
39	,	O
40	heart	O
41	rate	O
42	,	O
43	blood	O
44	pressure	O
45	and	O
46	self	O
47	-	O
48	rating	O
49	scales	O
50	for	O
51	alertness	O
52	,	O
53	anxiety	O
54	,	O
55	tension	O
56	,	O
57	detachment	O
58	and	O
59	depression	O
60	were	O
61	compared	O
62	with	O
63	those	O
64	of	O
65	diazepam	O
66	(	O
67	5	O
68	mg	O
69	and	O
70	7	O
71	.	O
72	5	O
73	mg	O
74	)	O
75	and	O
76	placebo	O
77	or	O
78	propranolol	O
79	(	O
80	60	O
81	mg	O
82	).	O

1	Stress	O
2	effects	O
3	on	O
4	affiliation	O
5	preferences	O
6	among	O
7	subjects	O
8	possessing	O
9	the	O
10	type	O
11	A	O
12	coronary	O
13	-	O
14	prone	O
15	behavior	O
16	pattern	O
17	.	O

1	These	O
2	show	O
3	that	O
4	the	O
5	collagen	B
6	in	O
7	this	O
8	tissue	O
9	is	O
10	modified	O
11	compared	O
12	with	O
13	that	O
14	in	O
15	tendon	O
16	.	O

1	Smoking	O
2	was	O
3	regarded	O
4	as	O
5	the	O
6	major	O
7	contribution	O
8	to	O
9	pulmonary	O
10	dysfunction	O
11	.	O

1	The	O
2	malignity	O
3	of	O
4	nevoid	O
5	lentigo	O
6	.	O

1	Elimination	O
2	of	O
3	bagassosis	O
4	in	O
5	Louisiana	O
6	paper	O
7	manufacturing	O
8	plant	O
9	workers	O
10	.	O

1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	labetalol	O
25	is	O
26	explained	O
27	by	O
28	concurrent	O
29	blockade	O
30	of	O
31	alpha	B
32	-	I
33	and	I
34	beta	I
35	-	I
36	adrenoceptors	I
37	.	O

1	Diuretics	O
2	:	O
3	basic	O
4	clinical	O
5	pharmacology	O
6	and	O
7	therapeutic	O
8	use	O
9	.	O

1	Three	O
2	patients	O
3	with	O
4	four	O
5	renoureteral	O
6	units	O
7	have	O
8	undergone	O
9	single	O
10	-	O
11	stage	O
12	reconstruction	O
13	involving	O
14	ureteroureterostomy	O
15	and	O
16	ipsilateral	O
17	ureteroneocystostomy	O
18	following	O
19	temporary	O
20	loop	O
21	cutaneous	O
22	ureterostomy	O
23	.	O

1	Evaluation	O
2	of	O
3	the	O
4	Du	O
5	Pont	O
6	aca	O
7	ammonia	O
8	procedure	O
9	.	O

1	Internally	O
2	oriented	O
3	patients	O
4	'	O
5	scores	O
6	on	O
7	Rotter	O
8	'	O
9	s	O
10	Internal	O
11	-	O
12	External	O
13	Locus	O
14	of	O
15	Control	O
16	Scale	O
17	remained	O
18	the	O
19	same	O
20	over	O
21	treatment	O
22	but	O
23	those	O
24	of	O
25	externally	O
26	oriented	O
27	patients	O
28	shifted	O
29	toward	O
30	greater	O
31	internal	O
32	control	O
33	.	O

1	Action	O
2	of	O
3	strontium	O
4	-	O
5	90	O
6	and	O
7	metaphos	O
8	on	O
9	Cyprinus	O
10	carpio	O

1	Kodak	O
2	XV	O
3	-	O
4	2	O
5	film	O
6	is	O
7	wrapped	O
8	around	O
9	a	O
10	cylindrical	O
11	water	O
12	-	O
13	filled	O
14	phantom	O
15	and	O
16	the	O
17	dose	O
18	distribution	O
19	is	O
20	recorded	O
21	.	O

1	Diagnosis	O
2	and	O
3	differential	O
4	diagnosis	O

1	The	O
2	multiple	O
3	factors	O
4	affecting	O
5	plasma	O
6	renin	B
7	activity	O
8	in	O
9	essential	O
10	hypertension	O
11	.	O

1	Cortisone	O
2	induced	O
3	bone	O
4	changes	O
5	and	O
6	its	O
7	response	O
8	to	O
9	lipid	O
10	clearing	O
11	agents	O
12	.	O

1	2	O
2	)	O
3	The	O
4	time	O
5	-	O
6	sharing	O
7	principle	O
8	was	O
9	applied	O
10	to	O
11	gain	O
12	high	O
13	stability	O
14	.	O

1	When	O
2	blood	O
3	samples	O
4	of	O
5	patients	O
6	with	O
7	hyperbilirubinemia	O
8	were	O
9	analyzed	O
10	,	O
11	direct	O
12	measurement	O
13	of	O
14	ZPP	O
15	by	O
16	this	O
17	fluorimeter	O
18	yielded	O
19	significantly	O
20	higher	O
21	levels	O
22	than	O
23	did	O
24	an	O
25	alternate	O
26	extraction	O
27	method	O
28	.	O

1	Delayed	O
2	hypersensitivity	O
3	in	O
4	man	O
5	:	O
6	effects	O
7	of	O
8	systemic	O
9	anticoagulation	O
10	.	O

1	In	O
2	three	O
3	of	O
4	the	O
5	seven	O
6	,	O
7	inhalation	O
8	of	O
9	2	O
10	ml	O
11	normal	O
12	saline	O
13	produced	O
14	FEV1	O
15	falls	O
16	of	O
17	25	O
18	%	O
19	to	O
20	30	O
21	%,	O
22	but	O
23	these	O
24	falls	O
25	were	O
26	not	O
27	as	O
28	great	O
29	as	O
30	each	O
31	subject	O
32	'	O
33	s	O
34	reactions	O
35	to	O
36	the	O
37	test	O
38	solutions	O
39	.	O

1	Experimental	O
2	studies	O
3	on	O
4	virus	O
5	excretion	O
6	and	O
7	non	O
8	-	O
9	arthropod	O
10	transmission	O
11	.	O

1	Potency	O
2	of	O
3	enflurane	O
4	in	O
5	dogs	O
6	:	O
7	comparison	O
8	with	O
9	halothane	O
10	and	O
11	isoflurane	O
12	.	O

1	Prevention	O
2	of	O
3	acute	O
4	paraquat	O
5	toxicity	O
6	in	O
7	rats	O
8	by	O
9	superoxide	B
10	dismutase	I
11	.	O

1	Measurement	O
2	of	O
3	magnesium	O
4	absorption	O
5	in	O
6	man	O
7	using	O
8	stable	O
9	26Mg	O
10	as	O
11	a	O
12	tracer	O
13	.	O

1	Increased	O
2	urinary	O
3	riboflavin	O
4	excretion	O
5	resulting	O
6	from	O
7	boric	O
8	acid	O
9	ingestion	O
10	.	O

1	Radionuclide	O
2	angiography	O
3	and	O
4	static	O
5	whole	O
6	body	O
7	imaging	O
8	performed	O
9	with	O
10	technetium	O
11	-	O
12	99m	O
13	-	O
14	labeled	O
15	particulates	O
16	can	O
17	clearly	O
18	demonstrate	O
19	differential	O
20	shunting	O
21	in	O
22	patients	O
23	with	O
24	patent	O
25	ductus	O
26	arteriosus	O
27	(	O
28	PDA	O
29	)	O
30	with	O
31	Eisenmenger	O
32	physiology	O
33	.	O

1	Looming	O
2	detectors	O
3	in	O
4	the	O
5	human	O
6	visual	O
7	pathway	O
8	.	O

1	Escherichia	O
2	of	O
3	a	O
4	single	O
5	sero	O
6	-	O
7	anzymatic	O
8	type	O
9	(	O
10	06a6b	O
11	:	O
12	K13	O
13	:	O
14	H1	O
15	)	O
16	were	O
17	isolated	O
18	in	O
19	a	O
20	group	O
21	affection	O
22	.	O

1	The	O
2	method	O
3	described	O
4	may	O
5	prove	O
6	useful	O
7	in	O
8	studying	O
9	the	O
10	physiology	O
11	of	O
12	the	O
13	nasal	O
14	cycle	O
15	.	O

1	At	O
2	the	O
3	same	O
4	time	O
5	we	O
6	obtained	O
7	easily	O
8	understandable	O
9	EEG	O
10	-	O
11	information	O
12	which	O
13	has	O
14	never	O
15	previously	O
16	been	O
17	available	O
18	to	O
19	us	O
20	.	O

1	Analysis	O
2	of	O
3	liver	O
4	biopsy	O
5	specimens	O
6	from	O
7	patients	O
8	with	O
9	hepatitis	O
10	showed	O
11	a	O
12	large	O
13	variation	O
14	in	O
15	the	O
16	mean	O
17	iron	O
18	content	O
19	of	O
20	the	O
21	liver	O
22	ferritin	B
23	molecules	O
24	.	O

1	Female	O
2	mice	O
3	were	O
4	significantly	O
5	more	O
6	resistant	O
7	to	O
8	infection	O
9	than	O
10	males	O
11	.	O

1	During	O
2	the	O
3	following	O
4	9	O
5	1	O
6	/	O
7	2	O
8	years	O
9	three	O
10	sequential	O
11	liver	O
12	biopsies	O
13	were	O
14	performed	O
15	.	O

1	Angiotensin	B
2	effect	O
3	in	O
4	the	O
5	human	O
6	kidney	O
7	.	O

1	Procion	O
2	yellow	O
3	dye	O
4	was	O
5	injected	O
6	intracellularly	O
7	into	O
8	large	O
9	auditory	O
10	fibers	O
11	of	O
12	goldfish	O
13	to	O
14	investigate	O
15	the	O
16	relationship	O
17	between	O
18	the	O
19	response	O
20	type	O
21	of	O
22	these	O
23	fibers	O
24	and	O
25	their	O
26	site	O
27	of	O
28	termination	O
29	in	O
30	the	O
31	saccular	O
32	macula	O
33	.	O

1	Incidental	O
2	findings	O
3	in	O
4	the	O
5	epidermis	O
6	and	O
7	in	O
8	the	O
9	intraepidermal	O
10	eccrine	O
11	sweat	O
12	duct	O
13	units	O
14	.	O

1	Silicosis	O
2	mortality	O

1	These	O
2	consisted	O
3	of	O
4	beading	O
5	and	O
6	strictures	O
7	mainly	O
8	of	O
9	the	O
10	intrahepatic	O
11	biliary	O
12	tree	O
13	(	O
14	IHB	O
15	).	O

1	Pentane	O
2	and	O
3	ethane	O
4	,	O
5	which	O
6	arise	O
7	during	O
8	lipid	O
9	peroxidation	O
10	in	O
11	vivo	O
12	,	O
13	were	O
14	measured	O
15	by	O
16	gas	O
17	chromatography	O
18	in	O
19	breath	O
20	samples	O
21	of	O
22	rats	O
23	fed	O
24	for	O
25	8	O
26	weeks	O
27	a	O
28	vitamin	O
29	E	O
30	-	O
31	deficient	O
32	diet	O
33	to	O
34	which	O
35	had	O
36	been	O
37	added	O
38	0	O
39	,	O
40	11	O
41	,	O
42	or	O
43	40	O
44	IU	O
45	vitamin	O
46	E	O
47	acetate	O
48	per	O
49	kg	O
50	.	O

1	Thromboplastic	O
2	and	O
3	fibrynolytic	O
4	activity	O
5	of	O
6	the	O
7	blood	O
8	after	O
9	administration	O
10	of	O
11	intralipid	O
12	in	O
13	men	O
14	with	O
15	history	O
16	of	O
17	myocardial	O
18	infarction	O
19	up	O
20	to	O
21	45	O
22	year	O
23	of	O
24	life	O

1	The	O
2	authors	O
3	report	O
4	the	O
5	clinicopathologic	O
6	findings	O
7	in	O
8	four	O
9	cases	O
10	of	O
11	adult	O
12	women	O
13	with	O
14	rhabdomyosarcomas	O
15	that	O
16	originated	O
17	in	O
18	the	O
19	endometrium	O
20	or	O
21	cervix	O
22	,	O
23	or	O
24	both	O
25	.	O

1	The	O
2	effect	O
3	of	O
4	pure	O
5	natural	O
6	porcine	B
7	secretin	I
8	on	O
9	endocrine	O
10	and	O
11	exocrine	O
12	pancreatic	O
13	secretion	O
14	was	O
15	studied	O
16	in	O
17	the	O
18	totally	O
19	isolated	O
20	perfused	O
21	porcine	O
22	pancreas	O
23	.	O

1	Biometric	O
2	analysis	O
3	of	O
4	intraocular	O
5	lens	O
6	power	O
7	required	O
8	to	O
9	produce	O
10	emmetropia	O
11	:	O
12	results	O
13	of	O
14	450	O
15	implants	O
16	.	O

1	Urine	O
2	antibodies	O
3	could	O
4	not	O
5	be	O
6	demonstrated	O
7	in	O
8	any	O
9	other	O
10	cases	O
11	.	O

1	Althoug	O
2	RBF	O
3	tended	O
4	to	O
5	increase	O
6	after	O
7	the	O
8	therapy	O
9	,	O
10	there	O
11	was	O
12	no	O
13	statistically	O
14	significant	O
15	change	O
16	in	O
17	RBF	O
18	,	O
19	GFR	O
20	and	O
21	cardiac	O
22	output	O
23	.	O

1	99mTc	O
2	phytate	O
3	,	O
4	198Au	O
5	colloid	O
6	,	O
7	and	O
8	99mTc	O
9	antimony	O
10	sulfide	O
11	have	O
12	been	O
13	used	O
14	;	O
15	the	O
16	last	O
17	appears	O
18	to	O
19	have	O
20	been	O
21	the	O
22	most	O
23	satisfactory	O
24	.	O

1	Six	O
2	patients	O
3	with	O
4	glomerulonephritis	O
5	in	O
6	association	O
7	with	O
8	a	O
9	ventriculovascular	O
10	shunt	O
11	were	O
12	treated	O
13	with	O
14	three	O
15	basic	O
16	modes	O
17	of	O
18	therapy	O
19	.	O

1	The	O
2	mass	O
3	of	O
4	UO2	O
5	in	O
6	the	O
7	extrapulmonary	O
8	bronchi	O
9	and	O
10	first	O
11	bifurcation	O
12	decreased	O
13	more	O
14	slowly	O
15	over	O
16	0	O
17	--	O
18	8	O
19	d	O
20	after	O
21	inhalation	O
22	than	O
23	the	O
24	corresponding	O
25	mass	O
26	on	O
27	the	O
28	trachea	O
29	.	O

1	Synovial	O
2	cysts	O
3	of	O
4	the	O
5	hip	O
6	joint	O

1	A	O
2	suspected	O
3	hypothalamic	O
4	dysfunction	O
5	and	O
6	a	O
7	slightly	O
8	impaired	O
9	pituitary	O
10	function	O
11	manifested	O
12	as	O
13	GH	B
14	deficiency	O
15	were	O
16	their	O
17	common	O
18	endocrinological	O
19	features	O
20	.	O

1	A	O
2	sharp	O
3	outbreak	O
4	of	O
5	influenza	O
6	A	O
7	occurred	O
8	on	O
9	the	O
10	base	O
11	during	O
12	February	O
13	that	O
14	was	O
15	due	O
16	to	O
17	an	O
18	A	O
19	/	O
20	Texas	O
21	/	O
22	1	O
23	/	O
24	77	O
25	-	O
26	like	O
27	virus	O
28	,	O
29	a	O
30	variant	O
31	of	O
32	the	O
33	A	O
34	/	O
35	Victoria	O
36	/	O
37	3	O
38	/	O
39	75	O
40	prototpye	O
41	.	O

1	Because	O
2	decreases	O
3	in	O
4	the	O
5	disfluency	O
6	rates	O
7	of	O
8	stutterers	O
9	were	O
10	observed	O
11	during	O
12	the	O
13	presentation	O
14	of	O
15	all	O
16	three	O
17	stimulus	O
18	words	O
19	,	O
20	the	O
21	data	O
22	failed	O
23	to	O
24	support	O
25	the	O
26	operant	O
27	model	O
28	.	O

1	Effect	O
2	of	O
3	time	O
4	and	O
5	dose	O
6	on	O
7	alterations	O
8	following	O
9	inhalation	O
10	of	O
11	plutonium	O
12	-	O
13	239	O
14	dioxide	O
15	aerosol	O
16	in	O
17	rat	O
18	.	O

1	In	O
2	biopsies	O
3	CK	B
4	-	I
5	MB	I
6	fraction	O
7	of	O
8	total	O
9	myocardial	O
10	CPK	B
11	was	O
12	37	O
13	%,	O
14	the	O
15	total	B
16	-	I
17	CPK	I
18	activity	O
19	of	O
20	human	O
21	skeletal	O
22	muscles	O
23	still	O
24	shows	O
25	a	O
26	5	O
27	%	O
28	fraction	O
29	of	O
30	CK	B
31	-	I
32	MB	I
33	.	O

1	Value	O
2	of	O
3	determination	O
4	of	O
5	alkaline	B
6	phosphatase	I
7	isoenzymes	I
8	for	O
9	differential	O
10	diagnosis	O
11	of	O
12	obstructive	O
13	jaundice	O
14	and	O
15	biliary	O
16	liver	O
17	cirrhosis	O

1	A	O
2	one	O
3	-	O
4	way	O
5	analysis	O
6	of	O
7	variance	O
8	,	O
9	performed	O
10	separately	O
11	for	O
12	men	O
13	and	O
14	women	O
15	for	O
16	differences	O
17	among	O
18	the	O
19	three	O
20	phobic	O
21	groups	O
22	on	O
23	field	O
24	dependence	O
25	,	O
26	showed	O
27	significance	O
28	(	O
29	rho	O
30	less	O
31	than	O
32	.	O
33	05	O
34	)	O
35	for	O
36	the	O
37	females	O
38	,	O
39	with	O
40	the	O
41	famale	O
42	agoraphobic	O
43	being	O
44	more	O
45	field	O
46	dependent	O
47	than	O
48	the	O
49	female	O
50	simple	O
51	phobic	O
52	groups	O
53	,	O
54	but	O
55	not	O
56	for	O
57	the	O
58	males	O
59	.	O

1	Several	O
2	free	O
3	2nd	O
4	-	O
5	generation	O
6	schizonts	O
7	,	O
8	which	O
9	varied	O
10	in	O
11	diameter	O
12	from	O
13	11	O
14	to	O
15	21	O
16	.	O
17	6	O
18	micrometer	O
19	,	O
20	were	O
21	found	O
22	on	O
23	the	O
24	epithelial	O
25	surface	O
26	of	O
27	the	O
28	cecum	O
29	.	O

1	The	O
2	calculated	O
3	pD2	O
4	values	O
5	were	O
6	8	O
7	.	O
8	8	O
9	for	O
10	E	O
11	,	O
12	8	O
13	.	O
14	6	O
15	for	O
16	DHE	O
17	and	O
18	6	O
19	.	O
20	6	O
21	for	O
22	M	O
23	.	O

1	Newcastle	O
2	disease	O
3	virus	O
4	surveillance	O
5	in	O
6	Hong	O
7	Kong	O
8	on	O
9	local	O
10	and	O
11	imported	O
12	poultry	O
13	.	O

1	It	O
2	was	O
3	postulated	O
4	that	O
5	persistent	O
6	challenge	O
7	by	O
8	M	O
9	.	O
10	leprae	O
11	or	O
12	its	O
13	antigens	O
14	to	O
15	the	O
16	IgA	B
17	immunocytes	O
18	of	O
19	the	O
20	intestinal	O
21	epithelium	O
22	might	O
23	have	O
24	induced	O
25	tolerance	O
26	leading	O
27	to	O
28	IgA	B
29	deficiency	O
30	and	O
31	subsequent	O
32	subtotal	O
33	atrophy	O
34	of	O
35	the	O
36	intestinal	O
37	villi	O
38	in	O
39	the	O
40	patients	O
41	with	O
42	lepromatous	O
43	leprosy	O
44	.	O

1	Treatment	O
2	of	O
3	hypertension	O
4	with	O
5	a	O
6	combination	O
7	of	O
8	the	O
9	adrenergic	B
10	beta	I
11	receptor	I
12	blockader	O
13	,	O
14	obsidan	O
15	,	O
16	and	O
17	the	O
18	vasodilator	O
19	,	O
20	apressin	O

1	Orthop	O
2	.	O

1	Thyroid	O
2	disease	O
3	and	O
4	pregnancy	O
5	.	O

1	Residues	O
2	removed	O
3	from	O
4	transcripts	O
5	by	O
6	splicing	O
7	were	O
8	identified	O
9	.	O

1	To	O
2	minimize	O
3	reflux	O
4	into	O
5	the	O
6	blind	O
7	loop	O
8	,	O
9	a	O
10	number	O
11	of	O
12	technical	O
13	steps	O
14	are	O
15	considered	O
16	indispensable	O
17	:	O
18	1	O
19	)	O
20	fluted	O
21	section	O
22	of	O
23	the	O
24	jejunal	O
25	stump	O
26	;	O
27	2	O
28	)	O
29	isoperistaltic	O
30	construction	O
31	of	O
32	the	O
33	anastomosis	O
34	and	O
35	,	O
36	particularly	O
37	,	O
38	3	O
39	)	O
40	the	O
41	creation	O
42	of	O
43	a	O
44	single	O
45	or	O
46	double	O
47	valve	O
48	system	O
49	upstream	O
50	from	O
51	the	O
52	anastomosis	O
53	by	O
54	spiral	O
55	introflexion	O
56	of	O
57	the	O
58	mucosa	O
59	using	O
60	seroserous	O
61	stitches	O
62	parallel	O
63	and	O
64	perpendicular	O
65	to	O
66	the	O
67	ileal	O
68	lumen	O
69	.	O

1	At	O
2	this	O
3	stage	O
4	,	O
5	the	O
6	eventual	O
7	high	O
8	mortality	O
9	of	O
10	acute	O
11	ischemia	O
12	is	O
13	established	O
14	whatever	O
15	the	O
16	urgency	O
17	of	O
18	the	O
19	operation	O
20	or	O
21	the	O
22	skill	O
23	with	O
24	which	O
25	it	O
26	is	O
27	performed	O
28	.	O

1	Pathogens	O
2	(	O
3	Staphylococcus	O
4	aureus	O
5	or	O
6	Gram	O
7	-	O
8	negative	O
9	bacilli	O
10	)	O
11	were	O
12	isolated	O
13	from	O
14	only	O
15	one	O
16	member	O
17	of	O
18	staff	O
19	in	O
20	small	O
21	numbers	O
22	and	O
23	irregularly	O
24	and	O
25	rarely	O
26	in	O
27	large	O
28	numbers	O
29	from	O
30	patients	O
31	.	O

1	The	O
2	histochemistry	O
3	and	O
4	ultrastructure	O
5	of	O
6	calcified	O
7	cerebellar	O
8	deposits	O
9	described	O
10	by	O
11	Tonge	O
12	et	O
13	al	O
14	.	O

1	A	O
2	36	O
3	year	O
4	-	O
5	old	O
6	woman	O
7	was	O
8	given	O
9	Ergotamine	O
10	Tartrate	O
11	4	O
12	.	O
13	5	O
14	mg	O
15	p	O
16	.	O
17	d	O
18	.	O
19	during	O
20	seven	O
21	days	O
22	,	O
23	after	O
24	an	O
25	abortion	O
26	(	O
27	a	O
28	still	O
29	birth	O
30	).	O

1	Reaction	O
2	times	O
3	to	O
4	tachistoscopically	O
5	presented	O
6	stimuli	O
7	in	O
8	diabetics	O

1	Two	O
2	out	O
3	of	O
4	five	O
5	patients	O
6	undergoing	O
7	selective	O
8	spinal	O
9	arteriography	O
10	developed	O
11	transient	O
12	neurological	O
13	complications	O
14	during	O
15	the	O
16	injection	O
17	of	O
18	Urografin	O
19	310	O
20	M	O
21	.	O

1	The	O
2	data	O
3	indicate	O
4	a	O
5	three	O
6	-	O
7	phase	O
8	reaction	O
9	after	O
10	B1	O
11	injection	O
12	:	O
13	Phase	O
14	1	O
15	--	O
16	shortly	O
17	after	O
18	injection	O
19	there	O
20	is	O
21	a	O
22	drop	O
23	of	O
24	all	O
25	parameters	O
26	lasting	O
27	for	O
28	30	O
29	sec	O
30	.	O

1	Serum	B
2	relaxin	I
3	levels	O
4	in	O
5	prostaglandin	O
6	E2	O
7	induced	O
8	abortions	O
9	.	O

1	A	O
2	--	O
3	A	O
4	natural	O
5	hydrostatic	O
6	phenomenon	O
7	,	O
8	at	O
9	the	O
10	level	O
11	of	O
12	the	O
13	ends	O
14	of	O
15	the	O
16	plantar	O
17	arcs	O
18	,	O
19	diffuses	O
20	body	O
21	weight	O
22	,	O
23	as	O
24	PAIN	O
25	plays	O
26	the	O
27	role	O
28	of	O
29	outsentry	O
30	(	O
31	fig	O
32	.--	O
33	1	O
34	)	O
35	(	O
36	5	O
37	);	O
38	B	O
39	--	O
40	Plantar	O
41	perforating	O
42	ulceration	O
43	(	O
44	PPU	O
45	)	O
46	is	O
47	caused	O
48	by	O
49	a	O
50	combination	O
51	of	O
52	INSENSITIVITY	O
53	and	O
54	TRAUMATIS	O
55	(	O
56	1	O
57	);	O
58	C	O
59	--	O
60	The	O
61	patient	O
62	reposing	O
63	,	O
64	as	O
65	body	O
66	weight	O
67	(	O
68	traumatism	O
69	)	O
70	effects	O
71	disappear	O
72	,	O
73	cicatrization	O
74	process	O
75	can	O
76	be	O
77	easily	O
78	observed	O
79	;	O
80	D	O
81	--	O
82	PNEUMATIC	O
83	INSOLE	O
84	,	O
85	being	O
86	elastic	O
87	,	O
88	diffuses	O
89	localized	O
90	compression	O
91	at	O
92	the	O
93	ends	O
94	of	O
95	the	O
96	plantar	O
97	arcs	O
98	,	O
99	reduces	O
100	attrition	O
101	,	O
102	makes	O
103	easier	O
104	blood	O
105	circulation	O
106	,	O
107	as	O
108	well	O
109	as	O
110	cure	O
111	and	O
112	prophylaxis	O
113	of	O
114	PPU	O
115	(	O
116	fig	O
117	.--	O
118	6	O
119	)	O
120	(	O
121	3	O
122	).	O

1	Effect	O
2	of	O
3	indoramin	O
4	in	O
5	small	O
6	doses	O
7	on	O
8	the	O
9	central	O
10	vasomotor	O
11	loci	O
12	has	O
13	been	O
14	studied	O
15	in	O
16	chloralose	O
17	anesthetized	O
18	cats	O
19	by	O
20	localizing	O
21	it	O
22	to	O
23	the	O
24	central	O
25	sites	O
26	.	O

1	As	O
2	expected	O
3	,	O
4	the	O
5	heparin	O
6	did	O
7	produce	O
8	increased	O
9	recalcification	O
10	times	O
11	and	O
12	the	O
13	development	O
14	of	O
15	occasional	O
16	subcutaneous	O
17	hematomas	O
18	.	O

1	Contingency	O
2	contracting	O
3	between	O
4	clients	O
5	and	O
6	their	O
7	parents	O
8	/	O
9	caregivers	O
10	was	O
11	used	O
12	to	O
13	specify	O
14	consequences	O
15	for	O
16	daily	O
17	self	O
18	-	O
19	monitoring	O
20	,	O
21	reduced	O
22	caloric	O
23	intake	O
24	,	O
25	weight	O
26	loss	O
27	,	O
28	and	O
29	exercise	O
30	.	O

1	Dietetics	O
2	of	O
3	childhood	O
4	-	O
5	and	O
6	juvenile	O
7	diabetes	O

1	The	O
2	results	O
3	of	O
4	a	O
5	quantitative	O
6	study	O
7	of	O
8	vasculosyncytial	O
9	membranes	O
10	in	O
11	123	O
12	placentas	O
13	are	O
14	presented	O
15	.	O

1	The	O
2	micromethod	O
3	uses	O
4	microcuvettes	O
5	and	O
6	substitutes	O
7	ferrozine	O
8	for	O
9	the	O
10	bathophenanthroline	O
11	chromogen	O
12	of	O
13	the	O
14	ICSH	O
15	.	O

1	Platelet	O
2	serotonin	O
3	(	O
4	5	O
5	-	O
6	HT	O
7	)	O
8	and	O
9	5	B
10	-	I
11	HT	I
12	releasing	I
13	factor	I
14	in	O
15	plasma	O
16	of	O
17	migrainous	O
18	patients	O
19	.	O

1	The	O
2	overall	O
3	incidence	O
4	of	O
5	SIDS	O
6	was	O
7	1	O
8	.	O
9	43	O
10	per	O
11	1	O
12	,	O
13	000	O
14	live	O
15	births	O
16	.	O

1	The	O
2	vigilance	O
3	task	O
4	and	O
5	the	O
6	measurement	O
7	of	O
8	attentional	O
9	deficits	O
10	.	O

1	The	O
2	December	O
3	armed	O
4	revolt	O
5	in	O
6	Moscow	O
7	and	O
8	the	O
9	paramedical	O
10	personnel	O

1	Significant	O
2	increases	O
3	in	O
4	mean	O
5	serum	O
6	E2	O
7	concentration	O
8	(	O
9	100	O
10	to	O
11	150	O
12	pg	O
13	/	O
14	ml	O
15	)	O
16	were	O
17	noted	O
18	at	O
19	6	O
20	and	O
21	8	O
22	hours	O
23	after	O
24	administration	O
25	on	O
26	day	O
27	1	O
28	and	O
29	at	O
30	8	O
31	hours	O
32	on	O
33	day	O
34	4	O
35	.	O

1	The	O
2	motor	O
3	unit	O
4	viewed	O
5	from	O
6	above	O
7	.	O

1	Avian	O
2	reproductive	O
3	system	O
4	:	O
5	daily	O
6	variations	O
7	in	O
8	responses	O
9	to	O
10	hormones	O
11	.	O

1	Biological	O
2	properties	O
3	of	O
4	sumithion	O
5	.	O

1	Serological	O
2	studies	O
3	of	O
4	antibodies	O
5	to	O
6	Epstein	O
7	-	O
8	Barr	O
9	virus	O
10	in	O
11	infectious	O
12	mononucleosis	O

1	Carcinoembryonic	B
2	antigen	I
3	(	O
4	CEA	B
5	)	O
6	procedures	O
7	and	O
8	clinical	O
9	evaluation	O
10	.	O

1	We	O
2	remain	O
3	convinced	O
4	that	O
5	antilymphocyte	B
6	globulin	I
7	(	O
8	ALG	B
9	)	O
10	is	O
11	a	O
12	potent	O
13	immunosuppressive	O
14	agent	O
15	in	O
16	humans	O
17	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	global	O
7	assessment	O
8	patients	O
9	showed	O
10	a	O
11	highly	O
12	significant	O
13	preference	O
14	for	O
15	imipramine	O
16	compared	O
17	with	O
18	placebo	O
19	as	O
20	adjunctive	O
21	therapy	O
22	.	O

1	39	O
2	-	O
3	47	O
4	.	O

1	Patients	O
2	were	O
3	subclassified	O
4	into	O
5	age	O
6	-	O
7	matched	O
8	groups	O
9	of	O
10	primary	O
11	untreated	O
12	cancer	O
13	(	O
14	21	O
15	),	O
16	recurrent	O
17	cancer	O
18	(	O
19	18	O
20	),	O
21	and	O
22	"	O
23	cured	O
24	"	O
25	patients	O
26	who	O
27	had	O
28	been	O
29	free	O
30	of	O
31	disease	O
32	for	O
33	at	O
34	least	O
35	9	O
36	months	O
37	(	O
38	16	O
39	).	O

1	Absorption	O
2	varied	O
3	between	O
4	65	O
5	and	O
6	95	O
7	per	O
8	cent	O
9	,	O
10	with	O
11	a	O
12	mean	O
13	absorption	O
14	of	O
15	80	O
16	per	O
17	cent	O
18	,	O
19	in	O
20	both	O
21	pregnant	O
22	and	O
23	non	O
24	-	O
25	pregnant	O
26	subjects	O
27	.	O

1	Bacteriostatic	O
2	and	O
3	bacteriacidal	O
4	activity	O
5	of	O
6	hydroxy	O
7	-	O
8	9	O
9	ellipticine	O
10	in	O
11	vitro	O

1	Advances	O
2	in	O
3	the	O
4	management	O
5	of	O
6	gynecologic	O
7	cancer	O
8	--	O
9	radiation	O
10	therapy	O
11	.	O

1	The	O
2	clinico	O
3	-	O
4	pathological	O
5	data	O
6	from	O
7	a	O
8	patient	O
9	with	O
10	irreversible	O
11	post	O
12	-	O
13	partum	O
14	renal	O
15	failure	O
16	(	O
17	IPRF	O
18	)	O
19	are	O
20	presented	O
21	.	O

1	Personal	O
2	satisfaction	O
3	in	O
4	nursing	O
5	:	O
6	an	O
7	encounter	O
8	with	O
9	extremely	O
10	hostile	O
11	patients	O

1	Dialyzable	O
2	transfer	B
3	factor	I
4	.	O

1	19	O
2	-	O
3	32	O
4	.	O

1	Rheumatoid	B
2	factor	I
3	and	O
4	antinuclear	O
5	antibody	O
6	tests	O
7	were	O
8	frequently	O
9	positive	O
10	,	O
11	and	O
12	reactions	O
13	to	O
14	gold	O
15	therapy	O
16	were	O
17	more	O
18	frequent	O
19	than	O
20	in	O
21	other	O
22	rheumatoid	O
23	populations	O
24	.	O

1	The	O
2	effect	O
3	of	O
4	hydrostatic	O
5	pressure	O
6	on	O
7	the	O
8	swimming	O
9	activity	O
10	of	O
11	three	O
12	hyponeustonic	O
13	crustacea	O
14	,	O
15	Anomalocera	O
16	patersoni	O
17	,	O
18	Pontella	O
19	mediterranea	O
20	,	O
21	Labidocera	O
22	wollastoni	O

1	This	O
2	report	O
3	presents	O
4	an	O
5	analysis	O
6	of	O
7	the	O
8	vocal	O
9	repertoire	O
10	of	O
11	howler	O
12	monkeys	O
13	(	O
14	Alouatta	O
15	palliata	O
16	)	O
17	observed	O
18	during	O
19	a	O
20	field	O
21	study	O
22	in	O
23	southwestern	O
24	Panama	O
25	.	O

1	Up	O
2	to	O
3	now	O
4	the	O
5	number	O
6	of	O
7	patients	O
8	examined	O
9	is	O
10	about	O
11	300	O
12	,	O
13	additionally	O
14	6	O
15	persons	O
16	who	O
17	underwent	O
18	binephrectomy	O
19	.	O

1	Deflunia	O
2	was	O
3	well	O
4	tolerated	O
5	by	O
6	25	O
7	patients	O
8	,	O
9	very	O
10	well	O
11	tolerated	O
12	by	O
13	2	O
14	.	O

1	III	O
2	.	O

1	A	O
2	new	O
3	instrument	O
4	has	O
5	been	O
6	designed	O
7	for	O
8	freeze	O
9	-	O
10	fracturing	O
11	of	O
12	biological	O
13	material	O
14	in	O
15	ultra	O
16	high	O
17	vacuum	O
18	.	O

1	Pancreatic	O
2	and	O
3	biliary	O
4	secretion	O
5	and	O
6	gastric	O
7	emptying	O
8	rates	O
9	of	O
10	a	O
11	liquid	O
12	test	O
13	meal	O
14	(	O
15	LTM	O
16	)	O
17	were	O
18	determined	O
19	in	O
20	normal	O
21	persons	O
22	,	O
23	in	O
24	patients	O
25	with	O
26	subtotal	O
27	gastrectomy	O
28	with	O
29	gastroduodenostomy	O
30	(	O
31	STG	O
32	-	O
33	BI	O
34	)	O
35	or	O
36	with	O
37	gastrojejunostomy	O
38	(	O
39	STG	O
40	-	O
41	BII	O
42	),	O
43	and	O
44	in	O
45	patients	O
46	with	O
47	truncal	O
48	vagotomy	O
49	and	O
50	pyloroplasty	O
51	(	O
52	V	O
53	&	O
54	P	O
55	).	O

1	Abnormal	O
2	calcium	O
3	metabolism	O
4	in	O
5	normocalcaemic	O
6	sarcoidosis	O
7	.	O

1	Also	O
2	,	O
3	except	O
4	in	O
5	one	O
6	patient	O
7	who	O
8	developed	O
9	gallstones	O
10	following	O
11	institution	O
12	of	O
13	colestipol	O
14	,	O
15	saturation	O
16	of	O
17	gallbladder	O
18	bile	O
19	with	O
20	cholesterol	O
21	was	O
22	not	O
23	markedly	O
24	increased	O
25	by	O
26	this	O
27	drug	O
28	alone	O
29	.	O

1	A	O
2	five	O
3	-	O
4	phase	O
5	experiment	O
6	was	O
7	designed	O
8	to	O
9	investigate	O
10	(	O
11	a	O
12	)	O
13	whether	O
14	contingent	O
15	music	O
16	-	O
17	listening	O
18	would	O
19	act	O
20	as	O
21	a	O
22	reinforcer	O
23	to	O
24	increase	O
25	arithmetic	O
26	performance	O
27	of	O
28	EMR	O
29	children	O
30	and	O
31	(	O
32	b	O
33	)	O
34	whether	O
35	this	O
36	contingent	O
37	reinforcement	O
38	would	O
39	affect	O
40	preference	O
41	for	O
42	that	O
43	reinforcer	O
44	.	O

1	The	O
2	responsiveness	O
3	of	O
4	visual	O
5	cortex	O
6	(	O
7	VC	O
8	)	O
9	and	O
10	superior	O
11	colliculus	O
12	(	O
13	SC	O
14	)	O
15	was	O
16	simultaneously	O
17	compared	O
18	following	O
19	conditioning	O
20	"	O
21	ON	O
22	"	O
23	or	O
24	"	O
25	OFF	O
26	"	O
27	stimulation	O
28	,	O
29	in	O
30	the	O
31	rabbit	O
32	.	O

1	A	O
2	diagnosis	O
3	of	O
4	MS	O
5	was	O
6	made	O
7	based	O
8	on	O
9	subtle	O
10	neurologic	O
11	signs	O
12	,	O
13	spinal	O
14	fluid	O
15	gamma	B
16	globulin	I
17	elevations	O
18	,	O
19	and	O
20	abnormalities	O
21	in	O
22	neuropsychological	O
23	testing	O
24	.	O

1	If	O
2	,	O
3	however	O
4	,	O
5	the	O
6	mean	O
7	temperature	O
8	rise	O
9	was	O
10	higher	O
11	(	O
12	0	O
13	.	O
14	57	O
15	degrees	O
16	C	O
17	or	O
18	0	O
19	.	O
20	69	O
21	degrees	O
22	C	O
23	),	O
24	such	O
25	a	O
26	selection	O
27	practically	O
28	resulted	O
29	in	O
30	the	O
31	disappearance	O
32	of	O
33	'	O
34	passable	O
35	'	O
36	qualifications	O
37	in	O
38	the	O
39	triplet	O
40	groups	O
41	and	O
42	a	O
43	great	O
44	predominance	O
45	of	O
46	'	O
47	to	O
48	be	O
49	rejected	O
50	'	O
51	qualifications	O
52	in	O
53	the	O
54	large	O
55	groups	O
56	.	O

1	The	O
2	elevated	O
3	Viso	O
4	V	O
5	in	O
6	the	O
7	RDS	O
8	group	O
9	suggests	O
10	an	O
11	increase	O
12	in	O
13	small	O
14	airway	O
15	resistance	O
16	secondary	O
17	to	O
18	the	O
19	disease	O
20	or	O
21	to	O
22	its	O
23	therapy	O
24	.	O

1	The	O
2	psychological	O
3	tests	O
4	consisted	O
5	of	O
6	a	O
7	free	O
8	-	O
9	recall	O
10	task	O
11	,	O
12	a	O
13	test	O
14	for	O
15	visuomotor	O
16	coordination	O
17	and	O
18	a	O
19	recognition	O
20	task	O
21	.	O

1	Selective	O
2	bronchial	O
3	intubation	O
4	in	O
5	the	O
6	management	O
7	of	O
8	unilateral	O
9	pulmonary	O
10	interstitial	O
11	emphysema	O
12	.	O

1	The	O
2	background	O
3	processes	O
4	depending	O
5	on	O
6	the	O
7	etiological	O
8	factor	O
9	and	O
10	the	O
11	character	O
12	of	O
13	lesion	O
14	of	O
15	the	O
16	epithelium	O
17	are	O
18	divided	O
19	into	O
20	dyshormonal	O
21	,	O
22	inflammatory	O
23	,	O
24	and	O
25	posttraumatic	O
26	.	O

1	The	O
2	sense	O
3	of	O
4	self	O
5	.	O

1	Eleven	O
2	strains	O
3	of	O
4	Fusarium	O
5	poae	O
6	and	O
7	F	O
8	.	O
9	sporotrichioides	O
10	from	O
11	the	O
12	U	O
13	.	O
14	S	O
15	.	O
16	S	O
17	.	O
18	R	O
19	.	O
20	and	O
21	7	O
22	strains	O
23	of	O
24	these	O
25	species	O
26	and	O
27	one	O
28	of	O
29	F	O
30	.	O
31	sporotrichioides	O
32	var	O
33	.	O
34	tricinctum	O
35	from	O
36	U	O
37	.	O
38	S	O
39	.	O
40	A	O
41	.	O
42	and	O
43	France	O
44	have	O
45	been	O
46	compared	O
47	as	O
48	to	O
49	their	O
50	capacity	O
51	to	O
52	yield	O
53	T	B
54	-	I
55	2	I
56	toxin	I
57	.	O

1	Current	O
2	diagnostic	O
3	uses	O
4	of	O
5	computerized	O
6	tomography	O
7	in	O
8	clinical	O
9	medicine	O
10	.	O

1	A	O
2	follow	O
3	-	O
4	up	O
5	study	O
6	of	O
7	22	O
8	patients	O
9	with	O
10	Ebstein	O
11	'	O
12	s	O
13	anomaly	O
14	has	O
15	been	O
16	performed	O
17	.	O

1	Deaths	O
2	stopped	O
3	11	O
4	hours	O
5	after	O
6	copper	O
7	concentrations	O
8	decreased	O
9	below	O
10	0	O
11	.	O
12	2	O
13	ppm	O
14	and	O
15	signs	O
16	of	O
17	distress	O
18	stopped	O
19	in	O
20	surviving	O
21	pinfish	O
22	by	O
23	approximately	O
24	6	O
25	hours	O
26	after	O
27	the	O
28	last	O
29	death	O
30	.	O

1	Recurrence	O
2	of	O
3	bladder	O
4	tumors	O
5	among	O
6	the	O
7	original	O
8	9	O
9	cases	O
10	has	O
11	occurred	O
12	only	O
13	among	O
14	the	O
15	5	O
16	whose	O
17	properdin	B
18	levels	O
19	remained	O
20	below	O
21	the	O
22	median	O
23	.	O

1	Adaptation	O
2	of	O
3	taurocholate	O
4	transport	O
5	maximum	O
6	to	O
7	increased	O
8	secretory	O
9	load	O
10	in	O
11	the	O
12	rat	O
13	.	O

1	Dangers	O
2	in	O
3	use	O
4	of	O
5	live	O
6	-	O
7	virus	O
8	vaccines	O
9	.	O

1	Treatment	O
2	with	O
3	heparin	O
4	,	O
5	plasminogen	B
6	activators	O
7	and	O
8	fibrinogenolytic	O
9	agents	O
10	was	O
11	disappointing	O
12	although	O
13	renal	O
14	function	O
15	has	O
16	stabilized	O
17	in	O
18	one	O
19	patient	O
20	on	O
21	long	O
22	term	O
23	oral	O
24	anticoagulant	O
25	therapy	O
26	.	O

1	In	O
2	diethyl	O
3	ether	O
4	solution	O
5	the	O
6	main	O
7	peak	O
8	is	O
9	that	O
10	of	O
11	2	O
12	-	O
13	benzylidenamio	O
14	-	O
15	1	O
16	-	O
17	phenylpropane	O
18	,	O
19	which	O
20	has	O
21	a	O
22	retention	O
23	time	O
24	of	O
25	23	O
26	,	O
27	2	O
28	minutes	O
29	under	O
30	the	O
31	condition	O
32	delineated	O
33	.	O

1	Amikacin	O
2	was	O
3	used	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	56	O
9	serious	O
10	gram	O
11	-	O
12	negative	O
13	infections	O
14	in	O
15	54	O
16	patients	O
17	of	O
18	whom	O
19	47	O
20	survived	O
21	.	O

1	The	O
2	data	O
3	normally	O
4	available	O
5	are	O
6	insufficient	O
7	and	O
8	take	O
9	no	O
10	account	O
11	of	O
12	the	O
13	direction	O
14	of	O
15	recirculation	O
16	,	O
17	which	O
18	may	O
19	be	O
20	a	O
21	determining	O
22	factor	O
23	.	O

1	During	O
2	activity	O
3	III	O
4	,	O
5	one	O
6	patient	O
7	developed	O
8	angina	O
9	.	O

1	Estimation	O
2	of	O
3	L	O
4	-	O
5	alanine	O
6	in	O
7	serum	O
8	or	O
9	plasma	O
10	using	O
11	the	O
12	LKB	O
13	reaction	O
14	rate	O
15	analyser	O
16	.	O

1	The	O
2	acids	O
3	were	O
4	obtained	O
5	by	O
6	hydrolysis	O
7	of	O
8	the	O
9	corresponding	O
10	esters	O
11	,	O
12	and	O
13	their	O
14	anti	O
15	-	O
16	inflammatory	O
17	activity	O
18	was	O
19	tested	O
20	.	O

1	Unrecognized	O
2	amnionitis	O
3	and	O
4	prematurity	O
5	:	O
6	a	O
7	preliminary	O
8	report	O
9	.	O

1	Evaluation	O
2	of	O
3	the	O
4	new	O
5	Gravigard	O
6	IUCD	O
7	inserter	O
8	.	O

1	Bacterial	O
2	meningitis	O
3	secondary	O
4	to	O
5	abscess	O
6	of	O
7	the	O
8	nasal	O
9	septum	O
10	.	O

1	Serum	B
2	amylase	I
3	became	O
4	markedly	O
5	elevated	O
6	(	O
7	2	O
8	,	O
9	624	O
10	CU	O
11	/	O
12	100	O
13	ml	O
14	),	O
15	as	O
16	did	O
17	the	O
18	serum	O
19	FFA	O
20	(	O
21	29	O
22	.	O
23	19	O
24	mEq	O
25	/	O
26	liter	O
27	).	O

1	In	O
2	the	O
3	control	O
4	preparation	O
5	before	O
6	weight	O
7	was	O
8	allowed	O
9	to	O
10	increase	O
11	,	O
12	isogravimetric	O
13	capillary	O
14	pressure	O
15	(	O
16	Pci	O
17	)	O
18	averaged	O
19	8	O
20	mmHg	O
21	lower	O
22	than	O
23	colloid	O
24	osmotic	O
25	pressure	O
26	of	O
27	the	O
28	plasma	O
29	(	O
30	IIp	O
31	).	O

1	Infants	O
2	who	O
3	died	O
4	in	O
5	the	O
6	first	O
7	12	O
8	hours	O
9	from	O
10	'	O
11	IVH	O
12	only	O
13	'	O
14	had	O
15	suffered	O
16	severe	O
17	birth	O
18	asphyxia	O
19	but	O
20	in	O
21	those	O
22	who	O
23	died	O
24	later	O
25	the	O
26	main	O
27	symptom	O
28	was	O
29	recurrent	O
30	apnoea	O
31	.	O

1	The	O
2	morphological	O
3	effects	O
4	of	O
5	two	O
6	snake	O
7	venoms	O
8	,	O
9	N	O
10	.	O
11	naja	O
12	and	O
13	A	O
14	.	O
15	piscivorus	O
16	,	O
17	and	O
18	of	O
19	the	O
20	Direct	B
21	Lytic	I
22	Factor	I
23	and	O
24	Phospholipase	B
25	-	I
26	A	I
27	,	O
28	compounds	O
29	purified	O
30	from	O
31	N	O
32	.	O
33	naja	O
34	crude	O
35	venom	O
36	,	O
37	were	O
38	investigated	O
39	on	O
40	lung	O
41	and	O
42	cremaster	O
43	vessels	O
44	of	O
45	rats	O
46	.	O

1	Since	O
2	GAGs	O
3	are	O
4	the	O
5	components	O
6	of	O
7	cartilage	O
8	matrix	O
9	,	O
10	the	O
11	depletion	O
12	of	O
13	which	O
14	is	O
15	associated	O
16	with	O
17	osteoarthrosis	O
18	,	O
19	a	O
20	method	O
21	for	O
22	measuring	O
23	sulphated	O
24	GAG	O
25	synthesis	O
26	in	O
27	culture	O
28	has	O
29	been	O
30	investigated	O
31	.	O

1	The	O
2	length	O
3	scales	O
4	of	O
5	the	O
6	turbulence	O
7	were	O
8	also	O
9	estimated	O
10	:	O
11	at	O
12	a	O
13	Reynolds	O
14	number	O
15	near	O
16	4	O
17	,	O
18	000	O
19	the	O
20	macroscale	O
21	is	O
22	about	O
23	1	O
24	.	O
25	25	O
26	mm	O
27	,	O
28	the	O
29	Taylor	O
30	microscale	O
31	is	O
32	about	O
33	0	O
34	.	O
35	85	O
36	mm	O
37	,	O
38	and	O
39	the	O
40	Kolmogoroff	O
41	scale	O
42	is	O
43	near	O
44	0	O
45	.	O
46	075	O
47	mm	O
48	.	O

1	Well	O
2	-	O
3	visualised	O
4	arteriograms	O
5	of	O
6	the	O
7	limbs	O
8	can	O
9	be	O
10	obtained	O
11	by	O
12	xeroradiography	O
13	after	O
14	rapid	O
15	manual	O
16	injection	O
17	of	O
18	contrast	O
19	-	O
20	medium	O
21	into	O
22	an	O
23	arm	O
24	vein	O
25	,	O
26	as	O
27	demonstrated	O
28	in	O
29	28	O
30	patients	O
31	.	O

1	No	O
2	hypotension	O
3	was	O
4	noted	O
5	in	O
6	patients	O
7	with	O
8	toxemia	O
9	and	O
10	only	O
11	2	O
12	ran	O
13	a	O
14	fever	O
15	above	O
16	37	O
17	.	O
18	5	O
19	degrees	O
20	C	O
21	.	O

1	The	O
2	sera	O
3	and	O
4	nasal	O
5	secretions	O
6	of	O
7	142	O
8	patients	O
9	,	O
10	who	O
11	were	O
12	positive	O
13	in	O
14	HD	O
15	or	O
16	mites	O
17	skin	O
18	test	O
19	,	O
20	were	O
21	subjected	O
22	to	O
23	a	O
24	radioallergosorbent	O
25	test	O
26	(	O
27	RAST	O
28	)	O
29	for	O
30	estimating	O
31	the	O
32	specific	O
33	IgE	B
34	antibody	I
35	activity	O
36	to	O
37	mites	O
38	.	O

1	Wherever	O
2	the	O
3	site	O
4	of	O
5	the	O
6	conditioning	O
7	stimulation	O
8	,	O
9	these	O
10	modifications	O
11	disappeared	O
12	after	O
13	ischaemia	O
14	of	O
15	the	O
16	leg	O
17	.	O

1	Diallylnitrosamine	O
2	(	O
3	DAN	O
4	),	O
5	one	O
6	of	O
7	the	O
8	few	O
9	nitrosamines	O
10	tested	O
11	thus	O
12	far	O
13	that	O
14	has	O
15	not	O
16	induced	O
17	neoplasms	O
18	in	O
19	rats	O
20	,	O
21	caused	O
22	a	O
23	high	O
24	incidence	O
25	of	O
26	respiratory	O
27	tract	O
28	tumors	O
29	in	O
30	Syrian	O
31	golden	O
32	hamsters	O
33	treated	O
34	sc	O
35	with	O
36	single	O
37	or	O
38	weekly	O
39	doses	O
40	of	O
41	the	O
42	compound	O
43	.	O

1	Near	O
2	term	O
3	,	O
4	under	O
5	experimental	O
6	conditions	O
7	,	O
8	maternal	O
9	and	O
10	fetal	O
11	blood	O
12	gases	O
13	,	O
14	pH	O
15	,	O
16	uterine	O
17	and	O
18	umbilical	O
19	blood	O
20	flows	O
21	were	O
22	measured	O
23	or	O
24	calculated	O
25	.	O

1	Haemodynamic	O
2	responses	O
3	to	O
4	antagonism	O
5	of	O
6	bocurarine	O
7	block	O
8	with	O
9	atropine	O
10	-	O
11	neostigmine	O
12	mixture	O
13	in	O
14	children	O
15	.	O

1	The	O
2	mechanism	O
3	by	O
4	which	O
5	large	O
6	molecules	O
7	,	O
8	such	O
9	as	O
10	the	O
11	diphosphonate	O
12	99mTc	O
13	-	O
14	labeled	O
15	EHDP	O
16	or	O
17	99mTc	O
18	-	O
19	labeled	O
20	pyrophosphate	O
21	,	O
22	pass	O
23	through	O
24	capillaries	O
25	in	O
26	bone	O
27	is	O
28	by	O
29	passive	O
30	diffusion	O
31	.	O

1	Twenty	O
2	-	O
3	nine	O
4	days	O
5	after	O
6	injection	O
7	of	O
8	5	O
9	.	O
10	8	O
11	mCi	O
12	of	O
13	Tc	O
14	-	O
15	99m	O
16	,	O
17	which	O
18	gives	O
19	28	O
20	rads	O
21	to	O
22	the	O
23	testis	O
24	,	O
25	the	O
26	number	O
27	of	O
28	sperm	O
29	hads	O
30	decreased	O
31	to	O
32	70	O
33	%	O
34	of	O
35	control	O
36	.	O

1	Self	O
2	-	O
3	emasculation	O
4	is	O
5	the	O
6	end	O
7	result	O
8	of	O
9	an	O
10	unusual	O
11	psychiatric	O
12	disorder	O
13	,	O
14	which	O
15	initially	O
16	requires	O
17	surgical	O
18	treatment	O
19	.	O

1	Possibility	O
2	of	O
3	a	O
4	TSH	B
5	-	O
6	Screening	O
7	method	O
8	for	O
9	detection	O
10	of	O
11	hypothyroidism	O
12	in	O
13	the	O
14	newborn	O

1	Thus	O
2	analysis	O
3	indicated	O
4	no	O
5	reliable	O
6	evidence	O
7	that	O
8	conscious	O
9	presleep	O
10	suggestions	O
11	become	O
12	incorporated	O
13	into	O
14	dream	O
15	content	O
16	.	O

1	The	O
2	prevalence	O
3	of	O
4	hepatitis	B
5	B	I
6	surface	I
7	antigen	I
8	(	O
9	HBsAg	B
10	)	O
11	and	O
12	anti	B
13	-	I
14	HBs	I
15	was	O
16	determined	O
17	by	O
18	a	O
19	sensitive	O
20	double	O
21	-	O
22	antibody	O
23	radio	O
24	-	O
25	immunoassay	O
26	technique	O
27	in	O
28	a	O
29	series	O
30	of	O
31	patients	O
32	with	O
33	chronic	O
34	liver	O
35	diseases	O
36	.	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	patients	O
6	with	O
7	acute	O
8	respiratory	O
9	failure	O
10	requiring	O
11	artificial	O
12	ventilation	O
13	have	O
14	two	O
15	componenents	O
16	of	O
17	the	O
18	pulmonary	O
19	shunt	O
20	,	O
21	one	O
22	parallel	O
23	with	O
24	and	O
25	the	O
26	other	O
27	inversely	O
28	related	O
29	with	O
30	the	O
31	PAO2	O
32	.	O

1	Decreased	O
2	cardiac	O
3	glycogen	O
4	following	O
5	phenformin	O
6	injection	O
7	in	O
8	hyperglycemic	O
9	,	O
10	hyperinsulinemic	O
11	anaesthetized	O
12	rats	O
13	.	O

1	Biological	O
2	evaluation	O
3	of	O
4	mibolerone	O
5	in	O
6	the	O
7	female	O
8	Beagle	O
9	.	O

1	Levels	O
2	of	O
3	both	O
4	PGF	O
5	and	O
6	PGFM	O
7	were	O
8	significantly	O
9	higher	O
10	during	O
11	early	O
12	spontaneous	O
13	labour	O
14	,	O
15	at	O
16	a	O
17	cervical	O
18	dilatation	O
19	of	O
20	less	O
21	than	O
22	4	O
23	cm	O
24	,	O
25	than	O
26	before	O
27	the	O
28	onset	O
29	of	O
30	labour	O
31	.	O

1	The	O
2	most	O
3	common	O
4	cause	O
5	of	O
6	renal	O
7	deterioration	O
8	in	O
9	the	O
10	spinal	O
11	cord	O
12	injured	O
13	patient	O
14	is	O
15	irreversible	O
16	vesicoureteral	O
17	reflux	O
18	.	O

1	Propranolol	O
2	(	O
3	Inderal	O
4	)	O
5	administered	O
6	in	O
7	a	O
8	dose	O
9	which	O
10	blocks	O
11	the	O
12	beta	O
13	-	O
14	adrenergic	O
15	apparatus	O
16	of	O
17	the	O
18	heart	O
19	prevents	O
20	the	O
21	development	O
22	of	O
23	the	O
24	positive	O
25	inotropic	O
26	effect	O
27	of	O
28	therapeutic	O
29	doses	O
30	of	O
31	strophanthin	O
32	K	O
33	on	O
34	a	O
35	hypodynamic	O
36	left	O
37	ventricular	O
38	myocardium	O
39	.	O

1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	the	O
6	rat	O
7	larynx	O
8	to	O
9	be	O
10	an	O
11	important	O
12	organ	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	irritancy	O
18	of	O
19	inhaled	O
20	materials	O
21	.	O

1	Scanning	O
2	electron	O
3	microscopic	O
4	investigations	O
5	on	O
6	the	O
7	formation	O
8	of	O
9	Reissner	O
10	'	O
11	s	O
12	fiber	O
13	in	O
14	Rattus	O
15	rattus	O

1	Feeding	O
2	behavior	O
3	,	O
4	circannual	O
5	body	O
6	weight	O
7	and	O
8	hibernation	O
9	rhythms	O
10	in	O
11	European	O
12	hamsters	O
13	lesioned	O
14	in	O
15	the	O
16	noradrenergic	O
17	ascending	O
18	bundles	O

1	Role	O
2	of	O
3	the	O
4	infectious	O
5	-	O
6	disease	O
7	specialist	O
8	of	O
9	a	O
10	polyclinic	O
11	in	O
12	reducing	O
13	the	O
14	incidence	O
15	of	O
16	communicable	O
17	diseases	O

1	These	O
2	observed	O
3	drug	O
4	interactions	O
5	,	O
6	plus	O
7	the	O
8	known	O
9	effect	O
10	of	O
11	probenecid	O
12	to	O
13	block	O
14	secretion	O
15	of	O
16	PZA	O
17	,	O
18	have	O
19	to	O
20	be	O
21	considered	O
22	in	O
23	evaluating	O
24	the	O
25	effect	O
26	of	O
27	the	O
28	two	O
29	drugs	O
30	given	O
31	together	O
32	,	O
33	compared	O
34	to	O
35	the	O
36	effect	O
37	of	O
38	each	O
39	drug	O
40	given	O
41	separately	O
42	.	O

1	Circulatory	O
2	arrest	O
3	in	O
4	the	O
5	operating	O
6	room	O
7	.	O

1	At	O
2	a	O
3	systolic	O
4	blood	O
5	pressure	O
6	(	O
7	BP	O
8	)	O
9	of	O
10	60	O
11	mmHg	O
12	,	O
13	C02	O
14	responsiveness	O
15	was	O
16	abolished	O
17	,	O
18	but	O
19	was	O
20	maintained	O
21	at	O
22	higher	O
23	levels	O
24	of	O
25	BP	O
26	.	O

1	Iodine	O
2	-	O
3	123	O
4	was	O
5	satisfactorily	O
6	imaged	O
7	only	O
8	with	O
9	the	O
10	MEC	O
11	and	O
12	pinhole	O
13	collimators	O
14	,	O
15	which	O
16	in	O
17	turn	O
18	yielded	O
19	MTF	O
20	values	O
21	comparable	O
22	to	O
23	those	O
24	measured	O
25	for	O
26	99mTc	O
27	.	O

1	Petrous	O
2	meningioma	O
3	en	O
4	plaque	O
5	presenting	O
6	as	O
7	a	O
8	right	O
9	middle	O
10	ear	O
11	tumor	O
12	.	O

1	The	O
2	difficulties	O
3	to	O
4	analyse	O
5	prostaglandins	O
6	(	O
7	PG	O
8	)	O
9	by	O
10	gas	O
11	-	O
12	liquid	O
13	chromatography	O
14	are	O
15	mainly	O
16	due	O
17	to	O
18	the	O
19	lack	O
20	of	O
21	sensitivity	O
22	of	O
23	the	O
24	gas	O
25	-	O
26	chromatograph	O
27	itself	O
28	(	O
29	higher	O
30	than	O
31	200	O
32	ng	O
33	)	O
34	and	O
35	to	O
36	the	O
37	poor	O
38	resolution	O
39	of	O
40	the	O
41	packed	O
42	columns	O
43	.	O

1	On	O
2	cessation	O
3	of	O
4	steroid	O
5	therapy	O
6	the	O
7	patient	O
8	was	O
9	noted	O
10	to	O
11	have	O
12	radiologic	O
13	manifestations	O
14	of	O
15	hypertrophic	O
16	osteoarthropathy	O
17	(	O
18	HOA	O
19	)	O
20	as	O
21	well	O
22	as	O
23	clinical	O
24	and	O
25	laboratory	O
26	features	O
27	of	O
28	rheumatoid	O
29	arthritis	O
30	(	O
31	RA	O
32	).	O

1	The	O
2	effect	O
3	of	O
4	food	O
5	on	O
6	procainamide	O
7	absorption	O
8	.	O

1	After	O
2	giving	O
3	a	O
4	survey	O
5	on	O
6	the	O
7	situation	O
8	of	O
9	antibiotic	O
10	resistance	O
11	in	O
12	the	O
13	region	O
14	of	O
15	Northern	O
16	Bavaria	O
17	during	O
18	1973	O
19	/	O
20	74	O
21	and	O
22	comparing	O
23	the	O
24	activity	O
25	of	O
26	a	O
27	sulfamethoxazole	O
28	(	O
29	SMZ	O
30	)	O
31	trimethoprim	O
32	(	O
33	TMP	O
34	)	O
35	combination	O
36	to	O
37	other	O
38	commonly	O
39	used	O
40	antibiotics	O
41	and	O
42	chemotherapeutic	O
43	agents	O
44	,	O
45	the	O
46	results	O
47	of	O
48	tests	O
49	with	O
50	the	O
51	new	O
52	combination	O
53	of	O
54	N1	O
55	-(	O
56	4	O
57	,	O
58	5	O
59	-	O
60	dimethyl	O
61	-	O
62	2	O
63	-	O
64	oxazolyl	O
65	)-	O
66	sulfanilamide	O
67	)	O
68	(	O
69	sulfamoxole	O
70	)	O
71	and	O
72	2	O
73	,	O
74	4	O
75	-	O
76	diamino	O
77	-	O
78	5	O
79	-(	O
80	3	O
81	,	O
82	4	O
83	,	O
84	5	O
85	-	O
86	trimethoxy	O
87	-	O
88	benzyl	O
89	)-	O
90	pyrimidine	O
91	(	O
92	trimethoprim	O
93	)	O
94	at	O
95	a	O
96	ratio	O
97	of	O
98	5	O
99	:	O
100	1	O
101	(	O
102	CN	O
103	3123	O
104	;	O
105	Nevin	O
106	,	O
107	Supristol	O
108	)	O
109	are	O
110	compared	O
111	to	O
112	those	O
113	of	O
114	tests	O
115	with	O
116	TMP	O
117	/	O
118	SMZ	O
119	.	O

1	RESULTS	O
2	:	O
3	Total	O
4	IgE	B
5	levels	O
6	showed	O
7	a	O
8	tendency	O
9	to	O
10	diminish	O
11	.	O

1	Does	O
2	afferent	O
3	loop	O
4	syndrome	O
5	exist	O
6	?]	O
7	It	O
8	is	O
9	the	O
10	author	O
11	'	O
12	s	O
13	opinion	O
14	that	O
15	diagnosis	O
16	of	O
17	the	O
18	"	O
19	adducent	O
20	loop	O
21	syndrome	O
22	"	O
23	is	O
24	unlikely	O
25	to	O
26	be	O
27	correct	O
28	in	O
29	patients	O
30	subjected	O
31	to	O
32	Billroth	O
33	-	O
34	II	O
35	gastrectomy	O
36	.	O

1	Letter	O
2	:	O
3	Is	O
4	actinic	O
5	(	O
6	solar	O
7	)	O
8	damage	O
9	the	O
10	provoking	O
11	cause	O
12	of	O
13	'	O
14	post	O
15	-	O
16	inflammatory	O
17	elastolysis	O
18	and	O
19	cutis	O
20	laxa	O
21	(	O
22	PECL	O
23	)'?	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	spontaneous	O
6	recovery	O
7	of	O
8	central	O
9	respiratory	O
10	function	O
11	after	O
12	intoxication	O
13	with	O
14	Soman	O
15	or	O
16	Sarin	O
17	may	O
18	not	O
19	be	O
20	related	O
21	to	O
22	the	O
23	return	O
24	of	O
25	AChE	B
26	activity	O
27	.	O

1	Batch	O
2	cultures	O
3	of	O
4	S	O
5	.	O
6	mutans	O
7	serotype	O
8	a	O
9	demonstrated	O
10	no	O
11	growth	O
12	on	O
13	MSB	O
14	agar	O
15	.	O

1	Also	O
2	,	O
3	samples	O
4	of	O
5	serum	O
6	were	O
7	absorbed	O
8	with	O
9	the	O
10	various	O
11	solid	O
12	-	O
13	phase	O
14	allergens	O
15	and	O
16	the	O
17	reactivity	O
18	of	O
19	the	O
20	remaining	O
21	IgE	B
22	antibodies	I
23	was	O
24	determined	O
25	.	O

1	Crisis	O
2	of	O
3	the	O
4	therapeutic	O
5	community	O
6	in	O
7	Great	O
8	Britain	O

1	Pregnant	O
2	women	O
3	at	O
4	term	O
5	had	O
6	the	O
7	lowest	O
8	levels	O
9	of	O
10	antithrombin	B
11	III	I
12	.	O

1	Hematology	O
2	problem	O
3	of	O
4	the	O
5	month	O
6	:	O
7	band	O
8	or	O
9	seg	O
10	?	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	cyclic	O
6	variations	O
7	in	O
8	heme	O
9	turnover	O
10	are	O
11	related	O
12	to	O
13	changes	O
14	in	O
15	erythrocyte	O
16	characteristics	O
17	during	O
18	the	O
19	progesterone	O
20	phase	O
21	.	O

1	Haemodilution	O
2	in	O
3	cardiopulmonary	O
4	bypass	O
5	using	O
6	a	O
7	gelatine	O
8	derivative	O
9	for	O
10	priming	O
11	.	O

1	Extramedullary	O
2	plasmacytoma	O
3	of	O
4	the	O
5	parotid	O
6	gland	O

1	I	O
2	.	O

1	The	O
2	recovered	O
3	calves	O
4	were	O
5	tested	O
6	for	O
7	immunity	O
8	to	O
9	homologous	O
10	severe	O
11	challenge	O
12	,	O
13	50	O
14	or	O
15	73	O
16	days	O
17	after	O
18	the	O
19	first	O
20	infection	O
21	.	O

1	The	O
2	performance	O
3	of	O
4	three	O
5	commonly	O
6	used	O
7	chemical	O
8	cartridge	O
9	respirators	O
10	for	O
11	SO2	O
12	was	O
13	measured	O
14	under	O
15	working	O
16	conditions	O
17	in	O
18	a	O
19	copper	O
20	smelter	O
21	.	O

1	The	O
2	neuroleptic	O
3	-	O
4	induced	O
5	increase	O
6	in	O
7	central	O
8	DA	O
9	turnover	O
10	(	O
11	an	O
12	indicator	O
13	for	O
14	the	O
15	degree	O
16	of	O
17	DA	B
18	receptor	I
19	blocking	O
20	)	O
21	was	O
22	found	O
23	to	O
24	be	O
25	positively	O
26	correlated	O
27	with	O
28	the	O
29	therapeutic	O
30	effect	O
31	of	O
32	neuroleptics	O
33	and	O
34	the	O
35	development	O
36	of	O
37	hypokinetic	O
38	-	O
39	rigid	O
40	symptoms	O
41	.	O

1	Rainbow	O
2	trout	O
3	were	O
4	obtained	O
5	from	O
6	a	O
7	commercial	O
8	trout	O
9	farm	O
10	,	O
11	kept	O
12	in	O
13	running	O
14	water	O
15	and	O
16	feeding	O
17	in	O
18	experimental	O
19	pellets	O
20	for	O
21	4	O
22	to	O
23	8	O
24	weeks	O
25	.	O

1	Stimulation	O
2	of	O
3	macrophage	O
4	function	O
5	by	O
6	killed	O
7	Bordetella	O
8	pertussis	O
9	cells	O
10	did	O
11	not	O
12	show	O
13	any	O
14	beneficial	O
15	effect	O
16	as	O
17	an	O
18	increased	O
19	susceptibility	O
20	became	O
21	apparent	O
22	.	O

1	Primary	O
2	amenorrhoea	O
3	in	O
4	a	O
5	phenotypically	O
6	female	O
7	individual	O
8	with	O
9	a	O
10	karyotype	O
11	46	O
12	,	O
13	xy	O
14	and	O
15	bilateral	O
16	gonadoblastoma	O

1	Toward	O
2	absolute	O
3	methods	O
4	in	O
5	clinical	O
6	chemistry	O
7	:	O
8	application	O
9	of	O
10	mass	O
11	fragmentography	O
12	to	O
13	high	O
14	-	O
15	accuracy	O
16	analyses	O
17	.	O

1	Application	O
2	of	O
3	the	O
4	2	O
5	-	O
6	deoxy	O
7	-	O
8	D	O
9	-	O
10	glucose	O
11	method	O
12	to	O
13	the	O
14	coupling	O
15	of	O
16	cerebral	O
17	metabolism	O
18	and	O
19	blood	O
20	flow	O
21	.	O

1	Serum	O
2	gastrin	B
3	levels	O
4	did	O
5	not	O
6	change	O
7	in	O
8	either	O
9	group	O
10	;	O
11	however	O
12	,	O
13	background	O
14	serum	O
15	gastrin	B
16	concentrations	O
17	were	O
18	significantly	O
19	greater	O
20	for	O
21	V	O
22	&	O
23	P	O
24	patients	O
25	than	O
26	V	O
27	&	O
28	A	O
29	patients	O
30	throughout	O
31	the	O
32	study	O
33	.	O

1	Efferent	O
2	projections	O
3	of	O
4	the	O
5	ventral	O
6	portion	O
7	of	O
8	the	O
9	putamen	O
10	to	O
11	the	O
12	frontal	O
13	,	O
14	parietal	O
15	and	O
16	temporal	O
17	regions	O
18	of	O
19	the	O
20	cat	O
21	cerebral	O
22	cortex	O

1	Preflight	O
2	,	O
3	inflight	O
4	,	O
5	and	O
6	postflight	O
7	exercise	O
8	response	O
9	tests	O
10	were	O
11	conducted	O
12	on	O
13	the	O
14	astronauts	O
15	of	O
16	the	O
17	second	O
18	Skylab	O
19	mission	O
20	(	O
21	Skylab	O
22	3	O
23	)	O
24	as	O
25	part	O
26	of	O
27	an	O
28	evaluation	O
29	of	O
30	physiological	O
31	adaptation	O
32	to	O
33	long	O
34	-	O
35	term	O
36	weightlessness	O
37	.	O

1	Mean	O
2	corpuscular	B
3	hemoglobin	I
4	concentrations	O
5	remained	O
6	normal	O
7	for	O
8	48	O
9	h	O
10	and	O
11	then	O
12	decreased	O
13	in	O
14	both	O
15	groups	O
16	,	O
17	the	O
18	CO2	O
19	group	O
20	showing	O
21	the	O
22	larger	O
23	decrease	O
24	.	O

1	All	O
2	Cu	O
3	values	O
4	obtained	O
5	from	O
6	the	O
7	organs	O
8	investigated	O
9	had	O
10	reached	O
11	a	O
12	saturation	O
13	level	O
14	at	O
15	8	O
16	mug	O
17	Cu	O
18	/	O
19	g	O
20	diet	O
21	with	O
22	the	O
23	exception	O
24	of	O
25	the	O
26	values	O
27	for	O
28	body	O
29	Cu	O
30	found	O
31	in	O
32	the	O
33	dams	O
34	that	O
35	were	O
36	killed	O
37	on	O
38	the	O
39	day	O
40	of	O
41	delivery	O
42	.	O

1	The	O
2	effect	O
3	of	O
4	calcitonin	B
5	,	O
6	a	O
7	large	O
8	amount	O
9	of	O
10	calcium	O
11	given	O
12	orally	O
13	,	O
14	pentagastrin	O
15	and	O
16	glucagon	B
17	on	O
18	plasma	O
19	47Ca	O
20	radioactivity	O
21	curves	O
22	in	O
23	subjects	O
24	pretreated	O
25	with	O
26	47Ca	O
27	was	O
28	examined	O
29	.	O

1	State	O
2	of	O
3	the	O
4	body	O
5	in	O
6	disorders	O
7	of	O
8	diurnal	O
9	physiological	O
10	rhythms	O
11	and	O
12	long	O
13	-	O
14	term	O
15	hypokinesia	O

1	Oxygen	O
2	tension	O
3	of	O
4	the	O
5	small	O
6	lymph	O
7	vessels	O
8	(	O
9	PLO2	O
10	)	O
11	of	O
12	the	O
13	rabbit	O
14	hind	O
15	limb	O
16	was	O
17	measured	O
18	with	O
19	both	O
20	a	O
21	flow	O
22	-	O
23	through	O
24	micro	O
25	chamber	O
26	and	O
27	a	O
28	polarographic	O
29	catheter	O
30	-	O
31	tip	O
32	oxygen	O
33	electrode	O
34	to	O
35	obtain	O
36	experimental	O
37	data	O
38	on	O
39	the	O
40	source	O
41	of	O
42	oxygen	O
43	in	O
44	the	O
45	lymph	O
46	.	O

1	The	O
2	response	O
3	of	O
4	the	O
5	plasma	B
6	fibrinogen	I
7	level	O
8	to	O
9	the	O
10	subucutaneous	O
11	injection	O
12	of	O
13	turpentine	O
14	and	O
15	to	O
16	the	O
17	intravenous	O
18	injection	O
19	of	O
20	endotoxin	O
21	was	O
22	measured	O
23	in	O
24	normal	O
25	rabbits	O
26	and	O
27	in	O
28	rabbits	O
29	made	O
30	granulocytopenic	O
31	and	O
32	thrombocytopenic	O
33	with	O
34	busulfan	O
35	.	O

1	Constantly	O
2	rectilinear	O
3	pressure	O
4	curves	O
5	without	O
6	uterine	O
7	activities	O
8	are	O
9	interpreted	O
10	as	O
11	characteristic	O
12	tocographic	O
13	criteria	O
14	of	O
15	an	O
16	advanced	O
17	ectopic	O
18	gravidity	O
19	.	O

1	Since	O
2	myoglobin	B
3	is	O
4	co	O
5	-	O
6	extracted	O
7	with	O
8	the	O
9	hemoglobin	B
10	,	O
11	the	O
12	2	O
13	heme	O
14	pigments	O
15	are	O
16	separated	O
17	in	O
18	one	O
19	portion	O
20	of	O
21	the	O
22	extract	O
23	by	O
24	precipitating	O
25	the	O
26	hemoglobin	B
27	in	O
28	an	O
29	85	O
30	%	O
31	(	O
32	NH4	O
33	)	O
34	2SO4	O
35	solution	O
36	.	O

1	Considering	O
2	these	O
3	sources	O
4	of	O
5	error	O
6	some	O
7	of	O
8	the	O
9	variability	O
10	in	O
11	the	O
12	present	O
13	investigation	O
14	might	O
15	be	O
16	avoided	O
17	by	O
18	systematic	O
19	instructions	O
20	.	O

1	E	O
2	50	O
3	,	O
4	843	O
5	(	O
6	1994	O
7	)].	O

1	Six	O
2	patients	O
3	with	O
4	the	O
5	diagnosis	O
6	of	O
7	acute	O
8	mania	O
9	were	O
10	treated	O
11	with	O
12	high	O
13	doses	O
14	of	O
15	the	O
16	beta	O
17	-	O
18	adrenergic	O
19	blocking	O
20	agent	O
21	propranolol	O
22	.	O

1	Effect	O
2	of	O
3	trauma	O
4	on	O
5	plasma	B
6	glucagon	I
7	and	O
8	insulin	B
9	concentrations	O
10	in	O
11	sheep	O
12	.	O

1	With	O
2	the	O
3	help	O
4	of	O
5	a	O
6	nomogram	O
7	one	O
8	can	O
9	read	O
10	off	O
11	the	O
12	refraction	O
13	,	O
14	when	O
15	axis	O
16	length	O
17	and	O
18	corneal	O
19	curvature	O
20	are	O
21	known	O
22	.	O

1	This	O
2	up	O
3	-	O
4	grading	O
5	of	O
6	the	O
7	final	O
8	score	O
9	by	O
10	the	O
11	CA	O
12	component	O
13	is	O
14	greater	O
15	(	O
16	3	O
17	-	O
18	8	O
19	%)	O
20	in	O
21	the	O
22	less	O
23	able	O
24	students	O
25	with	O
26	scores	O
27	below	O
28	the	O
29	mean	O
30	level	O
31	.	O

1	Compared	O
2	to	O
3	controls	O
4	,	O
5	both	O
6	UB	O
7	and	O
8	OCS	O
9	rats	O
10	showed	O
11	a	O
12	small	O
13	but	O
14	significant	O
15	post	O
16	-	O
17	operative	O
18	reduction	O
19	in	O
20	the	O
21	nocturnality	O
22	of	O
23	drinking	O
24	.	O

1	Effect	O
2	of	O
3	indomethacin	O
4	on	O
5	coronary	O
6	circulation	O
7	:	O
8	effect	O
9	on	O
10	ECG	O
11	tracing	O

1	Dual	O
2	innervation	O
3	of	O
4	fast	O
5	fibers	O
6	in	O
7	trunk	O
8	muscles	O
9	of	O
10	lamprey	O
11	larvae	O

1	The	O
2	feed	O
3	consumed	O
4	which	O
5	was	O
6	lowered	O
7	by	O
8	25	O
9	%	O
10	initially	O
11	,	O
12	did	O
13	not	O
14	alter	O
15	later	O
16	.	O

1	Certain	O
2	characteristics	O
3	of	O
4	eye	O
5	changes	O
6	in	O
7	patients	O
8	with	O
9	pheochromocytoma	O
10	including	O
11	Sipple	O
12	'	O
13	s	O
14	syndrome	O

1	The	O
2	color	O
3	-	O
4	word	O
5	interference	O
6	effect	O
7	previously	O
8	reported	O
9	with	O
10	normal	O
11	populations	O
12	when	O
13	given	O
14	the	O
15	Stroop	O
16	test	O
17	was	O
18	demonstrated	O
19	for	O
20	this	O
21	retarded	O
22	sample	O
23	using	O
24	a	O
25	special	O
26	format	O
27	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	under	O
6	the	O
7	selected	O
8	conditions	O
9	a	O
10	linear	O
11	dependence	O
12	exists	O
13	between	O
14	the	O
15	betaI	O
16	%	O
17	value	O
18	and	O
19	lgC	O
20	within	O
21	the	O
22	range	O
23	of	O
24	0	O
25	.	O
26	5	O
27	--	O
28	10	O
29	mug	O
30	ruscogenin	O
31	.	O

1	The	O
2	influence	O
3	of	O
4	adrenergic	O
5	nerves	O
6	of	O
7	the	O
8	response	O
9	of	O
10	blood	O
11	vessels	O
12	in	O
13	the	O
14	rabbit	O
15	ear	O
16	to	O
17	2	B
18	--	I
19	phenylalanine	I
20	-	I
21	8	I
22	-	I
23	lysine	I
24	vasopressin	I
25	(	O
26	Octapressin	B
27	).	O

1	Potscoital	O
2	test	O

1	I	O
2	.	O

1	When	O
2	a	O
3	tumour	O
4	is	O
5	present	O
6	nipple	O
7	discharge	O
8	is	O
9	of	O
10	little	O
11	importance	O
12	for	O
13	the	O
14	diagnosis	O
15	and	O
16	treatment	O
17	.	O

1	Studies	O
2	of	O
3	biochemical	O
4	and	O
5	morphological	O
6	changes	O
7	(	O
8	between	O
9	normal	O
10	and	O
11	treated	O
12	animals	O
13	)	O
14	show	O
15	that	O
16	chrysotile	O
17	induces	O
18	an	O
19	increase	O
20	in	O
21	the	O
22	lung	O
23	free	O
24	cell	O
25	population	O
26	and	O
27	pulmonary	O
28	surfactant	O
29	levels	O
30	.	O

1	Infrared	O
2	measurements	O
3	of	O
4	temperature	O
5	changes	O
6	and	O
7	estimates	O
8	of	O
9	the	O
10	heating	O
11	produced	O
12	at	O
13	the	O
14	mical	O
15	.	O

1	Who	O
2	says	O
3	'	O
4	National	O
5	Health	O
6	Dis	O
7	-	O
8	service	O
9	'.	O

1	Is	O
2	criticism	O
3	of	O
4	patient	O
5	care	O
6	justified	O
7	and	O
8	does	O
9	it	O
10	have	O
11	educational	O
12	value	O
13	?	O
14	Patients	O
15	'	O
16	criticism	O
17	contributes	O
18	to	O
19	improved	O
20	patient	O
21	care	O

1	Critique	O
2	of	O
3	"	O
4	Interactive	O
5	Effects	O
6	of	O
7	Test	O
8	Anxiety	O
9	and	O
10	Credit	O
11	/	O
12	No	O
13	Credit	O
14	or	O
15	A	O
16	-	O
17	F	O
18	Grade	O
19	Condition	O
20	upon	O
21	Short	O
22	-	O
23	term	O
24	and	O
25	Long	O
26	-	O
27	term	O
28	Recall	O
29	of	O
30	Course	O
31	Information	O
32	.	O

1	These	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	majority	O
8	of	O
9	tested	O
10	staphylococci	O
11	were	O
12	resistant	O
13	to	O
14	penicillin	O
15	G	O
16	,	O
17	erythromycin	O
18	,	O
19	and	O
20	produced	O
21	beta	B
22	-	I
23	lactamase	I
24	.	O

1	Since	O
2	1968	O
3	,	O
4	a	O
5	steep	O
6	decrease	O
7	in	O
8	the	O
9	number	O
10	of	O
11	strains	O
12	resistant	O
13	to	O
14	three	O
15	or	O
16	more	O
17	antibiotics	O
18	(	O
19	multiple	O
20	-	O
21	resistant	O
22	)	O
23	and	O
24	in	O
25	strains	O
26	of	O
27	the	O
28	83A	O
29	complex	O
30	was	O
31	noticed	O
32	.	O

1	Improvement	O
2	of	O
3	nursing	O
4	instruction	O
5	to	O
6	be	O
7	given	O
8	at	O
9	the	O
10	time	O
11	of	O
12	discharge	O
13	from	O
14	the	O
15	ward	O
16	for	O
17	premature	O
18	infants	O

1	No	O
2	difference	O
3	in	O
4	the	O
5	clinical	O
6	acceptability	O
7	could	O
8	be	O
9	ascertained	O
10	between	O
11	the	O
12	two	O
13	groups	O
14	.	O

1	After	O
2	90	O
3	d	O
4	a	O
5	subsurface	O
6	,	O
7	radiolucent	O
8	caries	O
9	-	O
10	like	O
11	lesion	O
12	was	O
13	observed	O
14	in	O
15	two	O
16	specimens	O
17	only	O
18	.	O

1	The	O
2	contraceptive	O
3	pattern	O
4	of	O
5	157	O
6	women	O
7	was	O
8	analysed	O
9	and	O
10	13	O
11	.	O
12	8	O
13	percent	O
14	were	O
15	using	O
16	inefficient	O
17	methods	O
18	.	O

1	Plethysmographic	O
2	technique	O
3	and	O
4	indirect	O
5	blood	O
6	pressure	O
7	recordings	O
8	were	O
9	used	O
10	.	O

1	I	O
2	.	O

1	The	O
2	second	O
3	and	O
4	third	O
5	responded	O
6	similarly	O
7	to	O
8	either	O
9	a	O
10	combined	O
11	cyclophosphamide	O
12	+	O
13	antilymphocyte	B
14	globulin	I
15	(	O
16	ALG	B
17	)	O
18	treatment	O
19	or	O
20	to	O
21	ALG	B
22	administration	O
23	preceded	O
24	by	O
25	a	O
26	small	O
27	dosage	O
28	of	O
29	cyclophosphamide	O
30	,	O
31	which	O
32	had	O
33	proved	O
34	ineffective	O
35	when	O
36	administered	O
37	alone	O
38	.	O

1	Evidence	O
2	is	O
3	presented	O
4	that	O
5	Leber	O
6	'	O
7	s	O
8	military	O
9	aneurysm	O
10	retinitis	O
11	is	O
12	not	O
13	a	O
14	separate	O
15	entity	O
16	but	O
17	a	O
18	special	O
19	form	O
20	of	O
21	Coats	O
22	'	O
23	disease	O
24	.	O

1	Fibrin	B
2	cloaking	O
3	along	O
4	the	O
5	catheter	O
6	was	O
7	found	O
8	in	O
9	20	O
10	patients	O
11	studied	O
12	by	O
13	pull	O
14	-	O
15	out	O
16	arteriography	O
17	and	O
18	was	O
19	unassociated	O
20	with	O
21	clinical	O
22	symptoms	O
23	.	O

1	The	O
2	influence	O
3	of	O
4	a	O
5	mobile	O
6	pupil	O
7	on	O
8	the	O
9	response	O
10	in	O
11	the	O
12	DC	O
13	-	O
14	ERG	O
15	is	O
16	demonstrated	O
17	.	O

1	A	O
2	newly	O
3	synthesized	O
4	anti	O
5	-	O
6	inflammatory	O
7	agent	O
8	,	O
9	Y	O
10	-	O
11	8004	O
12	demonstrated	O
13	a	O
14	greater	O
15	inhibition	O
16	than	O
17	did	O
18	indomethacin	O
19	(	O
20	IM	O
21	).	O
22	on	O
23	inflammatory	O
24	response	O
25	such	O
26	as	O
27	ultraviolet	O
28	erythema	O
29	in	O
30	guinea	O
31	pigs	O
32	,	O
33	carrageenin	O
34	edema	O
35	,	O
36	evans	O
37	blue	O
38	and	O
39	carrageenin	O
40	-	O
41	induced	O
42	pleuritis	O
43	and	O
44	acetic	O
45	acid	O
46	-	O
47	induced	O
48	peritonitis	O
49	in	O
50	rats	O
51	.	O

1	As	O
2	stands	O
3	shifted	O
4	in	O
5	dominance	O
6	from	O
7	pine	O
8	to	O
9	fir	O
10	with	O
11	age	O
12	,	O
13	subalpine	O
14	fir	O
15	appeared	O
16	to	O
17	maintain	O
18	gradually	O
19	increasing	O
20	rates	O
21	of	O
22	whole	O
23	-	O
24	forest	O
25	productivity	O
26	until	O
27	stands	O
28	were	O
29	approximately	O
30	400	O
31	years	O
32	old	O
33	.	O

1	Alpha	B
2	-	I
3	1	I
4	antitrypsin	I
5	and	O
6	Indian	O
7	childhood	O
8	cirrhosis	O
9	.	O

1	Lymphocyte	O
2	subpopulations	O
3	,	O
4	serum	B
5	IgE	I
6	and	O
7	total	O
8	eosinophil	O
9	counts	O
10	in	O
11	patients	O
12	with	O
13	bronchial	O
14	asthma	O
15	.	O

1	A	O
2	range	O
3	of	O
4	normal	O
5	ventricular	O
6	measurements	O
7	for	O
8	the	O
9	EMI	O
10	scan	O
11	is	O
12	suggested	O
13	.	O

1	A	O
2	comparison	O
3	of	O
4	physical	O
5	and	O
6	cytogenetic	O
7	estimates	O
8	of	O
9	radiation	O
10	dose	O
11	in	O
12	patients	O
13	treated	O
14	with	O
15	iodine	O
16	-	O
17	131	O
18	for	O
19	thyroid	O
20	carcinoma	O
21	.	O

1	Technique	O
2	for	O
3	obtaining	O
4	refined	O
5	ceramics	O
6	with	O
7	dense	O
8	mass	O

1	Mean	O
2	total	O
3	lung	O
4	capacity	O
5	,	O
6	functional	O
7	residual	O
8	capacity	O
9	,	O
10	and	O
11	residual	O
12	volume	O
13	increased	O
14	significantly	O
15	,	O
16	and	O
17	the	O
18	mean	O
19	closing	O
20	volume	O
21	,	O
22	the	O
23	lung	O
24	volume	O
25	above	O
26	residual	O
27	volume	O
28	at	O
29	which	O
30	phase	O
31	IV	O
32	begins	O
33	,	O
34	decreased	O
35	significantly	O
36	with	O
37	11	O
38	cm	O
39	H20	O
40	continuous	O
41	positive	O
42	airway	O
43	pressure	O
44	;	O
45	differences	O
46	at	O
47	5	O
48	cm	O
49	H20	O
50	were	O
51	not	O
52	significant	O
53	.	O

1	Current	O
2	status	O
3	of	O
4	zinc	O
5	deficiency	O
6	in	O
7	the	O
8	pathogenesis	O
9	of	O
10	neurological	O
11	,	O
12	dermatological	O
13	and	O
14	musculoskeletal	O
15	disorders	O
16	.	O

1	Calcium	O
2	and	O
3	phosphorus	O
4	metabolism	O
5	in	O
6	chronic	O
7	uremia	O
8	.	O

1	Modern	O
2	studies	O
3	,	O
4	conducted	O
5	with	O
6	Delta	O
7	-	O
8	9	O
9	-	O
10	THC	O
11	,	O
12	in	O
13	healthy	O
14	voluntaries	O
15	,	O
16	again	O
17	suggest	O
18	the	O
19	comparison	O
20	or	O
21	even	O
22	the	O
23	identity	O
24	of	O
25	the	O
26	modifications	O
27	caused	O
28	by	O
29	cannabis	O
30	with	O
31	sleep	O
32	and	O
33	dream	O
34	.	O

1	The	O
2	correcting	O
3	action	O
4	of	O
5	tropatepine	O
6	hydrochloride	O
7	upon	O
8	the	O
9	extrapyramidal	O
10	effects	O
11	induced	O
12	by	O
13	neuroleptics	O
14	has	O
15	been	O
16	studied	O
17	in	O
18	32	O
19	acute	O
20	psychotic	O
21	states	O
22	.	O

1	Epididymal	O
2	growth	O
3	was	O
4	retarded	O
5	in	O
6	animals	O
7	maintained	O
8	solely	O
9	on	O
10	chickpea	O
11	haulm	O
12	and	O
13	improved	O
14	with	O
15	supplementation	O
16	.	O

1	Two	O
2	patients	O
3	were	O
4	treated	O
5	with	O
6	both	O
7	regimens	O
8	.	O

1	Results	O
2	obtained	O
3	for	O
4	chloramphenicol	O
5	-	O
6	containing	O
7	preparations	O
8	are	O
9	presented	O
10	,	O
11	and	O
12	both	O
13	dissolution	O
14	curves	O
15	and	O
16	cup	O
17	-	O
18	plate	O
19	assays	O
20	demonstrate	O
21	that	O
22	chloramphenicol	O
23	has	O
24	far	O
25	superior	O
26	release	O
27	(	O
28	and	O
29	hence	O
30	activity	O
31	)	O
32	from	O
33	creams	O
34	than	O
35	from	O
36	ophthalmic	O
37	ointments	O
38	.	O

1	IgG	B
2	levels	O
3	of	O
4	1	O
5	/	O
6	100	O
7	were	O
8	present	O
9	in	O
10	only	O
11	four	O
12	out	O
13	of	O
14	ten	O
15	samples	O
16	obtained	O
17	150	O
18	days	O
19	after	O
20	the	O
21	clinical	O
22	onset	O
23	.	O

1	Letter	O
2	:	O
3	Perspectives	O
4	in	O
5	bone	O
6	marrow	O
7	transplantation	O
8	.	O

1	Assessment	O
2	of	O
3	the	O
4	carcinogenicity	O
5	of	O
6	non	O
7	-	O
8	nutritive	O
9	sweetners	O
10	II	O
11	:	O
12	Cyclamates	O
13	and	O
14	cyclohexylamine	O
15	.	O

1	The	O
2	discordant	O
3	behaviour	O
4	in	O
5	weakly	O
6	infected	O
7	mice	O
8	was	O
9	due	O
10	to	O
11	the	O
12	occurrence	O
13	in	O
14	some	O
15	animals	O
16	of	O
17	a	O
18	second	O
19	phase	O
20	of	O
21	more	O
22	rapid	O
23	increase	O
24	of	O
25	the	O
26	parasitemia	O
27	.	O

1	Residual	O
2	amphotericin	O
3	B	O
4	was	O
5	detected	O
6	in	O
7	the	O
8	feces	O
9	of	O
10	the	O
11	mice	O
12	only	O
13	while	O
14	they	O
15	were	O
16	receiving	O
17	the	O
18	0	O
19	.	O
20	3	O
21	mg	O
22	/	O
23	ml	O
24	dose	O
25	level	O
26	.	O

1	There	O
2	was	O
3	a	O
4	slight	O
5	increase	O
6	in	O
7	total	O
8	transferrin	B
9	2	O
10	hr	O
11	after	O
12	1	O
13	tablet	O
14	and	O
15	values	O
16	remained	O
17	high	O
18	throughout	O
19	the	O
20	experiment	O
21	.	O

1	Following	O
2	intravenous	O
3	administration	O
4	,	O
5	the	O
6	myocardial	O
7	concentration	O
8	of	O
9	tracer	O
10	thallium	O
11	-	O
12	201	O
13	,	O
14	potassium	O
15	-	O
16	43	O
17	,	O
18	and	O
19	rubidium	O
20	-	O
21	81	O
22	were	O
23	determined	O
24	in	O
25	mice	O
26	;	O
27	thallium	O
28	was	O
29	present	O
30	in	O
31	the	O
32	greatest	O
33	concentration	O
34	in	O
35	the	O
36	myocardium	O
37	(	O
38	2	O
39	.	O
40	08	O
41	%	O
42	compared	O
43	1	O
44	.	O
45	25	O
46	%	O
47	for	O
48	potassium	O
49	and	O
50	1	O
51	.	O
52	15	O
53	%	O
54	for	O
55	rubidium	O
56	at	O
57	10	O
58	minutes	O
59	).	O

1	Thromboplastin	B
2	time	O
3	,	O
4	partial	O
5	thromboplastin	B
6	time	O
7	,	O
8	thrombin	B
9	time	O
10	,	O
11	heat	O
12	-	O
13	dependent	O
14	fibrin	B
15	,	O
16	clot	O
17	retraction	O
18	,	O
19	and	O
20	clotting	B
21	factors	I
22	II	I
23	,	I
24	V	I
25	,	I
26	VIII	I
27	,	I
28	IX	I
29	,	I
30	X	I
31	,	O
32	and	O
33	the	O
34	platelet	O
35	count	O
36	were	O
37	determined	O
38	.	O

1	The	O
2	data	O
3	support	O
4	the	O
5	notion	O
6	that	O
7	suppression	O
8	of	O
9	images	O
10	during	O
11	binocular	O
12	rivalry	O
13	is	O
14	independent	O
15	in	O
16	both	O
17	eyes	O
18	.	O

1	Glycogen	O
2	utilization	O
3	was	O
4	increased	O
5	,	O
6	but	O
7	tissue	O
8	levels	O
9	of	O
10	creatine	O
11	phosphate	O
12	,	O
13	ATP	O
14	,	O
15	and	O
16	lactate	O
17	were	O
18	similar	O
19	to	O
20	those	O
21	in	O
22	hearts	O
23	receiving	O
24	normal	O
25	flow	O
26	.	O

1	The	O
2	records	O
3	from	O
4	1948	O
5	through	O
6	1967	O
7	of	O
8	344	O
9	previously	O
10	untreated	O
11	patients	O
12	with	O
13	squamous	O
14	cell	O
15	carcinoma	O
16	of	O
17	the	O
18	oral	O
19	cavity	O
20	,	O
21	oropharynx	O
22	,	O
23	supraglottic	O
24	larynx	O
25	and	O
26	hypopharynx	O
27	who	O
28	had	O
29	clinically	O
30	positive	O
31	cervical	O
32	lymph	O
33	node	O
34	metastases	O
35	staged	O
36	N1	O
37	,	O
38	N2A	O
39	,	O
40	or	O
41	N2B	O
42	,	O
43	and	O
44	whose	O
45	initial	O
46	neck	O
47	treatment	O
48	consisted	O
49	of	O
50	external	O
51	radiation	O
52	therapy	O
53	alone	O
54	were	O
55	reviewed	O
56	.	O

1	With	O
2	0	O
3	.	O
4	5	O
5	vol	O
6	.-%,	O
7	the	O
8	corresponding	O
9	values	O
10	were	O
11	345	O
12	mumol	O
13	/	O
14	1	O
15	(	O
16	5	O
17	.	O
18	72	O
19	mg	O
20	/	O
21	100	O
22	ml	O
23	)	O
24	and	O
25	137	O
26	mumol	O
27	/	O
28	1	O
29	(	O
30	2	O
31	.	O
32	25	O
33	mg	O
34	/	O
35	100	O
36	ml	O
37	)	O
38	respectively	O
39	.	O

1	The	O
2	authors	O
3	describe	O
4	the	O
5	technique	O
6	of	O
7	transverse	O
8	axial	O
9	tomography	O
10	of	O
11	the	O
12	spine	O
13	and	O
14	give	O
15	a	O
16	detailed	O
17	description	O
18	of	O
19	the	O
20	axial	O
21	anatomy	O
22	of	O
23	the	O
24	normal	O
25	lumbar	O
26	spine	O
27	from	O
28	L	O
29	-	O
30	4	O
31	to	O
32	the	O
33	sacrum	O
34	.	O

1	Owing	O
2	to	O
3	parental	O
4	attitude	O
5	,	O
6	a	O
7	low	O
8	protein	O
9	diet	O
10	(	O
11	1	O
12	-	O
13	5	O
14	g	O
15	/	O
16	kg	O
17	)	O
18	was	O
19	introduced	O
20	only	O
21	late	O
22	.	O

1	In	O
2	none	O
3	of	O
4	the	O
5	44	O
6	type	O
7	I	O
8	attacks	O
9	and	O
10	29	O
11	type	O
12	II	O
13	attacks	O
14	which	O
15	were	O
16	recorded	O
17	did	O
18	circulatory	O
19	changes	O
20	;	O
21	the	O
22	latter	O
23	were	O
24	different	O
25	in	O
26	the	O
27	two	O
28	groups	O
29	.	O

1	A	O
2	clinically	O
3	useful	O
4	diagnostic	O
5	method	O
6	has	O
7	been	O
8	developed	O
9	for	O
10	detecting	O
11	and	O
12	quantitating	O
13	periods	O
14	of	O
15	apnea	O
16	in	O
17	pediatric	O
18	patients	O
19	.	O

1	The	O
2	other	O
3	hypoglycaemic	O
4	patient	O
5	showed	O
6	an	O
7	exaggerated	O
8	insulin	B
9	release	O
10	in	O
11	response	O
12	to	O
13	tolbutamide	O
14	.	O

1	Nerve	O
2	stimulation	O
3	(	O
4	1	O
5	.	O
6	5	O
7	-	O
8	12	O
9	cycles	O
10	/	O
11	s	O
12	)	O
13	produced	O
14	frequency	O
15	-	O
16	dependent	O
17	reductions	O
18	in	O
19	CBF	O
20	,	O
21	a	O
22	decrease	O
23	of	O
24	50	O
25	percent	O
26	occurring	O
27	with	O
28	the	O
29	highest	O
30	frequency	O
31	.	O

1	Effect	O
2	of	O
3	ingestion	O
4	of	O
5	Norbiogest	O
6	during	O
7	the	O
8	quiescent	O
9	period	O
10	of	O
11	the	O
12	genital	O
13	organs	O

1	Risk	O
2	of	O
3	infection	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	fractures	O

1	Bulbar	O
2	pouches	O
3	were	O
4	perfused	O
5	with	O
6	solutions	O
7	of	O
8	0	O
9	.	O
10	9	O
11	%	O
12	Na	O
13	C1	O
14	,	O
15	0	O
16	.	O
17	1	O
18	N	O
19	HC1	O
20	,	O
21	40	O
22	%	O
23	glucose	O
24	,	O
25	40	O
26	%	O
27	NaC1	O
28	,	O
29	and	O
30	40	O
31	%	O
32	peptone	O
33	or	O
34	with	O
35	0	O
36	.	O
37	1	O
38	%	O
39	solutions	O
40	of	O
41	acetylcholine	O
42	chloride	O
43	.	O

1	Liver	O
2	microsomes	O
3	of	O
4	the	O
5	shag	O
6	showed	O
7	smaller	O
8	than	O
9	8	O
10	%	O
11	of	O
12	the	O
13	epoxide	B
14	hydrase	I
15	activity	O
16	and	O
17	smaller	O
18	than	O
19	14	O
20	%	O
21	of	O
22	the	O
23	hydroxylating	O
24	capacity	O
25	of	O
26	liver	O
27	microsomes	O
28	from	O
29	the	O
30	rat	O
31	.	O

1	Prolonged	O
2	heavy	O
3	work	O
4	effected	O
5	an	O
6	increase	O
7	of	O
8	10	O
9	.	O
10	3	O
11	plus	O
12	or	O
13	minus	O
14	0	O
15	.	O
16	9	O
17	mmHg	O
18	in	O
19	in	O
20	vivo	O
21	P50	O
22	(	O
23	7	O
24	.	O
25	30	O
26	PH	O
27	-	O
28	v	O
29	,	O
30	41	O
31	degrees	O
32	C	O
33	-	O
34	v	O
35	,	O
36	and	O
37	45	O
38	Pv	O
39	-	O
40	CO2	O
41	);	O
42	due	O
43	entirely	O
44	to	O
45	the	O
46	additive	O
47	effects	O
48	of	O
49	increased	O
50	venous	O
51	temperature	O
52	and	O
53	[	O
54	H	O
55	+].	O

1	A	O
2	clinical	O
3	,	O
4	serological	O
5	and	O
6	prognostic	O
7	study	O

1	The	O
2	American	O
3	Burkitt	O
4	Lymphoma	O
5	Registry	O
6	:	O
7	a	O
8	progress	O
9	report	O
10	.	O

1	Vitrectomy	O
2	with	O
3	an	O
4	alternative	O
5	instrument	O
6	system	O
7	.	O

1	The	O
2	metabolic	O
3	clearance	O
4	rate	O
5	of	O
6	progesterone	O
7	was	O
8	295	O
9	+/-	O
10	49	O
11	(	O
12	S	O
13	.	O
14	E	O
15	.)	O
16	1	O
17	/	O
18	day	O
19	.	O

1	This	O
2	sequence	O
3	is	O
4	almost	O
5	identical	O
6	with	O
7	that	O
8	of	O
9	human	B
10	luteinizing	I
11	hormone	I
12	(	O
13	Sairam	O
14	,	O
15	M	O
16	.	O

1	The	O
2	mean	O
3	plasma	O
4	sodium	O
5	concentration	O
6	which	O
7	was	O
8	135	O
9	.	O
10	95	O
11	(+/-	O
12	SD	O
13	4	O
14	.	O
15	14	O
16	)	O
17	mEq	O
18	/	O
19	kg	O
20	before	O
21	diuretic	O
22	treatment	O
23	was	O
24	significantly	O
25	decreased	O
26	during	O
27	treatment	O
28	to	O
29	129	O
30	.	O
31	19	O
32	(+/-	O
33	SD	O
34	2	O
35	.	O
36	77	O
37	)	O
38	mEq	O
39	/	O
40	kg	O
41	,	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	001	O
48	.	O

1	Editorial	O
2	:	O
3	Low	O
4	-	O
5	dose	O
6	heparin	O
7	and	O
8	the	O
9	prevention	O
10	of	O
11	venous	O
12	thromboembolic	O
13	disease	O
14	.	O

1	At	O
2	the	O
3	very	O
4	high	O
5	dose	O
6	levels	O
7	used	O
8	,	O
9	sodium	O
10	saccharin	O
11	and	O
12	sodium	O
13	cyclamate	O
14	were	O
15	weak	O
16	solitary	O
17	carcinogens	O
18	producing	O
19	4	O
20	/	O
21	253	O
22	and	O
23	3	O
24	/	O
25	228	O
26	bladder	O
27	tumours	O
28	respectively	O
29	,	O
30	and	O
31	the	O
32	first	O
33	of	O
34	these	O
35	tumours	O
36	did	O
37	not	O
38	appear	O
39	for	O
40	more	O
41	than	O
42	80	O
43	weeks	O
44	.	O

1	Effects	O
2	of	O
3	perceptual	O
4	salience	O
5	on	O
6	the	O
7	matrix	O
8	task	O
9	performance	O
10	of	O
11	four	O
12	-	O
13	and	O
14	six	O
15	-	O
16	year	O
17	-	O
18	old	O
19	children	O
20	.	O

1	Glucose	B
2	-	I
3	6	I
4	-	I
5	phosphate	I
6	dehydrogenase	I
7	(	O
8	G	B
9	-	I
10	6	I
11	-	I
12	PD	I
13	)	O
14	deficiency	O
15	in	O
16	the	O
17	newborn	O
18	.	O

1	The	O
2	eluting	O
3	solvent	O
4	was	O
5	methanol	O
6	-	O
7	chloroform	O
8	(	O
9	10	O
10	+	O
11	90	O
12	)	O
13	at	O
14	a	O
15	flow	O
16	rate	O
17	of	O
18	2	O
19	.	O
20	0	O
21	ml	O
22	/	O
23	min	O
24	.	O

1	The	O
2	bronchial	O
3	epithelia	O
4	of	O
5	all	O
6	smoke	O
7	-	O
8	exposed	O
9	animals	O
10	were	O
11	hyperplastic	O
12	,	O
13	and	O
14	their	O
15	ultrastructure	O
16	showed	O
17	invaginations	O
18	,	O
19	tilt	O
20	of	O
21	nuclear	O
22	axes	O
23	,	O
24	an	O
25	increase	O
26	in	O
27	the	O
28	number	O
29	and	O
30	size	O
31	of	O
32	lysosomes	O
33	and	O
34	multivesiculated	O
35	bodies	O
36	,	O
37	and	O
38	increased	O
39	numbers	O
40	of	O
41	enlarged	O
42	intramitochondrial	O
43	granules	O
44	.	O

1	The	O
2	routine	O
3	administration	O
4	of	O
5	fat	O
6	-	O
7	soluble	O
8	vitamins	O
9	appears	O
10	unnecessary	O
11	but	O
12	it	O
13	is	O
14	prudent	O
15	to	O
16	measure	O
17	prothrombin	B
18	time	O
19	and	O
20	serum	O
21	vitamins	O
22	A	O
23	and	O
24	E	O
25	at	O
26	intervals	O
27	.	O

1	Prostaglandins	O
2	F	O
3	(	O
4	PGF	O
5	)	O
6	were	O
7	measured	O
8	in	O
9	uterine	O
10	vein	O
11	,	O
12	ovarian	O
13	artery	O
14	,	O
15	and	O
16	jugular	O
17	vein	O
18	plasma	O
19	and	O
20	in	O
21	the	O
22	endometrial	O
23	tissues	O
24	at	O
25	various	O
26	times	O
27	during	O
28	the	O
29	bovine	O
30	estrous	O
31	cycle	O
32	,	O
33	and	O
34	were	O
35	compared	O
36	to	O
37	peripheral	O
38	plasma	O
39	progesterone	O
40	levels	O
41	.	O

1	Before	O
2	this	O
3	date	O
4	,	O
5	the	O
6	drug	O
7	directly	O
8	inhibits	O
9	fetal	O
10	weight	O
11	gain	O
12	,	O
13	whereas	O
14	the	O
15	sensitivity	O
16	of	O
17	the	O
18	placenta	O
19	is	O
20	only	O
21	transient	O
22	at	O
23	day	O
24	16	O
25	resulting	O
26	in	O
27	maximum	O
28	weight	O
29	decrease	O
30	of	O
31	this	O
32	organ	O
33	24	O
34	h	O
35	later	O
36	.	O

1	Groups	O
2	of	O
3	ten	O
4	dependent	O
5	and	O
6	ten	O
7	saline	O
8	mice	O
9	were	O
10	singly	O
11	tested	O
12	in	O
13	both	O
14	light	O
15	and	O
16	dark	O
17	conditions	O
18	in	O
19	each	O
20	of	O
21	five	O
22	covered	O
23	cylinders	O
24	(	O
25	2	O
26	-	O
27	23	O
28	in	O
29	high	O
30	).	O

1	The	O
2	effects	O
3	initiated	O
4	from	O
5	the	O
6	nucleus	O
7	accumbens	O
8	septi	O
9	were	O
10	most	O
11	marked	O
12	.	O

1	The	O
2	appearance	O
3	of	O
4	dyskinetic	O
5	movement	O
6	disorders	O
7	in	O
8	humans	O
9	following	O
10	the	O
11	chronic	O
12	use	O
13	of	O
14	levodopa	O
15	or	O
16	amphetamine	O
17	may	O
18	be	O
19	a	O
20	manifestation	O
21	of	O
22	similarly	O
23	increased	O
24	dopamine	B
25	receptor	I
26	site	I
27	sensitivity	O
28	within	O
29	the	O
30	striatum	O
31	.	O

1	Association	O
2	with	O
3	HL	B
4	-	I
5	A	I
6	W	I
7	-	I
8	27	I
9	.	O

1	Letter	O
2	:	O
3	Lactose	O
4	tolerance	O
5	tests	O
6	as	O
7	a	O
8	predictor	O
9	of	O
10	milk	O
11	tolerance	O
12	.	O

1	Retinoblastoma	O
2	:	O
3	a	O
4	study	O
5	of	O
6	natural	O
7	history	O
8	and	O
9	prognosis	O
10	of	O
11	268	O
12	cases	O
13	.	O

1	Like	O
2	pineal	O
3	melatonin	O
4	,	O
5	serum	O
6	melatonin	O
7	was	O
8	high	O
9	at	O
10	mid	O
11	-	O
12	dark	O
13	and	O
14	low	O
15	at	O
16	mid	O
17	-	O
18	light	O
19	.	O

1	D	O
2	.	O

1	Atherosclerosis	O

1	The	O
2	authors	O
3	concluded	O
4	that	O
5	ultrasonic	O
6	Doppler	O
7	-	O
8	cardiography	O
9	can	O
10	be	O
11	used	O
12	for	O
13	measuring	O
14	the	O
15	relative	O
16	changes	O
17	in	O
18	the	O
19	stroke	O
20	volume	O
21	.	O

1	The	O
2	attainment	O
3	of	O
4	sexual	O
5	maturity	O
6	in	O
7	terms	O
8	of	O
9	secondary	O
10	sexual	O
11	characteristics	O
12	,	O
13	the	O
14	production	O
15	of	O
16	spermatozoa	O
17	in	O
18	the	O
19	male	O
20	,	O
21	and	O
22	the	O
23	cyclical	O
24	female	O
25	pattern	O
26	with	O
27	release	O
28	of	O
29	ova	O
30	are	O
31	end	O
32	-	O
33	points	O
34	of	O
35	the	O
36	developmental	O
37	process	O
38	.	O

1	However	O
2	,	O
3	a	O
4	10	O
5	--	O
6	15	O
7	%	O
8	lengthening	O
9	of	O
10	the	O
11	partial	O
12	thromboplastin	B
13	time	O
14	is	O
15	evident	O
16	after	O
17	24	O
18	hours	O
19	of	O
20	storage	O
21	.	O

1	Caution	O
2	should	O
3	be	O
4	exercised	O
5	in	O
6	the	O
7	use	O
8	of	O
9	these	O
10	dyes	O
11	for	O
12	lymphograms	O
13	.	O

1	This	O
2	reveals	O
3	a	O
4	new	O
5	test	O
6	for	O
7	short	O
8	saphenous	O
9	incompetence	O
10	and	O
11	shows	O
12	that	O
13	14	O
14	per	O
15	cent	O
16	of	O
17	varices	O
18	stem	O
19	from	O
20	a	O
21	saphenopopliteal	O
22	reflux	O
23	.	O

1	Three	O
2	groups	O
3	of	O
4	patients	O
5	who	O
6	had	O
7	undergone	O
8	subtotal	O
9	thyroidectomy	O
10	for	O
11	Graves	O
12	'	O
13	s	O
14	disease	O
15	,	O
16	toxic	O
17	multinodular	O
18	goitre	O
19	,	O
20	or	O
21	euthyroid	O
22	multinodular	O
23	goitre	O
24	12	O
25	to	O
26	15	O
27	years	O
28	before	O
29	and	O
30	in	O
31	whom	O
32	a	O
33	normal	O
34	serum	O
35	thyroxine	O
36	(	O
37	T	O
38	-	O
39	4	O
40	)	O
41	level	O
42	was	O
43	found	O
44	were	O
45	each	O
46	divided	O
47	into	O
48	two	O
49	subgroups	O
50	on	O
51	the	O
52	basis	O
53	of	O
54	a	O
55	normal	O
56	or	O
57	a	O
58	raised	O
59	serum	O
60	thyrotrophin	B
61	concentration	O
62	.	O

1	Routine	O
2	isotope	O
3	cystography	O
4	using	O
5	99M	O
6	Tc	O
7	sulfur	O
8	colloid	O
9	for	O
10	detection	O
11	and	O
12	follow	O
13	-	O
14	up	O
15	of	O
16	vesico	O
17	-	O
18	ureteral	O
19	reflux	O

1	Air	O
2	ion	O
3	action	O
4	on	O
5	bacteria	O
6	.	O

1	No	O
2	evidence	O
3	of	O
4	either	O
5	positive	O
6	or	O
7	negative	O
8	chemography	O
9	was	O
10	found	O
11	.	O

1	The	O
2	interpretation	O
3	of	O
4	antibiotic	O
5	disc	O
6	sensitivities	O
7	.	O

1	Following	O
2	retransfusion	O
3	,	O
4	the	O
5	affected	O
6	epithelial	O
7	lining	O
8	appeared	O
9	greatly	O
10	distended	O
11	over	O
12	the	O
13	oedematous	O
14	lamina	O
15	propria	O
16	,	O
17	with	O
18	almost	O
19	complete	O
20	loss	O
21	of	O
22	structural	O
23	detail	O
24	.	O

1	A	O
2	study	O
3	of	O
4	chromosomes	O
5	of	O
6	lymphocytes	O
7	from	O
8	patients	O
9	treated	O
10	with	O
11	hycanthone	O
12	.	O

1	Characteristics	O
2	of	O
3	anesthesia	O
4	and	O
5	resuscitation	O
6	in	O
7	emergency	O
8	lung	O
9	surgery	O

1	Study	O
2	of	O
3	the	O
4	physico	O
5	-	O
6	chemical	O
7	state	O
8	of	O
9	plutonium	O
10	-	O
11	239	O
12	in	O
13	a	O
14	citrate	O
15	solution	O
16	-	O
17	blood	O
18	system	O

1	Tobramycin	O
2	60	O
3	mg	O
4	did	O
5	not	O
6	show	O
7	any	O
8	remarkable	O
9	effect	O
10	,	O
11	but	O
12	dibecacin	O
13	100	O
14	mg	O
15	produced	O
16	a	O
17	slight	O
18	potentiating	O
19	effect	O
20	on	O
21	the	O
22	action	O
23	of	O
24	d	O
25	-	O
26	tubocurarine	O
27	.	O

1	In	O
2	about	O
3	one	O
4	third	O
5	of	O
6	the	O
7	cases	O
8	this	O
9	operation	O
10	results	O
11	in	O
12	tonal	O
13	and	O
14	vocal	O
15	improvement	O
16	for	O
17	patients	O
18	suffering	O
19	from	O
20	progressive	O
21	perceptive	O
22	deafness	O
23	.	O

1	The	O
2	specific	O
3	electrical	O
4	resistance	O
5	of	O
6	the	O
7	cerebrospinal	O
8	fluid	O
9	was	O
10	measured	O
11	by	O
12	means	O
13	of	O
14	conductometry	O
15	in	O
16	14	O
17	cases	O
18	of	O
19	meningitis	O
20	purulenta	O
21	,	O
22	17	O
23	cases	O
24	of	O
25	meningitis	O
26	serosa	O
27	,	O
28	10	O
29	cases	O
30	of	O
31	encephalitis	O
32	and	O
33	in	O
34	32	O
35	control	O
36	subjects	O
37	.	O

1	2	O
2	-	O
3	Chemical	O
4	occlusion	O
5	of	O
6	vas	O
7	is	O
8	quite	O
9	effective	O
10	in	O
11	producing	O
12	a	O
13	block	O
14	in	O
15	the	O
16	vas	O
17	deferens	O
18	of	O
19	dogs	O
20	.	O

1	Besides	O
2	,	O
3	we	O
4	found	O
5	in	O
6	3	O
7	patients	O
8	increased	O
9	serum	B
10	immunoglobulins	I
11	,	O
12	chiefly	O
13	IgG	B
14	,	O
15	as	O
16	first	O
17	Russe	O
18	,	O
19	Busey	O
20	and	O
21	Barbeau	O
22	demonstrated	O
23	in	O
24	a	O
25	large	O
26	French	O
27	-	O
28	Canadian	O
29	family	O
30	.	O

1	We	O
2	suggest	O
3	that	O
4	such	O
5	occlusions	O
6	occurred	O
7	at	O
8	the	O
9	time	O
10	of	O
11	the	O
12	infarction	O
13	.	O

1	Streptococcal	O
2	preparation	O
3	(	O
4	OK	O
5	-	O
6	432	O
7	),	O
8	a	O
9	new	O
10	type	O
11	of	O
12	anti	O
13	-	O
14	cancer	O
15	agent	O
16	,	O
17	was	O
18	given	O
19	to	O
20	the	O
21	patients	O
22	with	O
23	advanced	O
24	cancer	O
25	in	O
26	combination	O
27	with	O
28	Mitomycin	O
29	-	O
30	C	O
31	,	O
32	5	O
33	-	O
34	FU	O
35	and	O
36	Cytosine	O
37	arabinoside	O
38	.	O

1	Generally	O
2	,	O
3	a	O
4	correlation	O
5	was	O
6	observed	O
7	between	O
8	highest	O
9	concentrations	O
10	of	O
11	CSF	B
12	immunoglobulins	I
13	and	O
14	degree	O
15	of	O
16	meningeal	O
17	inflammatory	O
18	response	O
19	,	O
20	even	O
21	if	O
22	this	O
23	was	O
24	a	O
25	component	O
26	of	O
27	other	O
28	neurological	O
29	diseases	O
30	.	O

1	Maternal	O
2	lactation	O

1	Experimental	O
2	cardiotoxicity	O
3	of	O
4	adriamycin	O

1	Muscular	O
2	pathology	O

1	Demonstration	O
2	of	O
3	the	O
4	agent	O
5	was	O
6	performed	O
7	from	O
8	the	O
9	6th	O
10	to	O
11	the	O
12	11th	O
13	day	O
14	p	O
15	.	O
16	i	O
17	.	O
18	by	O
19	direct	O
20	microscopic	O
21	methods	O
22	(	O
23	Stamp	O
24	and	O
25	auramine	O
26	staining	O
27	,	O
28	fluorescent	O
29	antibody	O
30	technique	O
31	);	O
32	the	O
33	Coxiella	O
34	content	O
35	was	O
36	determined	O
37	by	O
38	titration	O
39	in	O
40	embryonated	O
41	hen	O
42	'	O
43	s	O
44	eggs	O
45	.	O

1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	4	O
7	groups	O
8	receiving	O
9	NLA	O
10	II	O
11	with	O
12	or	O
13	without	O
14	nalorphine	O
15	,	O
16	morphine	O
17	or	O
18	Micoren	O
19	.	O

1	The	O
2	alterations	O
3	of	O
4	5	O
5	-	O
6	HT	O
7	and	O
8	5	O
9	-	O
10	HIAA	O
11	levels	O
12	in	O
13	several	O
14	regions	O
15	of	O
16	the	O
17	brain	O
18	under	O
19	the	O
20	conditions	O
21	examined	O
22	may	O
23	indicate	O
24	that	O
25	IDPN	O
26	'	O
27	s	O
28	neurotoxicity	O
29	primarily	O
30	affects	O
31	5	O
32	-	O
33	HT	O
34	-	O
35	containing	O
36	neurones	O
37	.	O

1	(	O
2	5	O
3	)	O
4	An	O
5	increase	O
6	in	O
7	leukocyte	O
8	-	O
9	counts	O
10	occurred	O
11	on	O
12	the	O
13	administration	O
14	of	O
15	serum	O
16	obtained	O
17	from	O
18	rabbit	O
19	during	O
20	phase	O
21	-	O
22	2	O
23	.	O

1	The	O
2	results	O
3	obtained	O
4	tend	O
5	to	O
6	prove	O
7	that	O
8	the	O
9	reticuloendothelial	O
10	system	O
11	mainly	O
12	participated	O
13	in	O
14	beryllium	O
15	retention	O
16	.	O

1	In	O
2	both	O
3	cases	O
4	,	O
5	at	O
6	the	O
7	end	O
8	of	O
9	exposure	O
10	the	O
11	same	O
12	level	O
13	of	O
14	blood	B
15	carboxyhemoglobin	I
16	(	O
17	COHb	B
18	)	O
19	(	O
20	about	O
21	50	O
22	%)	O
23	was	O
24	reached	O
25	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	increased	O
6	pulmonary	O
7	blood	O
8	flow	O
9	and	O
10	decreased	O
11	pulmonary	O
12	vascular	O
13	resistance	O
14	with	O
15	advancing	O
16	gestation	O
17	are	O
18	due	O
19	to	O
20	an	O
21	increase	O
22	in	O
23	the	O
24	total	O
25	number	O
26	of	O
27	vessels	O
28	and	O
29	increased	O
30	vasomotor	O
31	reactivity	O
32	is	O
33	related	O
34	to	O
35	an	O
36	increase	O
37	in	O
38	the	O
39	total	O
40	amount	O
41	of	O
42	smooth	O
43	muscle	O
44	while	O
45	the	O
46	thickness	O
47	of	O
48	muscle	O
49	in	O
50	individual	O
51	vessels	O
52	remains	O
53	constant	O
54	.	O

1	Reduction	O
2	in	O
3	dosage	O
4	restored	O
5	normal	O
6	taste	O
7	sense	O
8	in	O
9	all	O
10	three	O
11	,	O
12	but	O
13	in	O
14	two	O
15	the	O
16	drug	O
17	had	O
18	to	O
19	be	O
20	discontinued	O
21	because	O
22	of	O
23	persisting	O
24	high	O
25	transaminase	O
26	levels	O
27	.	O

1	The	O
2	calcium	O
3	ratio	O
4	(	O
5	mean	O
6	ratio	O
7	of	O
8	the	O
9	predicted	O
10	to	O
11	measured	O
12	TBCa	O
13	)	O
14	in	O
15	men	O
16	was	O
17	1	O
18	.	O
19	000	O
20	+/-	O
21	7	O
22	.	O
23	8	O
24	%	O
25	and	O
26	in	O
27	women	O
28	0	O
29	.	O
30	996	O
31	+/-	O
32	7	O
33	.	O
34	1	O
35	%.	O

1	A	O
2	late	O
3	diagnosis	O
4	of	O
5	retinoblastoma	O
6	is	O
7	an	O
8	unquestionable	O
9	fact	O
10	that	O
11	allows	O
12	its	O
13	growth	O
14	and	O
15	leads	O
16	to	O
17	a	O
18	deterioration	O
19	in	O
20	the	O
21	outlook	O
22	.	O

1	Total	O
2	cholesterol	O
3	was	O
4	measured	O
5	in	O
6	amniotic	O
7	fluids	O
8	collected	O
9	at	O
10	different	O
11	stages	O
12	of	O
13	gestation	O
14	.	O

1	Her	O
2	serum	O
3	FT3	O
4	concentration	O
5	was	O
6	,	O
7	however	O
8	,	O
9	much	O
10	higher	O
11	than	O
12	the	O
13	ranges	O
14	in	O
15	normal	O
16	pregnancy	O
17	or	O
18	in	O
19	GTD	O
20	patients	O
21	without	O
22	clinical	O
23	hyperthyroidism	O
24	.	O

1	The	O
2	authors	O
3	found	O
4	that	O
5	except	O
6	for	O
7	fear	O
8	and	O
9	pugnacity	O
10	all	O
11	husband	O
12	-	O
13	wife	O
14	trait	O
15	correlations	O
16	were	O
17	positive	O
18	,	O
19	in	O
20	contrast	O
21	to	O
22	Winch	O
23	'	O
24	s	O
25	principle	O
26	of	O
27	type	O
28	I	O
29	complementarity	O
30	.	O

1	A	O
2	note	O
3	on	O
4	the	O
5	phase	O
6	-	O
7	plane	O
8	technique	O
9	representation	O
10	of	O
11	cardiac	O
12	action	O
13	potentials	O
14	.	O

1	3	O
2	activities	O
3	of	O
4	the	O
5	factor	B
6	II	I
7	molecule	O
8	in	O
9	the	O
10	newborn	O
11	infant	O
12	at	O
13	term	O

1	The	O
2	concept	O
3	of	O
4	"	O
5	structural	O
6	identifiability	O
7	"	O
8	is	O
9	employed	O
10	in	O
11	this	O
12	analysis	O
13	to	O
14	determine	O
15	which	O
16	model	O
17	parameters	O
18	can	O
19	be	O
20	and	O
21	which	O
22	cannot	O
23	be	O
24	determined	O
25	"	O
26	uniquely	O
27	"	O
28	from	O
29	given	O
30	input	O
31	-	O
32	output	O
33	data	O
34	;	O
35	a	O
36	step	O
37	-	O
38	by	O
39	-	O
40	step	O
41	procedure	O
42	based	O
43	on	O
44	an	O
45	extension	O
46	of	O
47	this	O
48	concept	O
49	is	O
50	presented	O
51	for	O
52	adapting	O
53	the	O
54	overall	O
55	approach	O
56	to	O
57	the	O
58	experimental	O
59	design	O
60	problem	O
61	.	O

1	However	O
2	,	O
3	we	O
4	did	O
5	detect	O
6	lot	O
7	-	O
8	to	O
9	-	O
10	lot	O
11	variation	O
12	and	O
13	differences	O
14	in	O
15	performance	O
16	between	O
17	narrow	O
18	bandpass	O
19	and	O
20	wide	O
21	bandpass	O
22	spectrophotometers	O
23	.	O

1	The	O
2	cochlear	O
3	compromise	O
4	.	O

1	A	O
2	case	O
3	observed	O
4	in	O
5	Saigon	O

1	Hypertonic	O
2	glucose	O
3	administered	O
4	intrajejunally	O
5	in	O
6	Heidenhain	O
7	pouch	O
8	dogs	O
9	resulted	O
10	in	O
11	an	O
12	equal	O
13	inhibition	O
14	of	O
15	pentagastrin	O
16	-	O
17	induced	O
18	acid	O
19	secretion	O
20	from	O
21	the	O
22	pouch	O
23	and	O
24	the	O
25	main	O
26	stomach	O
27	,	O
28	whereas	O
29	hypertonic	O
30	saline	O
31	had	O
32	no	O
33	effect	O
34	.	O

1	Acquired	O
2	factor	B
3	VIII	I
4	inhibitor	O
5	in	O
6	non	O
7	-	O
8	hemophilic	O
9	patients	O

1	Biohydrogenation	O
2	of	O
3	linoleic	O
4	acid	O
5	into	O
6	octadecenoic	O
7	acid	O
8	was	O
9	observed	O
10	.	O

1	The	O
2	study	O
3	of	O
4	calcium	O
5	metabolism	O
6	in	O
7	ten	O
8	thalassaemic	O
9	children	O
10	comperatively	O
11	with	O
12	controls	O
13	after	O
14	oral	O
15	administration	O
16	of	O
17	47Ca	O
18	has	O
19	shown	O
20	diminished	O
21	intestinal	O
22	absorption	O
23	.	O

1	Chlamydial	O
2	agents	O
3	were	O
4	isolated	O
5	from	O
6	the	O
7	semen	O
8	near	O
9	the	O
10	end	O
11	of	O
12	the	O
13	chlamydemic	O
14	phase	O
15	.	O

1	Because	O
2	of	O
3	the	O
4	increased	O
5	CPK	B
6	activity	O
7	found	O
8	in	O
9	normal	O
10	newborns	O
11	,	O
12	screening	O
13	for	O
14	Duchenne	O
15	-	O
16	type	O
17	muscular	O
18	dystrophy	O
19	should	O
20	be	O
21	postponed	O
22	for	O
23	a	O
24	few	O
25	weeks	O
26	after	O
27	delivery	O
28	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	insulin	B
6	response	O
7	had	O
8	returned	O
9	to	O
10	the	O
11	non	O
12	-	O
13	pregnant	O
14	value	O
15	by	O
16	the	O
17	second	O
18	day	O
19	of	O
20	the	O
21	puerperium	O
22	.	O

1	The	O
2	authors	O
3	report	O
4	the	O
5	results	O
6	of	O
7	a	O
8	series	O
9	of	O
10	toxicological	O
11	tests	O
12	conducted	O
13	on	O
14	plastic	O
15	materials	O
16	(	O
17	polyethylene	O
18	)	O
19	activated	O
20	with	O
21	tetraphenylbutadiene	O
22	(	O
23	TPB	O
24	)	O
25	an	O
26	additive	O
27	recently	O
28	proposed	O
29	as	O
30	a	O
31	sensitizer	O
32	capable	O
33	of	O
34	photodegrading	O
35	plastic	O
36	materials	O
37	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	major	O
6	homology	O
7	region	O
8	of	O
9	Mason	O
10	-	O
11	Pfizer	O
12	monkey	O
13	virus	O
14	by	O
15	use	O
16	of	O
17	saturation	O
18	mutagenesis	O
19	.	O

1	One	O
2	site	O
3	,	O
4	PAL	B
5	,	O
6	occurs	O
7	within	O
8	the	O
9	10	O
10	bp	O
11	sequence	O
12	GGGGAGGAGG	O
13	.	O

1	Nuclear	O
2	extracts	O
3	prepared	O
4	from	O
5	both	O
6	neural	O
7	and	O
8	non	O
9	-	O
10	neural	O
11	cell	O
12	lines	O
13	,	O
14	mouse	O
15	brain	O
16	,	O
17	and	O
18	mouse	O
19	liver	O
20	contain	O
21	proteins	O
22	that	O
23	recognize	O
24	and	O
25	bind	O
26	to	O
27	the	O
28	PROX	O
29	and	O
30	PAL	O
31	sequences	O
32	indicating	O
33	that	O
34	proteins	O
35	which	O
36	bind	O
37	to	O
38	these	O
39	target	O
40	sequences	O
41	are	O
42	widespread	O
43	.	O

1	To	O
2	determine	O
3	if	O
4	the	O
5	NF	B
6	(	I
7	H	I
8	)	I
9	promoter	I
10	can	O
11	be	O
12	activated	O
13	in	O
14	a	O
15	tissue	O
16	specific	O
17	manner	O
18	during	O
19	development	O
20	transgenic	O
21	mice	O
22	containing	O
23	the	O
24	promoter	O
25	region	O
26	linked	O
27	to	O
28	a	O
29	beta	B
30	-	I
31	galactosidase	I
32	reporter	I
33	gene	I
34	were	O
35	generated	O
36	.	O

1	Here	O
2	we	O
3	describe	O
4	and	O
5	map	O
6	two	O
7	more	O
8	new	O
9	genes	O
10	identified	O
11	as	O
12	allele	O
13	-	O
14	specific	O
15	suppressors	O
16	that	O
17	compensate	O
18	for	O
19	carboxy	O
20	-	O
21	terminal	O
22	truncation	O
23	of	O
24	PET122	B
25	.	O

1	Previous	O
2	studies	O
3	have	O
4	shown	O
5	[	O
6	Hisanaga	O
7	,	O
8	S	O
9	.,	O
10	Kusubata	O
11	,	O
12	M	O
13	.,	O
14	Okumura	O
15	,	O
16	E	O
17	.	O
18	&	O
19	Kishimoto	O
20	,	O
21	T	O
22	.	O

1	Treatment	O
2	and	O
3	staining	O
4	of	O
5	smears	O
6	and	O
7	sections	O
8	for	O
9	detection	O
10	of	O
11	microorganisms	O

1	The	O
2	apparent	O
3	Kd	O
4	of	O
5	the	O
6	MetRS	B
7	/	I
8	CAU	I
9	operator	I
10	complex	I
11	is	O
12	one	O
13	order	O
14	magnitude	O
15	higher	O
16	than	O
17	that	O
18	of	O
19	the	O
20	ThrRS	B
21	/	I
22	CGU	I
23	operator	I
24	complex	I
25	.	O

1	A	O
2	significant	O
3	direct	O
4	relationship	O
5	was	O
6	observed	O
7	between	O
8	the	O
9	percent	O
10	area	O
11	density	O
12	of	O
13	smooth	O
14	muscle	O
15	and	O
16	the	O
17	percent	O
18	change	O
19	in	O
20	peak	O
21	urinary	O
22	flow	O
23	rate	O
24	.	O

1	Rabbit	B
2	skeletal	I
3	muscle	I
4	glycogenin	I
5	.	O

1	Characterization	O
2	of	O
3	the	O
4	human	B
5	gene	I
6	encoding	I
7	cytokeratin	I
8	17	I
9	and	O
10	its	O
11	expression	O
12	pattern	O
13	.	O

1	Animals	O
2	that	O
3	received	O
4	DSP	O
5	-	O
6	4	O
7	were	O
8	significantly	O
9	retarded	O
10	in	O
11	motor	O
12	recovery	O
13	compared	O
14	with	O
15	the	O
16	saline	O
17	group	O
18	.	O

1	The	O
2	prophylactic	O
3	use	O
4	of	O
5	new	O
6	medication	O
7	for	O
8	patients	O
9	between	O
10	the	O
11	first	O
12	and	O
13	second	O
14	cycle	O
15	of	O
16	chemotherapy	O
17	,	O
18	in	O
19	agreement	O
20	with	O
21	the	O
22	estimates	O
23	calculated	O
24	,	O
25	does	O
26	not	O
27	save	O
28	health	O
29	care	O
30	costs	O
31	but	O
32	may	O
33	improve	O
34	the	O
35	quality	O
36	of	O
37	life	O
38	in	O
39	these	O
40	patients	O
41	and	O
42	permit	O
43	the	O
44	continuation	O
45	of	O
46	a	O
47	therapeutic	O
48	schedule	O
49	without	O
50	interruption	O
51	which	O
52	may	O
53	improve	O
54	the	O
55	life	O
56	expectancy	O
57	of	O
58	the	O
59	patient	O
60	.	O

1	AP	O
2	was	O
3	induced	O
4	by	O
5	intraductal	O
6	infusion	O
7	of	O
8	two	O
9	different	O
10	concentrations	O
11	of	O
12	glycodeoxycholic	O
13	acid	O
14	(	O
15	GDOC	O
16	17	O
17	mmol	O
18	and	O
19	34	O
20	mmol	O
21	).	O

1	The	O
2	isolation	O
3	of	O
4	this	O
5	gene	O
6	was	O
7	based	O
8	on	O
9	the	O
10	identification	O
11	of	O
12	the	O
13	Y	O
14	-	O
15	231	O
16	cosmid	O
17	that	O
18	contains	O
19	CpG	O
20	rich	O
21	sequences	O
22	(	O
23	HTF	O
24	islands	O
25	)	O
26	in	O
27	its	O
28	human	O
29	insert	O
30	.	O

1	Tissue	B
2	plasminogen	I
3	activator	I
4	,	O
5	its	O
6	inhibitor	O
7	and	O
8	other	O
9	parameters	O
10	of	O
11	fibrinolysis	O
12	in	O
13	blood	O
14	of	O
15	patients	O
16	operated	O
17	for	O
18	mild	O
19	hypertrophy	O
20	of	O
21	the	O
22	prostate	O

1	Gene	O
2	constructs	O
3	consisting	O
4	of	O
5	human	B
6	growth	I
7	hormone	I
8	(	O
9	hGH	B
10	)	O
11	gene	O
12	driven	O
13	by	O
14	promoter	O
15	/	O
16	regulatory	O
17	sequence	O
18	of	O
19	mouse	B
20	metallothionein	I
21	(	O
22	mMT	B
23	),	O
24	viral	B
25	thymidine	I
26	kinase	I
27	(	O
28	vTK	B
29	),	O
30	rat	B
31	cholecystokinin	I
32	(	O
33	rCCK	B
34	),	O
35	or	O
36	chicken	B
37	beta	I
38	-	I
39	actin	I
40	(	O
41	cBA	B
42	)	O
43	gene	O
44	were	O
45	injected	O
46	into	O
47	the	O
48	cytoplasm	O
49	of	O
50	fertilized	O
51	medaka	O
52	eggs	O
53	via	O
54	the	O
55	micropyle	O
56	.	O

1	Serum	O
2	gastrin	B
3	and	O
4	AFP	B
5	levels	O
6	had	O
7	the	O
8	same	O
9	evolution	O
10	and	O
11	appear	O
12	to	O
13	have	O
14	the	O
15	same	O
16	interest	O
17	to	O
18	follow	O
19	the	O
20	course	O
21	of	O
22	the	O
23	disease	O
24	.	O

1	Prospects	O
2	for	O
3	controlled	O
4	-	O
5	delivery	O
6	systems	O
7	.	O

1	The	O
2	mean	O
3	(+/-	O
4	SD	O
5	)	O
6	PaO2	O
7	increased	O
8	from	O
9	80	O
10	.	O
11	8	O
12	+/-	O
13	26	O
14	.	O
15	9	O
16	mmHg	O
17	before	O
18	to	O
19	89	O
20	.	O
21	8	O
22	+/-	O
23	27	O
24	.	O
25	3	O
26	mmHg	O
27	after	O
28	the	O
29	infusion	O
30	(	O
31	P	O
32	<	O
33	0	O
34	.	O
35	05	O
36	)	O
37	and	O
38	the	O
39	PaCO2	O
40	decreased	O
41	from	O
42	42	O
43	.	O
44	4	O
45	+/-	O
46	8	O
47	.	O
48	3	O
49	to	O
50	39	O
51	.	O
52	6	O
53	+/-	O
54	7	O
55	.	O
56	9	O
57	mmHg	O
58	(	O
59	P	O
60	<	O
61	0	O
62	.	O
63	05	O
64	).	O

1	Though	O
2	hepatomegaly	O
3	and	O
4	mild	O
5	elevation	O
6	of	O
7	enzymes	O
8	can	O
9	be	O
10	observed	O
11	in	O
12	a	O
13	significant	O
14	proportion	O
15	of	O
16	patients	O
17	,	O
18	involvement	O
19	of	O
20	liver	O
21	leading	O
22	to	O
23	acute	O
24	hepatitis	O
25	or	O
26	liver	O
27	cell	O
28	necrosis	O
29	is	O
30	a	O
31	relatively	O
32	uncommon	O
33	complication	O
34	in	O
35	P	O
36	.	O
37	falciparum	O
38	malaria	O
39	.	O

1	For	O
2	the	O
3	first	O
4	group	O
5	,	O
6	the	O
7	maximal	O
8	decrease	O
9	in	O
10	plasma	O
11	potassium	O
12	elicited	O
13	by	O
14	salbutamol	O
15	was	O
16	0	O
17	.	O
18	80	O
19	+/-	O
20	0	O
21	.	O
22	19	O
23	,	O
24	0	O
25	.	O
26	48	O
27	+/-	O
28	0	O
29	.	O
30	22	O
31	,	O
32	and	O
33	0	O
34	.	O
35	78	O
36	+/-	O
37	0	O
38	.	O
39	46	O
40	mmol	O
41	/	O
42	l	O
43	,	O
44	and	O
45	for	O
46	the	O
47	second	O
48	group	O
49	,	O
50	maximal	O
51	decrement	O
52	was	O
53	1	O
54	.	O
55	31	O
56	+/-	O
57	0	O
58	.	O
59	37	O
60	,	O
61	0	O
62	.	O
63	70	O
64	+/-	O
65	0	O
66	.	O
67	24	O
68	,	O
69	and	O
70	0	O
71	.	O
72	84	O
73	+/-	O
74	0	O
75	.	O
76	17	O
77	mmol	O
78	/	O
79	l	O
80	for	O
81	the	O
82	iv	O
83	,	O
84	po	O
85	,	O
86	and	O
87	it	O
88	routes	O
89	,	O
90	respectively	O
91	.	O

1	The	O
2	two	O
3	drugs	O
4	increase	O
5	the	O
6	rate	O
7	of	O
8	early	O
9	diastolic	O
10	filling	O
11	.	O

1	A	O
2	statistically	O
3	significant	O
4	improvement	O
5	due	O
6	to	O
7	the	O
8	administration	O
9	of	O
10	Bromergon	O
11	was	O
12	observed	O
13	in	O
14	symptoms	O
15	associated	O
16	with	O
17	overreactiveness	O
18	to	O
19	normal	O
20	prolactin	B
21	levels	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	abdominal	O
28	tension	O
29	,	O
30	edema	O
31	,	O
32	weight	O
33	gain	O
34	and	O
35	breast	O
36	tenderness	O
37	.	O

1	The	O
2	magnitude	O
3	of	O
4	the	O
5	early	O
6	response	O
7	was	O
8	241	O
9	+/-	O
10	51	O
11	%	O
12	in	O
13	A	O
14	(%	O
15	baseline	O
16	RL	O
17	;	O
18	mean	O
19	+/-	O
20	SE	O
21	),	O
22	and	O
23	significantly	O
24	less	O
25	in	O
26	B	O
27	(	O
28	119	O
29	+/-	O
30	7	O
31	%)	O
32	and	O
33	C	O
34	(	O
35	131	O
36	+/-	O
37	16	O
38	%)	O
39	(	O
40	p	O
41	<	O
42	0	O
43	.	O
44	01	O
45	).	O

1	Most	O
2	of	O
3	the	O
4	patients	O
5	presented	O
6	with	O
7	Transient	O
8	Ischemic	O
9	Attacks	O
10	(	O
11	64	O
12	%)	O
13	or	O
14	Reversible	O
15	Ischemic	O
16	Neurologic	O
17	Deficits	O
18	(	O
19	19	O
20	%).	O

1	We	O
2	cloned	O
3	the	O
4	third	O
5	human	O
6	gene	O
7	for	O
8	the	O
9	LD78	B
10	,	O
11	termed	O
12	LD78	B
13	gamma	I
14	and	O
15	the	O
16	sequence	O
17	analysis	O
18	showed	O
19	that	O
20	it	O
21	is	O
22	a	O
23	5	O
24	'-	O
25	truncated	O
26	pseudogene	O
27	.	O

1	This	O
2	analysis	O
3	,	O
4	together	O
5	with	O
6	a	O
7	consideration	O
8	of	O
9	the	O
10	SCBs	O
11	found	O
12	upstream	O
13	of	O
14	known	O
15	SWI4	B
16	,	I
17	6	I
18	-	O
19	dependent	O
20	genes	O
21	,	O
22	leads	O
23	to	O
24	the	O
25	proposal	O
26	of	O
27	a	O
28	revised	O
29	consensus	O
30	sequence	O
31	for	O
32	this	O
33	important	O
34	regulatory	O
35	element	O
36	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	a	O
5	DNA	O
6	sequence	O
7	involved	O
8	in	O
9	linking	O
10	gene	O
11	expression	O
12	to	O
13	the	O
14	cell	O
15	cycle	O
16	.	O

1	The	O
2	natural	O
3	history	O
4	of	O
5	these	O
6	lesions	O
7	,	O
8	locoregional	O
9	efficiency	O
10	of	O
11	the	O
12	different	O
13	treatments	O
14	used	O
15	,	O
16	the	O
17	part	O
18	played	O
19	by	O
20	chemotherapy	O
21	,	O
22	survival	O
23	,	O
24	causes	O
25	of	O
26	death	O
27	and	O
28	therapeutic	O
29	modalities	O
30	used	O
31	as	O
32	a	O
33	last	O
34	measure	O
35	,	O
36	have	O
37	been	O
38	analysed	O
39	.	O

1	The	O
2	method	O
3	was	O
4	adapted	O
5	for	O
6	the	O
7	determination	O
8	of	O
9	nadolol	O
10	racemate	O
11	A	O
12	by	O
13	a	O
14	change	O
15	in	O
16	mobile	O
17	phase	O
18	composition	O
19	.	O

1	In	O
2	general	O
3	,	O
4	however	O
5	,	O
6	this	O
7	study	O
8	provided	O
9	little	O
10	evidence	O
11	of	O
12	any	O
13	effect	O
14	of	O
15	supplementation	O
16	to	O
17	athletic	O
18	performance	O
19	for	O
20	athletes	O
21	consuming	O
22	the	O
23	dietary	O
24	RDIs	O
25	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	histological	O
6	criteria	O
7	,	O
8	which	O
9	it	O
10	is	O
11	difficult	O
12	to	O
13	demand	O
14	in	O
15	view	O
16	of	O
17	the	O
18	variability	O
19	of	O
20	results	O
21	and	O
22	potential	O
23	dangers	O
24	of	O
25	endomyocardial	O
26	biopsy	O
27	involving	O
28	such	O
29	thin	O
30	and	O
31	fragile	O
32	ventricular	O
33	walls	O
34	,	O
35	the	O
36	diagnosis	O
37	of	O
38	ACRV	O
39	is	O
40	based	O
41	upon	O
42	the	O
43	concomitant	O
44	existence	O
45	of	O
46	:	O
47	(	O
48	1	O
49	)	O
50	electrophysiological	O
51	criteria	O
52	:	O
53	ventricular	O
54	arrhythmias	O
55	,	O
56	in	O
57	particular	O
58	sustained	O
59	monomorphous	O
60	VT	O
61	,	O
62	with	O
63	the	O
64	particular	O
65	feature	O
66	of	O
67	a	O
68	very	O
69	high	O
70	degree	O
71	of	O
72	sensitivity	O
73	to	O
74	adrenergic	O
75	stimulation	O
76	(	O
77	exercise	O
78	),	O
79	the	O
80	existence	O
81	of	O
82	late	O
83	potentials	O
84	on	O
85	the	O
86	high	O
87	amplification	O
88	ECG	O
89	,	O
90	a	O
91	highly	O
92	specific	O
93	sign	O
94	,	O
95	though	O
96	unfortunately	O
97	of	O
98	poor	O
99	sensitivity	O
100	in	O
101	localized	O
102	froms	O
103	,	O
104	those	O
105	which	O
106	are	O
107	most	O
108	difficult	O
109	to	O
110	identify	O
111	(	O
112	2	O
113	);	O
114	segmentary	O
115	morphological	O
116	and	O
117	kinetic	O
118	RV	O
119	abnormalities	O
120	,	O
121	most	O
122	often	O
123	resulting	O
124	in	O
125	localized	O
126	akinetic	O
127	or	O
128	dyskinetic	O
129	parietal	O
130	vaulting	O
131	,	O
132	with	O
133	stasis	O
134	"	O
135	in	O
136	situ	O
137	".	O

1	In	O
2	7	O
3	of	O
4	9	O
5	cases	O
6	,	O
7	the	O
8	enhancer	O
9	is	O
10	fused	O
11	to	O
12	the	O
13	c	B
14	-	I
15	myc	I
16	bearing	I
17	sequences	I
18	of	O
19	chromosome	O
20	8	O
21	.	O

1	These	O
2	components	O
3	both	O
4	had	O
5	a	O
6	median	O
7	R2	O
8	of	O
9	0	O
10	.	O
11	84	O
12	,	O
13	compared	O
14	to	O
15	median	O
16	R2s	O
17	ranging	O
18	from	O
19	0	O
20	.	O
21	37	O
22	to	O
23	0	O
24	.	O
25	83	O
26	for	O
27	five	O
28	commonly	O
29	used	O
30	ad	O
31	hoc	O
32	EEG	O
33	components	O
34	.	O

1	The	O
2	obtained	O
3	results	O
4	were	O
5	compared	O
6	with	O
7	control	O
8	group	O
9	(	O
10	10	O
11	female	O
12	volunteers	O
13	).	O

1	100	O
2	years	O
3	of	O
4	dentistry	O
5	at	O
6	the	O
7	Friedrich	O
8	Schiller	O
9	University	O
10	in	O
11	Jena	O

1	The	O
2	target	O
3	contained	O
4	between	O
5	positions	O
6	-	O
7	403	O
8	and	O
9	-	O
10	125	O
11	acts	O
12	independently	O
13	of	O
14	orientation	O
15	,	O
16	in	O
17	different	O
18	cell	O
19	types	O
20	and	O
21	species	O
22	,	O
23	and	O
24	in	O
25	the	O
26	context	O
27	of	O
28	a	O
29	heterologous	O
30	promoter	O
31	.	O

1	66	O
2	:	O
3	469	O
4	-	O
5	479	O
6	,	O
7	1992	O
8	).	O

1	Synergistic	O
2	transactivation	O
3	of	O
4	the	O
5	BMRF1	B
6	promoter	I
7	by	O
8	the	O
9	Z	B
10	/	O
11	c	B
12	-	I
13	myb	I
14	combination	O
15	appears	O
16	to	O
17	involve	O
18	direct	O
19	binding	O
20	by	O
21	the	O
22	Z	B
23	protein	I
24	but	O
25	not	O
26	the	O
27	c	B
28	-	I
29	myb	I
30	protein	I
31	.	O

1	The	O
2	UCR	O
3	core	O
4	sequence	O
5	,	O
6	CGCCATTTT	O
7	,	O
8	binds	O
9	a	O
10	ubiquitous	O
11	nuclear	O
12	factor	O
13	and	O
14	mediates	O
15	negative	O
16	regulation	O
17	of	O
18	MuLV	O
19	promoter	O
20	activity	O
21	.	O

1	These	O
2	studies	O
3	show	O
4	that	O
5	UCRBP	B
6	binds	O
7	to	O
8	various	O
9	target	O
10	motifs	O
11	that	O
12	are	O
13	distinct	O
14	from	O
15	the	O
16	UCR	O
17	motif	O
18	:	O
19	the	O
20	adeno	B
21	-	I
22	associated	I
23	virus	I
24	P5	I
25	promoter	I
26	and	O
27	elements	O
28	in	O
29	the	O
30	immunoglobulin	B
31	light	I
32	-	I
33	and	I
34	heavy	I
35	-	I
36	chain	I
37	genes	O
38	,	O
39	as	O
40	well	O
41	as	O
42	elements	O
43	in	O
44	ribosomal	B
45	protein	I
46	genes	I
47	.	O

1	Possibly	O
2	,	O
3	the	O
4	scr1	B
5	-	I
6	1	I
7	mutation	I
8	does	O
9	not	O
10	affect	O
11	signal	O
12	recognition	O
13	or	O
14	translational	O
15	arrest	O
16	but	O
17	instead	O
18	results	O
19	in	O
20	maintenance	O
21	of	O
22	translational	O
23	arrest	O
24	of	O
25	AEP	B
26	synthesis	O
27	.	O

1	The	O
2	cellular	O
3	sequences	O
4	5	O
5	'	O
6	to	O
7	the	O
8	viral	O
9	integration	O
10	site	O
11	exhibited	O
12	85	O
13	to	O
14	97	O
15	%	O
16	identity	O
17	to	O
18	several	O
19	sequences	O
20	belonging	O
21	to	O
22	the	O
23	mouse	B
24	L1	I
25	family	I
26	of	O
27	long	O
28	interspersed	O
29	repetitive	O
30	sequences	O
31	.	O

1	Both	O
2	Rep78	B
3	and	O
4	Rep68	B
5	cut	O
6	the	O
7	terminal	O
8	AAV	O
9	sequence	O
10	at	O
11	the	O
12	same	O
13	site	O
14	(	O
15	nucleotide	O
16	124	O
17	).	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	revealed	O
5	that	O
6	TAR	B
7	-	I
8	binding	I
9	protein	I
10	is	O
11	very	O
12	similar	O
13	to	O
14	the	O
15	CREB2	B
16	protein	I
17	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	N	O
7	-	O
8	and	O
9	C	O
10	-	O
11	terminal	O
12	mutations	O
13	are	O
14	required	O
15	to	O
16	inhibit	O
17	transrepression	O
18	by	O
19	FBR	B
20	protein	I
21	and	O
22	that	O
23	multiple	O
24	structural	O
25	mutations	O
26	accompanied	O
27	by	O
28	posttranslational	O
29	protein	O
30	modification	O
31	alter	O
32	gene	O
33	regulation	O
34	by	O
35	FBR	B
36	protein	I
37	.	O

1	The	O
2	JS78	O
3	mutation	O
4	changes	O
5	Gln243	O
6	in	O
7	gp0	O
8	.	O
9	7	O
10	to	O
11	an	O
12	amber	O
13	codon	O
14	,	O
15	which	O
16	explains	O
17	the	O
18	production	O
19	of	O
20	the	O
21	truncated	O
22	,	O
23	30	B
24	-	I
25	kDa	I
26	gp0	I
27	.	I
28	7	I
29	-	I
30	related	I
31	polypeptide	I
32	,	O
33	and	O
34	implicates	O
35	the	O
36	11	O
37	-	O
38	kDa	O
39	C	O
40	-	O
41	terminal	O
42	domain	O
43	in	O
44	host	O
45	transcription	O
46	shut	O
47	-	O
48	off	O
49	.	O

1	A	O
2	patient	O
3	suffering	O
4	from	O
5	heparin	O
6	-	O
7	associated	O
8	thrombocytopenia	O
9	(	O
10	HAT	O
11	),	O
12	recurrent	O
13	arteriothromboses	O
14	,	O
15	and	O
16	acute	O
17	renal	O
18	failure	O
19	after	O
20	treatment	O
21	with	O
22	standard	O
23	heparin	O
24	is	O
25	described	O
26	.	O

1	The	O
2	predicted	O
3	receptor	O
4	structure	O
5	includes	O
6	a	O
7	cysteine	O
8	-	O
9	rich	O
10	extracellular	O
11	domain	O
12	,	O
13	a	O
14	single	O
15	hydrophobic	O
16	transmembrane	O
17	domain	O
18	,	O
19	and	O
20	a	O
21	predicted	O
22	cytoplasmic	B
23	serine	I
24	/	I
25	threonine	I
26	kinase	I
27	domain	I
28	.	O

1	Drosophila	B
2	UbcD1	I
3	encodes	O
4	a	O
5	highly	O
6	conserved	O
7	ubiquitin	B
8	-	O
9	conjugating	O
10	enzyme	O
11	involved	O
12	in	O
13	selective	O
14	protein	O
15	degradation	O
16	.	O

1	Analysis	O
2	of	O
3	the	O
4	entire	O
5	16	O
6	.	O
7	7	O
8	-	O
9	kb	O
10	mt	O
11	genome	O
12	determined	O
13	that	O
14	a	O
15	MDP1	B
16	mediates	O
17	cleavage	O
18	of	O
19	chick	O
20	mtDNA	O
21	in	O
22	vitro	O
23	at	O
24	three	O
25	H	O
26	-	O
27	and	O
28	two	O
29	L	O
30	-	O
31	strand	O
32	sequence	O
33	-	O
34	specific	O
35	target	O
36	sites	O
37	located	O
38	within	O
39	a	O
40	90	O
41	-	O
42	bp	O
43	A	O
44	+	O
45	T	O
46	-	O
47	rich	O
48	genomic	O
49	tract	O
50	,	O
51	theoretically	O
52	capable	O
53	of	O
54	forming	O
55	stable	O
56	secondary	O
57	structures	O
58	,	O
59	approximately	O
60	200	O
61	bases	O
62	upstream	O
63	from	O
64	the	O
65	H	O
66	-	O
67	strand	O
68	origin	O
69	(	O
70	OH	O
71	)	O
72	of	O
73	replication	O
74	.	O

1	The	O
2	goal	O
3	of	O
4	the	O
5	present	O
6	study	O
7	was	O
8	to	O
9	determine	O
10	the	O
11	feasibility	O
12	of	O
13	retrovirus	O
14	mediated	O
15	expression	O
16	of	O
17	rp47phox	B
18	in	O
19	the	O
20	HL60	O
21	and	O
22	U937	O
23	human	O
24	hematopoietic	O
25	cell	O
26	lines	O
27	,	O
28	and	O
29	in	O
30	an	O
31	Epstein	O
32	-	O
33	Barr	O
34	virus	O
35	transformed	O
36	B	O
37	-	O
38	lymphocyte	O
39	cell	O
40	line	O
41	(	O
42	EBV	O
43	-	O
44	BCL	O
45	)	O
46	derived	O
47	from	O
48	a	O
49	p47phox	B
50	-	O
51	deficient	O
52	CGD	O
53	patient	O
54	.	O

1	Comparison	O
2	with	O
3	the	O
4	sequence	O
5	databanks	O
6	show	O
7	that	O
8	Tactile	B
9	is	O
10	a	O
11	member	O
12	of	O
13	the	O
14	immunoglobulin	B
15	gene	I
16	superfamily	I
17	,	O
18	with	O
19	similarity	O
20	to	O
21	Drosophila	B
22	amalgam	I
23	,	O
24	the	O
25	melanoma	B
26	Ag	I
27	MUC	I
28	-	I
29	18	I
30	,	O
31	members	O
32	of	O
33	the	O
34	carcinoembryonic	B
35	Ag	I
36	family	I
37	,	O
38	the	O
39	poliovirus	B
40	receptor	I
41	,	O
42	and	O
43	the	O
44	neural	B
45	cell	I
46	adhesion	I
47	molecule	I
48	.	O

1	A	O
2	rather	O
3	similar	O
4	pattern	O
5	of	O
6	results	O
7	was	O
8	obtained	O
9	with	O
10	respect	O
11	to	O
12	LMP2B	B
13	mRNA	I
14	expression	O
15	,	O
16	such	O
17	transcripts	O
18	being	O
19	detectable	O
20	only	O
21	in	O
22	a	O
23	subset	O
24	of	O
25	tumors	O
26	,	O
27	and	O
28	then	O
29	at	O
30	apparently	O
31	low	O
32	levels	O
33	.	O

1	The	O
2	phenotypes	O
3	of	O
4	the	O
5	ICP0	B
6	nonsense	O
7	mutants	O
8	were	O
9	intermediate	O
10	between	O
11	those	O
12	of	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	virus	O
18	and	O
19	7134	O
20	in	O
21	that	O
22	the	O
23	more	O
24	ICP0	B
25	-	I
26	coding	I
27	sequence	I
28	expressed	O
29	by	O
30	a	O
31	given	O
32	nonsense	O
33	mutant	O
34	,	O
35	the	O
36	more	O
37	wild	O
38	type	O
39	-	O
40	like	O
41	was	O
42	its	O
43	phenotype	O
44	.	O

1	Analysis	O
2	of	O
3	nucleotide	O
4	sequence	O
5	of	O
6	the	O
7	rightmost	O
8	43	O
9	kbp	O
10	of	O
11	herpesvirus	O
12	saimiri	O
13	(	O
14	HVS	O
15	)	O
16	L	O
17	-	O
18	DNA	O
19	:	O
20	general	O
21	conservation	O
22	of	O
23	genetic	O
24	organization	O
25	between	O
26	HVS	O
27	and	O
28	Epstein	O
29	-	O
30	Barr	O
31	virus	O
32	.	O

1	Treatment	O
2	with	O
3	MK	O
4	-	O
5	801	O
6	induced	O
7	a	O
8	burst	O
9	suppression	O
10	in	O
11	the	O
12	EEG	O
13	and	O
14	a	O
15	transient	O
16	drop	O
17	(	O
18	11	O
19	.	O
20	4	O
21	+/-	O
22	6	O
23	.	O
24	5	O
25	mm	O
26	Hg	O
27	)	O
28	in	O
29	the	O
30	mean	O
31	arterial	O
32	pressure	O
33	.	O

1	In	O
2	contrast	O
3	,	O
4	gel	O
5	mobility	O
6	shift	O
7	experiments	O
8	have	O
9	failed	O
10	to	O
11	reveal	O
12	that	O
13	HAP2	B
14	or	O
15	HAP3	B
16	binds	O
17	to	O
18	domain	O
19	1	O
20	or	O
21	that	O
22	hap3	B
23	mutations	O
24	affect	O
25	the	O
26	complexes	O
27	bound	O
28	to	O
29	it	O
30	.	O

1	Myogenic	O
2	differentiation	O
3	can	O
4	be	O
5	inhibited	O
6	by	O
7	the	O
8	adenovirus	O
9	E1a	B
10	protein	I
11	in	O
12	the	O
13	rat	O
14	L6	O
15	muscle	O
16	cell	O
17	line	O
18	.	O

1	The	O
2	experiment	O
3	results	O
4	showed	O
5	:	O
6	(	O
7	i	O
8	)	O
9	not	O
10	only	O
11	1O2	O
12	,	O
13	but	O
14	also	O
15	free	O
16	radicals	O
17	(	O
18	O2	O
19	-.	O
20	.	O
21	OH	O
22	and	O
23	YHPD	O
24	-.)	O
25	can	O
26	be	O
27	formed	O
28	by	O
29	the	O
30	aid	O
31	of	O
32	YHPD	O
33	;	O
34	and	O
35	(	O
36	ii	O
37	)	O
38	as	O
39	to	O
40	the	O
41	ability	O
42	of	O
43	producing	O
44	1O2	O
45	,	O
46	YHPD	O
47	less	O
48	than	O
49	BHPD	O
50	,	O
51	while	O
52	for	O
53	generating	O
54	O2	O
55	-.	O
56	and	O
57	.	O
58	OH	O
59	,	O
60	YHPD	O
61	greater	O
62	than	O
63	BHPD	O
64	.	O

1	Two	O
2	points	O
3	are	O
4	indicated	O
5	:	O
6	first	O
7	,	O
8	the	O
9	photosensitized	O
10	damage	O
11	of	O
12	YHPD	O
13	is	O
14	interrelated	O
15	to	O
16	not	O
17	only	O
18	1O2	O
19	,	O
20	but	O
21	also	O
22	free	O
23	radicals	O
24	(	O
25	O2	O
26	-.	O
27	.	O
28	OH	O
29	and	O
30	YHPD	O
31	-.);	O
32	second	O
33	,	O
34	although	O
35	the	O
36	photosensitized	O
37	damage	O
38	of	O
39	YHPD	O
40	is	O
41	stronger	O
42	than	O
43	that	O
44	of	O
45	BHPD	O
46	,	O
47	yet	O
48	the	O
49	photosensitized	O
50	damage	O
51	is	O
52	negatively	O
53	correlated	O
54	to	O
55	the	O
56	yield	O
57	of	O
58	1O2	O
59	but	O
60	positively	O
61	correlated	O
62	to	O
63	those	O
64	of	O
65	O2	O
66	-.	O
67	and	O
68	OH	O
69	.	O

1	Acad	O
2	.	O

1	Both	O
2	in	O
3	vitro	O
4	-	O
5	synthesized	O
6	S2	B
7	protein	I
8	and	O
9	synthetic	O
10	peptides	O
11	corresponding	O
12	to	O
13	S2	B
14	are	O
15	shown	O
16	to	O
17	react	O
18	positively	O
19	with	O
20	sera	O
21	obtained	O
22	from	O
23	EIAV	O
24	-	O
25	infected	O
26	horses	O
27	,	O
28	providing	O
29	the	O
30	first	O
31	direct	O
32	evidence	O
33	of	O
34	expression	O
35	of	O
36	this	O
37	protein	O
38	in	O
39	infected	O
40	animals	O
41	.	O

1	Many	O
2	canonical	O
3	TATA	O
4	sequences	O
5	are	O
6	present	O
7	upstream	O
8	from	O
9	these	O
10	VZV	O
11	transcriptional	O
12	start	O
13	sites	O
14	but	O
15	,	O
16	apparently	O
17	,	O
18	are	O
19	not	O
20	used	O
21	.	O

1	The	O
2	ORF	O
3	4	O
4	gene	O
5	was	O
6	minimally	O
7	active	O
8	,	O
9	whereas	O
10	the	O
11	ORF	O
12	62	O
13	gene	O
14	gave	O
15	twofold	O
16	induction	O
17	;	O
18	both	O
19	genes	O
20	,	O
21	acting	O
22	together	O
23	,	O
24	gave	O
25	fivefold	O
26	induction	O
27	.	O

1	Interestingly	O
2	,	O
3	the	O
4	IR5	B
5	ORF	I
6	of	O
7	EHV	O
8	-	O
9	1	O
10	possesses	O
11	a	O
12	sequence	O
13	of	O
14	13	O
15	amino	O
16	acids	O
17	(	O
18	CAYWCCLGHAFAC	O
19	)	O
20	that	O
21	is	O
22	a	O
23	perfect	O
24	match	O
25	to	O
26	the	O
27	consensus	O
28	zinc	O
29	finger	O
30	motif	O
31	(	O
32	C	O
33	-	O
34	X2	O
35	-	O
36	4	O
37	-	O
38	C	O
39	-	O
40	X2	O
41	-	O
42	15	O
43	-	O
44	C	O
45	/	O
46	H	O
47	-	O
48	X2	O
49	-	O
50	4	O
51	-	O
52	C	O
53	/	O
54	H	O
55	).	O

1	The	O
2	DNA	O
3	sequence	O
4	of	O
5	the	O
6	sulfate	B
7	activation	I
8	locus	I
9	from	O
10	Escherichia	O
11	coli	O
12	K	O
13	-	O
14	12	O
15	has	O
16	been	O
17	determined	O
18	.	O

1	The	O
2	unphosphorylated	O
3	form	O
4	of	O
5	RNA	B
6	polymerase	I
7	II	I
8	is	O
9	designated	O
10	IIA	O
11	,	O
12	whereas	O
13	the	O
14	phosphorylated	O
15	form	O
16	is	O
17	designated	O
18	IIO	O
19	.	O

1	RNA	B
2	polymerase	I
3	IIA	I
4	was	O
5	recovered	O
6	in	O
7	transcriptionally	O
8	active	O
9	complexes	O
10	in	O
11	reactions	O
12	in	O
13	which	O
14	the	O
15	input	O
16	enzyme	O
17	was	O
18	RNA	B
19	polymerase	I
20	IIA	I
21	.	O

1	Fructokinase	B
2	activity	O
3	is	O
4	elevated	O
5	up	O
6	to	O
7	twofold	O
8	when	O
9	Z	O
10	.	O
11	mobilis	O
12	was	O
13	grown	O
14	on	O
15	fructose	O
16	instead	O
17	of	O
18	glucose	O
19	,	O
20	and	O
21	there	O
22	was	O
23	a	O
24	parallel	O
25	increase	O
26	in	O
27	frk	B
28	mRNA	I
29	levels	O
30	.	O

1	Plasma	O
2	membranes	O
3	of	O
4	cultured	O
5	cells	O
6	contain	O
7	high	O
8	affinity	O
9	receptors	O
10	for	O
11	high	B
12	density	I
13	lipoprotein	I
14	(	O
15	HDL	B
16	)	O
17	that	O
18	appear	O
19	to	O
20	mediate	O
21	removal	O
22	of	O
23	excess	O
24	intracellular	O
25	cholesterol	O
26	.	O

1	After	O
2	the	O
3	first	O
4	28	O
5	patients	O
6	vincristine	O
7	was	O
8	replaced	O
9	by	O
10	teniposide	O
11	(	O
12	VM	O
13	-	O
14	26	O
15	)	O
16	due	O
17	to	O
18	neurotoxicity	O
19	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	an	O
6	internal	O
7	short	O
8	element	O
9	located	O
10	at	O
11	the	O
12	very	O
13	5	O
14	'	O
15	terminal	O
16	of	O
17	L1	B
18	sequence	I
19	and	O
20	the	O
21	nuclear	O
22	factor	O
23	binding	O
24	to	O
25	the	O
26	element	O
27	play	O
28	a	O
29	crucial	O
30	role	O
31	in	O
32	the	O
33	transcription	O
34	of	O
35	human	B
36	L1	I
37	.	O

1	Tumor	O
2	cells	O
3	were	O
4	focally	O
5	immunoreactive	O
6	for	O
7	neuron	B
8	-	I
9	specific	I
10	enolase	I
11	,	O
12	insulin	B
13	,	O
14	glucagon	B
15	and	O
16	VIP	B
17	.	O

1	A	O
2	recombinant	O
3	with	O
4	a	O
5	5	O
6	'	O
7	end	O
8	from	O
9	src	B
10	and	O
11	a	O
12	3	O
13	'	O
14	end	O
15	from	O
16	ros	B
17	,	O
18	called	O
19	SRC	B
20	x	O
21	ROS	B
22	,	O
23	transformed	O
24	chicken	O
25	embryo	O
26	fibroblasts	O
27	(	O
28	CEF	O
29	)	O
30	to	O
31	a	O
32	spindle	O
33	shape	O
34	morphology	O
35	,	O
36	mimicking	O
37	that	O
38	of	O
39	UR2	B
40	.	O

1	ROS	B
2	x	O
3	SRC	B
4	(	O
5	R	B
6	)	O
7	contains	O
8	a	O
9	16	O
10	-	O
11	amino	O
12	-	O
13	acid	O
14	deletion	O
15	that	O
16	includes	O
17	the	O
18	3	O
19	'	O
20	half	O
21	of	O
22	the	O
23	transmembrane	O
24	domain	O
25	of	O
26	ros	B
27	.	O

1	To	O
2	define	O
3	the	O
4	number	O
5	and	O
6	nature	O
7	of	O
8	the	O
9	E6	B
10	and	O
11	E7	B
12	gene	I
13	products	O
14	expressed	O
15	in	O
16	BPV	O
17	-	O
18	1	O
19	-	O
20	transformed	O
21	cells	O
22	,	O
23	we	O
24	performed	O
25	immunoprecipitation	O
26	experiments	O
27	with	O
28	antisera	O
29	raised	O
30	to	O
31	bacterially	O
32	expressed	O
33	BPV	B
34	-	I
35	1	I
36	E6	I
37	and	O
38	E7	B
39	fusion	I
40	proteins	I
41	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	showed	O
5	that	O
6	site	O
7	A	O
8	is	O
9	necessary	O
10	and	O
11	sufficient	O
12	for	O
13	RXR	B
14	alpha	I
15	-	O
16	mediated	O
17	transactivation	O
18	of	O
19	the	O
20	apoAI	B
21	gene	I
22	basal	I
23	promoter	I
24	in	O
25	human	O
26	hepatoma	O
27	HepG2	O
28	cells	O
29	in	O
30	the	O
31	presence	O
32	of	O
33	RA	O
34	and	O
35	that	O
36	this	O
37	transactivation	O
38	is	O
39	abolished	O
40	by	O
41	increasing	O
42	amounts	O
43	of	O
44	cotransfected	O
45	ARP	B
46	-	I
47	1	I
48	.	O

1	The	O
2	enhancer	O
3	region	O
4	of	O
5	Akv	O
6	murine	O
7	leukemia	O
8	virus	O
9	contains	O
10	the	O
11	sequence	O
12	motif	O
13	ACAGATGG	O
14	.	O

1	Two	O
2	splice	O
3	variants	O
4	of	O
5	ALF1	B
6	cDNA	I
7	have	O
8	been	O
9	found	O
10	,	O
11	differing	O
12	by	O
13	a	O
14	72	O
15	-	O
16	bp	O
17	insertion	O
18	,	O
19	coding	O
20	for	O
21	putative	O
22	proteins	O
23	of	O
24	682	O
25	and	O
26	706	O
27	amino	O
28	acids	O
29	.	O

1	A	O
2	third	O
3	prominent	O
4	component	O
5	of	O
6	apparent	O
7	molecular	O
8	mass	O
9	16	O
10	kDa	O
11	displayed	O
12	several	O
13	properties	O
14	,	O
15	including	O
16	ability	O
17	to	O
18	bind	O
19	45Ca2	O
20	+,	O
21	that	O
22	are	O
23	characteristic	O
24	of	O
25	the	O
26	regulatory	O
27	(	O
28	B	O
29	)	O
30	subunit	O
31	of	O
32	mammalian	B
33	calcineurin	I
34	and	O
35	was	O
36	recognized	O
37	by	O
38	an	O
39	antiserum	O
40	raised	O
41	against	O
42	bovine	B
43	calcineurin	I
44	.	O

1	As	O
2	was	O
3	observed	O
4	previously	O
5	for	O
6	MATa	B
7	cna1	I
8	cna2	I
9	double	O
10	mutants	O
11	,	O
12	MATa	B
13	cnb1	I
14	mutants	I
15	were	O
16	defective	O
17	in	O
18	their	O
19	ability	O
20	to	O
21	recover	O
22	from	O
23	alpha	B
24	-	I
25	factor	I
26	-	O
27	induced	O
28	growth	O
29	arrest	O
30	.	O

1	Antibodies	O
2	against	O
3	this	O
4	purified	O
5	protein	O
6	localize	O
7	RIM1	B
8	to	O
9	mitochondria	O
10	.	O

1	METHODS	O
2	:	O
3	IgG	B
4	antibodies	I
5	vs	O
6	HHV	O
7	-	O
8	6	O
9	(	O
10	anti	B
11	-	I
12	HHV	I
13	-	I
14	6	I
15	-	I
16	IgG	I
17	)	O
18	were	O
19	determined	O
20	by	O
21	indirect	O
22	immunofluorescence	O
23	in	O
24	100	O
25	IVDA	O
26	(	O
27	29	O
28	seronegative	O
29	and	O
30	71	O
31	seropositive	O
32	for	O
33	HIV	O
34	-	O
35	1	O
36	of	O
37	which	O
38	45	O
39	were	O
40	in	O
41	stage	O
42	II	O
43	and	O
44	26	O
45	in	O
46	IV	O
47	-	O
48	C1	O
49	of	O
50	CDC	O
51	)	O
52	as	O
53	well	O
54	as	O
55	in	O
56	100	O
57	healthy	O
58	subjects	O
59	of	O
60	a	O
61	similar	O
62	age	O
63	(	O
64	control	O
65	group	O
66	).	O

1	A	O
2	position	O
3	-	O
4	independent	O
5	activation	O
6	domain	O
7	which	O
8	contained	O
9	conserved	O
10	regions	O
11	II	O
12	and	O
13	III	O
14	was	O
15	identified	O
16	at	O
17	the	O
18	carboxyl	O
19	terminus	O
20	of	O
21	the	O
22	HNF	B
23	-	I
24	3	I
25	beta	I
26	protein	I
27	(	O
28	amino	O
29	acids	O
30	361	O
31	to	O
32	458	O
33	).	O

1	HNF	B
2	-	I
3	3	I
4	beta	I
5	amino	I
6	-	I
7	terminal	I
8	sequences	I
9	defined	O
10	by	O
11	conserved	O
12	region	O
13	IV	O
14	also	O
15	contributed	O
16	to	O
17	transactivation	O
18	,	O
19	but	O
20	region	O
21	IV	O
22	activity	O
23	required	O
24	the	O
25	participation	O
26	of	O
27	the	O
28	region	O
29	II	O
30	-	O
31	III	O
32	domain	O
33	.	O

1	Possible	O
2	roles	O
3	of	O
4	RAD5	B
5	putative	O
6	ATPase	B
7	/	O
8	DNA	B
9	helicase	I
10	activity	O
11	in	O
12	DNA	O
13	repair	O
14	and	O
15	in	O
16	the	O
17	maintenance	O
18	of	O
19	wild	O
20	-	O
21	type	O
22	rates	O
23	of	O
24	instability	O
25	of	O
26	simple	O
27	repetitive	O
28	sequences	O
29	are	O
30	discussed	O
31	.	O

1	Susceptibilities	O
2	of	O
3	540	O
4	anaerobic	O
5	gram	O
6	-	O
7	negative	O
8	bacilli	O
9	to	O
10	amoxicillin	O
11	,	O
12	amoxicillin	O
13	-	O
14	BRL	O
15	42715	O
16	,	O
17	amoxicillin	O
18	-	O
19	clavulanate	O
20	,	O
21	temafloxacin	O
22	,	O
23	and	O
24	clindamycin	O
25	.	O

1	Nocodazole	O
2	arrest	O
3	of	O
4	DU249	O
5	cells	O
6	was	O
7	exploited	O
8	for	O
9	the	O
10	detection	O
11	of	O
12	an	O
13	M	O
14	-	O
15	phase	O
16	-	O
17	activated	O
18	MBP	B
19	kinase	I
20	that	O
21	was	O
22	resolved	O
23	from	O
24	p41	B
25	MAP	I
26	kinase	I
27	by	O
28	phenyl	O
29	-	O
30	Superose	O
31	chromatography	O
32	.	O

1	The	O
2	hit1	B
3	-	I
4	1	I
5	mutation	O
6	caused	O
7	a	O
8	defect	O
9	in	O
10	synthesis	O
11	of	O
12	a	O
13	74	B
14	-	I
15	kD	I
16	heat	I
17	shock	I
18	protein	I
19	.	O

1	The	O
2	319	O
3	base	O
4	pair	O
5	region	O
6	immediately	O
7	upstream	O
8	of	O
9	the	O
10	CAP	O
11	site	O
12	is	O
13	characterized	O
14	by	O
15	the	O
16	lack	O
17	of	O
18	a	O
19	proximal	O
20	TATA	O
21	box	O
22	and	O
23	the	O
24	presence	O
25	of	O
26	sequences	O
27	similar	O
28	to	O
29	GC	O
30	boxes	O
31	,	O
32	CACCC	O
33	boxes	O
34	,	O
35	CCAAT	O
36	boxes	O
37	,	O
38	activator	B
39	protein	I
40	2	I
41	(	O
42	Ap	B
43	-	I
44	2	I
45	)	O
46	sites	O
47	,	O
48	partial	O
49	glucocorticoid	O
50	response	O
51	elements	O
52	(	O
53	GREs	O
54	),	O
55	and	O
56	partial	O
57	cyclic	O
58	AMP	O
59	response	O
60	elements	O
61	(	O
62	CREs	O
63	).	O

1	Cloning	O
2	and	O
3	primary	O
4	structure	O
5	of	O
6	neurocan	O
7	,	O
8	a	O
9	developmentally	O
10	regulated	O
11	,	O
12	aggregating	O
13	chondroitin	O
14	sulfate	O
15	proteoglycan	O
16	of	O
17	brain	O
18	.	O

1	In	O
2	rats	O
3	anaesthetized	O
4	with	O
5	+-	O
6	chloralose	O
7	the	O
8	changes	O
9	in	O
10	extracellular	O
11	pH	O
12	and	O
13	K	O
14	+	O
15	in	O
16	spinal	O
17	cord	O
18	dorsal	O
19	horn	O
20	were	O
21	studied	O
22	using	O
23	pH	O
24	and	O
25	K	O
26	+	O
27	ion	O
28	-	O
29	selective	O
30	electrodes	O
31	.	O

1	Replication	O
2	of	O
3	bovine	O
4	papillomavirus	O
5	-	O
6	1	O
7	(	O
8	BPV	O
9	-	O
10	1	O
11	)	O
12	DNA	O
13	requires	O
14	two	O
15	viral	O
16	gene	O
17	products	O
18	,	O
19	the	O
20	E1	B
21	protein	I
22	and	O
23	the	O
24	full	B
25	-	I
26	length	I
27	E2	I
28	protein	I
29	.	O

1	Insertional	O
2	inactivation	O
3	of	O
4	sms	B
5	led	O
6	to	O
7	increased	O
8	sensitivity	O
9	to	O
10	the	O
11	alkylating	O
12	agent	O
13	methylmethane	O
14	sulfonate	O
15	,	O
16	but	O
17	not	O
18	to	O
19	a	O
20	requirement	O
21	for	O
22	serine	O
23	or	O
24	other	O
25	metabolites	O
26	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	MAP	B
7	kinase	I
8	activator	I
9	/	O
10	MAP	B
11	kinase	I
12	system	O
13	may	O
14	be	O
15	the	O
16	downstream	O
17	components	O
18	of	O
19	ras	B
20	signal	O
21	transduction	O
22	pathways	O
23	.	O

1	NSCL	B
2	-	I
3	1	I
4	is	O
5	expressed	O
6	in	O
7	a	O
8	larger	O
9	number	O
10	of	O
11	these	O
12	cell	O
13	lines	O
14	.	O

1	Labile	O
2	LTR	B
3	-	I
4	binding	I
5	proteins	I
6	appear	O
7	to	O
8	be	O
9	essential	O
10	for	O
11	c	B
12	-	I
13	myc	I
14	hyperexpression	O
15	,	O
16	since	O
17	both	O
18	LTR	O
19	-	O
20	enhanced	O
21	transcription	O
22	and	O
23	the	O
24	activities	O
25	of	O
26	LTR	B
27	-	I
28	binding	I
29	proteins	I
30	are	O
31	specifically	O
32	decreased	O
33	after	O
34	inhibition	O
35	of	O
36	protein	O
37	synthesis	O
38	(	O
39	A	O
40	.	O

1	Ruddell	O
2	,	O
3	M	O
4	.	O

1	A	O
2	single	O
3	MEF	B
4	-	I
5	2	I
6	site	I
7	is	O
8	a	O
9	major	O
10	positive	O
11	regulatory	O
12	element	O
13	required	O
14	for	O
15	transcription	O
16	of	O
17	the	O
18	muscle	O
19	-	O
20	specific	O
21	subunit	O
22	of	O
23	the	O
24	human	B
25	phosphoglycerate	I
26	mutase	I
27	gene	I
28	in	O
29	skeletal	O
30	and	O
31	cardiac	O
32	muscle	O
33	cells	O
34	.	O

1	Truncation	O
2	variants	O
3	of	O
4	peptides	O
5	isolated	O
6	from	O
7	MHC	B
8	class	I
9	II	I
10	molecules	I
11	suggest	O
12	sequence	O
13	motifs	O
14	.	O

1	Although	O
2	the	O
3	E	O
4	-	O
5	box	O
6	consensus	O
7	is	O
8	minimally	O
9	defined	O
10	as	O
11	CANNTG	O
12	,	O
13	the	O
14	adjacent	O
15	nucleotides	O
16	of	O
17	functional	O
18	E	O
19	-	O
20	boxes	O
21	are	O
22	variable	O
23	for	O
24	genes	O
25	regulated	O
26	by	O
27	the	O
28	bHLH	B
29	proteins	I
30	.	O

1	Intermediate	O
2	levels	O
3	of	O
4	gene	O
5	activity	O
6	were	O
7	observed	O
8	for	O
9	TnI	B
10	enhancers	I
11	containing	O
12	E	O
13	-	O
14	boxes	O
15	derived	O
16	from	O
17	the	O
18	MCK	B
19	left	I
20	E	I
21	-	I
22	box	I
23	site	I
24	or	O
25	from	O
26	the	O
27	Ig	B
28	kappa	I
29	E2	I
30	E	I
31	-	I
32	box	I
33	.	O

1	T	B
2	-	I
3	cell	I
4	receptor	I
5	beta	I
6	(	O
7	TCR	B
8	beta	I
9	)	O
10	gene	O
11	rearrangements	O
12	occur	O
13	in	O
14	a	O
15	third	O
16	of	O
17	early	O
18	B	O
19	-	O
20	cell	O
21	acute	O
22	lymphoblastic	O
23	leukemias	O
24	(	O
25	ALLs	O
26	).	O

1	The	O
2	CANNTG	O
3	motifs	O
4	were	O
5	found	O
6	to	O
7	bind	O
8	MyoD	B
9	and	O
10	myogenin	B
11	fusion	I
12	proteins	I
13	and	O
14	to	O
15	interact	O
16	with	O
17	proteins	O
18	in	O
19	nuclear	O
20	extracts	O
21	from	O
22	cultured	O
23	myotubes	O
24	.	O

1	Peripheral	O
2	polyneuropathy	O
3	associated	O
4	with	O
5	multiple	O
6	myeloma	O
7	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	COX12	B
7	,	O
8	the	O
9	nuclear	O
10	gene	O
11	for	O
12	subunit	B
13	VIb	I
14	of	O
15	Saccharomyces	B
16	cerevisiae	I
17	cytochrome	I
18	c	I
19	oxidase	I
20	.	O

1	The	O
2	structure	O
3	of	O
4	the	O
5	calcineurin	B
6	A	I
7	gene	I
8	was	O
9	determined	O
10	by	O
11	comparison	O
12	of	O
13	the	O
14	genomic	O
15	and	O
16	cDNA	O
17	sequences	O
18	.	O

1	The	O
2	basal	O
3	promoter	O
4	elements	O
5	of	O
6	murine	B
7	cytochrome	I
8	c	I
9	oxidase	I
10	subunit	I
11	IV	I
12	gene	I
13	consist	O
14	of	O
15	tandemly	O
16	duplicated	O
17	ets	B
18	motifs	O
19	that	O
20	bind	O
21	to	O
22	GABP	B
23	-	I
24	related	I
25	transcription	I
26	factors	I
27	.	O

1	Lastly	O
2	,	O
3	there	O
4	are	O
5	multiple	O
6	instances	O
7	in	O
8	which	O
9	short	O
10	oligonucleotide	O
11	direct	O
12	repeats	O
13	flank	O
14	a	O
15	region	O
16	absent	O
17	from	O
18	either	O
19	variola	O
20	or	O
21	vaccinia	O
22	virus	O
23	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	short	O
6	synthetic	O
7	peptides	O
8	containing	O
9	the	O
10	pRB	B
11	-	I
12	binding	I
13	sequences	I
14	of	O
15	E1A	B
16	are	O
17	sufficient	O
18	for	O
19	interaction	O
20	with	O
21	p107	B
22	,	O
23	cyclin	B
24	A	I
25	,	O
26	and	O
27	p130	B
28	.	O

1	These	O
2	mutants	O
3	grow	O
4	normally	O
5	in	O
6	3T6	O
7	mouse	O
8	fibroblast	O
9	cells	O
10	,	O
11	and	O
12	they	O
13	do	O
14	not	O
15	complement	O
16	the	O
17	wild	O
18	-	O
19	type	O
20	virus	O
21	in	O
22	coinfection	O
23	experiments	O
24	of	O
25	C2	O
26	myoblasts	O
27	.	O

1	The	O
2	MICs	O
3	of	O
4	this	O
5	compound	O
6	against	O
7	90	O
8	%	O
9	of	O
10	these	O
11	organisms	O
12	,	O
13	except	O
14	for	O
15	methicillin	O
16	-	O
17	resistant	O
18	S	O
19	.	O
20	aureus	O
21	,	O
22	ranged	O
23	from	O
24	less	O
25	than	O
26	or	O
27	equal	O
28	to	O
29	0	O
30	.	O
31	006	O
32	to	O
33	3	O
34	.	O
35	13	O
36	micrograms	O
37	/	O
38	ml	O
39	.	O

1	The	O
2	minimal	O
3	promoter	O
4	of	O
5	the	O
6	RII	B
7	beta	I
8	gene	I
9	was	O
10	composed	O
11	of	O
12	two	O
13	adjacent	O
14	functional	O
15	elements	O
16	.	O

1	Mapping	O
2	the	O
3	cAMP	B
4	receptor	I
5	protein	I
6	contact	I
7	site	I
8	on	O
9	the	O
10	alpha	O
11	subunit	O
12	of	O
13	Escherichia	B
14	coli	I
15	RNA	I
16	polymerase	I
17	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	epidermal	B
6	growth	I
7	factor	I
8	or	O
9	platelet	B
10	-	I
11	derived	I
12	growth	I
13	factor	I
14	stimulation	O
15	of	O
16	intact	O
17	human	O
18	or	O
19	murine	O
20	cells	O
21	leads	O
22	to	O
23	phosphorylation	O
24	of	O
25	Nck	B
26	protein	I
27	on	O
28	tyrosine	O
29	,	O
30	serine	O
31	,	O
32	and	O
33	threonine	O
34	residues	O
35	.	O

1	A	O
2	major	O
3	mechanism	O
4	whereby	O
5	steroid	B
6	hydroxylase	I
7	gene	I
8	transcription	O
9	is	O
10	regulated	O
11	in	O
12	the	O
13	adrenal	O
14	cortex	O
15	requires	O
16	the	O
17	pituitary	O
18	peptide	O
19	hormone	O
20	,	O
21	ACTH	B
22	,	O
23	which	O
24	acts	O
25	via	O
26	cAMP	O
27	.	O

1	A	O
2	combination	O
3	of	O
4	comparative	O
5	sequence	O
6	analysis	O
7	and	O
8	thermodynamic	O
9	methods	O
10	reveals	O
11	the	O
12	conservation	O
13	of	O
14	tertiary	O
15	structure	O
16	elements	O
17	in	O
18	the	O
19	5	O
20	'	O
21	untranslated	O
22	region	O
23	(	O
24	UTR	O
25	)	O
26	of	O
27	human	O
28	enteroviruses	O
29	and	O
30	rhinoviruses	O
31	.	O

1	The	O
2	-	O
3	64	O
4	/-	O
5	37	O
6	region	O
7	interacted	O
8	with	O
9	purified	O
10	Sp1	B
11	and	O
12	an	O
13	unidentified	O
14	protein	O
15	(	O
16	s	O
17	),	O
18	proximal	B
19	regulatory	I
20	factor	I
21	(	I
22	s	I
23	)	I
24	I	I
25	(	O
26	PRF	B
27	-	I
28	I	I
29	).	O

1	Km	O
2	and	O
3	Vmax	O
4	for	O
5	two	O
6	substrates	O
7	,	O
8	src	B
9	-	I
10	related	I
11	peptide	I
12	and	O
13	poly	O
14	(	O
15	Glu	O
16	,	O
17	Tyr	O
18	)	O
19	(	O
20	4	O
21	:	O
22	1	O
23	),	O
24	were	O
25	2	O
26	.	O
27	4	O
28	mM	O
29	and	O
30	2	O
31	.	O
32	5	O
33	mumol	O
34	min	O
35	-	O
36	1	O
37	mg	O
38	-	O
39	1	O
40	and	O
41	0	O
42	.	O
43	26	O
44	mM	O
45	and	O
46	1	O
47	.	O
48	2	O
49	mumol	O
50	min	O
51	-	O
52	1	O
53	mg	O
54	-	O
55	1	O
56	,	O
57	respectively	O
58	.	O

1	This	O
2	soluble	O
3	form	O
4	of	O
5	the	O
6	HGFr	B
7	(	O
8	sHGFr	B
9	)	O
10	bound	O
11	HGF	B
12	with	O
13	an	O
14	affinity	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	the	O
20	authentic	O
21	,	O
22	membrane	O
23	-	O
24	associated	O
25	receptor	O
26	.	O

1	Strategies	O
2	for	O
3	blood	O
4	screening	O
5	for	O
6	the	O
7	hepatitis	O
8	C	O
9	virus	O
10	and	O
11	for	O
12	the	O
13	human	O
14	immunodeficiency	O
15	virus	O
16	in	O
17	high	O
18	risk	O
19	groups	O
20	.	O

1	Also	O
2	,	O
3	the	O
4	human	B
5	glycoprotein	I
6	alpha	I
7	-	I
8	subunit	I
9	promoter	I
10	was	O
11	induced	O
12	10	O
13	-	O
14	fold	O
15	by	O
16	FSK	B
17	in	O
18	GH4	O
19	rat	O
20	pituitary	O
21	cells	O
22	.(	O
23	ABSTRACT	O
24	TRUNCATED	O
25	AT	O
26	400	O
27	WORDS	O
28	)	O

1	Comparison	O
2	of	O
3	data	O
4	obtained	O
5	with	O
6	the	O
7	results	O
8	of	O
9	chronic	O
10	treatment	O
11	with	O
12	the	O
13	opioid	O
14	antagonist	O
15	permits	O
16	to	O
17	conclude	O
18	that	O
19	the	O
20	chronic	O
21	blockade	O
22	increases	O
23	the	O
24	fatiguability	O
25	to	O
26	a	O
27	great	O
28	extent	O
29	than	O
30	chronic	O
31	activation	O
32	of	O
33	opioid	O
34	system	O
35	.	O

1	Laboratory	O
2	studies	O
3	using	O
4	Ca45	O
5	labeled	O
6	teeth	O
7	and	O
8	biologically	O
9	stained	O
10	teeth	O
11	confirmed	O
12	that	O
13	the	O
14	dentifrice	O
15	did	O
16	not	O
17	decalcify	O
18	enamel	O
19	or	O
20	bleach	O
21	teeth	O
22	.	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	a	O
6	gene	O
7	from	O
8	Arabidopsis	O
9	thaliana	O
10	encoding	O
11	a	O
12	protein	O
13	related	O
14	to	O
15	SNF1	B
16	protein	O
17	kinase	O
18	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	characterized	O
6	a	O
7	55	O
8	-	O
9	kb	O
10	region	O
11	of	O
12	DNA	O
13	surrounding	O
14	HRAS1	B
15	.	O

1	The	O
2	ORF1	O
3	protein	O
4	was	O
5	found	O
6	to	O
7	be	O
8	highly	O
9	homologous	O
10	to	O
11	the	O
12	putative	O
13	potexvirus	B
14	RNA	I
15	replicases	I
16	;	O
17	ORF2	O
18	,	O
19	-	O
20	3	O
21	,	O
22	-	O
23	5	O
24	and	O
25	-	O
26	6	O
27	proteins	O
28	also	O
29	have	O
30	analogues	O
31	among	O
32	the	O
33	potex	O
34	-	O
35	and	O
36	/	O
37	or	O
38	carlavirus	O
39	-	O
40	encoded	O
41	proteins	O
42	.	O

1	A	O
2	total	O
3	of	O
4	281	O
5	patients	O
6	were	O
7	divided	O
8	into	O
9	groups	O
10	according	O
11	to	O
12	their	O
13	clinical	O
14	diagnosis	O
15	and	O
16	were	O
17	examined	O
18	using	O
19	capnography	O
20	,	O
21	spirometry	O
22	and	O
23	blood	O
24	-	O
25	gas	O
26	analysis	O
27	.	O

1	The	O
2	relationships	O
3	between	O
4	the	O
5	partial	O
6	pressures	O
7	of	O
8	O2	O
9	and	O
10	CO2	O
11	as	O
12	well	O
13	as	O
14	between	O
15	their	O
16	gradients	O
17	,	O
18	become	O
19	stronger	O
20	with	O
21	the	O
22	increase	O
23	of	O
24	the	O
25	ventilation	O
26	-	O
27	perfusion	O
28	ratio	O
29	.	O

1	No	O
2	significant	O
3	correlations	O
4	of	O
5	peak	O
6	VO2	O
7	were	O
8	observed	O
9	between	O
10	the	O
11	3	O
12	tests	O
13	.	O

1	An	O
2	RNA	B
3	-	I
4	binding	I
5	protein	I
6	gene	I
7	(	O
8	rbp1	B
9	)	O
10	from	O
11	Drosophila	O
12	melanogaster	O
13	,	O
14	encoding	O
15	an	O
16	RNA	O
17	recognition	O
18	motif	O
19	and	O
20	an	O
21	Arg	O
22	-	O
23	Ser	O
24	rich	O
25	(	O
26	RS	O
27	)	O
28	domain	O
29	,	O
30	has	O
31	been	O
32	characterized	O
33	.	O

1	Some	O
2	research	O
3	studies	O
4	have	O
5	related	O
6	this	O
7	kind	O
8	of	O
9	tumors	O
10	with	O
11	prolonged	O
12	ingestion	O
13	of	O
14	H2	O
15	inhibitors	O
16	and	O
17	others	O
18	antacid	O
19	.	O

1	A	O
2	comparative	O
3	study	O
4	of	O
5	the	O
6	total	O
7	protein	O
8	profiles	O
9	of	O
10	wild	O
11	-	O
12	type	O
13	S	O
14	.	O
15	entomophila	O
16	UC9	O
17	and	O
18	mutant	O
19	UC21	O
20	revealed	O
21	that	O
22	the	O
23	mutant	O
24	lacked	O
25	an	O
26	approximately	O
27	44	O
28	-	O
29	kDa	O
30	protein	O
31	and	O
32	overexpressed	O
33	an	O
34	approximately	O
35	20	O
36	-	O
37	kDa	O
38	protein	O
39	.	O

1	Characterization	O
2	of	O
3	the	O
4	regulon	O
5	controlled	O
6	by	O
7	the	O
8	leucine	B
9	-	I
10	responsive	I
11	regulatory	I
12	protein	I
13	in	O
14	Escherichia	O
15	coli	O
16	.	O

1	Mapping	O
2	of	O
3	the	O
4	mouse	B
5	ornithine	I
6	decarboxylase	I
7	-	I
8	related	I
9	sequence	I
10	family	I
11	.	O

1	This	O
2	mutation	O
3	also	O
4	results	O
5	in	O
6	markedly	O
7	decreased	O
8	levels	O
9	of	O
10	CAD	B
11	mRNA	I
12	and	O
13	protein	O
14	in	O
15	the	O
16	mutant	O
17	.	O

1	The	O
2	rationale	O
3	for	O
4	continuous	O
5	dopaminergic	O
6	stimulation	O
7	in	O
8	patients	O
9	with	O
10	Parkinson	O
11	'	O
12	s	O
13	disease	O
14	.	O

1	Mutational	O
2	studies	O
3	revealed	O
4	that	O
5	it	O
6	was	O
7	the	O
8	homeodomain	B
9	binding	I
10	site	I
11	II	I
12	sequence	I
13	that	O
14	was	O
15	required	O
16	for	O
17	this	O
18	regulation	O
19	.	O

1	Thus	O
2	,	O
3	the	O
4	pol	B
5	alpha	I
6	-	O
7	primase	B
8	complex	O
9	appears	O
10	to	O
11	act	O
12	processively	O
13	for	O
14	only	O
15	a	O
16	short	O
17	distance	O
18	.	O

1	Interestingly	O
2	,	O
3	the	O
4	positions	O
5	of	O
6	these	O
7	introns	O
8	have	O
9	been	O
10	conserved	O
11	in	O
12	comparison	O
13	with	O
14	the	O
15	genes	O
16	of	O
17	two	O
18	other	O
19	transglutaminase	O
20	-	O
21	like	O
22	activities	O
23	described	O
24	in	O
25	the	O
26	literature	O
27	,	O
28	but	O
29	the	O
30	TGM1	B
31	gene	I
32	is	O
33	by	O
34	far	O
35	the	O
36	smallest	O
37	characterized	O
38	to	O
39	date	O
40	because	O
41	its	O
42	introns	O
43	are	O
44	relatively	O
45	smaller	O
46	.	O

1	In	O
2	a	O
3	retrospective	O
4	analysis	O
5	of	O
6	data	O
7	from	O
8	35	O
9	cases	O
10	with	O
11	malignant	O
12	lymphoma	O
13	from	O
14	a	O
15	cohort	O
16	of	O
17	2017	O
18	HIV	O
19	-	O
20	infected	O
21	patients	O
22	,	O
23	the	O
24	stage	O
25	of	O
26	HIV	O
27	-	O
28	disease	O
29	,	O
30	the	O
31	CD4	B
32	counts	O
33	at	O
34	the	O
35	time	O
36	of	O
37	diagnosis	O
38	,	O
39	and	O
40	the	O
41	use	O
42	of	O
43	antineoplastic	O
44	agents	O
45	or	O
46	radiotherapy	O
47	were	O
48	correlated	O
49	with	O
50	outcome	O
51	.	O

1	1	O
2	.	O

1	Effects	O
2	of	O
3	dioxins	O
4	on	O
5	thyroid	O
6	function	O
7	in	O
8	newborn	O
9	babies	O
10	.	O

1	cDNA	O
2	clones	O
3	encoding	O
4	Arabidopsis	O
5	thaliana	O
6	and	O
7	Zea	B
8	mays	I
9	mitochondrial	I
10	chaperonin	I
11	HSP60	I
12	and	O
13	gene	O
14	expression	O
15	during	O
16	seed	O
17	germination	O
18	and	O
19	heat	O
20	shock	O
21	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	comparison	O
5	revealed	O
6	significant	O
7	homology	O
8	between	O
9	the	O
10	yeast	B
11	and	I
12	Escherichia	I
13	coli	I
14	gamma	I
15	-	I
16	glutamyl	I
17	kinases	I
18	throughout	O
19	their	O
20	lengths	O
21	.	O

1	The	O
2	single	O
3	site	O
4	of	O
5	glycosylation	O
6	is	O
7	located	O
8	near	O
9	the	O
10	C	O
11	-	O
12	terminus	O
13	in	O
14	the	O
15	N	O
16	-	O
17	glycosylation	O
18	sequon	O
19	-	O
20	Asn	O
21	-	O
22	Cys	O
23	-	O
24	Ser	O
25	-	O
26	in	O
27	which	O
28	Cys	O
29	forms	O
30	part	O
31	of	O
32	a	O
33	disulphide	O
34	bridge	O
35	.	O

1	The	O
2	pulmonary	O
3	toxic	O
4	events	O
5	induced	O
6	by	O
7	acute	O
8	nitrogen	O
9	dioxide	O
10	(	O
11	NO	O
12	)	O
13	2	O
14	exposure	O
15	were	O
16	studied	O
17	in	O
18	the	O
19	rat	O
20	to	O
21	develop	O
22	an	O
23	inhalation	O
24	model	O
25	to	O
26	investigate	O
27	therapeutic	O
28	measures	O
29	.	O

1	The	O
2	pulmonary	O
3	effects	O
4	observed	O
5	,	O
6	became	O
7	more	O
8	pronounced	O
9	with	O
10	increasing	O
11	NO2	O
12	concentrations	O
13	(	O
14	0	O
15	,	O
16	25	O
17	,	O
18	75	O
19	,	O
20	125	O
21	,	O
22	175	O
23	or	O
24	200	O
25	ppm	O
26	,	O
27	1	O
28	ppm	O
29	NO2	O
30	=	O
31	1	O
32	.	O
33	88	O
34	mg	O
35	m	O
36	-	O
37	3	O
38	NO2	O
39	)	O
40	and	O
41	exposure	O
42	times	O
43	(	O
44	5	O
45	,	O
46	10	O
47	,	O
48	20	O
49	or	O
50	30	O
51	min	O
52	).	O

1	Interaction	O
2	of	O
3	H	B
4	-	I
5	2Eb	I
6	with	O
7	an	O
8	IAP	B
9	retrotransposon	I
10	in	O
11	the	O
12	A20	O
13	/	O
14	2J	O
15	B	O
16	cell	O
17	lymphoma	O
18	.	O

1	Gestational	O
2	trophoblastic	O
3	diseases	O
4	:	O
5	recent	O
6	advances	O
7	in	O
8	the	O
9	understanding	O
10	of	O
11	cytogenetics	O
12	,	O
13	histopathology	O
14	,	O
15	and	O
16	natural	O
17	history	O
18	.	O

1	With	O
2	the	O
3	exception	O
4	of	O
5	mutants	O
6	that	O
7	remove	O
8	the	O
9	membrane	O
10	anchor	O
11	domain	O
12	,	O
13	all	O
14	of	O
15	the	O
16	mutant	O
17	glycoproteins	O
18	retained	O
19	the	O
20	ability	O
21	to	O
22	cause	O
23	fusion	O
24	of	O
25	CD4	B
26	-	O
27	bearing	O
28	cells	O
29	.	O

1	The	O
2	subunit	O
3	protein	O
4	of	O
5	curli	B
6	was	O
7	highly	O
8	homologous	O
9	at	O
10	its	O
11	amino	O
12	terminus	O
13	to	O
14	SEF	B
15	-	I
16	17	I
17	,	O
18	the	O
19	subunit	O
20	protein	O
21	of	O
22	thin	O
23	,	O
24	aggregative	O
25	fimbriae	O
26	of	O
27	Salmonella	O
28	enteritidis	O
29	27655	O
30	strain	O
31	3b	O
32	,	O
33	suggesting	O
34	that	O
35	these	O
36	fibres	O
37	form	O
38	a	O
39	novel	O
40	class	O
41	of	O
42	surface	O
43	organelles	O
44	on	O
45	enterobacteria	O
46	.	O

1	Substitution	O
2	of	O
3	the	O
4	DR1	B
5	beta	I
6	chain	I
7	with	O
8	H	B
9	-	I
10	2E	I
11	beta	I
12	k	I
13	led	O
14	to	O
15	a	O
16	dramatic	O
17	loss	O
18	of	O
19	recognition	O
20	;	O
21	alpha	O
22	chain	O
23	substitution	O
24	had	O
25	a	O
26	less	O
27	marked	O
28	effect	O
29	.	O

1	This	O
2	negative	O
3	regulatory	O
4	pathway	O
5	may	O
6	be	O
7	important	O
8	for	O
9	determining	O
10	cell	O
11	fate	O
12	or	O
13	maintaining	O
14	an	O
15	inducible	O
16	state	O
17	in	O
18	the	O
19	ventroposterior	O
20	region	O
21	of	O
22	the	O
23	embryo	O
24	.	O

1	The	O
2	distal	O
3	portion	O
4	of	O
5	the	O
6	rat	B
7	insulin	I
8	I	I
9	gene	I
10	5	I
11	'-	I
12	flanking	I
13	DNA	I
14	contains	O
15	two	O
16	sequence	O
17	elements	O
18	,	O
19	the	O
20	Far	O
21	and	O
22	FLAT	O
23	elements	O
24	,	O
25	that	O
26	can	O
27	function	O
28	in	O
29	combination	O
30	,	O
31	but	O
32	not	O
33	separately	O
34	,	O
35	as	O
36	a	O
37	beta	O
38	-	O
39	cell	O
40	-	O
41	specific	O
42	transcriptional	O
43	enhancer	O
44	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	exhibited	O
7	98	O
8	%	O
9	identity	O
10	to	O
11	the	O
12	human	O
13	cellular	O
14	transglutaminase	O
15	sequence	O
16	.	O

1	This	O
2	computation	O
3	is	O
4	performed	O
5	by	O
6	a	O
7	parallel	O
8	network	O
9	of	O
10	locally	O
11	connected	O
12	neuron	O
13	-	O
14	like	O
15	elements	O
16	.	O

1	Repeated	O
2	efforts	O
3	to	O
4	isolate	O
5	recombinant	O
6	baculoviruses	O
7	containing	O
8	a	O
9	wild	O
10	-	O
11	type	O
12	kinase	O
13	failed	O
14	,	O
15	whereas	O
16	recombinants	O
17	expressing	O
18	a	O
19	nonfunctional	O
20	kinase	O
21	with	O
22	a	O
23	catalytic	O
24	domain	O
25	II	O
26	mutation	O
27	were	O
28	readily	O
29	isolated	O
30	.	O

1	Finally	O
2	,	O
3	we	O
4	determined	O
5	that	O
6	the	O
7	P68	B
8	amino	O
9	terminus	O
10	was	O
11	both	O
12	necessary	O
13	and	O
14	sufficient	O
15	for	O
16	binding	O
17	dsRNA	O
18	as	O
19	we	O
20	were	O
21	able	O
22	to	O
23	transfer	O
24	dsRNA	O
25	-	O
26	binding	O
27	properties	O
28	to	O
29	a	O
30	reporter	O
31	gene	O
32	product	O
33	previously	O
34	unable	O
35	to	O
36	bind	O
37	RNA	O
38	.	O

1	From	O
2	August	O
3	1989	O
4	to	O
5	October	O
6	1990	O
7	,	O
8	83	O
9	pregnant	O
10	Chinese	O
11	women	O
12	were	O
13	the	O
14	subjects	O
15	for	O
16	measuring	O
17	the	O
18	levels	O
19	of	O
20	plasma	O
21	functional	O
22	antithrombin	B
23	III	I
24	(	O
25	AT	B
26	III	I
27	)	O
28	activity	O
29	.	O

1	Visual	O
2	acuity	O
3	may	O
4	be	O
5	decreased	O
6	by	O
7	transient	O
8	changes	O
9	in	O
10	refractive	O
11	error	O
12	caused	O
13	by	O
14	sulfonamides	O
15	,	O
16	the	O
17	antifungal	O
18	agent	O
19	metronidazole	O
20	,	O
21	thiazide	O
22	diuretics	O
23	,	O
24	and	O
25	carbonic	B
26	anhydrase	I
27	inhibitors	O
28	.	O

1	Currents	O
2	aspects	O
3	of	O
4	H2	B
5	receptor	I
6	antagonists	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	ulcers	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	21	O
6	-	O
7	mer	O
8	subrepeat	O
9	structure	O
10	is	O
11	also	O
12	present	O
13	in	O
14	each	O
15	unit	O
16	.	O

1	Sequencing	O
2	revealed	O
3	one	O
4	large	O
5	open	O
6	reading	O
7	frame	O
8	encoding	O
9	a	O
10	39	O
11	-	O
12	kDa	O
13	protein	O
14	.	O

1	These	O
2	sites	O
3	are	O
4	also	O
5	potential	O
6	keratan	O
7	sulfate	O
8	attachment	O
9	sites	O
10	.	O

1	We	O
2	propose	O
3	that	O
4	plasmids	O
5	of	O
6	the	O
7	pLS1	O
8	family	O
9	(	O
10	pE194	O
11	,	O
12	pADB201	O
13	,	O
14	and	O
15	pLB4	O
16	)	O
17	share	O
18	functional	O
19	and	O
20	structural	O
21	characteristics	O
22	for	O
23	the	O
24	regulation	O
25	of	O
26	their	O
27	copy	O
28	numbers	O
29	.	O

1	Perturbation	O
2	of	O
3	dNTP	O
4	pools	O
5	also	O
6	affected	O
7	the	O
8	frameshift	O
9	fidelity	O
10	of	O
11	the	O
12	replicative	O
13	yeast	B
14	DNA	I
15	polymerase	I
16	alpha	I
17	.	O

1	Differential	O
2	expression	O
3	of	O
4	the	O
5	"	O
6	B	O
7	"	O
8	subunit	O
9	of	O
10	the	O
11	vacuolar	B
12	H	I
13	(+)-	I
14	ATPase	I
15	in	O
16	bovine	O
17	tissues	O
18	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	hGCSFR	B
6	gene	I
7	was	O
8	chromosomally	O
9	localized	O
10	by	O
11	Southern	O
12	blot	O
13	analysis	O
14	of	O
15	its	O
16	segregation	O
17	pattern	O
18	in	O
19	a	O
20	panel	O
21	of	O
22	rodent	O
23	-	O
24	human	O
25	hybrid	O
26	DNAs	O
27	using	O
28	the	O
29	radiolabeled	O
30	cDNA	O
31	probe	O
32	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	characterised	O
6	a	O
7	differentially	O
8	-	O
9	regulated	O
10	gene	O
11	family	O
12	in	O
13	the	O
14	protozoan	O
15	parasite	O
16	Leishmania	O
17	major	O
18	.	O

1	At	O
2	some	O
3	sites	O
4	,	O
5	%	O
6	T	O
7	is	O
8	greatly	O
9	increased	O
10	by	O
11	Cl	O
12	-	O
13	concentrations	O
14	up	O
15	to	O
16	1	O
17	M	O
18	,	O
19	while	O
20	at	O
21	other	O
22	sites	O
23	%	O
24	T	O
25	is	O
26	reduced	O
27	or	O
28	unaffected	O
29	by	O
30	these	O
31	conditions	O
32	.	O

1	Necrosis	O
2	appears	O
3	6	O
4	h	O
5	after	O
6	TA	O
7	infusion	O
8	,	O
9	being	O
10	5	O
11	.	O
12	77	O
13	%	O
14	in	O
15	extent	O
16	after	O
17	12	O
18	h	O
19	,	O
20	14	O
21	.	O
22	9	O
23	%	O
24	after	O
25	24	O
26	h	O
27	and	O
28	animals	O
29	die	O
30	with	O
31	an	O
32	area	O
33	of	O
34	29	O
35	.	O
36	5	O
37	%	O
38	necrosis	O
39	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	segments	O
6	of	O
7	C3	B
8	represented	O
9	by	O
10	amino	O
11	acid	O
12	residues	O
13	1082	O
14	-	O
15	1118	O
16	,	O
17	1117	O
18	-	O
19	1155	O
20	,	O
21	1234	O
22	-	O
23	1294	O
24	and	O
25	1312	O
26	-	O
27	1404	O
28	accommodate	O
29	C3	B
30	(	I
31	D	I
32	)	I
33	epitopes	I
34	that	O
35	are	O
36	expressed	O
37	by	O
38	erythrocyte	O
39	-	O
40	bound	O
41	C3	B
42	fragments	I
43	,	O
44	but	O
45	not	O
46	by	O
47	the	O
48	corresponding	O
49	fluid	O
50	-	O
51	phase	O
52	fragment	O
53	,	O
54	whereas	O
55	the	O
56	segments	O
57	spanning	O
58	residues	O
59	973	O
60	-	O
61	1026	O
62	and	O
63	1477	O
64	-	O
65	1510	O
66	contain	O
67	C3	B
68	(	I
69	D	I
70	)	I
71	epitopes	I
72	that	O
73	are	O
74	exposed	O
75	exclusively	O
76	in	O
77	denatured	O
78	C3	B
79	and	O
80	therefore	O
81	hidden	O
82	in	O
83	physiological	O
84	fragments	O
85	of	O
86	the	O
87	protein	O
88	.	O

1	These	O
2	exons	O
3	,	O
4	further	O
5	identified	O
6	as	O
7	exons	O
8	9	O
9	,	O
10	10	O
11	,	O
12	and	O
13	11	O
14	,	O
15	together	O
16	encode	O
17	the	O
18	37	O
19	amino	O
20	acid	O
21	residues	O
22	present	O
23	in	O
24	alpha	B
25	s1	I
26	-	I
27	casein	I
28	variant	I
29	A	I
30	but	O
31	missing	O
32	in	O
33	variant	O
34	F	O
35	.	O

1	We	O
2	also	O
3	report	O
4	here	O
5	the	O
6	complete	O
7	structural	O
8	organization	O
9	of	O
10	the	O
11	goat	B
12	alpha	I
13	s1	I
14	-	I
15	casein	I
16	transcription	I
17	unit	I
18	,	O
19	deduced	O
20	from	O
21	polymerase	O
22	chain	O
23	reaction	O
24	experiments	O
25	.	O

1	Homodimers	O
2	of	O
3	the	O
4	three	O
5	proteins	O
6	specifically	O
7	recognize	O
8	the	O
9	G	O
10	-	O
11	box	O
12	motif	O
13	,	O
14	with	O
15	GBF1	B
16	and	O
17	GBF3	B
18	binding	O
19	symmetrically	O
20	to	O
21	this	O
22	palindromic	O
23	sequence	O
24	.	O

1	Neither	O
2	gene	O
3	possesses	O
4	a	O
5	distinct	O
6	transcriptional	O
7	start	O
8	site	O
9	as	O
10	shown	O
11	by	O
12	nuclease	B
13	S1	I
14	analysis	O
15	.	O

1	The	O
2	hydrophobicity	O
3	plot	O
4	of	O
5	NHE	B
6	-	I
7	3	I
8	is	O
9	very	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	NHE	B
15	-	I
16	1	I
17	and	O
18	NHE	B
19	-	I
20	2	I
21	.	O

1	The	O
2	initial	O
3	translation	O
4	protein	O
5	encoded	O
6	by	O
7	the	O
8	cDNA	O
9	is	O
10	53	O
11	,	O
12	932	O
13	kDa	O
14	and	O
15	possesses	O
16	a	O
17	hydrophilic	O
18	amino	O
19	acid	O
20	composition	O
21	with	O
22	glutamic	O
23	acid	O
24	comprising	O
25	22	O
26	%	O
27	of	O
28	the	O
29	total	O
30	amino	O
31	acid	O
32	residues	O
33	.	O

1	Each	O
2	group	O
3	received	O
4	15	O
5	ml	O
6	/	O
7	kg	O
8	of	O
9	either	O
10	6	O
11	%	O
12	pentafraction	O
13	,	O
14	6	O
15	%	O
16	pentastarch	O
17	,	O
18	or	O
19	plasma	O
20	followed	O
21	two	O
22	hours	O
23	later	O
24	by	O
25	1	O
26	.	O
27	5	O
28	micrograms	O
29	/	O
30	kg	O
31	/	O
32	0	O
33	.	O
34	5	O
35	hr	O
36	E	O
37	.	O

1	Genetic	O
2	and	O
3	biochemical	O
4	evidence	O
5	suggests	O
6	that	O
7	v	B
8	-	I
9	Crk	I
10	can	O
11	induce	O
12	transformation	O
13	of	O
14	chicken	O
15	embryo	O
16	fibroblasts	O
17	by	O
18	influencing	O
19	the	O
20	activity	O
21	of	O
22	cellular	O
23	proteins	O
24	involved	O
25	in	O
26	growth	O
27	regulation	O
28	.	O

1	We	O
2	have	O
3	constructed	O
4	,	O
5	using	O
6	synthetic	O
7	DNA	O
8	oligonucleotides	O
9	,	O
10	a	O
11	U14	B
12	snRNA	I
13	gene	I
14	which	O
15	has	O
16	been	O
17	positioned	O
18	behind	O
19	a	O
20	T7	B
21	RNA	I
22	polymerase	I
23	promoter	I
24	site	I
25	and	O
26	then	O
27	inserted	O
28	into	O
29	a	O
30	plasmid	O
31	.	O

1	Gene	O
2	and	O
3	pseudogene	O
4	of	O
5	the	O
6	mouse	O
7	cation	O
8	-	O
9	dependent	O
10	mannose	B
11	6	I
12	-	I
13	phosphate	I
14	receptor	I
15	.	O

1	The	O
2	chick	O
3	axon	O
4	-	O
5	associated	O
6	surface	O
7	glycoprotein	O
8	neurofascin	B
9	is	O
10	implicated	O
11	in	O
12	axonal	O
13	growth	O
14	and	O
15	fasciculation	O
16	as	O
17	revealed	O
18	by	O
19	antibody	O
20	perturbation	O
21	experiments	O
22	.	O

1	The	O
2	carcinoma	O
3	was	O
4	restricted	O
5	within	O
6	the	O
7	epithelium	O
8	in	O
9	one	O
10	,	O
11	the	O
12	mucosal	O
13	layer	O
14	in	O
15	five	O
16	,	O
17	and	O
18	the	O
19	submucosal	O
20	layer	O
21	in	O
22	two	O
23	.	O

1	In	O
2	addition	O
3	,	O
4	C	B
5	/	I
6	EBP	I
7	beta	I
8	and	O
9	C	B
10	/	I
11	EBP	I
12	gamma	I
13	readily	O
14	heterodimerize	O
15	with	O
16	each	O
17	other	O
18	as	O
19	well	O
20	as	O
21	with	O
22	C	B
23	/	I
24	EBP	I
25	alpha	I
26	.	O

1	In	O
2	contrast	O
3	,	O
4	tobacco	B
5	GS	I
6	-	I
7	2	I
8	is	O
9	composed	O
10	of	O
11	subunits	O
12	of	O
13	identical	O
14	size	O
15	in	O
16	all	O
17	organs	O
18	examined	O
19	.	O

1	Between	O
2	acoR	B
3	and	O
4	acoXABC	B
5	,	O
6	two	O
7	different	O
8	types	O
9	of	O
10	sequences	O
11	with	O
12	dual	O
13	rotational	O
14	symmetry	O
15	[	O
16	CAC	O
17	-(	O
18	N11	O
19	to	O
20	N18	O
21	)-	O
22	GTG	O
23	and	O
24	TGT	O
25	-(	O
26	N10	O
27	to	O
28	N14	O
29	)-	O
30	ACA	O
31	]	O
32	were	O
33	found	O
34	;	O
35	these	O
36	sequences	O
37	are	O
38	similar	O
39	to	O
40	NtrC	B
41	and	O
42	NifA	B
43	upstream	I
44	activator	I
45	sequences	I
46	,	O
47	respectively	O
48	.	O

1	Although	O
2	the	O
3	effects	O
4	of	O
5	the	O
6	calcium	O
7	supplement	O
8	or	O
9	calcium	O
10	antagonist	O
11	alone	O
12	were	O
13	significant	O
14	,	O
15	such	O
16	hypotensive	O
17	responses	O
18	were	O
19	not	O
20	optimal	O
21	or	O
22	predictable	O
23	or	O
24	clearly	O
25	dose	O
26	-	O
27	dependent	O
28	.	O

1	C	O
2	.,	O
3	Sun	O
4	,	O
5	J	O
6	.,	O
7	Hsu	O
8	,	O
9	M	O
10	.-	O
11	Y	O
12	.,	O
13	Vallejo	O
14	-	O
15	Ramirez	O
16	,	O
17	J	O
18	.,	O
19	Inouye	O
20	,	O
21	S	O
22	.,	O
23	and	O
24	Inouye	O
25	,	O
26	M	O
27	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	full	O
5	-	O
6	deletion	O
7	mutant	O
8	showed	O
9	a	O
10	strong	O
11	block	O
12	in	O
13	virus	O
14	release	O
15	,	O
16	suggesting	O
17	that	O
18	NC	B
19	is	O
20	involved	O
21	in	O
22	virus	O
23	assembly	O
24	.	O

1	Furthermore	O
2	it	O
3	was	O
4	suggested	O
5	that	O
6	FK506	O
7	plasma	O
8	levels	O
9	were	O
10	concerned	O
11	with	O
12	the	O
13	appearance	O
14	of	O
15	side	O
16	effect	O
17	.	O

1	Thirty	O
2	percent	O
3	of	O
4	patients	O
5	were	O
6	tapered	O
7	off	O
8	all	O
9	steroids	O
10	,	O
11	and	O
12	the	O
13	average	O
14	steroid	O
15	dose	O
16	in	O
17	the	O
18	group	O
19	who	O
20	received	O
21	steroids	O
22	was	O
23	8	O
24	.	O
25	6	O
26	mg	O
27	of	O
28	prednisone	O
29	per	O
30	day	O
31	.	O

1	Thus	O
2	,	O
3	cibenzoline	O
4	is	O
5	an	O
6	effective	O
7	antiarrhythmic	O
8	agent	O
9	with	O
10	a	O
11	favourable	O
12	pharmacokinetic	O
13	profile	O
14	that	O
15	may	O
16	be	O
17	considered	O
18	with	O
19	other	O
20	class	O
21	I	O
22	drugs	O
23	in	O
24	patients	O
25	requiring	O
26	therapy	O
27	for	O
28	high	O
29	risk	O
30	arrhythmias	O
31	.	O

1	T	B
2	antigen	I
3	contains	O
4	four	O
5	H	O
6	-	O
7	2Db	O
8	-	O
9	restricted	O
10	cytotoxic	O
11	T	O
12	lymphocyte	O
13	(	O
14	CTL	O
15	)	O
16	recognition	O
17	epitopes	O
18	that	O
19	are	O
20	targets	O
21	for	O
22	CTL	O
23	clones	O
24	Y	O
25	-	O
26	1	O
27	,	O
28	Y	O
29	-	O
30	2	O
31	,	O
32	Y	O
33	-	O
34	3	O
35	,	O
36	and	O
37	Y	O
38	-	O
39	5	O
40	.	O

1	The	O
2	method	O
3	requires	O
4	a	O
5	reversed	O
6	-	O
7	phase	O
8	column	O
9	and	O
10	a	O
11	paired	O
12	-	O
13	ion	O
14	technique	O
15	to	O
16	separate	O
17	docusate	O
18	sodium	O
19	from	O
20	other	O
21	components	O
22	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	protein	O
7	product	O
8	of	O
9	the	O
10	ref	B
11	-	I
12	1	I
13	gene	I
14	stimulates	O
15	the	O
16	DNA	O
17	binding	O
18	activity	O
19	of	O
20	Fos	B
21	-	O
22	Jun	B
23	heterodimers	O
24	,	O
25	Jun	B
26	-	O
27	Jun	B
28	homodimers	O
29	and	O
30	Hela	O
31	cell	O
32	AP	B
33	-	I
34	1	I
35	proteins	I
36	as	O
37	well	O
38	as	O
39	that	O
40	of	O
41	several	O
42	other	O
43	transcription	O
44	factors	O
45	including	O
46	NF	B
47	-	I
48	kappa	I
49	B	I
50	,	O
51	Myb	B
52	and	O
53	members	O
54	of	O
55	the	O
56	ATF	B
57	/	O
58	CREB	B
59	family	O
60	.	O

1	The	O
2	pulpal	O
3	tissues	O
4	of	O
5	the	O
6	permanent	O
7	mandibular	O
8	molars	O
9	were	O
10	amputated	O
11	and	O
12	then	O
13	dressed	O
14	with	O
15	calcium	O
16	hydrate	O
17	.	O

1	Northern	O
2	blot	O
3	analyses	O
4	demonstrate	O
5	that	O
6	3	O
7	.	O
8	9	O
9	-	O
10	and	O
11	5	O
12	-	O
13	kilobase	O
14	mRNAs	O
15	corresponding	O
16	to	O
17	the	O
18	cDNA	O
19	were	O
20	present	O
21	in	O
22	all	O
23	tissues	O
24	examined	O
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	protein	O
30	it	O
31	encodes	O
32	performs	O
33	a	O
34	housekeeping	O
35	function	O
36	.	O

1	The	O
2	ARG	B
3	SH2	I
4	domain	I
5	exhibited	O
6	relatively	O
7	weak	O
8	affinity	O
9	for	O
10	BCR	B
11	and	O
12	was	O
13	determined	O
14	to	O
15	bind	O
16	about	O
17	10	O
18	-	O
19	fold	O
20	less	O
21	strongly	O
22	than	O
23	the	O
24	ABL	B
25	SH2	I
26	domain	I
27	.	O

1	We	O
2	analyzed	O
3	an	O
4	EBV	O
5	B	O
6	-	O
7	cell	O
8	clone	O
9	,	O
10	E29	O
11	.	O
12	1	O
13	,	O
14	derived	O
15	from	O
16	an	O
17	11	O
18	week	O
19	-	O
20	old	O
21	embryo	O
22	,	O
23	and	O
24	secreting	O
25	both	O
26	IgM	B
27	kappa	I
28	and	O
29	IgM	B
30	lambda	I
31	.	O

1	Interestingly	O
2	,	O
3	this	O
4	activation	O
5	occurred	O
6	only	O
7	when	O
8	the	O
9	regions	O
10	were	O
11	cloned	O
12	in	O
13	the	O
14	same	O
15	relative	O
16	orientation	O
17	in	O
18	which	O
19	they	O
20	exist	O
21	on	O
22	wild	O
23	-	O
24	type	O
25	pCF10	O
26	.	O

1	In	O
2	rats	O
3	,	O
4	we	O
5	examined	O
6	the	O
7	effect	O
8	of	O
9	an	O
10	omentum	O
11	wrapping	O
12	on	O
13	the	O
14	vascularization	O
15	of	O
16	the	O
17	trachea	O
18	and	O
19	on	O
20	regeneration	O
21	of	O
22	the	O
23	mucosal	O
24	epithelium	O
25	in	O
26	the	O
27	very	O
28	early	O
29	stage	O
30	after	O
31	free	O
32	tracheal	O
33	grafting	O
34	.	O

1	To	O
2	study	O
3	a	O
4	possible	O
5	functional	O
6	role	O
7	of	O
8	this	O
9	putative	O
10	chicken	O
11	ICS	B
12	,	O
13	an	O
14	oligonucleotide	O
15	spanning	O
16	the	O
17	upstream	O
18	sequences	O
19	of	O
20	the	O
21	BF	B
22	-	I
23	IV	I
24	gene	I
25	(-	O
26	174	O
27	/-	O
28	194	O
29	)	O
30	was	O
31	cloned	O
32	singly	O
33	or	O
34	in	O
35	multiple	O
36	copies	O
37	before	O
38	the	O
39	herpes	O
40	TK	B
41	promoter	I
42	controlling	O
43	the	O
44	chloramphenicol	B
45	acetyl	I
46	transferase	I
47	(	O
48	CAT	B
49	)	O
50	gene	O
51	(	O
52	pBLCAT2	B
53	).	O

1	In	O
2	general	O
3	,	O
4	two	O
5	separate	O
6	high	O
7	-	O
8	performance	O
9	liquid	O
10	chromatographic	O
11	runs	O
12	were	O
13	performed	O
14	,	O
15	one	O
16	for	O
17	the	O
18	gamma	O
19	-	O
20	aminobutyric	O
21	acid	O
22	determination	O
23	and	O
24	one	O
25	for	O
26	the	O
27	determination	O
28	of	O
29	the	O
30	monoamines	O
31	.	O

1	We	O
2	report	O
3	the	O
4	successful	O
5	use	O
6	of	O
7	electroconvulsive	O
8	therapy	O
9	for	O
10	treatment	O
11	of	O
12	severe	O
13	depression	O
14	in	O
15	a	O
16	young	O
17	man	O
18	with	O
19	adult	O
20	GM2	O
21	gangliosidosis	O
22	.	O

1	Entry	O
2	of	O
3	yeast	O
4	cells	O
5	into	O
6	the	O
7	mitotic	O
8	cell	O
9	cycle	O
10	(	O
11	Start	O
12	)	O
13	involves	O
14	a	O
15	form	O
16	of	O
17	the	O
18	CDC28	B
19	kinase	I
20	that	O
21	associates	O
22	with	O
23	G1	O
24	-	O
25	specific	O
26	cyclins	B
27	encoded	O
28	by	O
29	CLN1	B
30	and	O
31	CLN2	B
32	(	O
33	ref	O
34	.	O

1	Through	O
2	Southern	O
3	blot	O
4	analyses	O
5	of	O
6	DNA	O
7	from	O
8	backcross	O
9	and	O
10	cogenic	O
11	mice	O
12	,	O
13	recombinant	O
14	inbred	O
15	strains	O
16	,	O
17	and	O
18	somatic	O
19	cell	O
20	hybrids	O
21	,	O
22	the	O
23	genetic	O
24	loci	O
25	that	O
26	produce	O
27	the	O
28	cyclin	B
29	B1	I
30	-	I
31	related	I
32	sequences	I
33	(	O
34	designated	O
35	loci	B
36	Cycb1	I
37	-	I
38	rs1	I
39	to	O
40	Cycb1	B
41	-	I
42	rs9	I
43	)	O
44	were	O
45	mapped	O
46	on	O
47	mouse	O
48	chromosomes	O
49	5	O
50	,	O
51	1	O
52	,	O
53	17	O
54	,	O
55	4	O
56	,	O
57	14	O
58	,	O
59	13	O
60	,	O
61	7	O
62	,	O
63	X	O
64	,	O
65	and	O
66	8	O
67	,	O
68	respectively	O
69	.	O

1	Again	O
2	residue	O
3	Glu	O
4	-	O
5	381	O
6	of	O
7	beta	O
8	was	O
9	notably	O
10	reduced	O
11	and	O
12	no	O
13	missing	O
14	residue	O
15	from	O
16	the	O
17	epsilon	O
18	peptide	O
19	could	O
20	be	O
21	identified	O
22	,	O
23	but	O
24	the	O
25	peptide	O
26	sequence	O
27	limited	O
28	the	O
29	possible	O
30	choices	O
31	to	O
32	Ser	O
33	-	O
34	106	O
35	,	O
36	Ser	O
37	-	O
38	107	O
39	,	O
40	or	O
41	Ser	O
42	-	O
43	108	O
44	.	O

1	Porcelain	O
2	to	O
3	dentin	O
4	bond	O
5	strength	O
6	with	O
7	a	O
8	dentin	O
9	adhesive	O
10	.	O

1	TBPf	O
2	is	O
3	defined	O
4	as	O
5	a	O
6	quotient	O
7	of	O
8	the	O
9	difference	O
10	of	O
11	the	O
12	first	O
13	and	O
14	the	O
15	second	O
16	measurement	O
17	:	O
18	TBPf	O
19	=	O
20	(	O
21	P1	O
22	-	O
23	P2	O
24	)/(	O
25	A1	O
26	-	O
27	A2	O
28	).	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	Scotchbond	O
6	2	O
7	and	O
8	Prisma	O
9	Universal	O
10	Bond	O
11	2	O
12	are	O
13	effective	O
14	and	O
15	are	O
16	the	O
17	dentine	O
18	bonding	O
19	agents	O
20	of	O
21	choice	O
22	.	O

1	From	O
2	all	O
3	clinically	O
4	important	O
5	yeasts	O
6	species	O
7	,	O
8	a	O
9	total	O
10	of	O
11	96	O
12	%	O
13	were	O
14	identified	O
15	by	O
16	ATB	O
17	method	O
18	according	O
19	to	O
20	conventional	O
21	methods	O
22	.	O

1	The	O
2	neurohypophysial	O
3	vasopressin	B
4	and	O
5	oxytocin	B
6	content	O
7	was	O
8	bioassayed	O
9	by	O
10	pressor	O
11	effect	O
12	following	O
13	Dekanski	O
14	or	O
15	milk	O
16	-	O
17	ejection	O
18	activity	O
19	in	O
20	vitro	O
21	following	O
22	van	O
23	Dongen	O
24	and	O
25	Hays	O
26	,	O
27	respectively	O
28	.	O

1	Comments	O
2	are	O
3	given	O
4	on	O
5	the	O
6	present	O
7	status	O
8	of	O
9	regulations	O
10	concerning	O
11	water	O
12	in	O
13	swimming	O
14	pools	O
15	and	O
16	baths	O
17	--	O
18	1991	O
19	--(	O
20	in	O
21	connection	O
22	with	O
23	the	O
24	KOK	O
25	regulations	O
26	--	O
27	1972	O
28	--	O
29	and	O
30	the	O
31	Federal	O
32	German	O
33	standard	O
34	[	O
35	DIN	O
36	]	O
37	No	O
38	.	O

1	If	O
2	no	O
3	reply	O
4	was	O
5	received	O
6	,	O
7	telephone	O
8	contact	O
9	or	O
10	home	O
11	visits	O
12	were	O
13	made	O
14	.	O

1	The	O
2	treatment	O
3	group	O
4	also	O
5	showed	O
6	in	O
7	vivo	O
8	T	O
9	-	O
10	cell	O
11	activation	O
12	with	O
13	an	O
14	initial	O
15	lymphopenia	O
16	followed	O
17	by	O
18	a	O
19	rebound	O
20	lymphocytosis	O
21	and	O
22	upregulation	O
23	of	O
24	the	O
25	subset	O
26	markers	O
27	CD25	B
28	(	O
29	interleukin	B
30	2	I
31	receptor	I
32	)	O
33	and	O
34	CD45RO	B
35	(	O
36	T	O
37	-	O
38	memory	O
39	cells	O
40	).	O

1	Urease	B
2	activity	O
3	,	O
4	judged	O
5	as	O
6	the	O
7	amount	O
8	of	O
9	ammonia	O
10	production	O
11	from	O
12	urea	O
13	,	O
14	could	O
15	be	O
16	measured	O
17	at	O
18	25	O
19	ng	O
20	per	O
21	tube	O
22	(	O
23	S	O
24	/	O
25	N	O
26	=	O
27	1	O
28	.	O
29	5	O
30	)	O
31	with	O
32	Jack	B
33	bean	I
34	meal	I
35	urease	I
36	.	O

1	Consequently	O
2	,	O
3	significant	O
4	differences	O
5	between	O
6	the	O
7	measured	O
8	and	O
9	calculated	O
10	methods	O
11	were	O
12	noted	O
13	in	O
14	oxygen	O
15	uptake	O
16	(	O
17	213	O
18	+/-	O
19	41	O
20	ml	O
21	/	O
22	min	O
23	vs	O
24	193	O
25	+/-	O
26	25	O
27	ml	O
28	/	O
29	min	O
30	,	O
31	p	O
32	<	O
33	0	O
34	.	O
35	001	O
36	),	O
37	oxygen	O
38	delivery	O
39	(	O
40	780	O
41	+/-	O
42	297	O
43	ml	O
44	/	O
45	min	O
46	vs	O
47	716	O
48	+/-	O
49	296	O
50	ml	O
51	/	O
52	min	O
53	,	O
54	p	O
55	<	O
56	0	O
57	.	O
58	001	O
59	),	O
60	and	O
61	cardiac	O
62	output	O
63	(	O
64	5	O
65	.	O
66	8	O
67	+/-	O
68	2	O
69	.	O
70	2	O
71	L	O
72	/	O
73	min	O
74	vs	O
75	5	O
76	.	O
77	3	O
78	+/-	O
79	1	O
80	.	O
81	8	O
82	L	O
83	/	O
84	min	O
85	,	O
86	p	O
87	<	O
88	0	O
89	.	O
90	001	O
91	).	O

1	Although	O
2	a	O
3	wide	O
4	range	O
5	of	O
6	cognitive	O
7	functions	O
8	had	O
9	been	O
10	tested	O
11	,	O
12	all	O
13	but	O
14	one	O
15	seizure	O
16	occurred	O
17	during	O
18	assessment	O
19	of	O
20	memory	O
21	performance	O
22	.	O

1	The	O
2	experiments	O
3	show	O
4	that	O
5	it	O
6	is	O
7	the	O
8	micromilieu	O
9	of	O
10	the	O
11	alveoli	O
12	and	O
13	the	O
14	condition	O
15	of	O
16	the	O
17	AM	O
18	(	O
19	certain	O
20	physiological	O
21	activation	O
22	states	O
23	,	O
24	such	O
25	as	O
26	phagocytic	O
27	activity	O
28	)	O
29	that	O
30	essentially	O
31	determine	O
32	the	O
33	degree	O
34	of	O
35	recovery	O
36	.	O

1	Negatively	O
2	supercoiled	O
3	plasmid	O
4	pUC19	O
5	did	O
6	not	O
7	compete	O
8	,	O
9	whereas	O
10	an	O
11	otherwise	O
12	identical	O
13	plasmid	O
14	pUC19	O
15	(	O
16	CG	O
17	),	O
18	which	O
19	contained	O
20	a	O
21	(	O
22	dG	O
23	-	O
24	dC	O
25	)	O
26	7	O
27	segment	O
28	in	O
29	the	O
30	Z	O
31	-	O
32	form	O
33	was	O
34	an	O
35	excellent	O
36	competitor	O
37	.	O

1	A	O
2	cDNA	O
3	library	O
4	of	O
5	tumour	O
6	cells	O
7	was	O
8	screened	O
9	with	O
10	an	O
11	interleukin	B
12	2	I
13	gene	O
14	-	O
15	specific	O
16	probe	O
17	.	O

1	Our	O
2	experiments	O
3	suggest	O
4	that	O
5	the	O
6	SCL	B
7	gene	I
8	can	O
9	be	O
10	a	O
11	target	O
12	for	O
13	the	O
14	erythroid	B
15	transcription	I
16	factor	I
17	GATA	I
18	-	I
19	1	I
20	and	O
21	that	O
22	the	O
23	SCL	B
24	gene	I
25	product	I
26	serves	O
27	as	O
28	a	O
29	positive	O
30	regulator	O
31	of	O
32	erythroid	O
33	differentiation	O
34	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	lumenal	O
6	domains	O
7	of	O
8	Sec12p	B
9	,	O
10	Stl1p	B
11	and	O
12	Stl2p	B
13	are	O
14	very	O
15	different	O
16	in	O
17	size	O
18	and	O
19	do	O
20	not	O
21	show	O
22	any	O
23	appreciable	O
24	homology	O
25	.	O

1	Complexes	O
2	containing	O
3	wild	O
4	-	O
5	type	O
6	and	O
7	either	O
8	his175	B
9	or	I
10	his273	I
11	mutant	I
12	p53	I
13	proteins	I
14	are	O
15	completely	O
16	unable	O
17	to	O
18	bind	O
19	to	O
20	the	O
21	RGC	B
22	DNA	I
23	sequence	I
24	.	O

1	These	O
2	temperature	O
3	-	O
4	and	O
5	cold	O
6	-	O
7	sensitive	O
8	strains	O
9	were	O
10	used	O
11	to	O
12	prepare	O
13	extracts	O
14	deficient	O
15	in	O
16	BRF1	B
17	activity	O
18	and	O
19	were	O
20	tested	O
21	for	O
22	transcriptional	O
23	activity	O
24	by	O
25	RNA	B
26	polymerases	I
27	I	I
28	,	I
29	II	I
30	,	I
31	and	I
32	III	I
33	in	O
34	vitro	O
35	.	O

1	These	O
2	results	O
3	lead	O
4	us	O
5	to	O
6	hypothesize	O
7	that	O
8	a	O
9	single	O
10	multisubunit	B
11	TFIID	I
12	protein	I
13	supports	O
14	transcriptional	O
15	stimulation	O
16	by	O
17	diverse	O
18	activation	O
19	domains	O
20	and	O
21	from	O
22	a	O
23	TATA	O
24	-	O
25	less	O
26	promoter	O
27	.	O

1	The	O
2	gene	O
3	sequence	O
4	also	O
5	identified	O
6	a	O
7	340	O
8	-	O
9	nucleotide	O
10	RNA	O
11	in	O
12	total	O
13	yeast	O
14	RNA	O
15	and	O
16	in	O
17	purified	O
18	RNase	B
19	MRP	I
20	enzyme	I
21	preparations	O
22	.	O

1	The	O
2	RNase	B
3	MRP	I
4	RNA	I
5	gene	I
6	was	O
7	deleted	O
8	by	O
9	insertional	O
10	replacement	O
11	and	O
12	found	O
13	to	O
14	be	O
15	essential	O
16	for	O
17	cellular	O
18	viability	O
19	,	O
20	indicating	O
21	a	O
22	critical	O
23	nuclear	O
24	role	O
25	for	O
26	RNase	B
27	MRP	I
28	.	O

1	Clone	O
2	pSRc200	O
3	hybrid	O
4	selected	O
5	an	O
6	mRNA	O
7	that	O
8	on	O
9	cell	O
10	-	O
11	free	O
12	translation	O
13	produced	O
14	a	O
15	38	O
16	-	O
17	kDa	O
18	polypeptide	O
19	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	CBF	B
6	-	I
7	A	I
8	is	O
9	a	O
10	novel	O
11	CArG	O
12	box	O
13	-,	O
14	ssDNA	B
15	-	I
16	and	I
17	RNA	I
18	-	I
19	binding	I
20	protein	I
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	repressive	O
27	transcriptional	O
28	factor	O
29	.	O

1	Cleavage	O
2	by	O
3	the	O
4	intron	O
5	-	O
6	encoded	O
7	enzyme	O
8	(	O
9	I	B
10	-	I
11	CreI	I
12	)	O
13	occurs	O
14	5	O
15	bp	O
16	and	O
17	1	O
18	bp	O
19	3	O
20	'	O
21	to	O
22	the	O
23	intron	O
24	insertion	O
25	site	O
26	(	O
27	in	O
28	the	O
29	3	O
30	'-	O
31	exon	O
32	)	O
33	in	O
34	the	O
35	top	O
36	(/)	O
37	and	O
38	bottom	O
39	(,)	O
40	strands	O
41	,	O
42	respectively	O
43	,	O
44	resulting	O
45	in	O
46	4	O
47	-	O
48	nt	O
49	single	O
50	-	O
51	stranded	O
52	overhangs	O
53	with	O
54	3	O
55	'-	O
56	OH	O
57	termini	O
58	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	Xenopus	B
5	U7	I
6	gene	I
7	contains	O
8	two	O
9	adjacent	O
10	octamer	O
11	-	O
12	binding	O
13	motifs	O
14	located	O
15	only	O
16	12	O
17	and	O
18	24	O
19	bp	O
20	upstream	O
21	from	O
22	the	O
23	PSE	B
24	,	O
25	instead	O
26	of	O
27	the	O
28	usual	O
29	location	O
30	around	O
31	150	O
32	-	O
33	200	O
34	bp	O
35	upstream	O
36	.	O

1	The	O
2	results	O
3	support	O
4	earlier	O
5	reports	O
6	that	O
7	collagenase	B
8	inhibitors	O
9	are	O
10	useful	O
11	in	O
12	controlling	O
13	blister	O
14	formation	O
15	in	O
16	recessive	O
17	dystrophic	O
18	epidermolysis	O
19	bullosa	O
20	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	essential	O
5	IncP	O
6	alpha	O
7	plasmid	O
8	transfer	O
9	genes	O
10	traF	B
11	and	O
12	traG	B
13	and	O
14	involvement	O
15	of	O
16	traF	B
17	in	O
18	phage	O
19	sensitivity	O
20	.	O

1	The	O
2	promoter	O
3	was	O
4	stimulated	O
5	8	O
6	-	O
7	20	O
8	-	O
9	fold	O
10	by	O
11	phorbol	O
12	esters	O
13	accounting	O
14	for	O
15	the	O
16	previously	O
17	observed	O
18	transcriptional	O
19	activation	O
20	of	O
21	protein	B
22	kinase	I
23	C	I
24	beta	I
25	.	O

1	In	O
2	humans	O
3	,	O
4	four	O
5	AMP	B
6	deaminase	I
7	variants	I
8	,	O
9	termed	O
10	M	B
11	(	O
12	muscle	O
13	),	O
14	L	B
15	(	O
16	liver	O
17	),	O
18	E1	B
19	,	O
20	and	O
21	E2	B
22	(	O
23	erythrocyte	O
24	)	O
25	can	O
26	be	O
27	distinguished	O
28	by	O
29	a	O
30	variety	O
31	of	O
32	biochemical	O
33	and	O
34	immunological	O
35	criteria	O
36	.	O

1	Western	O
2	blot	O
3	analyses	O
4	detect	O
5	anti	B
6	-	I
7	E	I
8	-	O
9	specific	O
10	immunoreactivity	O
11	in	O
12	affinity	O
13	-	O
14	purified	O
15	extracts	O
16	derived	O
17	from	O
18	the	O
19	bacterial	O
20	expression	O
21	of	O
22	a	O
23	truncated	B
24	AMPD3	I
25	cDNA	I
26	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	endogenous	O
6	N	O
7	-	O
8	methylation	O
9	of	O
10	salsolinol	O
11	into	O
12	N	O
13	-	O
14	methylsalsolinol	O
15	occurs	O
16	in	O
17	the	O
18	brain	O
19	in	O
20	vivo	O
21	.	O

1	DR1	B
2	molecules	I
3	purified	O
4	from	O
5	human	O
6	lymphoblastoid	O
7	cell	O
8	lines	O
9	could	O
10	specifically	O
11	bind	O
12	to	O
13	these	O
14	peptide	O
15	sequences	O
16	expressed	O
17	on	O
18	the	O
19	phage	O
20	surface	O
21	.	O

1	This	O
2	article	O
3	describes	O
4	the	O
5	collaborative	O
6	care	O
7	of	O
8	the	O
9	woman	O
10	participating	O
11	in	O
12	maternal	O
13	blood	O
14	donation	O
15	for	O
16	intrauterine	O
17	transfusion	O
18	.	O

1	Chronic	O
2	hepatitis	O
3	B	O
4	in	O
5	adopted	O
6	Romanian	O
7	children	O
8	.	O

1	Behind	O
2	the	O
3	ATPase	B
4	cluster	I
5	,	O
6	two	O
7	open	O
8	reading	O
9	frames	O
10	were	O
11	detected	O
12	that	O
13	are	O
14	not	O
15	homologous	O
16	to	O
17	any	O
18	known	O
19	chloroplast	O
20	gene	O
21	.	O

1	Therefore	O
2	,	O
3	recombinant	O
4	human	O
5	Ads	O
6	that	O
7	express	O
8	noninfectious	O
9	HIV	O
10	or	O
11	other	O
12	microbial	O
13	proteins	O
14	are	O
15	attractive	O
16	vaccine	O
17	candidates	O
18	.	O

1	Alignment	O
2	of	O
3	the	O
4	selected	O
5	sequences	O
6	allowed	O
7	us	O
8	to	O
9	predict	O
10	a	O
11	consensus	O
12	sequence	O
13	for	O
14	binding	O
15	of	O
16	the	O
17	individual	O
18	homodimeric	O
19	Rel	B
20	-	I
21	related	I
22	proteins	I
23	,	O
24	and	O
25	DNA	O
26	-	O
27	protein	O
28	binding	O
29	analysis	O
30	of	O
31	the	O
32	selected	O
33	DNA	O
34	sequences	O
35	revealed	O
36	sequence	O
37	specificity	O
38	of	O
39	the	O
40	proteins	O
41	.	O

1	Using	O
2	either	O
3	a	O
4	p50	B
5	-	O
6	or	O
7	p65	B
8	-	I
9	selected	I
10	kappa	I
11	B	I
12	motif	I
13	,	O
14	which	O
15	displayed	O
16	differential	O
17	binding	O
18	with	O
19	respect	O
20	to	O
21	the	O
22	other	O
23	protein	O
24	,	O
25	little	O
26	to	O
27	no	O
28	binding	O
29	was	O
30	observed	O
31	with	O
32	the	O
33	heterodimeric	B
34	NF	I
35	-	I
36	kappa	I
37	B	I
38	complex	I
39	.	O

1	However	O
2	,	O
3	a	O
4	cosmid	O
5	clone	O
6	containing	O
7	the	O
8	entire	O
9	mouse	B
10	alpha	I
11	1	I
12	(	I
13	I	I
14	)	I
15	gene	I
16	,	O
17	including	O
18	3	O
19	.	O
20	7	O
21	kb	O
22	of	O
23	5	O
24	'-	O
25	and	O
26	4	O
27	kb	O
28	of	O
29	3	O
30	'-	O
31	flanking	O
32	DNA	O
33	,	O
34	was	O
35	expressed	O
36	at	O
37	reduced	O
38	levels	O
39	in	O
40	fibroblasts	O
41	overexpressing	O
42	oncogenic	B
43	ras	I
44	.	O

1	To	O
2	define	O
3	transcriptional	O
4	control	O
5	elements	O
6	responsible	O
7	for	O
8	muscle	O
9	-	O
10	specific	O
11	expression	O
12	of	O
13	the	O
14	human	B
15	myoglobin	I
16	gene	I
17	,	O
18	we	O
19	performed	O
20	mutational	O
21	analysis	O
22	of	O
23	upstream	O
24	sequences	O
25	(	O
26	nucleotide	O
27	positions	O
28	-	O
29	373	O
30	to	O
31	+	O
32	7	O
33	relative	O
34	to	O
35	the	O
36	transcriptional	O
37	start	O
38	site	O
39	)	O
40	linked	O
41	to	O
42	a	O
43	firefly	B
44	luciferase	I
45	gene	I
46	.	O

1	Sequencing	O
2	analysis	O
3	has	O
4	shown	O
5	that	O
6	each	O
7	rap1t	B
8	allele	I
9	contains	O
10	a	O
11	nonsense	O
12	mutation	O
13	within	O
14	a	O
15	discrete	O
16	region	O
17	between	O
18	amino	O
19	acids	O
20	663	O
21	and	O
22	684	O
23	.	O

1	By	O
2	screening	O
3	a	O
4	Y1	O
5	cell	O
6	cDNA	O
7	library	O
8	with	O
9	the	O
10	DNA	O
11	-	O
12	binding	O
13	region	O
14	of	O
15	the	O
16	H	B
17	-	I
18	2RIIBP	I
19	nuclear	I
20	hormone	I
21	receptor	I
22	cDNA	I
23	,	O
24	we	O
25	isolated	O
26	a	O
27	cDNA	O
28	that	O
29	is	O
30	selectively	O
31	expressed	O
32	in	O
33	steroidogenic	O
34	cells	O
35	.	O

1	Autopsy	O
2	demonstrated	O
3	good	O
4	survival	O
5	of	O
6	the	O
7	transplanted	O
8	cells	O
9	with	O
10	good	O
11	integration	O
12	with	O
13	the	O
14	brain	O
15	of	O
16	the	O
17	recipient	O
18	and	O
19	traces	O
20	of	O
21	positive	O
22	immunocytochemical	O
23	reaction	O
24	for	O
25	tyrosine	B
26	hydroxylase	I
27	.	O

1	The	O
2	technique	O
3	of	O
4	the	O
5	TEE	O
6	visualization	O
7	of	O
8	the	O
9	proximal	O
10	coronary	O
11	arteries	O
12	is	O
13	described	O
14	.	O

1	The	O
2	sequence	O
3	of	O
4	this	O
5	region	O
6	shows	O
7	high	O
8	G	O
9	+	O
10	C	O
11	content	O
12	(	O
13	62	O
14	%),	O
15	which	O
16	is	O
17	particularly	O
18	emphasized	O
19	in	O
20	the	O
21	200	O
22	bp	O
23	upstream	O
24	from	O
25	the	O
26	mRNA	O
27	start	O
28	(	O
29	80	O
30	%	O
31	G	O
32	+	O
33	C	O
34	).	O

1	In	O
2	the	O
3	eight	O
4	patients	O
5	with	O
6	persistent	O
7	generalized	O
8	lymph	O
9	-	O
10	adenopathy	O
11	(	O
12	PGL	O
13	)	O
14	and	O
15	nontender	O
16	,	O
17	nonenlarging	O
18	nodes	O
19	,	O
20	pathologic	O
21	analysis	O
22	revealed	O
23	lymphoid	O
24	hyperplasia	O
25	.	O

1	PaO2	O
2	threshold	O
3	was	O
4	determined	O
5	through	O
6	an	O
7	indwelling	O
8	O2	O
9	sensor	O
10	catheter	O
11	.	O

1	We	O
2	found	O
3	that	O
4	both	O
5	the	O
6	E26	O
7	virus	O
8	-	O
9	encoded	O
10	v	B
11	-	I
12	ets	I
13	and	O
14	the	O
15	myeloid	B
16	/	I
17	B	I
18	-	I
19	cell	I
20	-	I
21	specific	I
22	factor	I
23	PU	I
24	.	I
25	1	I
26	bind	O
27	efficiently	O
28	to	O
29	this	O
30	site	O
31	in	O
32	vitro	O
33	.	O

1	By	O
2	using	O
3	lambda	O
4	gt11	O
5	expression	O
6	cloning	O
7	with	O
8	oligonucleotides	O
9	corresponding	O
10	to	O
11	the	O
12	human	O
13	immunodeficiency	O
14	virus	O
15	1	O
16	TATA	O
17	element	O
18	,	O
19	we	O
20	report	O
21	the	O
22	identification	O
23	of	O
24	a	O
25	cellular	O
26	protein	O
27	with	O
28	a	O
29	calculated	O
30	molecular	O
31	mass	O
32	of	O
33	123	O
34	kDa	O
35	that	O
36	we	O
37	designate	O
38	TATA	B
39	element	I
40	modulatory	I
41	factor	I
42	(	O
43	TMF	B
44	).	O

1	Blood	O
2	levels	O
3	of	O
4	melatonin	O
5	,	O
6	serotonin	O
7	,	O
8	cortisol	O
9	,	O
10	and	O
11	prolactin	B
12	in	O
13	relation	O
14	to	O
15	the	O
16	circadian	O
17	rhythm	O
18	of	O
19	platelet	O
20	serotonin	O
21	uptake	O
22	.	O

1	We	O
2	couldn	O
3	'	O
4	t	O
5	detect	O
6	any	O
7	effect	O
8	of	O
9	n	O
10	-	O
11	3	O
12	FA	O
13	supplementation	O
14	on	O
15	total	O
16	cholesterol	O
17	,	O
18	HDL	B
19	cholesterol	I
20	,	O
21	LDL	B
22	cholesterol	I
23	,	O
24	apo	B
25	A1	I
26	,	O
27	Lp	O
28	(	O
29	a	O
30	),	O
31	HbA1C	B
32	,	O
33	glucose	O
34	,	O
35	fibrinogen	B
36	,	O
37	factor	B
38	VIII	I
39	,	O
40	antithrombin	B
41	III	I
42	,	O
43	plasminogen	B
44	activator	I
45	inhibitor	I
46	,	O
47	tissue	B
48	plasminogen	I
49	activator	I
50	and	O
51	von	B
52	Willebrand	I
53	factor	I
54	concentration	O
55	,	O
56	on	O
57	bleeding	O
58	time	O
59	or	O
60	on	O
61	systolic	O
62	or	O
63	diastolic	O
64	blood	O
65	pressure	O
66	.	O

1	In	O
2	8	O
3	healthy	O
4	volunteers	O
5	there	O
6	were	O
7	no	O
8	significant	O
9	differences	O
10	in	O
11	AUC	O
12	,	O
13	peak	O
14	plasma	O
15	concentrations	O
16	or	O
17	time	O
18	to	O
19	peak	O
20	concentration	O
21	when	O
22	OXC	O
23	was	O
24	administered	O
25	either	O
26	with	O
27	or	O
28	without	O
29	ERY	O
30	.	O

1	Using	O
2	5	O
3	ng	O
4	/	O
5	mL	O
6	as	O
7	the	O
8	cutoff	O
9	,	O
10	the	O
11	sensitivity	O
12	of	O
13	CEA	B
14	was	O
15	68	O
16	%.	O

1	Rolandic	O
2	spikes	O
3	and	O
4	cognitive	O
5	function	O
6	.	O

1	The	O
2	effect	O
3	of	O
4	sodium	O
5	18	O
6	beta	O
7	-	O
8	glycyrrhetate	O
9	(	O
10	SGA	O
11	)	O
12	on	O
13	experimental	O
14	arrhythmia	O
15	was	O
16	investigated	O
17	.	O

1	Thus	O
2	,	O
3	chronic	O
4	hematocrit	O
5	decrease	O
6	induced	O
7	by	O
8	H	O
9	or	O
10	P	O
11	resulted	O
12	in	O
13	a	O
14	significant	O
15	fall	O
16	in	O
17	blood	O
18	pressure	O
19	compared	O
20	to	O
21	control	O
22	(	O
23	201	O
24	+/-	O
25	3	O
26	v	O
27	175	O
28	+/-	O
29	4	O
30	,	O
31	167	O
32	+/-	O
33	4	O
34	mm	O
35	Hg	O
36	,	O
37	respectively	O
38	;	O
39	P	O
40	<	O
41	.	O
42	05	O
43	).	O

1	The	O
2	effects	O
3	of	O
4	diltiazem	O
5	were	O
6	stereoselective	O
7	,	O
8	thus	O
9	the	O
10	potentiation	O
11	induced	O
12	by	O
13	d	O
14	-	O
15	cis	O
16	diltiazem	O
17	was	O
18	significantly	O
19	greater	O
20	in	O
21	all	O
22	cases	O
23	than	O
24	that	O
25	induced	O
26	by	O
27	l	O
28	-	O
29	cis	O
30	diltiazem	O
31	,	O
32	which	O
33	suggests	O
34	that	O
35	calcium	O
36	channel	O
37	blockade	O
38	plays	O
39	a	O
40	role	O
41	in	O
42	these	O
43	interactions	O
44	.	O

1	Localization	O
2	of	O
3	the	O
4	brachial	O
5	plexus	O
6	with	O
7	the	O
8	nerve	O
9	stimulator	O
10	is	O
11	equally	O
12	effective	O
13	at	O
14	the	O
15	interscalene	O
16	,	O
17	supraclavicular	O
18	,	O
19	and	O
20	axillary	O
21	sites	O
22	.	O

1	Substitution	O
2	of	O
3	either	O
4	Val33	O
5	(	O
6	by	O
7	Gly	O
8	)	O
9	or	O
10	Gly28	O
11	(	O
12	by	O
13	Ser	O
14	),	O
15	two	O
16	of	O
17	the	O
18	most	O
19	conserved	O
20	residues	O
21	in	O
22	all	O
23	protein	O
24	kinases	O
25	,	O
26	resulted	O
27	in	O
28	enzyme	O
29	with	O
30	marginally	O
31	detectable	O
32	activity	O
33	.	O

1	Significance	O
2	of	O
3	the	O
4	biopsy	O
5	site	O
6	of	O
7	the	O
8	latissimus	O
9	dorsi	O
10	muscle	O
11	for	O
12	fiber	O
13	typing	O
14	.	O

1	The	O
2	TIMP	B
3	(-	O
4	59	O
5	/	O
6	-	O
7	53	O
8	)	O
9	AP1	B
10	site	O
11	is	O
12	a	O
13	promiscuous	O
14	motif	O
15	that	O
16	binds	O
17	c	B
18	-	I
19	Fos	I
20	/	O
21	c	B
22	-	I
23	Jun	I
24	AP1	I
25	translated	O
26	in	O
27	vitro	O
28	and	O
29	is	O
30	an	O
31	effective	O
32	competitor	O
33	for	O
34	binding	O
35	of	O
36	nuclear	B
37	AP1	I
38	factors	I
39	to	O
40	the	O
41	consensus	O
42	TRE	O
43	,	O
44	but	O
45	in	O
46	addition	O
47	it	O
48	binds	O
49	factors	O
50	that	O
51	do	O
52	not	O
53	associate	O
54	with	O
55	the	O
56	consensus	O
57	TRE	O
58	.	O

1	Involvement	O
2	of	O
3	AP1	B
4	and	O
5	PEA3	B
6	binding	I
7	sites	I
8	in	O
9	the	O
10	regulation	O
11	of	O
12	murine	B
13	tissue	I
14	inhibitor	I
15	of	I
16	metalloproteinases	I
17	-	I
18	1	I
19	(	O
20	TIMP	B
21	-	I
22	1	I
23	)	O
24	transcription	O
25	.	O

1	Of	O
2	the	O
3	serum	B
4	neutralizing	I
5	(	I
6	SN	I
7	)	I
8	antibody	I
9	negative	O
10	calves	O
11	89	O
12	.	O
13	7	O
14	%	O
15	(	O
16	26	O
17	/	O
18	29	O
19	)	O
20	and	O
21	92	O
22	.	O
23	8	O
24	%	O
25	(	O
26	90	O
27	/	O
28	97	O
29	)	O
30	developed	O
31	SN	B
32	antibody	I
33	1	O
34	month	O
35	after	O
36	intranasal	O
37	and	O
38	intramuscular	O
39	vaccination	O
40	,	O
41	respectively	O
42	.	O

1	Fractionation	O
2	of	O
3	crude	O
4	nuclear	O
5	extracts	O
6	by	O
7	heparin	O
8	-	O
9	agarose	O
10	chromatography	O
11	indicates	O
12	that	O
13	PCAT	B
14	-	I
15	1	I
16	is	O
17	more	O
18	prevalent	O
19	in	O
20	extracts	O
21	prepared	O
22	from	O
23	salt	O
24	-	O
25	stressed	O
26	leaf	O
27	tissue	O
28	.	O

1	A	O
2	controlled	O
3	trial	O
4	of	O
5	recombinant	B
6	human	I
7	granulocyte	I
8	-	I
9	macrophage	I
10	colony	I
11	-	I
12	stimulating	I
13	factor	I
14	after	O
15	total	O
16	body	O
17	irradiation	O
18	,	O
19	high	O
20	-	O
21	dose	O
22	chemotherapy	O
23	,	O
24	and	O
25	autologous	O
26	bone	O
27	marrow	O
28	transplantation	O
29	for	O
30	acute	O
31	lymphoblastic	O
32	leukemia	O
33	or	O
34	malignant	O
35	lymphoma	O
36	.	O

1	These	O
2	data	O
3	demonstrate	O
4	that	O
5	DMVA	O
6	does	O
7	not	O
8	cause	O
9	more	O
10	myocardial	O
11	trauma	O
12	than	O
13	CPB	O
14	when	O
15	used	O
16	to	O
17	provide	O
18	resuscitative	O
19	circulatory	O
20	support	O
21	.	O

1	The	O
2	IgG	B
3	subclass	O
4	profile	O
5	of	O
6	untreated	O
7	coeliac	O
8	disease	O
9	was	O
10	found	O
11	to	O
12	be	O
13	the	O
14	same	O
15	as	O
16	in	O
17	healthy	O
18	controls	O
19	(	O
20	IgG1	B
21	approximately	O
22	IgG2	B
23	>	O
24	IgG3	B
25	>	O
26	IgG4	B
27	),	O
28	with	O
29	only	O
30	the	O
31	magnitude	O
32	of	O
33	the	O
34	individual	O
35	subclass	O
36	responses	O
37	being	O
38	increased	O
39	in	O
40	coeliac	O
41	patients	O
42	.	O

1	Examination	O
2	of	O
3	ANCA	B
4	is	O
5	not	O
6	only	O
7	a	O
8	significant	O
9	contribution	O
10	towards	O
11	a	O
12	more	O
13	accurate	O
14	diagnosis	O
15	of	O
16	renal	O
17	vasculitis	O
18	,	O
19	but	O
20	also	O
21	an	O
22	indicator	O
23	of	O
24	the	O
25	activity	O
26	of	O
27	the	O
28	disease	O
29	and	O
30	thus	O
31	of	O
32	the	O
33	effectiveness	O
34	of	O
35	immunosuppressive	O
36	treatment	O
37	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	total	O
7	pinealectomy	O
8	in	O
9	these	O
10	already	O
11	sympathectomized	O
12	blinded	O
13	rabbits	O
14	always	O
15	resulted	O
16	in	O
17	a	O
18	substantial	O
19	deceleration	O
20	of	O
21	the	O
22	rhythms	O
23	(	O
24	mean	O
25	delta	O
26	tau	O
27	=	O
28	+	O
29	0	O
30	.	O
31	23	O
32	h	O
33	).	O

1	Cicatricial	O
2	pemphigoid	O
3	is	O
4	an	O
5	autoimmune	O
6	systemic	O
7	disease	O
8	characterized	O
9	by	O
10	chronic	O
11	conjunctival	O
12	cicatrization	O
13	.	O

1	The	O
2	effects	O
3	of	O
4	two	O
5	levels	O
6	of	O
7	caffeine	O
8	ingestion	O
9	on	O
10	excess	O
11	postexercise	O
12	oxygen	O
13	consumption	O
14	in	O
15	untrained	O
16	women	O
17	.	O

1	The	O
2	distinguishing	O
3	features	O
4	involved	O
5	eight	O
6	amino	O
7	acid	O
8	changes	O
9	,	O
10	including	O
11	a	O
12	single	O
13	lysine	O
14	deletion	O
15	relative	O
16	to	O
17	a	O
18	primate	O
19	consensus	O
20	sequence	O
21	in	O
22	the	O
23	first	O
24	complementary	O
25	-	O
26	determing	O
27	region	O
28	of	O
29	V1J1	B
30	.	O

1	4	O
2	.	O

1	The	O
2	in	O
3	vivo	O
4	profile	O
5	of	O
6	ZFH	B
7	-	I
8	2	I
9	in	O
10	the	O
11	larval	O
12	CNS	O
13	shows	O
14	intriguing	O
15	overlap	O
16	with	O
17	DDC	B
18	in	O
19	specific	O
20	serotonin	O
21	and	O
22	dopamine	O
23	neurons	O
24	.	O

1	Unlike	O
2	the	O
3	introns	O
4	of	O
5	other	O
6	duplicated	O
7	ribosomal	B
8	protein	I
9	genes	I
10	which	O
11	are	O
12	highly	O
13	diverged	O
14	,	O
15	the	O
16	duplicated	O
17	S13	B
18	genes	I
19	have	O
20	two	O
21	nearly	O
22	identical	O
23	DNA	O
24	sequences	O
25	of	O
26	25	O
27	and	O
28	31	O
29	bp	O
30	in	O
31	length	O
32	within	O
33	their	O
34	introns	O
35	.	O

1	In	O
2	a	O
3	prospective	O
4	,	O
5	randomized	O
6	clinical	O
7	trial	O
8	we	O
9	compared	O
10	the	O
11	efficacy	O
12	of	O
13	subcutaneously	O
14	(	O
15	SC	O
16	)	O
17	administered	O
18	(	O
19	every	O
20	8	O
21	h	O
22	)	O
23	calcium	O
24	heparin	O
25	to	O
26	intravenous	O
27	(	O
28	IV	O
29	)	O
30	sodium	O
31	heparin	O
32	in	O
33	the	O
34	treatment	O
35	of	O
36	proximal	O
37	deep	O
38	-	O
39	vein	O
40	thrombosis	O
41	(	O
42	DVT	O
43	).	O

1	The	O
2	highest	O
3	prevalence	O
4	of	O
5	reported	O
6	pet	O
7	allergy	O
8	,	O
9	chronic	O
10	cough	O
11	,	O
12	wheeze	O
13	,	O
14	attacks	O
15	of	O
16	shortness	O
17	of	O
18	breath	O
19	with	O
20	wheezing	O
21	,	O
22	and	O
23	doctor	O
24	-	O
25	diagnosed	O
26	asthma	O
27	was	O
28	found	O
29	in	O
30	children	O
31	who	O
32	had	O
33	pets	O
34	in	O
35	the	O
36	past	O
37	but	O
38	not	O
39	anymore	O
40	.	O

1	Therefore	O
2	,	O
3	it	O
4	would	O
5	be	O
6	advantageous	O
7	to	O
8	identify	O
9	such	O
10	persons	O
11	and	O
12	treat	O
13	them	O
14	preferentially	O
15	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	these	O
6	unique	O
7	properties	O
8	,	O
9	the	O
10	newly	O
11	characterized	O
12	hemagglutinin	B
13	has	O
14	been	O
15	termed	O
16	Limulus	B
17	18K	I
18	agglutination	I
19	-	I
20	aggregation	I
21	factor	I
22	(	O
23	18K	B
24	-	I
25	LAF	I
26	).	O

1	The	O
2	shift	O
3	to	O
4	the	O
5	nonpermissive	O
6	temperature	O
7	is	O
8	accompanied	O
9	by	O
10	the	O
11	loss	O
12	of	O
13	guanyl	O
14	nucleotide	O
15	-	O
16	dependent	O
17	activity	O
18	of	O
19	adenylylcyclase	B
20	in	O
21	vitro	O
22	.	O

1	Clin	O
2	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	catalytic	O
8	domain	O
9	of	O
10	Nmt1p	B
11	is	O
12	located	O
13	between	O
14	Ile59	O
15	-->	O
16	Phe96	O
17	and	O
18	Gly451	O
19	-->	O
20	Leu455	O
21	.	O

1	It	O
2	corresponds	O
3	to	O
4	the	O
5	complete	O
6	mitochondrial	O
7	presequence	O
8	and	O
9	the	O
10	lipoyl	O
11	-	O
12	bearing	O
13	domain	O
14	that	O
15	are	O
16	encoded	O
17	by	O
18	exons	O
19	I	O
20	through	O
21	IV	O
22	of	O
23	the	O
24	functional	O
25	E2	B
26	gene	I
27	.	O

1	Human	O
2	neutrophil	O
3	response	O
4	to	O
5	short	O
6	-	O
7	term	O
8	exposure	O
9	to	O
10	F	O
11	-	O
12	75	O
13	cobalt	O
14	-	O
15	based	O
16	alloy	O
17	.	O

1	Disruption	O
2	of	O
3	microtubules	O
4	did	O
5	not	O
6	affect	O
7	the	O
8	fidelity	O
9	or	O
10	kinetics	O
11	of	O
12	vacuolar	O
13	protein	O
14	sorting	O
15	,	O
16	indicating	O
17	that	O
18	Vps1p	B
19	function	O
20	is	O
21	not	O
22	dependent	O
23	on	O
24	microtubules	O
25	.	O

1	A	O
2	mutant	O
3	form	O
4	of	O
5	Vps1p	B
6	lacking	O
7	the	O
8	entire	O
9	GTP	O
10	-	O
11	binding	O
12	domain	O
13	interfered	O
14	with	O
15	vacuolar	O
16	protein	O
17	sorting	O
18	in	O
19	wild	O
20	-	O
21	type	O
22	cells	O
23	.	O

1	According	O
2	to	O
3	out	O
4	field	O
5	research	O
6	,	O
7	the	O
8	tick	O
9	fauna	O
10	was	O
11	very	O
12	rich	O
13	throughout	O
14	that	O
15	area	O
16	,	O
17	and	O
18	it	O
19	was	O
20	permissible	O
21	enough	O
22	to	O
23	determine	O
24	ticks	O
25	as	O
26	the	O
27	vectors	O
28	,	O
29	based	O
30	on	O
31	arising	O
32	of	O
33	anti	B
34	-	I
35	SF	I
36	group	I
37	rickettsiae	I
38	(	O
39	SFGR	B
40	)	O
41	antibody	O
42	in	O
43	mice	O
44	inoculated	O
45	with	O
46	some	O
47	tick	O
48	emulsions	O
49	,	O
50	findings	O
51	of	O
52	rickettsiae	O
53	reactive	O
54	to	O
55	patient	O
56	sera	O
57	or	O
58	a	O
59	species	O
60	-	O
61	specific	O
62	monoclonal	O
63	antibody	O
64	to	O
65	JSFR	B
66	in	O
67	the	O
68	hemolymph	O
69	cells	O
70	of	O
71	some	O
72	ticks	O
73	,	O
74	and	O
75	electron	O
76	microscopical	O
77	observations	O
78	of	O
79	SFGR	B
80	in	O
81	various	O
82	internal	O
83	organs	O
84	including	O
85	the	O
86	salivary	O
87	gland	O
88	of	O
89	ticks	O
90	.	O

1	The	O
2	second	O
3	method	O
4	,	O
5	the	O
6	"	O
7	macro	O
8	"	O
9	assay	O
10	,	O
11	has	O
12	a	O
13	sensitivity	O
14	range	O
15	of	O
16	0	O
17	.	O
18	03	O
19	-	O
20	5	O
21	.	O
22	0	O
23	micrograms	O
24	phosphorus	O
25	with	O
26	100	O
27	-	O
28	500	O
29	microliters	O
30	HClO4	O
31	.	O

1	Nucleotide	O
2	sequence	O
3	and	O
4	transcriptional	O
5	analysis	O
6	of	O
7	the	O
8	polyhedrin	B
9	gene	I
10	of	O
11	Spodoptera	O
12	exigua	O
13	nuclear	O
14	polyhedrosis	O
15	virus	O
16	.	O

1	Validation	O
2	of	O
3	automated	O
4	systems	O
5	--	O
6	system	O
7	definition	O
8	.	O

1	As	O
2	a	O
3	consequence	O
4	of	O
5	dark	O
6	rearing	O
7	,	O
8	the	O
9	numerical	O
10	density	O
11	of	O
12	cortical	O
13	neurons	O
14	in	O
15	area	O
16	17	O
17	amounted	O
18	to	O
19	about	O
20	double	O
21	of	O
22	the	O
23	value	O
24	observed	O
25	in	O
26	normally	O
27	reared	O
28	kittens	O
29	and	O
30	was	O
31	also	O
32	significantly	O
33	higher	O
34	in	O
35	area	O
36	18	O
37	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	decreased	O
6	class	O
7	I	O
8	enhancer	O
9	activity	O
10	in	O
11	Ad12	O
12	-	O
13	transformed	O
14	cells	O
15	may	O
16	,	O
17	at	O
18	least	O
19	in	O
20	part	O
21	,	O
22	be	O
23	due	O
24	to	O
25	the	O
26	higher	O
27	levels	O
28	of	O
29	an	O
30	enhancer	O
31	-	O
32	specific	O
33	factor	O
34	,	O
35	possibly	O
36	acting	O
37	as	O
38	a	O
39	repressor	O
40	.	O

1	A	O
2	second	O
3	domain	O
4	,	O
5	located	O
6	in	O
7	the	O
8	C	O
9	-	O
10	terminal	O
11	437	O
12	amino	O
13	acids	O
14	of	O
15	IE1	B
16	,	O
17	is	O
18	required	O
19	for	O
20	inhibitory	O
21	and	O
22	DNA	O
23	-	O
24	binding	O
25	activities	O
26	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	the	O
6	blood	O
7	compatibility	O
8	of	O
9	autogenous	O
10	vein	O
11	graft	O
12	(	O
13	AVG	O
14	),	O
15	changes	O
16	in	O
17	prostacyclin	O
18	(	O
19	PGI2	O
20	)	O
21	production	O
22	following	O
23	harvesting	O
24	and	O
25	arterial	O
26	implantation	O
27	were	O
28	studied	O
29	experimentally	O
30	.	O

1	Subcutaneous	O
2	administration	O
3	of	O
4	the	O
5	somatostatin	B
6	analogue	O
7	,	O
8	octreotide	O
9	,	O
10	100	O
11	micrograms	O
12	thrice	O
13	daily	O
14	,	O
15	resulted	O
16	in	O
17	a	O
18	sustained	O
19	improvement	O
20	in	O
21	diarrhoea	O
22	and	O
23	disappearance	O
24	of	O
25	faecal	O
26	incontinence	O
27	without	O
28	reducing	O
29	calcitonin	B
30	levels	O
31	.	O

1	Anti	B
2	-	I
3	CRK	I
4	antibodies	I
5	detect	O
6	a	O
7	53kDa	O
8	protein	O
9	in	O
10	extracts	O
11	of	O
12	C	O
13	.	O
14	fasciculata	O
15	in	O
16	agreement	O
17	with	O
18	the	O
19	size	O
20	predicted	O
21	from	O
22	the	O
23	nucleotide	O
24	sequence	O
25	of	O
26	the	O
27	cloned	O
28	gene	O
29	.	O

1	205	O
2	,	O
3	285	O
4	-	O
5	290	O
6	]	O
7	and	O
8	was	O
9	subsequently	O
10	cloned	O
11	and	O
12	sequenced	O
13	[	O
14	J	O
15	.	O

1	Nonreplicating	O
2	vaccinia	O
3	vector	O
4	efficiently	O
5	expresses	O
6	recombinant	O
7	genes	O
8	.	O

1	Use	O
2	of	O
3	free	O
4	-	O
5	access	O
6	minerals	O
7	.	O

1	Interferon	B
2	type	I
3	I	I
4	in	O
5	protective	O
6	body	O
7	reactions	O
8	in	O
9	an	O
10	experimental	O
11	Klebsiella	O
12	infection	O

1	No	O
2	other	O
3	changes	O
4	in	O
5	hematopoietic	O
6	differentiation	O
7	status	O
8	were	O
9	observed	O
10	in	O
11	association	O
12	with	O
13	Id	B
14	-	I
15	SCL	I
16	expression	O
17	.	O

1	Respiratory	O
2	interaction	O
3	after	O
4	spinal	O
5	anesthesia	O
6	and	O
7	sedation	O
8	with	O
9	midazolam	O
10	.	O

1	For	O
2	pressure	O
3	greater	O
4	than	O
5	121	O
6	atm	O
7	abs	O
8	,	O
9	an	O
10	increased	O
11	excitability	O
12	of	O
13	the	O
14	tadpoles	O
15	made	O
16	it	O
17	difficult	O
18	to	O
19	distinguish	O
20	the	O
21	righting	O
22	reflex	O
23	from	O
24	involuntary	O
25	movements	O
26	.	O

1	One	O
2	air	O
3	embolism	O
4	occurred	O
5	;	O
6	this	O
7	was	O
8	the	O
9	only	O
10	filter	O
11	-	O
12	or	O
13	retrieval	O
14	-	O
15	related	O
16	complication	O
17	.	O

1	The	O
2	5	O
3	'	O
4	region	O
5	of	O
6	ADH5	B
7	contains	O
8	consensus	O
9	binding	O
10	sites	O
11	for	O
12	the	O
13	transcriptional	O
14	regulatory	O
15	proteins	O
16	,	O
17	Sp1	B
18	,	O
19	AP2	B
20	,	O
21	LF	B
22	-	I
23	A1	I
24	,	O
25	NF	B
26	-	I
27	1	I
28	,	O
29	NF	B
30	-	I
31	A2	I
32	,	O
33	and	O
34	NF	B
35	-	I
36	E1	I
37	.	O

1	V	O
2	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	RNK	B
6	-	I
7	Met	I
8	-	I
9	1	I
10	is	O
11	a	O
12	serine	B
13	protease	I
14	with	O
15	unique	O
16	activity	O
17	that	O
18	is	O
19	expressed	O
20	in	O
21	the	O
22	granules	O
23	of	O
24	large	O
25	granular	O
26	lymphocytes	O
27	.	O

1	Purification	O
2	and	O
3	cloning	O
4	of	O
5	a	O
6	novel	O
7	serine	B
8	protease	I
9	,	O
10	RNK	B
11	-	I
12	Met	I
13	-	I
14	1	I
15	,	O
16	from	O
17	the	O
18	granules	O
19	of	O
20	a	O
21	rat	O
22	natural	O
23	killer	O
24	cell	O
25	leukemia	O
26	.	O

1	We	O
2	describe	O
3	here	O
4	17	O
5	dominant	B
6	GCN2	I
7	mutations	I
8	that	O
9	lead	O
10	to	O
11	derepression	O
12	of	O
13	GCN4	B
14	expression	O
15	in	O
16	the	O
17	absence	O
18	of	O
19	amino	O
20	acid	O
21	starvation	O
22	.	O

1	Administration	O
2	of	O
3	growth	B
4	hormone	I
5	leads	O
6	to	O
7	faster	O
8	growth	O
9	,	O
10	but	O
11	also	O
12	faster	O
13	bone	O
14	maturation	O
15	.	O

1	Comparisons	O
2	with	O
3	the	O
4	available	O
5	amino	O
6	acid	O
7	residue	O
8	(	O
9	aa	O
10	)	O
11	sequence	O
12	information	O
13	from	O
14	the	O
15	complete	O
16	CPMV	B
17	RNA	I
18	1	I
19	sequence	I
20	and	O
21	the	O
22	partial	O
23	sequence	O
24	of	O
25	red	B
26	clover	I
27	mottle	I
28	virus	I
29	RNA	I
30	1	I
31	suggest	O
32	that	O
33	CPSMV	B
34	RNA	I
35	1	I
36	specifies	O
37	the	O
38	expected	O
39	set	O
40	of	O
41	five	O
42	mature	O
43	proteins	O
44	:	O
45	32K	B
46	proteinase	I
47	cofactor	I
48	,	O
49	58K	B
50	presumed	I
51	helicase	I
52	,	O
53	VPg	B
54	5	I
55	'-	I
56	linked	I
57	protein	I
58	of	O
59	the	O
60	genomic	O
61	RNAs	O
62	,	O
63	24K	B
64	proteinase	I
65	,	O
66	and	O
67	87K	B
68	presumed	I
69	polymerase	I
70	,	O
71	separated	O
72	by	O
73	four	O
74	cleavage	O
75	sites	O
76	.	O

1	Rice	B
2	dwarf	I
3	phytoreovirus	I
4	segment	I
5	S12	I
6	transcript	I
7	is	O
8	tricistronic	O
9	in	O
10	vitro	O
11	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	utility	O
6	of	O
7	beta	B
8	2	I
9	transferrin	I
10	assay	O
11	in	O
12	the	O
13	diagnosis	O
14	of	O
15	cerebrospinal	O
16	fluid	O
17	otorrhea	O
18	is	O
19	presented	O
20	.	O

1	Cold	O
2	cardioplegia	O
3	was	O
4	administered	O
5	at	O
6	45	O
7	mm	O
8	Hg	O
9	every	O
10	20	O
11	minutes	O
12	for	O
13	2	O
14	hours	O
15	.	O

1	The	O
2	addition	O
3	of	O
4	diatrizoate	O
5	to	O
6	the	O
7	IPRK	O
8	led	O
9	to	O
10	a	O
11	dose	O
12	-	O
13	dependent	O
14	biphasic	O
15	change	O
16	in	O
17	RPF	O
18	and	O
19	GFR	O
20	characterized	O
21	by	O
22	an	O
23	initial	O
24	transient	O
25	increase	O
26	followed	O
27	by	O
28	a	O
29	marked	O
30	and	O
31	sustained	O
32	decrease	O
33	.	O

1	To	O
2	prepare	O
3	for	O
4	analyses	O
5	with	O
6	the	O
7	family	O
8	variables	O
9	,	O
10	we	O
11	next	O
12	present	O
13	descriptive	O
14	data	O
15	based	O
16	on	O
17	separate	O
18	principal	O
19	components	O
20	analysis	O
21	(	O
22	PCA	O
23	)	O
24	and	O
25	multidimensional	O
26	scaling	O
27	analysis	O
28	(	O
29	MDS	O
30	)	O
31	of	O
32	14	O
33	self	O
34	-	O
35	reported	O
36	health	O
37	scores	O
38	for	O
39	husbands	O
40	and	O
41	for	O
42	wives	O
43	.	O

1	The	O
2	structural	O
3	genes	O
4	encoding	O
5	glyceraldehyde	B
6	-	I
7	3	I
8	-	I
9	phosphate	I
10	dehydrogenase	I
11	(	O
12	GAPDH	B
13	),	O
14	3	B
15	-	I
16	phosphoglycerate	I
17	kinase	I
18	(	O
19	PGK	B
20	)	O
21	and	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	part	O
27	of	O
28	triosephosphate	B
29	isomerase	I
30	(	O
31	TIM	B
32	)	O
33	from	O
34	mesophilic	O
35	Bacillus	O
36	megaterium	O
37	DSM319	O
38	have	O
39	been	O
40	cloned	O
41	as	O
42	a	O
43	gene	O
44	cluster	O
45	(	O
46	gap	B
47	operon	I
48	)	O
49	by	O
50	complementation	O
51	of	O
52	an	O
53	Escherichia	O
54	coli	O
55	gap	B
56	amber	I
57	mutant	I
58	.	O

1	Pseudomonas	B
2	aeruginosa	I
3	exotoxin	I
4	A	I
5	:	O
6	its	O
7	role	O
8	in	O
9	retardation	O
10	of	O
11	wound	O
12	healing	O
13	:	O
14	the	O
15	1992	O
16	Lindberg	O
17	Award	O
18	.	O

1	Laboratory	O
2	studies	O
3	showed	O
4	that	O
5	the	O
6	direct	O
7	fluorescent	O
8	-	O
9	antibody	O
10	kits	O
11	were	O
12	the	O
13	least	O
14	sensitive	O
15	in	O
16	this	O
17	case	O
18	and	O
19	did	O
20	not	O
21	detect	O
22	fewer	O
23	than	O
24	10	O
25	(	O
26	4	O
27	)	O
28	elementary	O
29	bodies	O
30	per	O
31	ml	O
32	,	O
33	while	O
34	most	O
35	ELISA	O
36	kits	O
37	detected	O
38	between	O
39	130	O
40	and	O
41	600	O
42	elementary	O
43	bodies	O
44	per	O
45	ml	O
46	.	O

1	To	O
2	study	O
3	the	O
4	significance	O
5	of	O
6	these	O
7	domains	O
8	and	O
9	the	O
10	overall	O
11	evolutionary	O
12	conservation	O
13	of	O
14	the	O
15	gene	O
16	,	O
17	the	O
18	homolog	O
19	from	O
20	Drosophila	O
21	melanogaster	O
22	was	O
23	isolated	O
24	by	O
25	low	O
26	stringency	O
27	hybridizations	O
28	using	O
29	two	O
30	flanking	O
31	probes	O
32	of	O
33	the	O
34	human	B
35	ERCC3	I
36	cDNA	I
37	.	O

1	Mono	O
2	-	O
3	ADP	O
4	-	O
5	ribosylation	O
6	is	O
7	a	O
8	reversible	O
9	modification	O
10	of	O
11	proteins	O
12	,	O
13	with	O
14	NAD	O
15	:	O
16	arginine	B
17	ADP	I
18	-	I
19	ribosyltransferases	I
20	(	O
21	EC	B
22	2	I
23	.	I
24	4	I
25	.	I
26	2	I
27	.	I
28	31	I
29	)	O
30	and	O
31	ADP	B
32	-	I
33	ribosylarginine	I
34	hydrolases	I
35	(	O
36	EC	B
37	3	I
38	.	I
39	2	I
40	.	I
41	2	I
42	.	I
43	19	I
44	)	O
45	catalyzing	O
46	the	O
47	opposing	O
48	reactions	O
49	in	O
50	an	O
51	ADP	O
52	-	O
53	ribosylation	O
54	cycle	O
55	.	O

1	For	O
2	this	O
3	reason	O
4	,	O
5	the	O
6	particle	O
7	forming	O
8	capacity	O
9	of	O
10	derivatives	O
11	of	O
12	the	O
13	HIV	B
14	-	I
15	1	I
16	group	I
17	specific	I
18	core	I
19	antigen	I
20	p55	I
21	gag	I
22	was	O
23	assayed	O
24	and	O
25	compared	O
26	dependent	O
27	on	O
28	various	O
29	expression	O
30	systems	O
31	:	O
32	recombinant	O
33	bacteria	O
34	,	O
35	vaccinia	O
36	-	O
37	and	O
38	baculoviruses	O
39	were	O
40	established	O
41	encoding	O
42	the	O
43	entire	O
44	core	B
45	protein	I
46	p55	I
47	either	O
48	in	O
49	its	O
50	authentic	O
51	sequence	O
52	or	O
53	lacking	O
54	the	O
55	myristylation	O
56	consensus	O
57	signal	O
58	.	O

1	The	O
2	tramtrack	B
3	(	O
4	ttk	B
5	)	O
6	gene	O
7	of	O
8	Drosophila	O
9	encodes	O
10	69	O
11	-	O
12	kDa	O
13	and	O
14	88	O
15	-	O
16	kDa	O
17	proteins	O
18	through	O
19	alternative	O
20	splicing	O
21	of	O
22	the	O
23	primary	O
24	ttk	B
25	transcript	I
26	.	O

1	Removal	O
2	of	O
3	beta	B
4	2	I
5	-	I
6	microglobulin	I
7	by	O
8	hemodialysis	O
9	and	O
10	hemofiltration	O
11	:	O
12	a	O
13	four	O
14	year	O
15	follow	O
16	up	O
17	.	O

1	Removal	O
2	of	O
3	beta	B
4	2	I
5	-	I
6	microglobulin	I
7	by	O
8	hemodialysis	O
9	and	O
10	hemofiltration	O
11	:	O
12	a	O
13	four	O
14	year	O
15	follow	O
16	up	O
17	.	O

1	Adapromine	O
2	was	O
3	established	O
4	to	O
5	evoke	O
6	a	O
7	decrease	O
8	of	O
9	the	O
10	amplitude	O
11	of	O
12	the	O
13	dominant	O
14	peak	O
15	and	O
16	dominant	O
17	theta	O
18	-	O
19	activity	O
20	in	O
21	power	O
22	spectra	O
23	of	O
24	the	O
25	EEG	O
26	in	O
27	the	O
28	cortex	O
29	and	O
30	hippocamp	O
31	,	O
32	with	O
33	an	O
34	increase	O
35	of	O
36	rapid	O
37	wave	O
38	activity	O
39	in	O
40	the	O
41	beta	O
42	2	O
43	range	O
44	in	O
45	the	O
46	right	O
47	cortex	O
48	and	O
49	hippocamp	O
50	.	O

1	These	O
2	sequences	O
3	were	O
4	then	O
5	used	O
6	to	O
7	clone	O
8	the	O
9	full	O
10	-	O
11	length	O
12	genes	O
13	from	O
14	a	O
15	yeast	O
16	genomic	O
17	library	O
18	.	O

1	GAL4	B
2	-	O
3	VP16	B
4	-	O
5	mediated	O
6	antirepression	O
7	required	O
8	an	O
9	auxiliary	O
10	factor	O
11	,	O
12	denoted	O
13	as	O
14	a	O
15	co	O
16	-	O
17	antirepressor	O
18	,	O
19	which	O
20	was	O
21	partially	O
22	purified	O
23	from	O
24	Drosophila	O
25	embryos	O
26	.	O

1	After	O
2	28	O
3	days	O
4	of	O
5	haloperidol	O
6	treatment	O
7	,	O
8	similar	O
9	changes	O
10	were	O
11	observed	O
12	for	O
13	delta	O
14	,	O
15	together	O
16	with	O
17	an	O
18	increase	O
19	of	O
20	alpha	O
21	1	O
22	,	O
23	and	O
24	a	O
25	decrease	O
26	of	O
27	fast	O
28	beta	O
29	.	O

1	Four	O
2	ruminally	O
3	and	O
4	duodenally	O
5	cannulated	O
6	Hampshire	O
7	wethers	O
8	were	O
9	used	O
10	in	O
11	a	O
12	4	O
13	x	O
14	4	O
15	Latin	O
16	square	O
17	experiment	O
18	to	O
19	determine	O
20	whether	O
21	linoleoyl	O
22	methionine	O
23	and	O
24	calcium	O
25	linoleate	O
26	would	O
27	increase	O
28	duodenal	O
29	flow	O
30	of	O
31	unsaturated	O
32	fatty	O
33	acids	O
34	(	O
35	C18	O
36	:	O
37	2	O
38	+	O
39	cis	O
40	C18	O
41	:	O
42	1	O
43	).	O

1	Truncated	B
2	ICSBP	I
3	lacking	O
4	the	O
5	first	O
6	33	O
7	amino	O
8	-	O
9	terminal	O
10	amino	O
11	acids	O
12	fails	O
13	to	O
14	bind	O
15	to	O
16	the	O
17	ICS	B
18	,	O
19	indicating	O
20	that	O
21	at	O
22	least	O
23	part	O
24	of	O
25	the	O
26	DNA	O
27	binding	O
28	domain	O
29	is	O
30	located	O
31	within	O
32	the	O
33	well	O
34	conserved	O
35	amino	O
36	terminus	O
37	.	O

1	Therefore	O
2	,	O
3	ICSBP	B
4	may	O
5	be	O
6	involved	O
7	in	O
8	maintaining	O
9	submaximal	O
10	transcriptional	O
11	activity	O
12	of	O
13	IFN	B
14	-	O
15	inducible	O
16	genes	O
17	in	O
18	hematopoietic	O
19	cells	O
20	.	O

1	A	O
2	case	O
3	of	O
4	chronic	O
5	hepatitis	O
6	C	O
7	with	O
8	primary	O
9	hypothyroidism	O
10	manifested	O
11	during	O
12	interferon	B
13	treatment	O

1	Dynamic	O
2	decision	O
3	making	O
4	:	O
5	human	O
6	control	O
7	of	O
8	complex	O
9	systems	O
10	.	O

1	A	O
2	coiled	B
3	-	I
4	coil	I
5	related	I
6	protein	I
7	specific	O
8	for	O
9	synapsed	O
10	regions	O
11	of	O
12	meiotic	O
13	prophase	O
14	chromosomes	O
15	.	O

1	Comparable	O
2	amounts	O
3	of	O
4	alpha	B
5	5	I
6	beta	I
7	1	I
8	integrin	I
9	were	O
10	isolated	O
11	from	O
12	these	O
13	cells	O
14	by	O
15	chromatography	O
16	of	O
17	detergent	O
18	extracts	O
19	on	O
20	a	O
21	fibronectin	B
22	cell	O
23	-	O
24	binding	O
25	fragment	O
26	affinity	O
27	column	O
28	and	O
29	elution	O
30	with	O
31	EDTA	O
32	.	O

1	Abstracts	O
2	.	O

1	These	O
2	results	O
3	indicate	O
4	a	O
5	possible	O
6	involvement	O
7	of	O
8	endogenous	O
9	opioid	O
10	peptides	O
11	in	O
12	the	O
13	cardiac	O
14	effects	O
15	due	O
16	to	O
17	myocardial	O
18	ischaemia	O
19	and	O
20	reperfusion	O
21	,	O
22	mediated	O
23	by	O
24	opiate	B
25	receptors	I
26	through	O
27	opiate	O
28	antagonism	O
29	.	O

1	From	O
2	this	O
3	library	O
4	,	O
5	LEU2	B
6	and	O
7	HIS3	B
8	cDNAs	O
9	were	O
10	recovered	O
11	at	O
12	a	O
13	frequency	O
14	of	O
15	about	O
16	1	O
17	in	O
18	10	O
19	(	O
20	4	O
21	)	O
22	and	O
23	in	O
24	12	O
25	out	O
26	of	O
27	13	O
28	cases	O
29	these	O
30	were	O
31	expressed	O
32	in	O
33	a	O
34	galactose	O
35	-	O
36	dependent	O
37	manner	O
38	.	O

1	Among	O
2	these	O
3	,	O
4	ACT1	B
5	was	O
6	isolated	O
7	four	O
8	times	O
9	,	O
10	and	O
11	NSR1	B
12	three	O
13	times	O
14	.	O

1	Since	O
2	CENP	B
3	-	I
4	B	I
5	gene	I
6	is	O
7	conserved	O
8	in	O
9	mammalian	O
10	species	O
11	and	O
12	CENP	B
13	-	I
14	B	I
15	boxes	I
16	are	O
17	found	O
18	also	O
19	in	O
20	mouse	O
21	centromere	O
22	satellite	O
23	DNA	O
24	(	O
25	minor	O
26	satellite	O
27	),	O
28	this	O
29	sequence	O
30	-	O
31	specific	O
32	DNA	O
33	-	O
34	protein	O
35	interaction	O
36	may	O
37	be	O
38	important	O
39	for	O
40	some	O
41	kind	O
42	of	O
43	common	O
44	centromere	O
45	function	O
46	.	O

1	Interestingly	O
2	,	O
3	a	O
4	portion	O
5	of	O
6	the	O
7	tail	O
8	domain	O
9	(	O
10	aa	O
11	,	O
12	1	O
13	,	O
14	094	O
15	-	O
16	1	O
17	,	O
18	830	O
19	)	O
20	shares	O
21	58	O
22	%	O
23	amino	O
24	acid	O
25	sequence	O
26	identity	O
27	with	O
28	a	O
29	723	O
30	-	O
31	aa	O
32	protein	O
33	from	O
34	mouse	O
35	brain	O
36	reported	O
37	to	O
38	be	O
39	a	O
40	glutamic	B
41	acid	I
42	decarboxylase	I
43	.	O

1	However	O
2	,	O
3	in	O
4	the	O
5	subgroup	O
6	with	O
7	normal	O
8	Ht	O
9	(<	O
10	0	O
11	.	O
12	45	O
13	l	O
14	/	O
15	l	O
16	;	O
17	n	O
18	=	O
19	201	O
20	)	O
21	there	O
22	was	O
23	a	O
24	significant	O
25	reduction	O
26	(	O
27	p	O
28	<	O
29	0	O
30	.	O
31	05	O
32	)	O
33	of	O
34	the	O
35	mortality	O
36	after	O
37	3	O
38	months	O
39	(	O
40	27	O
41	%	O
42	and	O
43	16	O
44	%,	O
45	respectively	O
46	)	O
47	and	O
48	an	O
49	increase	O
50	of	O
51	independence	O
52	at	O
53	home	O
54	(	O
55	35	O
56	%	O
57	and	O
58	48	O
59	%,	O
60	respectively	O
61	)	O
62	due	O
63	to	O
64	a	O
65	reduction	O
66	of	O
67	the	O
68	viscosity	O
69	by	O
70	means	O
71	of	O
72	haemodilution	O
73	with	O
74	albumin	B
75	(	O
76	a	O
77	specific	O
78	viscosity	O
79	effect	O
80	in	O
81	the	O
82	normovolaemic	O
83	group	O
84	).	O

1	Distribution	O
2	and	O
3	changing	O
4	morphological	O
5	course	O

1	The	O
2	appropriate	O
3	use	O
4	and	O
5	benefits	O
6	of	O
7	bile	O
8	acid	O
9	sequestrants	O
10	,	O
11	nicotinic	O
12	acid	O
13	,	O
14	fibric	O
15	acids	O
16	,	O
17	3	B
18	-	I
19	hydroxy	I
20	-	I
21	3	I
22	-	I
23	methylglutaryl	I
24	coenzyme	I
25	A	I
26	(	I
27	HMG	I
28	-	I
29	CoA	I
30	)	I
31	reductase	I
32	inhibitors	O
33	,	O
34	and	O
35	probucol	O
36	are	O
37	individually	O
38	discussed	O
39	,	O
40	whereas	O
41	nonpharmacologic	O
42	approaches	O
43	used	O
44	in	O
45	conjunction	O
46	with	O
47	the	O
48	drugs	O
49	are	O
50	recommended	O
51	emphatically	O
52	.	O

1	This	O
2	may	O
3	result	O
4	in	O
5	more	O
6	reabsorption	O
7	and	O
8	hence	O
9	reduced	O
10	renal	O
11	clearance	O
12	.	O

1	The	O
2	major	O
3	pathological	O
4	findings	O
5	of	O
6	the	O
7	placenta	O
8	were	O
9	prematuration	O
10	and	O
11	hypoplasia	O
12	.	O

1	Green	O
2	pepper	O
3	significantly	O
4	inhibited	O
5	N	O
6	-	O
7	nitrosothiazolidine	O
8	-	O
9	carboxylic	O
10	acid	O
11	formation	O
12	relative	O
13	to	O
14	ascorbic	O
15	acid	O
16	alone	O
17	.	O

1	A	O
2	genomic	O
3	clone	O
4	,	O
5	pTt21	O
6	,	O
7	containing	O
8	DNA	O
9	apparently	O
10	transcribed	O
11	specifically	O
12	in	O
13	Trypanosoma	O
14	cruzi	O
15	trypomastigotes	O
16	,	O
17	was	O
18	obtained	O
19	by	O
20	differentially	O
21	screening	O
22	a	O
23	genomic	O
24	library	O
25	with	O
26	trypomastigote	O
27	and	O
28	epimastigote	O
29	cDNA	O
30	.	O

1	Brucellosis	O
2	--	O
3	1990	O

1	Assay	O
2	of	O
3	urea	O
4	by	O
5	immobilized	O
6	urease	B
7	coupled	O
8	to	O
9	a	O
10	differential	O
11	pH	O
12	-	O
13	meter	O
14	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	AGA	O
6	group	O
7	,	O
8	both	O
9	fetal	O
10	and	O
11	maternal	O
12	serum	O
13	prolactin	B
14	concentration	O
15	increased	O
16	significantly	O
17	with	O
18	gestation	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	and	O
26	P	O
27	<	O
28	0	O
29	.	O
30	01	O
31	,	O
32	respectively	O
33	).	O

1	One	O
2	phage	O
3	clone	O
4	contains	O
5	a	O
6	junction	O
7	between	O
8	alpha	O
9	satellite	O
10	DNA	O
11	and	O
12	a	O
13	novel	O
14	low	O
15	-	O
16	copy	O
17	repeated	O
18	sequence	O
19	.	O

1	The	O
2	5	O
3	'-	O
4	flanking	O
5	region	O
6	of	O
7	the	O
8	human	B
9	lactoferrin	I
10	gene	I
11	was	O
12	isolated	O
13	from	O
14	a	O
15	human	O
16	placental	O
17	genomic	O
18	library	O
19	.	O

1	Therefore	O
2	,	O
3	the	O
4	molecular	O
5	mechanisms	O
6	of	O
7	the	O
8	estrogen	O
9	action	O
10	that	O
11	govern	O
12	the	O
13	lactoferrin	B
14	gene	I
15	expression	O
16	differ	O
17	between	O
18	mouse	O
19	and	O
20	human	O
21	.	O

1	BiP670	B
2	retains	O
3	basal	O
4	and	O
5	Ca2	O
6	+	O
7	ionophore	O
8	A23187	O
9	-	O
10	inducible	O
11	activities	O
12	.	O

1	The	O
2	CEM	O
3	receives	O
4	registration	O
5	updates	O
6	via	O
7	an	O
8	HL7	O
9	message	O
10	and	O
11	evaluates	O
12	data	O
13	dependencies	O
14	in	O
15	rules	O
16	via	O
17	an	O
18	interface	O
19	to	O
20	the	O
21	relational	O
22	database	O
23	.	O

1	Magnetic	O
2	resonance	O
3	spectroscopy	O
4	(	O
5	MRS	O
6	)	O
7	and	O
8	imaging	O
9	(	O
10	MRI	O
11	)	O
12	are	O
13	now	O
14	well	O
15	established	O
16	techniques	O
17	for	O
18	the	O
19	study	O
20	of	O
21	cellular	O
22	metabolism	O
23	and	O
24	gross	O
25	structure	O
26	of	O
27	muscle	O
28	.	O

1	Simultaneously	O
2	a	O
3	greater	O
4	NA	O
5	was	O
6	found	O
7	with	O
8	no	O
9	change	O
10	in	O
11	plasma	O
12	epinephrine	O
13	response	O
14	.	O

1	We	O
2	investigated	O
3	the	O
4	diagnostic	O
5	value	O
6	of	O
7	a	O
8	new	O
9	in	O
10	vitro	O
11	test	O
12	,	O
13	Pharmacia	O
14	CAP	O
15	System	O
16	(	O
17	Pharmacia	O
18	Diagnostics	O
19	AB	O
20	,	O
21	Uppsala	O
22	,	O
23	Sweden	O
24	),	O
25	for	O
26	the	O
27	quantitative	O
28	measurement	O
29	of	O
30	allergen	B
31	-	I
32	specific	I
33	IgE	I
34	antibodies	I
35	by	O
36	comparison	O
37	with	O
38	RAST	O
39	in	O
40	2	O
41	groups	O
42	of	O
43	patients	O
44	,	O
45	71	O
46	atopic	O
47	and	O
48	48	O
49	non	O
50	-	O
51	atopic	O
52	.	O

1	Patients	O
2	receiving	O
3	VPA	O
4	showed	O
5	differences	O
6	in	O
7	attention	O
8	,	O
9	visuomotor	O
10	performance	O
11	,	O
12	verbal	O
13	span	O
14	and	O
15	sensory	O
16	discrimination	O
17	tasks	O
18	at	O
19	T1	O
20	,	O
21	in	O
22	visuomotor	O
23	performance	O
24	at	O
25	T2	O
26	and	O
27	in	O
28	spatial	O
29	span	O
30	at	O
31	T3	O
32	,	O
33	whereas	O
34	no	O
35	differences	O
36	were	O
37	detected	O
38	at	O
39	T4	O
40	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	gene	O
6	segment	O
7	containing	O
8	the	O
9	mu	O
10	m	O
11	poly	O
12	(	O
13	A	O
14	)	O
15	signals	O
16	,	O
17	along	O
18	with	O
19	536	O
20	bp	O
21	of	O
22	downstream	O
23	flanking	O
24	sequence	O
25	,	O
26	acted	O
27	as	O
28	a	O
29	transcription	O
30	terminator	O
31	in	O
32	both	O
33	myeloma	O
34	cells	O
35	and	O
36	L	O
37	cell	O
38	fibroblasts	O
39	.	O

1	As	O
2	a	O
3	part	O
4	of	O
5	a	O
6	large	O
7	examination	O
8	,	O
9	total	O
10	and	O
11	free	O
12	serum	O
13	cholesterol	O
14	,	O
15	total	O
16	lipid	O
17	and	O
18	triglyceride	O
19	levels	O
20	were	O
21	determined	O
22	.	O

1	Alena	O
2	is	O
3	a	O
4	nurse	O
5	in	O
6	Prague	O
7	--	O
8	she	O
9	dreams	O
10	of	O
11	higher	O
12	wages	O
13	and	O
14	a	O
15	trip	O
16	across	O
17	the	O
18	ocean	O

1	Dopamine	O
2	neurons	O
3	in	O
4	subjects	O
5	that	O
6	received	O
7	6	O
8	-	O
9	OHDA	O
10	were	O
11	protected	O
12	by	O
13	pre	O
14	-	O
15	treatment	O
16	with	O
17	GBR	O
18	-	O
19	12909	O
20	.	O

1	DIBA	O
2	was	O
3	more	O
4	sensitive	O
5	and	O
6	had	O
7	a	O
8	better	O
9	negative	O
10	predictive	O
11	value	O
12	and	O
13	a	O
14	lower	O
15	false	O
16	negative	O
17	percentage	O
18	than	O
19	DFAT	O
20	.	O

1	Caries	O
2	and	O
3	parodontitis	O
4	have	O
5	been	O
6	one	O
7	of	O
8	the	O
9	most	O
10	spread	O
11	diseases	O
12	of	O
13	mankind	O
14	.	O

1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	demonstrate	O
7	that	O
8	strongyloidiasis	O
9	was	O
10	the	O
11	cause	O
12	of	O
13	sudden	O
14	death	O
15	.	O

1	A	O
2	second	O
3	large	O
4	group	O
5	of	O
6	disorders	O
7	in	O
8	pregnancy	O
9	is	O
10	caused	O
11	by	O
12	effects	O
13	of	O
14	infections	O
15	of	O
16	the	O
17	mother	O
18	without	O
19	pathogens	O
20	being	O
21	transmitted	O
22	to	O
23	the	O
24	embryo	O
25	or	O
26	the	O
27	placenta	O
28	.	O

1	Four	O
2	short	O
3	nucleotide	O
4	sequences	O
5	(	O
6	boxes	O
7	I	O
8	to	O
9	IV	O
10	)	O
11	contribute	O
12	to	O
13	the	O
14	light	O
15	responsiveness	O
16	of	O
17	the	O
18	parsley	B
19	chalcone	I
20	synthase	I
21	promoter	I
22	.	O

1	The	O
2	case	O
3	described	O
4	is	O
5	that	O
6	of	O
7	a	O
8	72	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	with	O
15	ochronosis	O
16	who	O
17	suffered	O
18	a	O
19	hyperextension	O
20	injury	O
21	to	O
22	his	O
23	spine	O
24	in	O
25	a	O
26	fall	O
27	,	O
28	resulting	O
29	in	O
30	a	O
31	fracture	O
32	through	O
33	an	O
34	ankylosed	O
35	L2	O
36	-	O
37	L3	O
38	disk	O
39	space	O
40	.	O

1	The	O
2	mean	O
3	blood	O
4	flow	O
5	in	O
6	the	O
7	penile	O
8	foreskin	O
9	was	O
10	estimated	O
11	to	O
12	be	O
13	15	O
14	ml	O
15	/	O
16	min	O
17	/	O
18	100	O
19	g	O
20	and	O
21	it	O
22	increased	O
23	to	O
24	150	O
25	-	O
26	200	O
27	%	O
28	after	O
29	the	O
30	induction	O
31	of	O
32	anesthesia	O
33	,	O
34	and	O
35	then	O
36	decreased	O
37	to	O
38	72	O
39	%	O
40	at	O
41	the	O
42	tip	O
43	of	O
44	the	O
45	created	O
46	parameatal	O
47	foreskin	O
48	flap	O
49	.	O

1	ME1a1	B
2	,	O
3	a	O
4	16	O
5	-	O
6	base	O
7	-	O
8	pair	O
9	nuclear	O
10	factor	O
11	binding	O
12	site	O
13	residing	O
14	between	O
15	the	O
16	c	B
17	-	I
18	MYC	I
19	P1	I
20	and	I
21	P2	I
22	transcription	I
23	initiation	I
24	sites	I
25	,	O
26	is	O
27	required	O
28	for	O
29	P2	O
30	activity	O
31	.	O

1	The	O
2	next	O
3	twenty	O
4	years	O
5	of	O
6	prevention	O
7	in	O
8	Indian	O
9	country	O
10	:	O
11	visionary	O
12	,	O
13	complex	O
14	,	O
15	and	O
16	practical	O
17	.	O

1	Exogenous	O
2	LHRH	B
3	is	O
4	also	O
5	known	O
6	to	O
7	facilitate	O
8	mating	O
9	behavior	O
10	in	O
11	several	O
12	species	O
13	.	O

1	The	O
2	first	O
3	146	O
4	consecutive	O
5	patients	O
6	treated	O
7	with	O
8	EVL	O
9	during	O
10	the	O
11	period	O
12	from	O
13	August	O
14	,	O
15	1986	O
16	to	O
17	July	O
18	,	O
19	1989	O
20	are	O
21	reported	O
22	.	O

1	Replacing	O
2	the	O
3	aspartic	O
4	acid	O
5	with	O
6	a	O
7	lysine	O
8	but	O
9	not	O
10	with	O
11	an	O
12	alanine	O
13	or	O
14	valine	O
15	residue	O
16	allowed	O
17	formation	O
18	of	O
19	disulfide	O
20	-	O
21	linked	O
22	dimers	O
23	.	O

1	During	O
2	V	O
3	-	O
4	A	O
5	bypass	O
6	,	O
7	hemodynamics	O
8	were	O
9	stable	O
10	.	O

1	Greater	O
2	rupture	O
3	force	O
4	was	O
5	required	O
6	in	O
7	the	O
8	adult	O
9	pigs	O
10	than	O
11	in	O
12	the	O
13	young	O
14	pigs	O
15	.	O

1	At	O
2	rest	O
3	AFF	O
4	was	O
5	significantly	O
6	higher	O
7	in	O
8	UT	O
9	(	O
10	29	O
11	%)	O
12	as	O
13	compared	O
14	to	O
15	AT	O
16	(	O
17	25	O
18	%)	O
19	and	O
20	UEA	O
21	(	O
22	25	O
23	%).	O

1	We	O
2	investigated	O
3	the	O
4	smoking	O
5	habits	O
6	of	O
7	relapsers	O
8	1	O
9	year	O
10	after	O
11	quitting	O
12	in	O
13	a	O
14	smoking	O
15	cessation	O
16	trial	O
17	using	O
18	nicotine	O
19	or	O
20	placebo	O
21	patches	O
22	.	O

1	Exposure	O
2	to	O
3	hepatitis	O
4	B	O
5	virus	O
6	in	O
7	the	O
8	general	O
9	population	O
10	of	O
11	Hisayama	O
12	,	O
13	Japan	O
14	:	O
15	significance	O
16	of	O
17	isolated	O
18	antibody	O
19	to	O
20	hepatitis	B
21	B	I
22	surface	I
23	antigen	I
24	in	O
25	general	O
26	population	O
27	.	O

1	Because	O
2	of	O
3	this	O
4	latter	O
5	phenomenon	O
6	,	O
7	we	O
8	were	O
9	able	O
10	to	O
11	identify	O
12	a	O
13	particular	O
14	cysteine	O
15	motif	O
16	that	O
17	was	O
18	repeated	O
19	multiple	O
20	times	O
21	in	O
22	Dfurin2	B
23	but	O
24	present	O
25	only	O
26	twice	O
27	in	O
28	mammalian	B
29	furin	I
30	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	neither	O
7	phosphate	O
8	buffered	O
9	saline	O
10	injection	O
11	into	O
12	the	O
13	ES	O
14	nor	O
15	primary	O
16	KLH	B
17	challenges	O
18	of	O
19	the	O
20	ES	O
21	were	O
22	capable	O
23	of	O
24	elevating	O
25	the	O
26	threshold	O
27	level	O
28	and	O
29	changing	O
30	the	O
31	latency	O
32	.	O

1	A	O
2	newly	O
3	developed	O
4	broad	O
5	-	O
6	spectrum	O
7	fluoroquinolone	O
8	,	O
9	levofloxacin	O
10	(	O
11	LVFX	O
12	,	O
13	DR	O
14	-	O
15	3355	O
16	),	O
17	was	O
18	evaluated	O
19	in	O
20	vitro	O
21	and	O
22	in	O
23	vivo	O
24	in	O
25	comparison	O
26	with	O
27	ciprofloxacin	O
28	(	O
29	CPFX	O
30	),	O
31	ofloxacin	O
32	(	O
33	OFLX	O
34	)	O
35	and	O
36	norfloxacin	O
37	(	O
38	NFLX	O
39	).	O

1	The	O
2	mean	O
3	serum	O
4	creatinine	O
5	levels	O
6	were	O
7	similar	O
8	at	O
9	one	O
10	year	O
11	(	O
12	SPK	O
13	1	O
14	.	O
15	8	O
16	,	O
17	KTA	O
18	1	O
19	.	O
20	9	O
21	mg	O
22	/	O
23	d	O
24	).(	O
25	ABSTRACT	O
26	TRUNCATED	O
27	AT	O
28	250	O
29	WORDS	O
30	)	O

1	Model	O
2	predictions	O
3	were	O
4	in	O
5	accord	O
6	with	O
7	the	O
8	nine	O
9	-	O
10	year	O
11	survival	O
12	experience	O
13	of	O
14	women	O
15	in	O
16	the	O
17	HIP	O
18	trial	O
19	,	O
20	and	O
21	,	O
22	with	O
23	the	O
24	exception	O
25	of	O
26	women	O
27	40	O
28	-	O
29	44	O
30	years	O
31	old	O
32	,	O
33	with	O
34	HIP	O
35	data	O
36	on	O
37	18	O
38	-	O
39	year	O
40	survival	O
41	.	O

1	High	O
2	-	O
3	resolution	O
4	computed	O
5	tomography	O
6	in	O
7	the	O
8	diagnosis	O
9	of	O
10	miliary	O
11	tuberculosis	O
12	.	O

1	Previously	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	SNF2	B
7	,	O
8	SNF5	B
9	,	O
10	and	O
11	SNF6	B
12	function	O
13	interdependently	O
14	in	O
15	transcriptional	O
16	activation	O
17	,	O
18	possibly	O
19	forming	O
20	a	O
21	heteromeric	O
22	complex	O
23	.	O

1	We	O
2	show	O
3	that	O
4	LexA	B
5	-	O
6	GAL4	B
7	and	O
8	LexA	B
9	-	O
10	Bicoid	B
11	fusion	O
12	proteins	O
13	are	O
14	both	O
15	dependent	O
16	on	O
17	SNF2	B
18	,	O
19	SNF5	B
20	,	O
21	and	O
22	SNF6	B
23	for	O
24	activation	O
25	of	O
26	target	O
27	genes	O
28	containing	O
29	one	O
30	or	O
31	multiple	O
32	lexA	B
33	operators	I
34	.	O

1	George	O
2	T	O
3	.	O

1	A	O
2	lambda	O
3	gt10	O
4	cDNA	O
5	library	O
6	was	O
7	constructed	O
8	from	O
9	poly	O
10	(	O
11	A	O
12	)+	O
13	RNA	O
14	of	O
15	young	O
16	green	O
17	leaves	O
18	of	O
19	spinach	O
20	.	O

1	NE	B
2	and	O
3	PR3	B
4	assist	O
5	in	O
6	the	O
7	destruction	O
8	of	O
9	phagocytosed	O
10	microorganisms	O
11	,	O
12	cleave	O
13	the	O
14	important	O
15	connective	B
16	-	I
17	tissue	I
18	protein	I
19	elastin	I
20	,	O
21	and	O
22	generate	O
23	chemotactic	O
24	activities	O
25	by	O
26	forming	O
27	alpha	B
28	1	I
29	-	I
30	proteinase	I
31	inhibitor	I
32	complexes	I
33	and	O
34	elastin	B
35	peptides	I
36	.	O

1	Selected	O
2	topics	O
3	in	O
4	pediatric	O
5	ultrasonography	O
6	--	O
7	1992	O
8	.	O

1	Methods	O
2	included	O
3	24	O
4	-	O
5	hour	O
6	dietary	O
7	recall	O
8	,	O
9	menu	O
10	weights	O
11	,	O
12	and	O
13	recipe	O
14	analysis	O
15	.	O

1	Factors	O
2	associated	O
3	with	O
4	afterdrop	O
5	included	O
6	age	O
7	,	O
8	end	O
9	-	O
10	of	O
11	-	O
12	surgery	O
13	temperature	O
14	(	O
15	both	O
16	positively	O
17	)	O
18	and	O
19	body	O
20	mass	O
21	(	O
22	negatively	O
23	).	O

1	Both	O
2	GH	B
3	deficiency	O
4	and	O
5	impaired	O
6	spinal	O
7	growth	O
8	may	O
9	result	O
10	in	O
11	short	O
12	stature	O
13	,	O
14	whereas	O
15	the	O
16	occurrence	O
17	of	O
18	early	O
19	puberty	O
20	in	O
21	association	O
22	with	O
23	GH	B
24	deficiency	O
25	reduces	O
26	the	O
27	time	O
28	available	O
29	for	O
30	GH	B
31	therapy	O
32	.	O

1	By	O
2	contrast	O
3	,	O
4	d	B
5	(	I
6	T2AG3T	I
7	)	I
8	and	O
9	d	B
10	(	I
11	T2G4T	I
12	)	I
13	form	O
14	only	O
15	the	O
16	G	O
17	-	O
18	quadruplex	O
19	monomer	O
20	structures	O
21	independent	O
22	of	O
23	K	O
24	cation	O
25	concentration	O
26	as	O
27	reported	O
28	previously	O
29	[	O
30	Sen	O
31	,	O
32	D	O
33	.,	O
34	&	O
35	Gilbert	O
36	,	O
37	W	O
38	.	O

1	Differentiating	O
2	among	O
3	renal	O
4	stones	O
5	.	O

1	IFI	B
2	16	I
3	mRNA	I
4	was	O
5	found	O
6	to	O
7	be	O
8	constitutively	O
9	expressed	O
10	in	O
11	lymphoid	O
12	cells	O
13	and	O
14	in	O
15	cell	O
16	lines	O
17	of	O
18	both	O
19	the	O
20	T	O
21	and	O
22	B	O
23	lineages	O
24	.	O

1	Mitochondria	O
2	-	O
3	lytic	O
4	action	O
5	of	O
6	warfarin	O
7	in	O
8	lymphocytes	O
9	.	O

1	Exon	O
2	-	O
3	intron	O
4	junctions	O
5	in	O
6	the	O
7	human	O
8	and	O
9	rat	B
10	AdoMet	I
11	decarboxylase	I
12	genes	I
13	were	O
14	in	O
15	identical	O
16	positions	O
17	except	O
18	that	O
19	exons	O
20	6	O
21	and	O
22	7	O
23	of	O
24	the	O
25	human	O
26	gene	O
27	formed	O
28	a	O
29	single	O
30	exon	O
31	in	O
32	the	O
33	rat	O
34	gene	O
35	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	-	O
5	induced	O
6	gene	O
7	expression	O
8	:	O
9	evidence	O
10	for	O
11	a	O
12	selective	O
13	effect	O
14	of	O
15	ouabain	O
16	on	O
17	activation	O
18	of	O
19	the	O
20	ISGF3	B
21	transcription	I
22	complex	I
23	.	O

1	The	O
2	cDNA	O
3	has	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	900	O
10	amino	O
11	acids	O
12	capable	O
13	of	O
14	encoding	O
15	a	O
16	97	O
17	-	O
18	kDa	O
19	protein	O
20	.	O

1	Moreover	O
2	,	O
3	LD50	O
4	in	O
5	mice	O
6	of	O
7	RP	O
8	-	O
9	170	O
10	(	O
11	4	O
12	.	O
13	3	O
14	g	O
15	/	O
16	kg	O
17	on	O
18	i	O
19	.	O
20	v	O
21	.)	O
22	was	O
23	increased	O
24	to	O
25	5	O
26	.	O
27	2	O
28	g	O
29	/	O
30	kg	O
31	by	O
32	oral	O
33	administration	O
34	.	O

1	Among	O
2	the	O
3	few	O
4	proteins	O
5	of	O
6	the	O
7	eukaryotic	O
8	nucleolus	O
9	that	O
10	have	O
11	been	O
12	characterized	O
13	,	O
14	four	O
15	proteins	O
16	,	O
17	nucleolin	B
18	,	O
19	fibrillarin	B
20	,	O
21	SSB1	B
22	and	O
23	NSR1	B
24	,	O
25	possess	O
26	a	O
27	common	O
28	structural	O
29	motif	O
30	,	O
31	the	O
32	GAR	O
33	domain	O
34	,	O
35	which	O
36	is	O
37	rich	O
38	in	O
39	glycine	O
40	and	O
41	arginine	O
42	residues	O
43	.	O

1	Thus	O
2	,	O
3	this	O
4	study	O
5	provides	O
6	evidence	O
7	that	O
8	a	O
9	novel	O
10	,	O
11	ubiquitous	O
12	factor	O
13	(	O
14	HF	B
15	-	I
16	1a	I
17	)	O
18	and	O
19	a	O
20	muscle	O
21	factor	O
22	(	O
23	HF	B
24	-	I
25	1b	I
26	/	O
27	MEF	B
28	-	I
29	2	I
30	)	O
31	can	O
32	form	O
33	a	O
34	novel	O
35	,	O
36	E	O
37	-	O
38	box	O
39	-	O
40	independent	O
41	pathway	O
42	for	O
43	muscle	O
44	-	O
45	specific	O
46	expression	O
47	in	O
48	ventricular	O
49	cardiac	O
50	muscle	O
51	cells	O
52	.	O

1	Mutations	O
2	in	O
3	either	O
4	gene	O
5	block	O
6	some	O
7	crucial	O
8	late	O
9	step	O
10	in	O
11	assembly	O
12	of	O
13	F1	B
14	,	O
15	causing	O
16	the	O
17	alpha	O
18	and	O
19	beta	O
20	subunits	O
21	to	O
22	accumulate	O
23	in	O
24	mitochondria	O
25	as	O
26	inactive	O
27	aggregates	O
28	(	O
29	Ackerman	O
30	,	O
31	S	O
32	.	O

1	Expense	O
2	limits	O
3	the	O
4	use	O
5	of	O
6	hepatitis	O
7	B	O
8	vaccines	O
9	,	O
10	but	O
11	low	O
12	-	O
13	dose	O
14	intradermal	O
15	immunization	O
16	has	O
17	been	O
18	evaluated	O
19	as	O
20	a	O
21	cost	O
22	-	O
23	saving	O
24	strategy	O
25	in	O
26	numerous	O
27	studies	O
28	.	O

1	Estrogen	O
2	replacement	O
3	therapy	O
4	and	O
5	risk	O
6	of	O
7	breast	O
8	cancer	O
9	:	O
10	results	O
11	of	O
12	two	O
13	meta	O
14	-	O
15	analyses	O
16	.	O

1	Switching	O
2	FDC	O
3	-	O
4	P1	O
5	/	O
6	MAC	O
7	cells	O
8	from	O
9	growth	O
10	in	O
11	M	B
12	-	I
13	CSF	I
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	caused	O
19	the	O
20	selective	O
21	degradation	O
22	of	O
23	c	B
24	-	I
25	fms	I
26	mRNA	I
27	within	O
28	6	O
29	h	O
30	after	O
31	factor	O
32	switching	O
33	.	O

1	There	O
2	was	O
3	however	O
4	,	O
5	no	O
6	significant	O
7	difference	O
8	in	O
9	the	O
10	prevalence	O
11	of	O
12	chronic	O
13	respiratory	O
14	symptoms	O
15	between	O
16	animal	O
17	food	O
18	workers	O
19	with	O
20	positive	O
21	and	O
22	negative	O
23	skin	O
24	tests	O
25	to	O
26	house	O
27	dust	O
28	or	O
29	to	O
30	fish	O
31	flour	O
32	or	O
33	among	O
34	those	O
35	with	O
36	increased	O
37	or	O
38	normal	O
39	IgE	B
40	(	O
41	except	O
42	for	O
43	dyspnea	O
44	).	O

1	An	O
2	unexpected	O
3	finding	O
4	was	O
5	the	O
6	presence	O
7	at	O
8	position	O
9	-	O
10	403	O
11	to	O
12	-	O
13	385	O
14	of	O
15	a	O
16	putative	O
17	dioxin	O
18	responsive	O
19	element	O
20	,	O
21	a	O
22	sequence	O
23	found	O
24	to	O
25	be	O
26	responsible	O
27	for	O
28	the	O
29	induction	O
30	of	O
31	transcription	O
32	of	O
33	the	O
34	cytochrome	B
35	P450IA1	I
36	gene	I
37	(	O
38	CYPIA1	B
39	)	O
40	and	O
41	other	O
42	genes	O
43	involved	O
44	in	O
45	detoxification	O
46	/	O
47	activation	O
48	of	O
49	polycyclic	O
50	aromatic	O
51	hydrocarbons	O
52	.	O

1	The	O
2	gene	O
3	encoding	O
4	TRP	B
5	-	I
6	2	I
7	maps	O
8	to	O
9	mouse	O
10	chromosome	O
11	14	O
12	,	O
13	in	O
14	the	O
15	region	O
16	of	O
17	the	O
18	coat	B
19	colour	I
20	mutation	I
21	slaty	I
22	.	O

1	Using	O
2	bovine	B
3	and	I
4	murine	I
5	c	I
6	-	I
7	myb	I
8	clones	O
9	,	O
10	no	O
11	change	O
12	in	O
13	the	O
14	rate	O
15	of	O
16	c	B
17	-	I
18	myb	I
19	gene	I
20	transcription	O
21	or	O
22	mRNA	O
23	stability	O
24	was	O
25	detected	O
26	during	O
27	the	O
28	cell	O
29	cycle	O
30	.	O

1	A	O
2	13	O
3	base	O
4	-	O
5	pair	O
6	oligonucleotide	O
7	spanning	O
8	nucleotides	O
9	+	O
10	80	O
11	to	O
12	+	O
13	92	O
14	of	O
15	the	O
16	5	B
17	S	I
18	RNA	I
19	gene	I
20	retained	O
21	specific	O
22	and	O
23	high	O
24	-	O
25	affinity	O
26	binding	O
27	,	O
28	although	O
29	the	O
30	latter	O
31	was	O
32	reduced	O
33	sixfold	O
34	relative	O
35	to	O
36	longer	O
37	DNA	O
38	fragments	O
39	.	O

1	Moreover	O
2	,	O
3	the	O
4	reconstitution	O
5	of	O
6	eUSF	B
7	and	O
8	TFIID	B
9	-	O
10	depleted	O
11	transcription	O
12	complexes	O
13	with	O
14	purified	O
15	protein	O
16	fractions	O
17	demonstrate	O
18	that	O
19	not	O
20	only	O
21	TFIID	B
22	but	O
23	also	O
24	eUSF	B
25	essentially	O
26	participates	O
27	in	O
28	complex	O
29	formation	O
30	even	O
31	on	O
32	H5	B
33	promoter	I
34	mutations	O
35	lacking	O
36	the	O
37	TATA	O
38	-	O
39	box	O
40	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	amino	O
6	acid	O
7	sequence	O
8	of	O
9	the	O
10	T	O
11	.	O
12	thermophilus	O
13	enzyme	O
14	with	O
15	that	O
16	of	O
17	the	O
18	Escherichia	O
19	coli	O
20	enzyme	O
21	showed	O
22	(	O
23	i	O
24	)	O
25	a	O
26	37	O
27	%	O
28	overall	O
29	similarity	O
30	;	O
31	(	O
32	ii	O
33	)	O
34	the	O
35	conservation	O
36	of	O
37	the	O
38	Ser	O
39	residue	O
40	,	O
41	which	O
42	is	O
43	known	O
44	to	O
45	be	O
46	phosphorylated	O
47	in	O
48	the	O
49	E	O
50	.	O
51	coli	O
52	enzyme	O
53	,	O
54	and	O
55	of	O
56	the	O
57	surrounding	O
58	sequence	O
59	;	O
60	and	O
61	(	O
62	iii	O
63	)	O
64	the	O
65	presence	O
66	of	O
67	141	O
68	extra	O
69	residues	O
70	at	O
71	the	O
72	C	O
73	terminus	O
74	of	O
75	the	O
76	T	O
77	.	O
78	thermophilus	O
79	enzyme	O
80	.	O

1	Radiolabelled	O
2	palmitate	O
3	was	O
4	not	O
5	incorporated	O
6	into	O
7	the	O
8	mutated	O
9	protein	O
10	,	O
11	showing	O
12	that	O
13	lipid	O
14	modification	O
15	occurs	O
16	at	O
17	the	O
18	Cys	O
19	-	O
20	22	O
21	residue	O
22	.	O

1	17	O
2	volunteer	O
3	deaf	O
4	Ss	O
5	were	O
6	compared	O
7	with	O
8	18	O
9	volunteer	O
10	hearing	O
11	Ss	O
12	on	O
13	the	O
14	Stanford	O
15	Hypnotic	O
16	Clinical	O
17	Scale	O
18	(	O
19	SHCS	O
20	)	O
21	of	O
22	Morgan	O
23	and	O
24	J	O
25	.	O

1	Mature	B
2	tobacco	I
3	L12	I
4	protein	I
5	has	O
6	44	O
7	%	O
8	amino	O
9	acid	O
10	identity	O
11	with	O
12	ribosomal	O
13	protein	O
14	L7	B
15	/	O
16	L12	B
17	of	O
18	Escherichia	O
19	coli	O
20	.	O

1	Nuclear	B
2	-	I
3	encoded	I
4	chloroplast	I
5	ribosomal	I
6	protein	I
7	L12	I
8	of	I
9	Nicotiana	I
10	tabacum	I
11	:	O
12	characterization	O
13	of	O
14	mature	O
15	protein	O
16	and	O
17	isolation	O
18	and	O
19	sequence	O
20	analysis	O
21	of	O
22	cDNA	O
23	clones	O
24	encoding	O
25	its	O
26	cytoplasmic	O
27	precursor	O
28	.	O

1	The	O
2	gene	O
3	encoding	O
4	IFN	B
5	-	I
6	gamma	I
7	was	O
8	previously	O
9	found	O
10	to	O
11	contain	O
12	an	O
13	intronic	O
14	enhancer	O
15	element	O
16	that	O
17	was	O
18	not	O
19	tissue	O
20	-	O
21	specific	O
22	in	O
23	its	O
24	activity	O
25	,	O
26	despite	O
27	the	O
28	restricted	O
29	expression	O
30	of	O
31	the	O
32	intact	O
33	IFN	B
34	-	I
35	gamma	I
36	-	I
37	encoding	I
38	gene	I
39	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	the	O
5	polypeptide	O
6	component	O
7	of	O
8	the	O
9	Rel	B
10	-	I
11	related	I
12	human	I
13	p75	I
14	nucleoprotein	I
15	complex	I
16	has	O
17	revealed	O
18	its	O
19	identity	O
20	with	O
21	the	O
22	65	O
23	-	O
24	kDa	O
25	(	O
26	p65	B
27	)	O
28	subunit	O
29	of	O
30	NF	B
31	-	I
32	kappa	I
33	B	I
34	.	O

1	Because	O
2	single	O
3	-	O
4	chamber	O
5	rate	O
6	-	O
7	adaptive	O
8	atrial	O
9	pacing	O
10	leaves	O
11	the	O
12	patient	O
13	exposed	O
14	to	O
15	the	O
16	risk	O
17	of	O
18	future	O
19	development	O
20	of	O
21	AV	O
22	block	O
23	and	O
24	DDD	O
25	pacing	O
26	does	O
27	not	O
28	provide	O
29	chronotropic	O
30	support	O
31	,	O
32	it	O
33	is	O
34	likely	O
35	that	O
36	the	O
37	new	O
38	rate	O
39	-	O
40	adaptive	O
41	dual	O
42	-	O
43	chamber	O
44	(	O
45	DDDR	O
46	)	O
47	devices	O
48	will	O
49	be	O
50	used	O
51	in	O
52	a	O
53	significant	O
54	number	O
55	of	O
56	these	O
57	patients	O
58	.(	O
59	ABSTRACT	O
60	TRUNCATED	O
61	AT	O
62	250	O
63	WORDS	O
64	)	O

1	When	O
2	transiently	O
3	transfected	O
4	into	O
5	K562	O
6	cells	O
7	,	O
8	this	O
9	Lg	B
10	genomic	O
11	clone	O
12	is	O
13	actively	O
14	transcribed	O
15	,	O
16	suggesting	O
17	that	O
18	,	O
19	although	O
20	it	O
21	possesses	O
22	the	O
23	characteristics	O
24	of	O
25	a	O
26	processed	O
27	pseudogene	O
28	,	O
29	it	O
30	is	O
31	likely	O
32	to	O
33	correspond	O
34	to	O
35	the	O
36	gene	O
37	encoding	O
38	this	O
39	new	O
40	ferritin	B
41	subunit	I
42	.	O

1	Of	O
2	the	O
3	drugs	O
4	orally	O
5	administered	O
6	,	O
7	WR	O
8	-	O
9	168643	O
10	was	O
11	the	O
12	best	O
13	protector	O
14	with	O
15	a	O
16	DMF	O
17	of	O
18	1	O
19	.	O
20	51	O
21	.	O

1	Characterization	O
2	of	O
3	these	O
4	R	O
5	subunits	O
6	by	O
7	their	O
8	8	O
9	-	O
10	azido	O
11	-	O
12	cAMP	O
13	photoaffinity	O
14	labeling	O
15	and	O
16	immunoreactivity	O
17	,	O
18	as	O
19	well	O
20	as	O
21	by	O
22	a	O
23	phosphorylation	O
24	-	O
25	dependent	O
26	mobility	O
27	shift	O
28	on	O
29	sodium	O
30	dodecyl	O
31	sulfate	O
32	-	O
33	polyacrylamide	O
34	gel	O
35	electrophoresis	O
36	(	O
37	SDS	O
38	-	O
39	PAGE	O
40	),	O
41	indicated	O
42	subunit	O
43	sizes	O
44	of	O
45	RII	B
46	beta	I
47	(	O
48	53	O
49	kDa	O
50	)	O
51	greater	O
52	than	O
53	RII	B
54	alpha	I
55	dephosphoform	O
56	(	O
57	51	O
58	kDa	O
59	)	O
60	greater	O
61	than	O
62	RI	B
63	alpha	I
64	(	O
65	49	O
66	kDa	O
67	).	O

1	Comparison	O
2	of	O
3	the	O
4	genomic	O
5	DNA	O
6	sequence	O
7	with	O
8	that	O
9	of	O
10	the	O
11	four	O
12	different	O
13	mRNAs	O
14	indicates	O
15	that	O
16	these	O
17	transcripts	O
18	are	O
19	produced	O
20	by	O
21	alternative	O
22	splicing	O
23	of	O
24	the	O
25	murine	O
26	pre	O
27	-	O
28	mRNA	O
29	according	O
30	to	O
31	a	O
32	cassette	O
33	model	O
34	.	O

1	During	O
2	the	O
3	1980	O
4	'	O
5	s	O
6	,	O
7	quantifications	O
8	of	O
9	immunoserological	O
10	testings	O
11	,	O
12	especially	O
13	C	B
14	reactive	I
15	protein	I
16	,	O
17	rheumatoid	B
18	factor	I
19	and	O
20	antistreptolysin	B
21	O	I
22	,	O
23	progressed	O
24	rapidly	O
25	.	O

1	Within	O
2	the	O
3	human	O
4	enhancer	O
5	,	O
6	these	O
7	two	O
8	sites	O
9	are	O
10	located	O
11	within	O
12	the	O
13	previously	O
14	defined	O
15	DNase	B
16	I	I
17	footprints	I
18	,	O
19	NFAT	B
20	-	I
21	1	I
22	and	O
23	NFIL	B
24	-	I
25	2B	I
26	,	O
27	respectively	O
28	.	O

1	The	O
2	cardiac	B
3	myosin	I
4	light	I
5	chain	I
6	-	I
7	2	I
8	(	O
9	MLC	B
10	-	I
11	2	I
12	)	O
13	gene	O
14	promoter	O
15	contains	O
16	several	O
17	positive	O
18	and	O
19	negative	O
20	cis	O
21	-	O
22	acting	O
23	sequences	O
24	that	O
25	are	O
26	involved	O
27	in	O
28	the	O
29	regulation	O
30	of	O
31	its	O
32	expression	O
33	.	O

1	Deletion	O
2	mutagenesis	O
3	demonstrated	O
4	that	O
5	these	O
6	two	O
7	elements	O
8	are	O
9	involved	O
10	in	O
11	the	O
12	positive	O
13	regulation	O
14	of	O
15	MLC	B
16	-	I
17	2	I
18	gene	I
19	transcription	O
20	.	O

1	Disruption	O
2	mutations	O
3	have	O
4	been	O
5	constructed	O
6	in	O
7	the	O
8	SLK1	B
9	gene	I
10	.	O
11	slk1	B
12	null	I
13	mutants	I
14	cannot	O
15	grow	O
16	at	O
17	37	O
18	degrees	O
19	C	O
20	,	O
21	but	O
22	many	O
23	cells	O
24	can	O
25	grow	O
26	at	O
27	30	O
28	,	O
29	24	O
30	,	O
31	and	O
32	17	O
33	degrees	O
34	C	O
35	.	O

1	Molecular	O
2	and	O
3	genetic	O
4	analysis	O
5	of	O
6	the	O
7	yeast	B
8	early	I
9	meiotic	I
10	recombination	I
11	genes	I
12	REC102	I
13	and	O
14	REC107	B
15	/	O
16	MER2	B
17	.	O

1	The	O
2	p130	B
3	and	O
4	p62	B
5	tyrosine	O
6	-	O
7	phosphorylated	O
8	proteins	O
9	that	O
10	complexed	O
11	v	B
12	-	I
13	Src	I
14	SH2	I
15	in	O
16	vitro	O
17	also	O
18	associated	O
19	with	O
20	v	B
21	-	I
22	Src	I
23	in	O
24	v	B
25	-	I
26	src	I
27	-	O
28	transformed	O
29	Rat	O
30	-	O
31	2	O
32	cells	O
33	;	O
34	this	O
35	in	O
36	vivo	O
37	binding	O
38	was	O
39	dependent	O
40	on	O
41	the	O
42	v	B
43	-	I
44	Src	I
45	SH2	I
46	domain	O
47	.	O

1	Probable	O
2	progressive	O
3	multifocal	O
4	leukoencephalopathy	O
5	(	O
6	PML	O
7	)	O
8	was	O
9	diagnosed	O
10	on	O
11	the	O
12	basis	O
13	of	O
14	clinical	O
15	picture	O
16	and	O
17	magnetic	O
18	resonance	O
19	imaging	O
20	in	O
21	a	O
22	63	O
23	-	O
24	year	O
25	-	O
26	old	O
27	man	O
28	with	O
29	a	O
30	complete	O
31	remission	O
32	of	O
33	a	O
34	non	O
35	-	O
36	Hodgkin	O
37	'	O
38	s	O
39	lymphoma	O
40	.	O

1	These	O
2	data	O
3	support	O
4	a	O
5	possible	O
6	biological	O
7	significance	O
8	of	O
9	the	O
10	frameshift	O
11	to	O
12	occur	O
13	at	O
14	this	O
15	position	O
16	of	O
17	the	O
18	large	O
19	overlap	O
20	by	O
21	including	O
22	the	O
23	putative	O
24	RNA	O
25	template	O
26	-	O
27	binding	O
28	site	O
29	of	O
30	the	O
31	PLRV	B
32	replicase	I
33	in	O
34	the	O
35	ORF2a	B
36	/	I
37	ORF2b	I
38	transframe	I
39	protein	I
40	.	O

1	Proprotein	O
2	processing	O
3	occurs	O
4	intracellularly	O
5	.	O

1	A	O
2	32P	O
3	-	O
4	labeled	O
5	LAP	B
6	DNA	O
7	-	O
8	binding	O
9	and	O
10	dimerization	O
11	domain	O
12	"	O
13	zipper	O
14	probe	O
15	"	O
16	was	O
17	used	O
18	to	O
19	isolate	O
20	a	O
21	clone	O
22	that	O
23	encodes	O
24	a	O
25	new	O
26	C	B
27	/	I
28	EBP	I
29	-	I
30	homologous	I
31	protein	I
32	:	O
33	CHOP	B
34	-	I
35	10	I
36	.	O

1	Using	O
2	a	O
3	degenerate	O
4	oligodeoxyribonucleotide	O
5	(	O
6	oligo	O
7	)	O
8	based	O
9	on	O
10	the	O
11	N	O
12	-	O
13	terminal	O
14	aa	O
15	sequence	O
16	,	O
17	plus	O
18	an	O
19	internal	O
20	oligo	O
21	homologous	O
22	to	O
23	a	O
24	conserved	O
25	region	O
26	within	O
27	the	O
28	portion	O
29	of	O
30	CYP1	B
31	and	O
32	CYP2	B
33	that	O
34	had	O
35	been	O
36	deleted	O
37	in	O
38	the	O
39	genome	O
40	,	O
41	a	O
42	CYP3	B
43	-	I
44	specific	I
45	DNA	I
46	fragment	I
47	was	O
48	generated	O
49	by	O
50	the	O
51	polymerase	O
52	chain	O
53	reaction	O
54	(	O
55	PCR	O
56	)	O
57	using	O
58	GL81	O
59	genomic	O
60	DNA	O
61	as	O
62	a	O
63	substrate	O
64	.	O

1	Stringent	O
2	hybridization	O
3	of	O
4	EHS	B
5	-	I
6	1	I
7	back	O
8	to	O
9	primate	O
10	genomic	O
11	DNA	O
12	indicates	O
13	two	O
14	distinct	O
15	EHS	B
16	-	I
17	1	I
18	loci	I
19	in	O
20	normal	O
21	human	O
22	DNA	O
23	,	O
24	an	O
25	identical	O
26	band	O
27	pattern	O
28	in	O
29	chimpanzee	O
30	DNA	O
31	,	O
32	and	O
33	a	O
34	single	O
35	locus	O
36	in	O
37	rhesus	O
38	monkey	O
39	DNA	O
40	.	O

1	The	O
2	level	O
3	of	O
4	carboxyl	B
5	-	I
6	terminal	I
7	parathyroid	I
8	hormone	I
9	in	O
10	the	O
11	patients	O
12	with	O
13	thyroid	O
14	carcinoma	O
15	was	O
16	higher	O
17	than	O
18	that	O
19	in	O
20	the	O
21	patients	O
22	without	O
23	thyroid	O
24	carcinoma	O
25	(	O
26	P	O
27	less	O
28	than	O
29	0	O
30	.	O
31	05	O
32	).	O

1	The	O
2	Caenorhabditis	B
3	elegans	I
4	vitellogenin	I
5	genes	I
6	are	O
7	subject	O
8	to	O
9	sex	O
10	-,	O
11	stage	O
12	-,	O
13	and	O
14	tissue	O
15	-	O
16	specific	O
17	regulation	O
18	:	O
19	they	O
20	are	O
21	expressed	O
22	solely	O
23	in	O
24	the	O
25	adult	O
26	hermaphrodite	O
27	intestine	O
28	.	O

1	The	O
2	MET4	B
3	gene	O
4	was	O
5	cloned	O
6	,	O
7	and	O
8	its	O
9	sequence	O
10	reveals	O
11	that	O
12	it	O
13	encodes	O
14	a	O
15	protein	O
16	related	O
17	to	O
18	the	O
19	family	O
20	of	O
21	the	O
22	bZIP	B
23	transcriptional	I
24	activators	I
25	.	O

1	The	O
2	functions	O
3	of	O
4	isolated	O
5	portions	O
6	of	O
7	the	O
8	insulin	B
9	,	O
10	IAPP	B
11	,	O
12	and	O
13	beta	B
14	GK	I
15	promoters	I
16	were	O
17	studied	O
18	by	O
19	using	O
20	transient	O
21	expression	O
22	and	O
23	DNA	O
24	binding	O
25	assays	O
26	.	O

1	It	O
2	is	O
3	believed	O
4	that	O
5	these	O
6	domains	O
7	are	O
8	important	O
9	for	O
10	directing	O
11	specific	O
12	protein	O
13	-	O
14	protein	O
15	interactions	O
16	necessary	O
17	for	O
18	the	O
19	proper	O
20	functioning	O
21	of	O
22	Src	B
23	.	O

1	The	O
2	c	B
3	-	I
4	Ets	I
5	-	I
6	1	I
7	oncoprotein	I
8	is	O
9	a	O
10	transcription	O
11	activator	O
12	that	O
13	specifically	O
14	binds	O
15	to	O
16	DNA	O
17	.	O

1	Previous	O
2	transactivation	O
3	experiments	O
4	indicated	O
5	that	O
6	three	O
7	amino	O
8	acids	O
9	residing	O
10	in	O
11	this	O
12	region	O
13	,	O
14	Gly	O
15	,	O
16	Ser	O
17	and	O
18	Val	O
19	,	O
20	appear	O
21	to	O
22	be	O
23	critical	O
24	for	O
25	target	O
26	-	O
27	site	O
28	discrimination	O
29	.	O

1	GR63178A	O
2	is	O
3	a	O
4	water	O
5	-	O
6	soluble	O
7	analogue	O
8	of	O
9	mitoquidone	O
10	,	O
11	a	O
12	pentacyclic	O
13	pyrroloquinone	O
14	.	O

1	Marker	O
2	rescue	O
3	analysis	O
4	has	O
5	localized	O
6	ts8	B
7	to	O
8	a	O
9	910	O
10	-	O
11	bp	O
12	internal	O
13	segment	O
14	of	O
15	rpoB	B
16	that	O
17	encodes	O
18	the	O
19	Rif	B
20	domain	I
21	.	O

1	This	O
2	vector	O
3	transfected	O
4	into	O
5	the	O
6	yeast	O
7	Saccharomyces	O
8	cerevisiae	O
9	directs	O
10	expression	O
11	of	O
12	a	O
13	secreted	O
14	mature	O
15	protein	O
16	at	O
17	levels	O
18	up	O
19	to	O
20	200	O
21	mg	O
22	of	O
23	LAPP	O
24	/	O
25	liter	O
26	of	O
27	culture	O
28	medium	O
29	.	O

1	Competition	O
2	analysis	O
3	by	O
4	gel	O
5	mobility	O
6	shift	O
7	electrophoresis	O
8	indicates	O
9	that	O
10	this	O
11	DNA	O
12	-	O
13	protein	O
14	interaction	O
15	is	O
16	novel	O
17	and	O
18	not	O
19	related	O
20	to	O
21	many	O
22	transcription	O
23	factors	O
24	previously	O
25	reported	O
26	.	O

1	This	O
2	DNA	O
3	motif	O
4	represents	O
5	a	O
6	novel	O
7	protein	O
8	-	O
9	binding	O
10	sequence	O
11	.	O

1	OBJECTIVE	O
2	:	O
3	The	O
4	study	O
5	was	O
6	designed	O
7	to	O
8	investigate	O
9	the	O
10	frequency	O
11	of	O
12	alterations	O
13	in	O
14	serum	O
15	creatinine	O
16	in	O
17	patients	O
18	with	O
19	psoriasis	O
20	receiving	O
21	5	O
22	mg	O
23	/	O
24	kg	O
25	/	O
26	day	O
27	of	O
28	cyclosporine	O
29	.	O

1	Intrapocket	O
2	chemotherapy	O
3	in	O
4	adult	O
5	periodontitis	O
6	using	O
7	a	O
8	new	O
9	controlled	O
10	-	O
11	release	O
12	insert	O
13	containing	O
14	ofloxacin	O
15	(	O
16	PT	O
17	-	O
18	01	O
19	).	O

1	Electromagnetic	O
2	blood	O
3	flow	O
4	(	O
5	BF	O
6	)	O
7	probe	O
8	was	O
9	applied	O
10	on	O
11	the	O
12	left	O
13	anterior	O
14	descending	O
15	artery	O
16	(	O
17	LAD	O
18	).	O

1	Hence	O
2	temperature	O
3	and	O
4	virF	B
5	are	O
6	both	O
7	required	O
8	for	O
9	the	O
10	induction	O
11	of	O
12	the	O
13	yop	B
14	regulon	I
15	.	O

1	Problems	O
2	remain	O
3	to	O
4	be	O
5	resolved	O
6	in	O
7	the	O
8	area	O
9	of	O
10	quantitative	O
11	risk	O
12	assessment	O
13	.	O

1	The	O
2	recently	O
3	developed	O
4	gamma	B
5	-	I
6	interferon	I
7	(	O
8	IFN	B
9	-	I
10	gamma	I
11	)	O
12	assay	O
13	system	O
14	for	O
15	the	O
16	diagnosis	O
17	of	O
18	bovine	O
19	tuberculosis	O
20	in	O
21	cattle	O
22	has	O
23	been	O
24	accredited	O
25	by	O
26	the	O
27	Standing	O
28	Committee	O
29	on	O
30	Agriculture	O
31	for	O
32	use	O
33	in	O
34	Australia	O
35	.	O

1	Control	O
2	Tmuscle	O
3	was	O
4	35	O
5	.	O
6	8	O
7	+/-	O
8	0	O
9	.	O
10	7	O
11	degrees	O
12	C	O
13	,	O
14	with	O
15	control	O
16	Wi	O
17	,	O
18	max	O
19	being	O
20	51	O
21	.	O
22	6	O
23	(	O
24	SD	O
25	8	O
26	.	O
27	7	O
28	)	O
29	W	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	.	O

1	The	O
2	Klebsiella	B
3	aerogenes	I
4	gene	I
5	maoA	I
6	,	O
7	which	O
8	is	O
9	involved	O
10	in	O
11	the	O
12	synthesis	O
13	of	O
14	monoamine	B
15	oxidase	I
16	,	O
17	was	O
18	induced	O
19	by	O
20	tyramine	O
21	and	O
22	the	O
23	related	O
24	compounds	O
25	,	O
26	subjected	O
27	to	O
28	catabolite	O
29	and	O
30	ammonium	O
31	ion	O
32	repression	O
33	,	O
34	and	O
35	cloned	O
36	.	O

1	However	O
2	,	O
3	other	O
4	regions	O
5	of	O
6	the	O
7	plasmid	O
8	are	O
9	also	O
10	efficiently	O
11	repaired	O
12	.	O

1	Eight	O
2	of	O
3	14	O
4	infectious	O
5	or	O
6	inflammatory	O
7	lesions	O
8	could	O
9	be	O
10	detected	O
11	in	O
12	the	O
13	early	O
14	scan	O
15	(	O
16	4	O
17	-	O
18	6	O
19	h	O
20	p	O
21	.	O
22	i	O
23	.).	O

1	Thus	O
2	,	O
3	the	O
4	human	B
5	D1A	I
6	gene	I
7	belongs	O
8	to	O
9	the	O
10	category	O
11	of	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	regulated	O
17	genes	O
18	that	O
19	have	O
20	housekeeping	O
21	-	O
22	type	O
23	promoters	O
24	.	O

1	Similar	O
2	observations	O
3	have	O
4	been	O
5	made	O
6	previously	O
7	for	O
8	other	O
9	genes	O
10	.	O

1	Preceptorship	O
2	of	O
3	CNS	O
4	students	O
5	:	O
6	an	O
7	exploratory	O
8	study	O
9	.	O

1	To	O
2	determine	O
3	the	O
4	genetic	O
5	basis	O
6	for	O
7	the	O
8	differences	O
9	between	O
10	the	O
11	cardiac	O
12	and	O
13	brain	B
14	AE3	I
15	variants	I
16	,	O
17	we	O
18	isolated	O
19	and	O
20	characterized	O
21	the	O
22	rat	O
23	gene	O
24	.	O

1	The	O
2	1	O
3	.	O
4	7	O
5	kb	O
6	cloned	O
7	fragment	O
8	was	O
9	sequenced	O
10	and	O
11	shown	O
12	to	O
13	contain	O
14	the	O
15	entire	O
16	fliA	B
17	gene	I
18	.	O

1	Institution	O
2	of	O
3	both	O
4	intravenous	O
5	and	O
6	intracisternal	O
7	administration	O
8	of	O
9	amphotericin	O
10	B	O
11	and	O
12	possibly	O
13	concomitant	O
14	intravenous	O
15	administration	O
16	of	O
17	dexamethasone	O
18	may	O
19	be	O
20	warranted	O
21	in	O
22	situations	O
23	in	O
24	which	O
25	the	O
26	association	O
27	of	O
28	C	O
29	.	O
30	immitis	O
31	with	O
32	CNS	O
33	vasculitis	O
34	or	O
35	encephalitis	O
36	appears	O
37	likely	O
38	before	O
39	serologic	O
40	or	O
41	cultural	O
42	confirmation	O
43	of	O
44	C	O
45	.	O
46	immitis	O
47	infection	O
48	involving	O
49	the	O
50	CNS	O
51	is	O
52	available	O
53	.	O

1	Lac	B
2	operators	O
3	were	O
4	introduced	O
5	into	O
6	several	O
7	positions	O
8	within	O
9	the	O
10	CAB	B
11	promoter	I
12	and	O
13	operator	O
14	-	O
15	free	O
16	plasmid	O
17	was	O
18	used	O
19	as	O
20	control	O
21	.	O

1	Overproduction	O
2	,	O
3	purification	O
4	and	O
5	characterization	O
6	of	O
7	M	B
8	.	I
9	HinfI	I
10	methyltransferase	I
11	and	O
12	its	O
13	deletion	O
14	mutant	O
15	.	O

1	Various	O
2	companies	O
3	produce	O
4	this	O
5	type	O
6	of	O
7	lens	O
8	.	O

1	From	O
2	March	O
3	5	O
4	through	O
5	October	O
6	26	O
7	,	O
8	1991	O
9	,	O
10	eight	O
11	persons	O
12	were	O
13	diagnosed	O
14	with	O
15	elevated	O
16	blood	O
17	lead	O
18	levels	O
19	(	O
20	BLLs	O
21	)	O
22	at	O
23	a	O
24	local	O
25	hospital	O
26	and	O
27	were	O
28	reported	O
29	to	O
30	the	O
31	notifiable	O
32	disease	O
33	surveillance	O
34	system	O
35	maintained	O
36	by	O
37	the	O
38	Alabama	O
39	Department	O
40	of	O
41	Public	O
42	Health	O
43	(	O
44	ADPH	O
45	).	O

1	According	O
2	to	O
3	the	O
4	changes	O
5	of	O
6	perfusion	O
7	defects	O
8	between	O
9	Ex	O
10	,	O
11	RD	O
12	and	O
13	ReI	O
14	images	O
15	,	O
16	they	O
17	were	O
18	classified	O
19	into	O
20	3	O
21	types	O
22	:	O
23	Type	O
24	I	O
25	;	O
26	perfusion	O
27	defect	O
28	on	O
29	the	O
30	RD	O
31	image	O
32	was	O
33	identical	O
34	to	O
35	ReI	O
36	image	O
37	(	O
38	75	O
39	%)	O
40	Type	O
41	I	O
42	was	O
43	divided	O
44	into	O
45	2	O
46	subgroups	O
47	whether	O
48	perfusion	O
49	defect	O
50	at	O
51	Ex	O
52	was	O
53	unchanged	O
54	(	O
55	Ia	O
56	,	O
57	42	O
58	%)	O
59	or	O
60	improved	O
61	(	O
62	Ib	O
63	,	O
64	33	O
65	%)	O
66	on	O
67	the	O
68	RD	O
69	image	O
70	.	O

1	Keck	O
2	,	O
3	C	O
4	.	O
5	J	O
6	.	O

1	Twenty	O
2	-	O
3	eight	O
4	(	O
5	7	O
6	.	O
7	0	O
8	%)	O
9	infants	O
10	without	O
11	periventricular	O
12	hemorrhage	O
13	were	O
14	revealed	O
15	as	O
16	having	O
17	spastic	O
18	cerebral	O
19	palsy	O
20	by	O
21	neurodevelopmental	O
22	evaluation	O
23	in	O
24	later	O
25	infancy	O
26	.	O

1	A	O
2	possible	O
3	mechanism	O
4	is	O
5	that	O
6	elevated	O
7	alveolar	O
8	pressure	O
9	and	O
10	decreased	O
11	cardiac	O
12	output	O
13	eliminate	O
14	blood	O
15	flow	O
16	from	O
17	corner	O
18	vessels	O
19	in	O
20	nondependent	O
21	high	O
22	VA	O
23	/	O
24	Q	O
25	regions	O
26	.	O

1	Computer	O
2	-	O
3	aided	O
4	"	O
5	FRAME	O
6	"	O
7	analysis	O
8	revealed	O
9	four	O
10	possible	O
11	open	O
12	reading	O
13	frames	O
14	(	O
15	ORFs	O
16	),	O
17	three	O
18	in	O
19	one	O
20	direction	O
21	and	O
22	one	O
23	in	O
24	the	O
25	opposite	O
26	direction	O
27	.	O

1	Domain	O
2	II	O
3	is	O
4	highly	O
5	homologous	O
6	to	O
7	the	O
8	LDL	B
9	receptor	I
10	and	O
11	contains	O
12	four	O
13	repeats	O
14	with	O
15	perfect	O
16	conservation	O
17	of	O
18	all	O
19	6	O
20	consecutive	O
21	cysteines	O
22	.	O

1	In	O
2	both	O
3	cities	O
4	,	O
5	HTLV	O
6	-	O
7	I	O
8	/	O
9	II	O
10	prevalence	O
11	increased	O
12	significantly	O
13	with	O
14	age	O
15	,	O
16	and	O
17	the	O
18	New	O
19	Orleans	O
20	age	O
21	-	O
22	and	O
23	sex	O
24	-	O
25	adjusted	O
26	HTLV	O
27	-	O
28	I	O
29	/	O
30	II	O
31	prevalence	O
32	was	O
33	significantly	O
34	higher	O
35	than	O
36	that	O
37	of	O
38	Baltimore	O
39	(	O
40	P	O
41	less	O
42	than	O
43	.	O
44	001	O
45	).	O

1	Here	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	for	O
7	a	O
8	model	O
9	in	O
10	which	O
11	mRNA	O
12	sequences	O
13	up	O
14	to	O
15	around	O
16	100	O
17	nucleotides	O
18	downstream	O
19	from	O
20	the	O
21	start	O
22	codon	O
23	of	O
24	21K	O
25	fold	O
26	back	O
27	and	O
28	base	O
29	-	O
30	pair	O
31	to	O
32	the	O
33	21K	O
34	translation	O
35	initiation	O
36	region	O
37	,	O
38	thereby	O
39	decreasing	O
40	the	O
41	translation	O
42	initiation	O
43	frequency	O
44	.	O

1	Hybridization	O
2	data	O
3	indicate	O
4	that	O
5	6F6	B
6	.	I
7	2	I
8	corresponds	O
9	to	O
10	the	O
11	previously	O
12	characterized	O
13	m6F6	B
14	cDNA	I
15	clone	I
16	and	O
17	that	O
18	6F6	B
19	.	I
20	1	I
21	and	O
22	6F6	B
23	.	I
24	3	I
25	,	O
26	but	O
27	not	O
28	6F6	B
29	.	I
30	2	I
31	,	O
32	are	O
33	adjacent	O
34	to	O
35	alpha	B
36	-	I
37	type	I
38	genes	I
39	.	O

1	The	O
2	SEN1	B
3	gene	I
4	corresponds	O
5	to	O
6	a	O
7	6	O
8	,	O
9	336	O
10	-	O
11	bp	O
12	open	O
13	reading	O
14	frame	O
15	coding	O
16	for	O
17	a	O
18	2	O
19	,	O
20	112	O
21	-	O
22	amino	O
23	-	O
24	acid	O
25	protein	O
26	(	O
27	molecular	O
28	mass	O
29	,	O
30	239	O
31	kDa	O
32	).	O

1	Protein	B
2	tyrosine	I
3	kinases	I
4	(	O
5	PTKs	B
6	)	O
7	are	O
8	implicated	O
9	in	O
10	the	O
11	control	O
12	of	O
13	cell	O
14	growth	O
15	by	O
16	virtue	O
17	of	O
18	their	O
19	frequent	O
20	appearance	O
21	as	O
22	products	O
23	of	O
24	retroviral	O
25	oncogenes	O
26	,	O
27	as	O
28	intracellular	O
29	signal	O
30	transducers	O
31	,	O
32	and	O
33	as	O
34	growth	B
35	factor	I
36	receptors	I
37	or	O
38	components	O
39	thereof	O
40	.	O

1	The	O
2	IA4	B
3	mAb	I
4	was	O
5	identified	O
6	among	O
7	a	O
8	series	O
9	of	O
10	antibodies	O
11	raised	O
12	in	O
13	BALB	O
14	/	O
15	c	O
16	mice	O
17	after	O
18	immunization	O
19	against	O
20	a	O
21	HLA	B
22	class	O
23	I	O
24	-	O
25	deficient	O
26	,	O
27	lymphokine	O
28	-	O
29	activated	O
30	killer	O
31	(	O
32	LAK	O
33	)-	O
34	susceptible	O
35	EBV	O
36	-	O
37	B	O
38	lymphocyte	O
39	line	O
40	.	O

1	In	O
2	a	O
3	randomized	O
4	double	O
5	-	O
6	blind	O
7	cross	O
8	-	O
9	over	O
10	study	O
11	,	O
12	the	O
13	subjects	O
14	received	O
15	theophylline	O
16	5	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	per	O
23	day	O
24	with	O
25	omeprazole	O
26	20	O
27	mg	O
28	per	O
29	day	O
30	or	O
31	identical	O
32	placebo	O
33	during	O
34	two	O
35	periods	O
36	,	O
37	each	O
38	of	O
39	7	O
40	days	O
41	,	O
42	separated	O
43	by	O
44	a	O
45	washout	O
46	period	O
47	of	O
48	7	O
49	days	O
50	.	O

1	Primer	O
2	extension	O
3	and	O
4	mung	B
5	bean	I
6	and	I
7	S1	I
8	nuclease	I
9	mapping	O
10	indicated	O
11	multiple	O
12	transcription	O
13	initiation	O
14	sites	O
15	and	O
16	were	O
17	consistent	O
18	with	O
19	Northern	O
20	analyses	O
21	.	O

1	Two	O
2	variant	O
3	PRP	B
4	-	I
5	precursor	I
6	alleles	I
7	occur	O
8	which	O
9	slightly	O
10	differ	O
11	in	O
12	the	O
13	number	O
14	of	O
15	repeats	O
16	in	O
17	domain	O
18	C	O
19	.	O

1	Unlike	O
2	the	O
3	typical	O
4	enhancer	O
5	element	O
6	,	O
7	this	O
8	region	O
9	functions	O
10	in	O
11	an	O
12	orientation	O
13	-	O
14	dependent	O
15	manner	O
16	.	O

1	In	O
2	the	O
3	last	O
4	20	O
5	years	O
6	,	O
7	the	O
8	therapeutic	O
9	uses	O
10	of	O
11	botulinum	B
12	toxin	I
13	,	O
14	a	O
15	potent	O
16	neurotoxin	O
17	,	O
18	have	O
19	been	O
20	investigated	O
21	.	O

1	Allagille	O
2	'	O
3	s	O
4	syndrome	O
5	associated	O
6	with	O
7	antenatal	O
8	ascites	O

1	Sensitivity	O
2	and	O
3	specificity	O
4	was	O
5	established	O
6	for	O
7	the	O
8	Pharmacia	O
9	CAP	O
10	System	O
11	and	O
12	the	O
13	DPC	O
14	AlaSTAT	O
15	System	O
16	by	O
17	comparison	O
18	with	O
19	results	O
20	of	O
21	the	O
22	skin	O
23	prick	O
24	test	O
25	.	O

1	PSI	B
2	-	I
3	G	I
4	and	O
5	PSI	B
6	-	I
7	K	I
8	probably	O
9	have	O
10	evolved	O
11	from	O
12	a	O
13	gene	O
14	duplication	O
15	of	O
16	an	O
17	ancestral	O
18	gene	O
19	.	O

1	At	O
2	the	O
3	C	O
4	-	O
5	terminus	O
6	of	O
7	the	O
8	protein	O
9	is	O
10	a	O
11	domain	O
12	that	O
13	contains	O
14	sequences	O
15	very	O
16	similar	O
17	to	O
18	those	O
19	found	O
20	in	O
21	the	O
22	breakpoint	O
23	cluster	O
24	region	O
25	gene	O
26	product	O
27	,	O
28	n	B
29	-	I
30	chimerin	I
31	,	O
32	and	O
33	rho	B
34	GAP	I
35	,	O
36	all	O
37	of	O
38	which	O
39	have	O
40	been	O
41	shown	O
42	to	O
43	possess	O
44	intrinsic	O
45	GAP	B
46	activity	O
47	on	O
48	small	B
49	GTPases	I
50	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	revealed	O
6	that	O
7	two	O
8	clusters	O
9	of	O
10	basic	O
11	amino	O
12	acids	O
13	within	O
14	a	O
15	conserved	O
16	basic	O
17	region	O
18	and	O
19	two	O
20	amphipathic	O
21	helices	O
22	within	O
23	the	O
24	adjacent	O
25	HLH	O
26	domain	O
27	are	O
28	essential	O
29	for	O
30	sequence	O
31	-	O
32	specific	O
33	DNA	O
34	binding	O
35	and	O
36	hetero	O
37	-	O
38	oligomerization	O
39	,	O
40	respectively	O
41	.	O

1	Dimerization	O
2	of	O
3	Myf	B
4	-	I
5	5	I
6	with	O
7	the	O
8	ubiquitously	O
9	expressed	O
10	bHLH	O
11	protein	O
12	E12	B
13	not	O
14	only	O
15	increases	O
16	the	O
17	affinity	O
18	for	O
19	DNA	O
20	but	O
21	also	O
22	stimulates	O
23	transactivation	O
24	independently	O
25	of	O
26	DNA	O
27	binding	O
28	.	O

1	The	O
2	circadian	O
3	rhythmicity	O
4	of	O
5	sleep	O
6	was	O
7	pronounced	O
8	.	O

1	SEA	O
2	was	O
3	recorded	O
4	with	O
5	bidirectional	O
6	filters	O
7	at	O
8	25	O
9	-	O
10	250	O
11	HZ	O
12	and	O
13	40	O
14	-	O
15	250	O
16	Hz	O
17	using	O
18	Simson	O
19	method	O
20	.	O

1	Neural	O
2	-	O
3	specific	O
4	expression	O
5	,	O
6	genomic	O
7	structure	O
8	,	O
9	and	O
10	chromosomal	O
11	localization	O
12	of	O
13	the	O
14	gene	O
15	encoding	O
16	the	O
17	zinc	B
18	-	I
19	finger	I
20	transcription	I
21	factor	I
22	NGFI	I
23	-	I
24	C	I
25	.	O

1	An	O
2	experiment	O
3	examined	O
4	the	O
5	effects	O
6	of	O
7	treatment	O
8	with	O
9	gonadotrophin	B
10	releasing	I
11	hormone	I
12	(	O
13	100	O
14	micrograms	O
15	GnRH	B
16	injected	O
17	24	O
18	h	O
19	after	O
20	progestagen	O
21	sponge	O
22	removal	O
23	),	O
24	season	O
25	of	O
26	treatment	O
27	(	O
28	autumn	O
29	v	O
30	.	O
31	spring	O
32	),	O
33	the	O
34	effect	O
35	of	O
36	supplementary	O
37	feeding	O
38	with	O
39	lupin	O
40	grain	O
41	(	O
42	in	O
43	autumn	O
44	only	O
45	,	O
46	from	O
47	12	O
48	days	O
49	before	O
50	until	O
51	8	O
52	days	O
53	after	O
54	sponge	O
55	removal	O
56	)	O
57	on	O
58	the	O
59	time	O
60	of	O
61	ovulation	O
62	in	O
63	182	O
64	mature	O
65	Merino	O
66	ewes	O
67	superovulated	O
68	with	O
69	a	O
70	combination	O
71	of	O
72	400	O
73	I	O
74	.	O
75	U	O
76	.	O
77	pregnant	B
78	mare	I
79	serum	I
80	gonadotrophin	I
81	(	O
82	PMSG	B
83	)	O
84	and	O
85	12	O
86	mg	O
87	follicle	B
88	stimulating	I
89	hormone	I
90	(	O
91	FSH	B
92	-	I
93	P	I
94	).	O

1	Drug	O
2	-	O
3	drug	O
4	interactions	O
5	are	O
6	most	O
7	likely	O
8	to	O
9	occur	O
10	in	O
11	patients	O
12	receiving	O
13	multiple	O
14	medications	O
15	and	O
16	with	O
17	drugs	O
18	that	O
19	have	O
20	a	O
21	narrow	O
22	therapeutic	O
23	window	O
24	.	O

1	The	O
2	sequence	O
3	data	O
4	now	O
5	permit	O
6	a	O
7	detailed	O
8	interpretation	O
9	of	O
10	the	O
11	X	O
12	-	O
13	ray	O
14	crystallographic	O
15	structure	O
16	of	O
17	the	O
18	enzyme	O
19	and	O
20	the	O
21	cloning	O
22	and	O
23	expression	O
24	of	O
25	the	O
26	clostridial	O
27	gene	O
28	will	O
29	facilitate	O
30	site	O
31	-	O
32	directed	O
33	mutagenesis	O
34	.	O

1	Total	O
2	body	O
3	irradiation	O
4	was	O
5	delivered	O
6	according	O
7	to	O
8	a	O
9	hyperfractionated	O
10	scheme	O
11	of	O
12	12	O
13	fractions	O
14	given	O
15	three	O
16	per	O
17	day	O
18	5	O
19	hr	O
20	apart	O
21	for	O
22	4	O
23	days	O
24	.	O

1	A	O
2	reduction	O
3	in	O
4	blood	O
5	pressure	O
6	was	O
7	only	O
8	observed	O
9	at	O
10	the	O
11	end	O
12	of	O
13	the	O
14	study	O
15	,	O
16	from	O
17	142	O
18	+/-	O
19	17	O
20	/	O
21	86	O
22	.	O
23	6	O
24	+/-	O
25	9	O
26	.	O
27	1	O
28	to	O
29	139	O
30	+/-	O
31	13	O
32	/	O
33	82	O
34	.	O
35	9	O
36	+/-	O
37	8	O
38	.	O
39	9	O
40	mmHg	O
41	(	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	05	O
48	for	O
49	DBP	O
50	).	O

1	AgMNPV	O
2	and	O
3	Orgyia	O
4	pseudotsugata	O
5	MNPV	O
6	(	O
7	OpMNPV	O
8	)	O
9	are	O
10	similar	O
11	in	O
12	terms	O
13	of	O
14	promoter	O
15	structure	O
16	and	O
17	polyhedrin	B
18	primary	I
19	sequence	I
20	,	O
21	and	O
22	the	O
23	polyhedrin	B
24	gene	I
25	of	O
26	both	O
27	viruses	O
28	is	O
29	transcribed	O
30	in	O
31	the	O
32	anti	O
33	-	O
34	clockwise	O
35	direction	O
36	in	O
37	relation	O
38	to	O
39	their	O
40	physical	O
41	maps	O
42	.	O

1	A	O
2	gene	O
3	homologous	O
4	to	O
5	the	O
6	Escherichia	B
7	coli	I
8	dnaA	I
9	gene	I
10	was	O
11	isolated	O
12	from	O
13	Pseudomonas	O
14	putida	O
15	and	O
16	its	O
17	transcription	O
18	was	O
19	investigated	O
20	in	O
21	E	O
22	.	O
23	coli	O
24	as	O
25	well	O
26	as	O
27	in	O
28	P	O
29	.	O
30	putida	O
31	.	O

1	STP1	B
2	is	O
3	an	O
4	unessential	O
5	yeast	O
6	gene	O
7	involved	O
8	in	O
9	the	O
10	removal	O
11	of	O
12	intervening	O
13	sequences	O
14	from	O
15	some	O
16	,	O
17	but	O
18	not	O
19	all	O
20	,	O
21	families	O
22	of	O
23	intervening	O
24	sequence	O
25	-	O
26	containing	O
27	pre	O
28	-	O
29	tRNAs	O
30	.	O

1	Using	O
2	these	O
3	antibodies	O
4	,	O
5	we	O
6	were	O
7	able	O
8	to	O
9	define	O
10	the	O
11	conditions	O
12	to	O
13	completely	O
14	solubilize	O
15	the	O
16	Cdc25	B
17	protein	I
18	.	O

1	GCR1	B
2	gene	I
3	function	O
4	is	O
5	required	O
6	for	O
7	high	O
8	-	O
9	level	O
10	glycolytic	O
11	gene	O
12	expression	O
13	in	O
14	Saccharomyces	O
15	cerevisiae	O
16	.	O

1	The	O
2	decay	O
3	curves	O
4	of	O
5	chlorophyll	O
6	fluorescence	O
7	showed	O
8	a	O
9	superposition	O
10	of	O
11	three	O
12	exponentially	O
13	decaying	O
14	components	O
15	with	O
16	time	O
17	constants	O
18	of	O
19	T1	O
20	=	O
21	100	O
22	-	O
23	200	O
24	ps	O
25	,	O
26	T2	O
27	=	O
28	300	O
29	-	O
30	500	O
31	ps	O
32	and	O
33	T3	O
34	=	O
35	2	O
36	.	O
37	0	O
38	-	O
39	3	O
40	.	O
41	5	O
42	ns	O
43	.	O

1	After	O
2	tilting	O
3	,	O
4	systolic	O
5	blood	O
6	pressure	O
7	fell	O
8	an	O
9	average	O
10	of	O
11	17	O
12	%	O
13	in	O
14	patients	O
15	who	O
16	cramped	O
17	infrequently	O
18	(	O
19	p	O
20	=	O
21	0	O
22	.	O
23	0031	O
24	)	O
25	but	O
26	only	O
27	10	O
28	%	O
29	in	O
30	frequently	O
31	cramping	O
32	patients	O
33	.	O

1	These	O
2	results	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	roles	O
8	that	O
9	CCK	B
10	and	O
11	trypsin	B
12	inhibitors	O
13	are	O
14	believed	O
15	to	O
16	play	O
17	in	O
18	the	O
19	negative	O
20	feedback	O
21	control	O
22	of	O
23	pancreatic	O
24	exocrine	O
25	function	O
26	.	O

1	Most	O
2	apneic	O
3	events	O
4	occurred	O
5	during	O
6	Stages	O
7	I	O
8	and	O
9	II	O
10	,	O
11	and	O
12	REM	O
13	,	O
14	but	O
15	this	O
16	proportion	O
17	was	O
18	less	O
19	during	O
20	the	O
21	gamma	O
22	OH	O
23	study	O
24	(	O
25	77	O
26	.	O
27	9	O
28	+/-	O
29	8	O
30	.	O
31	9	O
32	%)	O
33	than	O
34	during	O
35	the	O
36	control	O
37	studies	O
38	(	O
39	92	O
40	.	O
41	3	O
42	+/-	O
43	1	O
44	.	O
45	9	O
46	and	O
47	95	O
48	.	O
49	9	O
50	+/-	O
51	2	O
52	.	O
53	2	O
54	%),	O
55	apneas	O
56	occurring	O
57	even	O
58	during	O
59	SWS	O
60	with	O
61	gamma	O
62	OH	O
63	.(	O
64	ABSTRACT	O
65	TRUNCATED	O
66	AT	O
67	250	O
68	WORDS	O
69	)	O

1	Eight	O
2	rabbits	O
3	were	O
4	exposed	O
5	to	O
6	0	O
7	.	O
8	7	O
9	+/-	O
10	0	O
11	.	O
12	4	O
13	mg	O
14	/	O
15	m3	O
16	Co2	O
17	+	O
18	as	O
19	CoCl2	O
20	and	O
21	1	O
22	.	O
23	2	O
24	+/-	O
25	0	O
26	.	O
27	7	O
28	mg	O
29	/	O
30	m3	O
31	Cr3	O
32	+	O
33	as	O
34	Cr	O
35	(	O
36	NO3	O
37	)	O
38	3	O
39	(	O
40	group	O
41	Co	O
42	+	O
43	Cr	O
44	),	O
45	eight	O
46	to	O
47	0	O
48	.	O
49	6	O
50	+/-	O
51	0	O
52	.	O
53	5	O
54	mg	O
55	/	O
56	m3	O
57	Co2	O
58	+	O
59	(	O
60	group	O
61	Co	O
62	),	O
63	and	O
64	eight	O
65	to	O
66	filtered	O
67	air	O
68	(	O
69	control	O
70	group	O
71	),	O
72	for	O
73	4	O
74	months	O
75	,	O
76	5	O
77	days	O
78	/	O
79	week	O
80	,	O
81	and	O
82	6	O
83	hr	O
84	/	O
85	day	O
86	.	O

1	16	O
2	women	O
3	were	O
4	treated	O
5	with	O
6	methadone	O
7	to	O
8	prevent	O
9	withdrawal	O
10	symptoms	O
11	.	O

1	Disruption	O
2	demonstrates	O
3	that	O
4	CDC14	B
5	is	O
6	an	O
7	essential	O
8	gene	O
9	.	O

1	Coronary	O
2	flow	O
3	was	O
4	reduced	O
5	by	O
6	10	O
7	%	O
8	in	O
9	the	O
10	phosphocreatine	O
11	and	O
12	by	O
13	18	O
14	%	O
15	in	O
16	the	O
17	control	O
18	group	O
19	.	O

1	The	O
2	60A	B
3	transcripts	I
4	and	O
5	protein	O
6	are	O
7	first	O
8	detected	O
9	at	O
10	the	O
11	onset	O
12	of	O
13	gastrulation	O
14	,	O
15	primarily	O
16	in	O
17	the	O
18	mesoderm	O
19	of	O
20	the	O
21	extending	O
22	germ	O
23	band	O
24	.	O

1	A	O
2	724	O
3	-	O
4	bp	O
5	segment	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	consisting	O
13	of	O
14	the	O
15	proximal	O
16	E	O
17	-	O
18	box	O
19	flanked	O
20	upstream	O
21	by	O
22	a	O
23	mammalian	O
24	-	O
25	specific	O
26	352	O
27	-	O
28	bp	O
29	region	O
30	was	O
31	sufficient	O
32	for	O
33	maximal	O
34	transcriptional	O
35	activation	O
36	in	O
37	postconfluent	O
38	BC3H1	O
39	myoblasts	O
40	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	baculovirus	O
6	-	O
7	expressed	O
8	TR	B
9	mediates	O
10	transcriptional	O
11	activation	O
12	and	O
13	repression	O
14	in	O
15	a	O
16	promoter	O
17	-	O
18	specific	O
19	manner	O
20	in	O
21	vitro	O
22	.	O

1	Influence	O
2	of	O
3	neural	O
4	regulation	O
5	on	O
6	anti	O
7	-	O
8	arrhythmic	O
9	effects	O
10	of	O
11	GABA	O
12	in	O
13	rats	O

1	Recent	O
2	investigations	O
3	have	O
4	detailed	O
5	a	O
6	selective	O
7	dye	O
8	release	O
9	technique	O
10	in	O
11	which	O
12	a	O
13	pulse	O
14	of	O
15	laser	O
16	light	O
17	induces	O
18	the	O
19	release	O
20	of	O
21	a	O
22	fluorescent	O
23	dye	O
24	from	O
25	temperature	O
26	-	O
27	sensitive	O
28	liposomes	O
29	circulating	O
30	in	O
31	the	O
32	retinal	O
33	vasculature	O
34	.	O

1	And	O
2	the	O
3	natural	O
4	barriers	O
5	?	O

1	Three	O
2	pyridoxine	O
3	derivatives	O
4	have	O
5	been	O
6	isolated	O
7	from	O
8	the	O
9	fresh	O
10	stem	O
11	bark	O
12	of	O
13	Albizzia	O
14	julibrissin	O
15	DURAZZ	O
16	..	O

1	The	O
2	serum	O
3	erythropoietin	B
4	(	O
5	EPO	B
6	)	O
7	concentrations	O
8	of	O
9	15	O
10	male	O
11	triathletes	O
12	(	O
13	26	O
14	.	O
15	3	O
16	U	O
17	.	O
18	ml	O
19	-	O
20	1	O
21	)	O
22	were	O
23	significantly	O
24	lower	O
25	than	O
26	those	O
27	of	O
28	45	O
29	male	O
30	distance	O
31	runners	O
32	(	O
33	31	O
34	.	O
35	6	O
36	U	O
37	.	O
38	ml	O
39	-	O
40	1	O
41	;	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	05	O
48	).	O

1	The	O
2	coating	O
3	materials	O
4	were	O
5	poloxamine	O
6	904	O
7	,	O
8	poloxamine	O
9	908	O
10	,	O
11	poloxamine	O
12	1508	O
13	,	O
14	poloxamer	O
15	338	O
16	,	O
17	and	O
18	Brij	O
19	35	O
20	.	O

1	The	O
2	eating	O
3	and	O
4	drinking	O
5	patterns	O
6	of	O
7	pygmy	O
8	goats	O
9	fed	O
10	ad	O
11	lib	O
12	and	O
13	kept	O
14	on	O
15	a	O
16	12	O
17	h	O
18	light	O
19	/	O
20	12	O
21	h	O
22	dark	O
23	cycle	O
24	were	O
25	recorded	O
26	and	O
27	analyzed	O
28	.	O

1	The	O
2	present	O
3	study	O
4	highlights	O
5	the	O
6	improvement	O
7	in	O
8	sputum	O
9	amoxycillin	O
10	(	O
11	amoxy	O
12	)	O
13	levels	O
14	when	O
15	a	O
16	combination	O
17	tablet	O
18	,	O
19	amoxy	O
20	500	O
21	mg	O
22	plus	O
23	bromhexeine	O
24	8	O
25	mg	O
26	,	O
27	is	O
28	administered	O
29	as	O
30	compared	O
31	to	O
32	plain	O
33	amoxy	O
34	500	O
35	mg	O
36	.	O

1	His	O
2	HC	B
3	II	I
4	activity	O
5	and	O
6	antigen	O
7	levels	O
8	were	O
9	49	O
10	%	O
11	and	O
12	50	O
13	%,	O
14	respectively	O
15	,	O
16	and	O
17	his	O
18	daughter	O
19	also	O
20	showed	O
21	similar	O
22	low	O
23	levels	O
24	.	O

1	Argatroban	O
2	may	O
3	be	O
4	more	O
5	effective	O
6	under	O
7	low	O
8	HC	B
9	II	I
10	conditions	O
11	because	O
12	of	O
13	its	O
14	potent	O
15	inhibition	O
16	of	O
17	thrombin	B
18	activity	O
19	at	O
20	sites	O
21	of	O
22	vascular	O
23	wall	O
24	damage	O
25	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	diagnostic	O
6	validity	O
7	of	O
8	NFPD	O
9	in	O
10	CP	O
11	/	O
12	NCA	O
13	patients	O
14	,	O
15	because	O
16	such	O
17	patients	O
18	had	O
19	a	O
20	family	O
21	history	O
22	of	O
23	panic	O
24	disorder	O
25	similar	O
26	to	O
27	patients	O
28	with	O
29	a	O
30	more	O
31	classical	O
32	panic	O
33	disorder	O
34	presentation	O
35	.	O

1	FDA	O
2	regulations	O
3	for	O
4	growth	O
5	factors	O
6	and	O
7	related	O
8	products	O
9	.	O

1	Because	O
2	the	O
3	adrenergic	O
4	nervous	O
5	system	O
6	influences	O
7	cardiac	O
8	arrhythmias	O
9	and	O
10	myocardial	O
11	infarction	O
12	can	O
13	directly	O
14	affect	O
15	sympathetic	O
16	innervation	O
17	in	O
18	the	O
19	heart	O
20	,	O
21	we	O
22	investigated	O
23	the	O
24	role	O
25	of	O
26	the	O
27	sympathetic	O
28	nervous	O
29	system	O
30	on	O
31	reentry	O
32	in	O
33	the	O
34	canine	O
35	heart	O
36	4	O
37	days	O
38	after	O
39	infarction	O
40	.	O

1	DESIGN	O
2	:	O
3	Serum	O
4	aldosterone	O
5	and	O
6	plasma	B
7	renin	I
8	activity	O
9	were	O
10	measured	O
11	supine	O
12	prior	O
13	to	O
14	and	O
15	60	O
16	,	O
17	90	O
18	,	O
19	120	O
20	minutes	O
21	after	O
22	oral	O
23	captopril	O
24	,	O
25	25	O
26	mg	O
27	.	O

1	Furthermore	O
2	,	O
3	no	O
4	transcripts	O
5	of	O
6	the	O
7	same	O
8	size	O
9	and	O
10	having	O
11	the	O
12	same	O
13	developmental	O
14	profile	O
15	as	O
16	those	O
17	generated	O
18	by	O
19	the	O
20	wild	B
21	-	I
22	type	I
23	E10	I
24	fragment	I
25	were	O
26	identified	O
27	by	O
28	probes	O
29	covering	O
30	the	O
31	remainder	O
32	of	O
33	the	O
34	cloned	O
35	region	O
36	.	O

1	Intravenous	O
2	amine	O
3	pressor	O
4	tests	O
5	in	O
6	healthy	O
7	volunteers	O
8	.	O

1	The	O
2	mean	O
3	minimum	O
4	steady	O
5	-	O
6	state	O
7	concentration	O
8	after	O
9	the	O
10	oral	O
11	regimen	O
12	(	O
13	23	O
14	micrograms	O
15	.	O
16	l	O
17	-	O
18	1	O
19	)	O
20	was	O
21	78	O
22	%	O
23	of	O
24	that	O
25	after	O
26	the	O
27	intramuscular	O
28	regime	O
29	(	O
30	29	O
31	micrograms	O
32	.	O
33	l	O
34	-	O
35	1	O
36	).	O

1	In	O
2	an	O
3	ongoing	O
4	study	O
5	the	O
6	performance	O
7	of	O
8	the	O
9	SMSP	O
10	is	O
11	being	O
12	compared	O
13	with	O
14	that	O
15	of	O
16	the	O
17	Mini	O
18	Speech	O
19	Processor	O
20	(	O
21	MSP	O
22	).	O

1	Both	O
2	parents	O
3	are	O
4	clinically	O
5	normal	O
6	and	O
7	unrelated	O
8	.	O

1	These	O
2	mutant	O
3	proteins	O
4	retained	O
5	the	O
6	ability	O
7	to	O
8	competitively	O
9	inhibit	O
10	kappa	B
11	B	I
12	-	O
13	mediated	O
14	transcriptional	O
15	activation	O
16	of	O
17	the	O
18	human	B
19	immunodeficiency	I
20	virus	I
21	long	I
22	terminal	I
23	repeat	I
24	but	O
25	failed	O
26	to	O
27	efficiently	O
28	transform	O
29	chicken	O
30	lymphoid	O
31	cells	O
32	both	O
33	in	O
34	vitro	O
35	and	O
36	in	O
37	vivo	O
38	.	O

1	The	O
2	sequence	O
3	-	O
4	specific	O
5	interaction	O
6	of	O
7	nuclear	B
8	factor	I
9	HiNF	I
10	-	I
11	D	I
12	with	O
13	this	O
14	key	O
15	proximal	O
16	promoter	O
17	element	O
18	of	O
19	the	O
20	H4	B
21	-	I
22	FO108	I
23	gene	I
24	is	O
25	cell	O
26	cycle	O
27	regulated	O
28	in	O
29	normal	O
30	diploid	O
31	cells	O
32	(	O
33	J	O
34	.	O

1	In	O
2	conclusion	O
3	,	O
4	to	O
5	study	O
6	and	O
7	overcome	O
8	TI	O
9	region	O
10	-	O
11	based	O
12	expression	O
13	problems	O
14	it	O
15	is	O
16	worthwhile	O
17	to	O
18	start	O
19	out	O
20	with	O
21	a	O
22	versatile	O
23	vector	O
24	containing	O
25	exhaustive	O
26	mutations	O
27	in	O
28	the	O
29	periShine	O
30	-	O
31	Dalgarno	O
32	sequences	O
33	;	O
34	as	O
35	a	O
36	rule	O
37	the	O
38	coding	O
39	MTI	O
40	subregion	O
41	can	O
42	be	O
43	kept	O
44	unchanged	O
45	.	O

1	Four	O
2	of	O
3	these	O
4	five	O
5	subjects	O
6	also	O
7	performed	O
8	mixed	O
9	sequences	O
10	under	O
11	conditional	O
12	control	O
13	of	O
14	the	O
15	words	O
16	(	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	A1	O
22	----	O
23	B2	O
24	----	O
25	A3	O
26	----	O
27	B4	O
28	----	O
29	A5	O
30	and	O
31	its	O
32	reversal	O
33	),	O
34	verifying	O
35	that	O
36	the	O
37	stimuli	O
38	which	O
39	occupied	O
40	the	O
41	same	O
42	position	O
43	in	O
44	each	O
45	sequence	O
46	were	O
47	members	O
48	of	O
49	the	O
50	same	O
51	class	O
52	.	O

1	UF	O
2	-	O
3	021	O
4	ophthalmic	O
5	solution	O
6	(	O
7	0	O
8	.	O
9	03	O
10	to	O
11	0	O
12	.	O
13	24	O
14	%),	O
15	when	O
16	topically	O
17	applied	O
18	to	O
19	the	O
20	eyes	O
21	of	O
22	rabbits	O
23	,	O
24	caused	O
25	dose	O
26	-	O
27	dependent	O
28	IOP	O
29	reduction	O
30	(	O
31	2	O
32	.	O
33	8	O
34	to	O
35	5	O
36	.	O
37	2	O
38	mmHg	O
39	),	O
40	without	O
41	transient	O
42	IOP	O
43	rise	O
44	.	O

1	While	O
2	blood	O
3	pressure	O
4	and	O
5	noradrenergic	O
6	activity	O
7	,	O
8	assessed	O
9	as	O
10	changes	O
11	in	O
12	the	O
13	plasma	O
14	levels	O
15	and	O
16	urinary	O
17	excretion	O
18	of	O
19	norepinephrine	O
20	,	O
21	remained	O
22	unaffected	O
23	in	O
24	the	O
25	Pl	O
26	group	O
27	,	O
28	a	O
29	significant	O
30	drop	O
31	in	O
32	the	O
33	supine	O
34	systolic	O
35	and	O
36	diastolic	O
37	blood	O
38	pressures	O
39	,	O
40	as	O
41	well	O
42	as	O
43	in	O
44	the	O
45	resting	O
46	venous	O
47	norepinephrine	O
48	level	O
49	and	O
50	in	O
51	urinary	O
52	norepinephrine	O
53	excretion	O
54	was	O
55	found	O
56	after	O
57	the	O
58	first	O
59	month	O
60	of	O
61	dF	O
62	administration	O
63	.	O

1	Wild	O
2	-	O
3	type	O
4	protein	O
5	bound	O
6	azido	O
7	-	O
8	ATP	O
9	well	O
10	,	O
11	but	O
12	mutants	O
13	with	O
14	substitutions	O
15	in	O
16	the	O
17	consensus	O
18	amino	O
19	acids	O
20	were	O
21	unable	O
22	to	O
23	bind	O
24	azido	O
25	-	O
26	ATP	O
27	.	O

1	Therefore	O
2	,	O
3	with	O
4	a	O
5	biopsy	O
6	from	O
7	the	O
8	stoma	O
9	site	O
10	there	O
11	is	O
12	a	O
13	risk	O
14	of	O
15	missing	O
16	early	O
17	rejection	O
18	.	O

1	Whole	O
2	blood	O
3	serotonin	O
4	levels	O
5	were	O
6	investigated	O
7	in	O
8	a	O
9	control	O
10	group	O
11	(	O
12	n	O
13	=	O
14	35	O
15	)	O
16	and	O
17	in	O
18	a	O
19	group	O
20	of	O
21	chronic	O
22	renal	O
23	failure	O
24	patients	O
25	(	O
26	n	O
27	=	O
28	127	O
29	)	O
30	on	O
31	various	O
32	treatment	O
33	regimen	O
34	i	O
35	.	O
36	e	O
37	.	O
38	conservative	O
39	treatment	O
40	(	O
41	n	O
42	=	O
43	39	O
44	),	O
45	maintenance	O
46	haemodialysis	O
47	(	O
48	n	O
49	=	O
50	35	O
51	)	O
52	and	O
53	after	O
54	renal	O
55	transplantation	O
56	(	O
57	n	O
58	=	O
59	53	O
60	).	O

1	Tissues	O
2	and	O
3	exudates	O
4	contain	O
5	sufficient	O
6	thymidine	O
7	for	O
8	growth	O
9	of	O
10	anaerobic	O
11	bacteria	O
12	in	O
13	the	O
14	presence	O
15	of	O
16	inhibitory	O
17	levels	O
18	of	O
19	trimethoprim	O
20	-	O
21	sulfamethoxazole	O
22	.	O

1	The	O
2	homologies	O
3	between	O
4	RAD16	B
5	,	O
6	RAD54	B
7	and	O
8	SNF2	B
9	are	O
10	also	O
11	shared	O
12	by	O
13	several	O
14	additional	O
15	,	O
16	recently	O
17	isolated	O
18	yeast	O
19	and	O
20	Drosophila	O
21	genes	O
22	.	O

1	But	O
2	the	O
3	application	O
4	solutions	O
5	of	O
6	instrument	O
7	disinfectants	O
8	should	O
9	not	O
10	be	O
11	used	O
12	longer	O
13	than	O
14	one	O
15	day	O
16	.	O

1	In	O
2	the	O
3	Rett	O
4	syndrome	O
5	we	O
6	,	O
7	therefore	O
8	,	O
9	suspect	O
10	there	O
11	are	O
12	disturbances	O
13	in	O
14	the	O
15	brain	O
16	stem	O
17	functions	O
18	especially	O
19	in	O
20	the	O
21	ascending	O
22	reticular	O
23	activating	O
24	system	O
25	which	O
26	is	O
27	related	O
28	to	O
29	elevation	O
30	of	O
31	the	O
32	conscious	O
33	level	O
34	.	O

1	In	O
2	a	O
3	similar	O
4	experiment	O
5	,	O
6	simultaneous	O
7	nitrofurazone	O
8	administration	O
9	and	O
10	S	O
11	.	O
12	enteritidis	O
13	challenge	O
14	resulted	O
15	in	O
16	no	O
17	significant	O
18	differences	O
19	in	O
20	S	O
21	.	O
22	enteritidis	O
23	isolation	O
24	frequency	O
25	.	O

1	In	O
2	agreement	O
3	with	O
4	this	O
5	southern	O
6	blotting	O
7	of	O
8	mouse	O
9	DNA	O
10	with	O
11	SmN	B
12	probes	O
13	reveals	O
14	bands	O
15	,	O
16	additional	O
17	to	O
18	those	O
19	derived	O
20	from	O
21	the	O
22	pseudogene	O
23	,	O
24	which	O
25	are	O
26	characteristic	O
27	of	O
28	an	O
29	intron	O
30	-	O
31	containing	O
32	SmN	B
33	gene	I
34	.	O

1	Two	O
2	cDNAs	O
3	encoding	O
4	casein	B
5	kinase	I
6	-	I
7	1	I
8	have	O
9	been	O
10	isolated	O
11	from	O
12	a	O
13	yeast	O
14	cDNA	O
15	library	O
16	and	O
17	termed	O
18	CKI1	B
19	and	O
20	CKI2	B
21	.	O

1	Incidence	O
2	rate	O
3	ranging	O
4	between	O
5	122	O
6	/	O
7	100	O
8	,	O
9	000	O
10	/	O
11	year	O
12	and	O
13	190	O
14	/	O
15	100	O
16	,	O
17	000	O
18	/	O
19	year	O
20	were	O
21	found	O
22	(	O
23	minimum	O
24	,	O
25	estimated	O
26	and	O
27	raw	O
28	datasets	O
29	).	O

1	The	O
2	observed	O
3	sequence	O
4	variation	O
5	disrupts	O
6	the	O
7	first	O
8	ORF	O
9	in	O
10	many	O
11	Y	B
12	'	O
13	s	O
14	while	O
15	most	O
16	of	O
17	the	O
18	second	O
19	ORF	O
20	including	O
21	the	O
22	putative	O
23	helicase	B
24	region	I
25	is	O
26	unaffected	O
27	.	O

1	The	O
2	final	O
3	screening	O
4	yielded	O
5	a	O
6	clone	O
7	containing	O
8	a	O
9	2	O
10	kilobase	O
11	(	O
12	kb	O
13	)	O
14	insert	O
15	.	O

1	Lesions	O
2	were	O
3	made	O
4	by	O
5	pressure	O
6	injection	O
7	of	O
8	kainic	O
9	acid	O
10	into	O
11	the	O
12	SOC	O
13	through	O
14	a	O
15	stereotaxically	O
16	positioned	O
17	glass	O
18	micropipette	O
19	.	O

1	A	O
2	38	O
3	-	O
4	bp	O
5	poly	O
6	(	O
7	dA	O
8	-	O
9	dT	O
10	)	O
11	region	O
12	was	O
13	found	O
14	to	O
15	be	O
16	a	O
17	positive	O
18	regulator	O
19	of	O
20	Act1	B
21	promoter	I
22	activity	O
23	.	O

1	We	O
2	identified	O
3	a	O
4	protein	O
5	,	O
6	termed	O
7	NFIL	B
8	-	I
9	1	I
10	beta	I
11	A	I
12	(	O
13	NF	B
14	beta	I
15	A	I
16	),	O
17	that	O
18	binds	O
19	to	O
20	a	O
21	highly	O
22	conserved	O
23	12	O
24	-	O
25	bp	O
26	DNA	O
27	sequence	O
28	(-	O
29	49	O
30	to	O
31	-	O
32	38	O
33	)	O
34	located	O
35	upstream	O
36	of	O
37	the	O
38	TATA	O
39	box	O
40	motif	O
41	in	O
42	both	O
43	the	O
44	human	B
45	and	I
46	murine	I
47	IL	I
48	-	I
49	1	I
50	beta	I
51	genes	I
52	.	O

1	We	O
2	tried	O
3	amphotericin	O
4	B	O
5	(	O
6	AmB	O
7	),	O
8	and	O
9	remission	O
10	of	O
11	the	O
12	tumor	O
13	was	O
14	obtained	O
15	.	O

1	Cutis	O
2	aplasia	O
3	.	O

1	The	O
2	DRF	B
3	-	I
4	2	I
5	nuclear	I
6	protein	I
7	has	O
8	characteristics	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	muscle	O
15	-	O
16	specific	O
17	regulatory	O
18	factor	O
19	,	O
20	MEF	B
21	-	I
22	2	I
23	(	O
24	Buskin	O
25	and	O
26	Hauschka	O
27	1989	O
28	;	O
29	Gossett	O
30	et	O
31	al	O
32	.,	O
33	1989	O
34	).	O

1	From	O
2	the	O
3	15	O
4	-	O
5	kb	O
6	clone	O
7	a	O
8	4	B
9	-	I
10	kb	I
11	EcoRI	I
12	fragment	I
13	containing	O
14	the	O
15	first	O
16	two	O
17	exons	O
18	and	O
19	2	O
20	.	O
21	6	O
22	kb	O
23	of	O
24	the	O
25	5	O
26	'	O
27	flanking	O
28	region	O
29	of	O
30	the	O
31	opn	B
32	gene	I
33	was	O
34	sequenced	O
35	,	O
36	and	O
37	the	O
38	transcriptional	O
39	start	O
40	site	O
41	determined	O
42	by	O
43	primer	O
44	extension	O
45	analysis	O
46	and	O
47	S1	B
48	nuclease	I
49	mapping	O
50	.	O

1	Cardiovascular	O
2	risk	O
3	factors	O
4	were	O
5	measured	O
6	by	O
7	standardized	O
8	techniques	O
9	.	O

1	Production	O
2	costs	O
3	included	O
4	feed	O
5	,	O
6	non	O
7	-	O
8	feed	O
9	operating	O
10	,	O
11	fixed	O
12	,	O
13	and	O
14	replacement	O
15	stock	O
16	costs	O
17	.	O

1	We	O
2	report	O
3	a	O
4	patient	O
5	developing	O
6	factor	B
7	VII	I
8	inhibitor	I
9	possibly	O
10	as	O
11	a	O
12	reaction	O
13	to	O
14	penicillin	O
15	administration	O
16	;	O
17	it	O
18	gave	O
19	rise	O
20	to	O
21	fatal	O
22	haemorrhage	O
23	.	O

1	This	O
2	is	O
3	in	O
4	contrast	O
5	with	O
6	the	O
7	classical	O
8	'	O
9	oxygen	O
10	debt	O
11	hypothesis	O
12	',	O
13	which	O
14	states	O
15	that	O
16	the	O
17	oxygen	O
18	debt	O
19	and	O
20	lactate	O
21	clearance	O
22	are	O
23	linked	O
24	.	O

1	Account	O
2	was	O
3	taken	O
4	of	O
5	noncellular	O
6	and	O
7	nonhuman	O
8	elements	O
9	in	O
10	the	O
11	smears	O
12	;	O
13	they	O
14	included	O
15	mucus	O
16	,	O
17	Charcot	O
18	-	O
19	Layden	O
20	crystals	O
21	,	O
22	pollen	O
23	grains	O
24	,	O
25	vegetal	O
26	fragments	O
27	and	O
28	fungi	O
29	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	carbon	O
7	-	O
8	perfused	O
9	areas	O
10	and	O
11	MBF	O
12	in	O
13	the	O
14	liver	O
15	,	O
16	renal	O
17	cortex	O
18	,	O
19	spleen	O
20	,	O
21	and	O
22	small	O
23	intestinal	O
24	serosa	O
25	(	O
26	only	O
27	MBF	O
28	)	O
29	increased	O
30	significantly	O
31	5	O
32	h	O
33	after	O
34	CLP	O
35	.	O

1	In	O
2	addition	O
3	a	O
4	greater	O
5	proportion	O
6	of	O
7	women	O
8	in	O
9	the	O
10	sweeping	O
11	group	O
12	had	O
13	a	O
14	cervical	O
15	dilatation	O
16	of	O
17	4	O
18	cm	O
19	or	O
20	more	O
21	at	O
22	the	O
23	first	O
24	vaginal	O
25	examination	O
26	in	O
27	the	O
28	labour	O
29	ward	O
30	(	O
31	16	O
32	/	O
33	33	O
34	(	O
35	49	O
36	%)	O
37	vs	O
38	5	O
39	/	O
40	32	O
41	(	O
42	16	O
43	%);	O
44	OR	O
45	4	O
46	.	O
47	39	O
48	;	O
49	95	O
50	%	O
51	CI	O
52	1	O
53	.	O
54	56	O
55	to	O
56	12	O
57	.	O
58	32	O
59	;	O
60	P	O
61	=	O
62	0	O
63	.	O
64	005	O
65	).	O

1	Lewis	O
2	,	O
3	N	O
4	.	O

1	A	O
2	control	O
3	group	O
4	of	O
5	nine	O
6	women	O
7	(	O
8	age	O
9	23	O
10	-	O
11	40	O
12	years	O
13	)	O
14	on	O
15	oral	O
16	contraceptives	O
17	(	O
18	Nordette	O
19	-	O
20	28	O
21	)	O
22	was	O
23	also	O
24	studied	O
25	four	O
26	times	O
27	during	O
28	a	O
29	pill	O
30	cycle	O
31	.	O

1	This	O
2	accurate	O
3	and	O
4	rapid	O
5	method	O
6	makes	O
7	the	O
8	MLPA	O
9	test	O
10	logistically	O
11	feasible	O
12	for	O
13	large	O
14	-	O
15	scale	O
16	screening	O
17	.	O

1	The	O
2	modalities	O
3	for	O
4	using	O
5	reference	O
6	values	O
7	for	O
8	individual	O
9	subjects	O
10	as	O
11	well	O
12	as	O
13	for	O
14	groups	O
15	are	O
16	then	O
17	discussed	O
18	and	O
19	the	O
20	main	O
21	points	O
22	of	O
23	research	O
24	which	O
25	must	O
26	be	O
27	faced	O
28	in	O
29	the	O
30	near	O
31	future	O
32	regarding	O
33	reference	O
34	values	O
35	are	O
36	highlighted	O
37	.	O

1	The	O
2	clinical	O
3	application	O
4	of	O
5	the	O
6	antibody	O
7	-	O
8	targeted	O
9	Phthalocyanine	O
10	was	O
11	performed	O
12	in	O
13	3	O
14	patients	O
15	suffering	O
16	from	O
17	an	O
18	advanced	O
19	ovarian	O
20	carcinoma	O
21	(	O
22	FIGO	O
23	III	O
24	).	O

1	We	O
2	found	O
3	that	O
4	lung	O
5	cancer	O
6	tissues	O
7	of	O
8	positive	O
9	67Ga	O
10	scan	O
11	expressed	O
12	TFR	B
13	,	O
14	but	O
15	those	O
16	of	O
17	a	O
18	negative	O
19	scan	O
20	did	O
21	not	O
22	.	O

1	This	O
2	open	O
3	reading	O
4	frame	O
5	was	O
6	confirmed	O
7	the	O
8	correct	O
9	one	O
10	by	O
11	direct	O
12	amino	O
13	-	O
14	terminal	O
15	sequence	O
16	analysis	O
17	of	O
18	the	O
19	overproduced	O
20	msgB	B
21	gene	I
22	product	I
23	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	purified	O
7	and	O
8	characterized	O
9	the	O
10	recombinant	B
11	furin	I
12	from	O
13	the	O
14	conditioned	O
15	medium	O
16	of	O
17	these	O
18	cells	O
19	.	O

1	The	O
2	virus	O
3	encodes	O
4	a	O
5	40	O
6	-	O
7	kDa	O
8	protein	O
9	,	O
10	tax	B
11	,	O
12	that	O
13	is	O
14	important	O
15	for	O
16	the	O
17	immortalization	O
18	of	O
19	T	O
20	cells	O
21	.	O

1	However	O
2	,	O
3	butyrate	O
4	was	O
5	at	O
6	least	O
7	2	O
8	-	O
9	fold	O
10	more	O
11	effective	O
12	in	O
13	stimulating	O
14	CAT	B
15	activity	O
16	of	O
17	fusion	O
18	genes	O
19	containing	O
20	upstream	O
21	sequences	O
22	(-	O
23	834	O
24	to	O
25	-	O
26	576	O
27	)	O
28	than	O
29	those	O
30	containing	O
31	proximal	O
32	sequences	O
33	(-	O
34	456	O
35	to	O
36	-	O
37	172	O
38	),	O
39	suggesting	O
40	two	O
41	regions	O
42	in	O
43	the	O
44	PSG1	B
45	-	I
46	I	I
47	gene	I
48	that	O
49	mediate	O
50	the	O
51	butyrate	O
52	response	O
53	.	O

1	An	O
2	examination	O
3	of	O
4	the	O
5	role	O
6	of	O
7	the	O
8	carboxyl	O
9	terminus	O
10	in	O
11	regulating	O
12	NGFI	B
13	-	I
14	B	I
15	transcriptional	O
16	activity	O
17	revealed	O
18	that	O
19	,	O
20	in	O
21	accordance	O
22	with	O
23	other	O
24	nuclear	O
25	receptors	O
26	,	O
27	mutants	O
28	lacking	O
29	portions	O
30	of	O
31	the	O
32	carboxyl	O
33	terminus	O
34	had	O
35	greatly	O
36	decreased	O
37	activity	O
38	.	O

1	Altogether	O
2	these	O
3	results	O
4	indicate	O
5	that	O
6	the	O
7	Syn	B
8	5	I
9	locus	I
10	segregates	O
11	from	O
12	the	O
13	gene	O
14	specifying	O
15	gH	B
16	,	O
17	to	O
18	a	O
19	region	O
20	encompassing	O
21	portions	O
22	of	O
23	the	O
24	TK	B
25	and	O
26	UL	B
27	24	I
28	genes	I
29	,	O
30	and	O
31	that	O
32	the	O
33	syn	B
34	mutation	I
35	does	O
36	not	O
37	affect	O
38	the	O
39	expression	O
40	or	O
41	activity	O
42	of	O
43	TK	B
44	.	O

1	Nucleoprotein	O
2	(	O
3	N	O
4	)	O
5	expressed	O
6	by	O
7	both	O
8	recombinant	O
9	vaccinia	O
10	virus	O
11	and	O
12	TGEV	O
13	had	O
14	a	O
15	relative	O
16	molecular	O
17	mass	O
18	(	O
19	Mr	O
20	)	O
21	of	O
22	47	O
23	,	O
24	000	O
25	and	O
26	was	O
27	susceptible	O
28	to	O
29	degradation	O
30	at	O
31	the	O
32	C	O
33	-	O
34	terminus	O
35	yielding	O
36	discrete	O
37	breakdown	O
38	products	O
39	.	O

1	Recently	O
2	,	O
3	the	O
4	3	B
5	.	I
6	6	I
7	-	I
8	kb	I
9	full	I
10	-	I
11	length	I
12	alpha	I
13	-	I
14	GalNAc	I
15	cDNA	I
16	sequence	I
17	was	O
18	isolated	O
19	and	O
20	found	O
21	to	O
22	have	O
23	remarkable	O
24	nucleotide	O
25	and	O
26	predicted	O
27	amino	O
28	acid	O
29	homology	O
30	(	O
31	55	O
32	.	O
33	8	O
34	and	O
35	46	O
36	.	O
37	9	O
38	%,	O
39	respectively	O
40	)	O
41	with	O
42	the	O
43	human	B
44	alpha	I
45	-	I
46	galactosidase	I
47	A	I
48	(	O
49	alpha	B
50	-	I
51	Gal	I
52	A	I
53	)	O
54	cDNA	O
55	.	O

1	Patients	O
2	with	O
3	an	O
4	enzymatic	O
5	activity	O
6	below	O
7	X	O
8	--	O
9	1	O
10	manifested	O
11	a	O
12	decrease	O
13	of	O
14	the	O
15	content	O
16	of	O
17	IgA	B
18	,	O
19	IgG	B
20	,	O
21	IgM	B
22	,	O
23	T	O
24	and	O
25	B	O
26	lymphocytes	O
27	,	O
28	and	O
29	of	O
30	phagocytic	O
31	activity	O
32	of	O
33	neutrophils	O
34	as	O
35	compared	O
36	to	O
37	patients	O
38	exhibiting	O
39	a	O
40	high	O
41	enzymatic	O
42	activity	O
43	.	O

1	The	O
2	reason	O
3	that	O
4	nitrous	O
5	oxide	O
6	does	O
7	not	O
8	produce	O
9	hydroxyl	O
10	radicals	O
11	readily	O
12	might	O
13	be	O
14	that	O
15	the	O
16	one	O
17	-	O
18	electron	O
19	reduction	O
20	proceeds	O
21	through	O
22	an	O
23	N2O	O
24	-	O
25	intermediate	O
26	which	O
27	is	O
28	energetically	O
29	very	O
30	unfavourable	O
31	:	O
32	EO	O
33	(	O
34	N2O	O
35	/	O
36	N2O	O
37	-)	O
38	=	O
39	-	O
40	1	O
41	.	O
42	1	O
43	V	O
44	.	O

1	All	O
2	mutant	B
3	JCV	I
4	T	I
5	antigens	I
6	bound	O
7	to	O
8	JCV	O
9	and	O
10	SV40	O
11	origins	O
12	of	O
13	DNA	O
14	replication	O
15	.	O

1	The	O
2	relation	O
3	between	O
4	myocardial	B
5	beta	I
6	-	I
7	adrenergic	I
8	receptor	I
9	and	O
10	left	O
11	ventricular	O
12	(	O
13	LV	O
14	)	O
15	function	O
16	was	O
17	studied	O
18	in	O
19	10	O
20	patients	O
21	,	O
22	aged	O
23	41	O
24	to	O
25	61	O
26	years	O
27	(	O
28	average	O
29	51	O
30	),	O
31	with	O
32	LV	O
33	volume	O
34	overload	O
35	mainly	O
36	due	O
37	to	O
38	chronic	O
39	mitral	O
40	regurgitation	O
41	.	O

1	Since	O
2	each	O
3	transcript	O
4	appears	O
5	to	O
6	encode	O
7	the	O
8	same	O
9	protein	O
10	,	O
11	this	O
12	complexity	O
13	may	O
14	reflect	O
15	the	O
16	need	O
17	for	O
18	lineage	O
19	-	O
20	specific	O
21	or	O
22	differentiation	O
23	-	O
24	dependent	O
25	control	O
26	of	O
27	expression	O
28	.	O

1	In	O
2	patients	O
3	with	O
4	limited	O
5	disease	O
6	,	O
7	the	O
8	survival	O
9	in	O
10	the	O
11	alternating	O
12	arm	O
13	was	O
14	significantly	O
15	superior	O
16	to	O
17	the	O
18	survival	O
19	in	O
20	the	O
21	CAV	O
22	arm	O
23	(	O
24	P	O
25	=	O
26	.	O
27	014	O
28	)	O
29	or	O
30	the	O
31	survival	O
32	in	O
33	the	O
34	PE	O
35	arm	O
36	(	O
37	P	O
38	=	O
39	.	O
40	023	O
41	).	O

1	We	O
2	identify	O
3	the	O
4	"	O
5	M	O
6	region	O
7	"	O
8	of	O
9	the	O
10	muscle	B
11	-	I
12	specific	I
13	Xenopus	I
14	cardiac	I
15	actin	I
16	gene	I
17	promoter	I
18	from	O
19	-	O
20	282	O
21	to	O
22	-	O
23	348	O
24	as	O
25	necessary	O
26	for	O
27	the	O
28	embryonic	O
29	expression	O
30	of	O
31	a	O
32	cardiac	O
33	actin	B
34	-	O
35	beta	B
36	-	I
37	globin	I
38	reporter	O
39	gene	O
40	injected	O
41	into	O
42	fertilized	O
43	eggs	O
44	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	previously	O
6	identified	O
7	and	O
8	characterized	O
9	attenuator	B
10	1	I
11	situated	O
12	93	O
13	nucleotides	O
14	downstream	O
15	from	O
16	the	O
17	major	O
18	late	O
19	transcription	O
20	start	O
21	site	O
22	,	O
23	a	O
24	second	O
25	attenuator	O
26	,	O
27	attenuator	B
28	2	I
29	,	O
30	situated	O
31	55	O
32	nucleotides	O
33	downstream	O
34	from	O
35	it	O
36	,	O
37	has	O
38	been	O
39	identified	O
40	.	O

1	EBNA	B
2	-	I
3	2	I
4	and	O
5	the	O
6	cis	O
7	-	O
8	acting	O
9	CD23	B
10	element	I
11	increased	O
12	TK	B
13	-	O
14	promoted	O
15	mRNA	O
16	and	O
17	did	O
18	not	O
19	alter	O
20	the	O
21	herpes	B
22	simplex	I
23	virus	I
24	TK	I
25	promoter	I
26	transcription	I
27	start	I
28	site	I
29	.	O

1	These	O
2	experiments	O
3	delineate	O
4	a	O
5	186	O
6	-	O
7	bp	O
8	,	O
9	EBNA	B
10	-	I
11	2	I
12	-	O
13	responsive	O
14	cell	O
15	DNA	O
16	fragment	O
17	and	O
18	provide	O
19	firm	O
20	evidence	O
21	that	O
22	EBNA	B
23	-	I
24	2	I
25	transactivates	O
26	transcription	O
27	of	O
28	cell	O
29	genes	O
30	.	O

1	Plasma	O
2	vitamin	O
3	E	O
4	,	O
5	total	O
6	lipids	O
7	and	O
8	myeloperoxidase	B
9	levels	O
10	during	O
11	spinal	O
12	surgery	O
13	.	O

1	Transfecting	O
2	the	O
3	cloned	O
4	bovine	O
5	PBR	B
6	/	O
7	IBP	B
8	cDNA	O
9	into	O
10	COS	O
11	-	O
12	7	O
13	cells	O
14	resulted	O
15	in	O
16	an	O
17	11	O
18	-	O
19	fold	O
20	increase	O
21	in	O
22	the	O
23	density	O
24	of	O
25	high	O
26	affinity	O
27	[	O
28	3H	O
29	]	O
30	PK	O
31	11195	O
32	binding	O
33	sites	O
34	which	O
35	had	O
36	only	O
37	low	O
38	affinity	O
39	for	O
40	Ro5	O
41	-	O
42	4864	O
43	.	O

1	The	O
2	initial	O
3	phase	O
4	of	O
5	increased	O
6	vascular	O
7	permeability	O
8	in	O
9	the	O
10	peritoneal	O
11	cavity	O
12	and	O
13	LTB4	O
14	production	O
15	was	O
16	dose	O
17	dependently	O
18	inhibited	O
19	by	O
20	the	O
21	5	O
22	-	O
23	LO	O
24	inhibitors	O
25	phenidone	O
26	,	O
27	BW	O
28	A4C	O
29	,	O
30	A63162	O
31	,	O
32	and	O
33	ICI	O
34	207	O
35	968	O
36	but	O
37	not	O
38	by	O
39	dexamethasone	O
40	or	O
41	colchicine	O
42	.	O

1	Discrepant	O
2	results	O
3	with	O
4	a	O
5	latex	O
6	agglutination	O
7	test	O
8	in	O
9	the	O
10	assessment	O
11	of	O
12	cytomegalovirus	O
13	antibody	O
14	status	O
15	of	O
16	cardiac	O
17	transplant	O
18	donors	O
19	.	O

1	Each	O
2	mRNA	O
3	contained	O
4	five	O
5	or	O
6	six	O
7	internal	O
8	uridine	O
9	residues	O
10	,	O
11	which	O
12	were	O
13	transcribed	O
14	using	O
15	a	O
16	mixture	O
17	of	O
18	UTP	O
19	and	O
20	thio	O
21	-	O
22	UTP	O
23	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	sequenced	O
6	two	O
7	overlapping	O
8	cDNA	O
9	fragments	O
10	which	O
11	could	O
12	encode	O
13	the	O
14	complete	O
15	amino	O
16	acid	O
17	sequence	O
18	of	O
19	rat	B
20	testis	I
21	fructose	I
22	-	I
23	6	I
24	-	I
25	phosphate	I
26	,	I
27	2	I
28	-	I
29	kinase	I
30	:	O
31	fructose	B
32	-	I
33	2	I
34	,	I
35	6	I
36	-	I
37	bisphosphatase	I
38	.	O

1	We	O
2	have	O
3	identified	O
4	SWI5	B
5	'	O
6	s	O
7	nuclear	O
8	localization	O
9	signal	O
10	(	O
11	NLS	O
12	)	O
13	and	O
14	show	O
15	that	O
16	it	O
17	can	O
18	confer	O
19	cell	O
20	cycle	O
21	-	O
22	dependent	O
23	nuclear	O
24	entry	O
25	to	O
26	a	O
27	heterologous	O
28	protein	O
29	.	O

1	In	O
2	contrast	O
3	to	O
4	behavioral	O
5	deviation	O
6	(	O
7	the	O
8	avoidance	O
9	conditioning	O
10	lost	O
11	),	O
12	the	O
13	haloperidol	O
14	intrastriatal	O
15	microinjections	O
16	did	O
17	not	O
18	affect	O
19	the	O
20	DA	O
21	synaptic	O
22	level	O
23	in	O
24	rostral	O
25	neostriatum	O
26	.	O

1	In	O
2	similar	O
3	transient	O
4	transfection	O
5	experiments	O
6	in	O
7	HeLa	O
8	cells	O
9	,	O
10	overexpression	O
11	of	O
12	the	O
13	wt	B
14	human	I
15	retinoblastoma	I
16	susceptibility	I
17	gene	I
18	product	I
19	,	O
20	RB	B
21	,	O
22	was	O
23	found	O
24	to	O
25	repress	O
26	the	O
27	serum	O
28	-	O
29	induced	O
30	IL	B
31	-	I
32	6	I
33	(-	O
34	225	O
35	to	O
36	+	O
37	13	O
38	),	O
39	c	B
40	-	I
41	fos	I
42	(-	O
43	711	O
44	to	O
45	+	O
46	42	O
47	),	O
48	and	O
49	beta	B
50	-	I
51	actin	I
52	(-	O
53	3400	O
54	to	O
55	+	O
56	912	O
57	)	O
58	promoters	O
59	but	O
60	not	O
61	the	O
62	PRV	O
63	-	O
64	induced	O
65	IL	B
66	-	I
67	6	I
68	(-	O
69	110	O
70	to	O
71	+	O
72	13	O
73	)	O
74	or	O
75	the	O
76	serum	O
77	-	O
78	induced	O
79	MHC	B
80	(-	O
81	528	O
82	to	O
83	-	O
84	38	O
85	)	O
86	promoters	O
87	.	O

1	This	O
2	repression	O
3	was	O
4	mediated	O
5	through	O
6	binding	O
7	to	O
8	the	O
9	E2	B
10	DNA	I
11	-	I
12	binding	I
13	site	I
14	immediately	O
15	upstream	O
16	of	O
17	the	O
18	P105	B
19	promoter	O
20	TATA	O
21	box	O
22	and	O
23	could	O
24	be	O
25	abrogated	O
26	by	O
27	preincubation	O
28	of	O
29	the	O
30	HPV	B
31	-	I
32	18	I
33	P105	I
34	promoter	I
35	template	O
36	with	O
37	the	O
38	nuclear	O
39	extract	O
40	allowing	O
41	the	O
42	formation	O
43	of	O
44	the	O
45	preinitiation	O
46	complex	O
47	.	O

1	We	O
2	did	O
3	not	O
4	detect	O
5	p50	B
6	in	O
7	association	O
8	with	O
9	native	B
10	glucocorticoid	I
11	receptor	I
12	in	O
13	L	O
14	cells	O
15	or	O
16	with	O
17	the	O
18	overexpressed	O
19	glucocorticoid	B
20	receptor	I
21	in	O
22	Chinese	O
23	hamster	O
24	ovary	O
25	cells	O
26	.	O

1	Two	O
2	putative	O
3	12	O
4	-	O
5	O	O
6	-	O
7	tetradecanoyl	O
8	-	O
9	phorbol	O
10	-	O
11	13	O
12	-	O
13	acetate	O
14	(	O
15	TPA	O
16	)	O
17	response	O
18	elements	O
19	,	O
20	that	O
21	might	O
22	serve	O
23	as	O
24	binding	O
25	sites	O
26	for	O
27	the	O
28	transcription	B
29	factor	I
30	AP	I
31	-	I
32	1	I
33	and	O
34	a	O
35	consensus	O
36	sequence	O
37	of	O
38	a	O
39	transforming	B
40	growth	I
41	factor	I
42	beta	I
43	1	I
44	(	O
45	TGF	B
46	-	I
47	beta	I
48	1	I
49	)	O
50	inhibitory	O
51	element	O
52	were	O
53	found	O
54	in	O
55	the	O
56	promoter	O
57	region	O
58	.	O

1	TPA	O
2	and	O
3	TGF	B
4	-	I
5	beta	I
6	1	I
7	did	O
8	not	O
9	markedly	O
10	affect	O
11	the	O
12	activities	O
13	of	O
14	the	O
15	72	O
16	-	O
17	kDa	O
18	enzyme	O
19	.	O

1	They	O
2	were	O
3	almost	O
4	regularly	O
5	excited	O
6	by	O
7	pressure	O
8	to	O
9	the	O
10	ipsilateral	O
11	cornea	O
12	or	O
13	to	O
14	both	O
15	corneas	O
16	at	O
17	a	O
18	strength	O
19	well	O
20	above	O
21	the	O
22	human	O
23	corneal	O
24	pain	O
25	threshold	O
26	.	O

1	Feed	O
2	intake	O
3	was	O
4	not	O
5	affected	O
6	by	O
7	dietary	O
8	KCl	O
9	or	O
10	NaHCO3	O
11	supplementation	O
12	,	O
13	but	O
14	average	O
15	daily	O
16	gain	O
17	increased	O
18	with	O
19	increased	O
20	K	O
21	and	O
22	tended	O
23	to	O
24	be	O
25	reduced	O
26	by	O
27	dietary	O
28	NaHCO3	O
29	.	O

1	Extraction	O
2	procedure	O
3	for	O
4	the	O
5	measurement	O
6	of	O
7	butyltin	O
8	compounds	O
9	in	O
10	biological	O
11	tissues	O
12	using	O
13	toluene	O
14	,	O
15	HBr	O
16	,	O
17	and	O
18	tropolone	O
19	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	a	O
9	region	O
10	that	O
11	complements	O
12	the	O
13	exoenzyme	B
14	S	I
15	-	O
16	deficient	O
17	phenotype	O
18	of	O
19	strain	O
20	388	O
21	exs1	B
22	::	O
23	Tn1	B
24	,	O
25	a	O
26	chromosomal	B
27	Tn1	I
28	insertional	I
29	mutation	I
30	.	O

1	axl	O
2	,	O
3	a	O
4	transforming	O
5	gene	O
6	isolated	O
7	from	O
8	primary	O
9	human	O
10	myeloid	O
11	leukemia	O
12	cells	O
13	,	O
14	encodes	O
15	a	O
16	novel	O
17	receptor	B
18	tyrosine	I
19	kinase	I
20	.	O

1	Alignment	O
2	of	O
3	the	O
4	amino	O
5	acid	O
6	sequences	O
7	surrounding	O
8	Tyr	O
9	-	O
10	766	O
11	with	O
12	corresponding	O
13	regions	O
14	of	O
15	other	O
16	FGFRs	B
17	revealed	O
18	conserved	O
19	tyrosine	O
20	residues	O
21	in	O
22	all	O
23	known	O
24	members	O
25	of	O
26	the	O
27	FGFR	B
28	family	I
29	.	O

1	The	O
2	single	O
3	most	O
4	important	O
5	element	O
6	,	O
7	by	O
8	linker	O
9	-	O
10	scanning	O
11	analysis	O
12	,	O
13	is	O
14	a	O
15	10	O
16	-	O
17	bp	O
18	region	O
19	that	O
20	contains	O
21	a	O
22	CCAAT	O
23	motif	O
24	.	O

1	Capnography	O
2	curves	O
3	of	O
4	40	O
5	HVS	O
6	patients	O
7	,	O
8	40	O
9	non	O
10	-	O
11	HVS	O
12	patients	O
13	with	O
14	psycho	O
15	-	O
16	somatic	O
17	complaints	O
18	and	O
19	26	O
20	healthy	O
21	controls	O
22	were	O
23	analyzed	O
24	.	O

1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	to	O
8	occur	O
9	66	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	initiating	O
15	Met	O
16	.	O

1	All	O
2	anti	B
3	-	I
4	I	I
5	and	O
6	anti	B
7	-	I
8	i	I
9	CA	I
10	were	O
11	shown	O
12	to	O
13	express	O
14	VH4	B
15	heavy	I
16	chains	I
17	,	O
18	and	O
19	14	O
20	of	O
21	17	O
22	CA	B
23	expressed	O
24	a	O
25	previously	O
26	described	O
27	VH4	B
28	second	O
29	hypervariable	O
30	region	O
31	determinant	O
32	,	O
33	termed	O
34	VH4	B
35	-	I
36	HV2a	I
37	.	O

1	Intron	O
2	K1	B
3	cox1	I
4	.	I
5	2	I
6	is	O
7	not	O
8	found	O
9	in	O
10	S	O
11	.	O
12	cerevisiae	O
13	and	O
14	appears	O
15	at	O
16	an	O
17	unique	O
18	location	O
19	in	O
20	K	O
21	.	O
22	lactis	O
23	.	O

1	We	O
2	have	O
3	determined	O
4	that	O
5	the	O
6	mutants	O
7	define	O
8	two	O
9	complementation	O
10	groups	O
11	,	O
12	designated	O
13	cgs1	B
14	+	I
15	and	O
16	cgs2	B
17	+	I
18	(	O
19	continues	O
20	to	O
21	grow	O
22	in	O
23	stationary	O
24	).	O

1	However	O
2	,	O
3	alterations	O
4	in	O
5	electrostatic	O
6	and	O
7	hydrophobic	O
8	interactions	O
9	created	O
10	by	O
11	the	O
12	three	O
13	amino	O
14	acid	O
15	substitutions	O
16	prevent	O
17	the	O
18	conformational	O
19	change	O
20	in	O
21	the	O
22	enzyme	O
23	usually	O
24	produced	O
25	by	O
26	calmodulin	B
27	binding	O
28	.	O

1	The	O
2	results	O
3	of	O
4	induced	O
5	coexpression	O
6	were	O
7	also	O
8	supported	O
9	by	O
10	rapid	O
11	generation	O
12	of	O
13	FeLV	O
14	recombinants	O
15	when	O
16	FeLV	O
17	-	O
18	C	O
19	was	O
20	used	O
21	to	O
22	infect	O
23	the	O
24	feline	O
25	3201B	O
26	cell	O
27	line	O
28	that	O
29	constitutively	O
30	expresses	O
31	high	O
32	levels	O
33	of	O
34	endogenous	O
35	FeLV	O
36	-	O
37	specific	O
38	mRNAs	O
39	.	O

1	Recombination	O
2	between	O
3	feline	O
4	leukemia	O
5	virus	O
6	subgroup	O
7	B	O
8	or	O
9	C	O
10	and	O
11	endogenous	O
12	env	B
13	elements	O
14	alters	O
15	the	O
16	in	O
17	vitro	O
18	biological	O
19	activities	O
20	of	O
21	the	O
22	viruses	O
23	.	O

1	The	O
2	nucleotide	O
3	sequences	O
4	at	O
5	the	O
6	5	O
7	'	O
8	and	O
9	3	O
10	'	O
11	ends	O
12	of	O
13	these	O
14	introns	O
15	are	O
16	characteristic	O
17	of	O
18	spliced	O
19	transcripts	O
20	from	O
21	eukaryotic	O
22	protein	O
23	-	O
24	encoding	O
25	genes	O
26	,	O
27	with	O
28	one	O
29	significant	O
30	difference	O
31	;	O
32	i	O
33	.	O
34	e	O
35	.,	O
36	the	O
37	5	O
38	'	O
39	end	O
40	of	O
41	the	O
42	LAT	B
43	intron	I
44	is	O
45	GC	O
46	instead	O
47	of	O
48	the	O
49	consensus	O
50	sequence	O
51	GT	O
52	.	O

1	At	O
2	1	O
3	,	O
4	5	O
5	,	O
6	and	O
7	9	O
8	months	O
9	after	O
10	initial	O
11	isolation	O
12	of	O
13	C	O
14	.	O
15	kutscheri	O
16	from	O
17	the	O
18	oral	O
19	cavity	O
20	,	O
21	hamsters	O
22	were	O
23	euthanatized	O
24	,	O
25	and	O
26	attempts	O
27	were	O
28	made	O
29	to	O
30	culture	O
31	C	O
32	.	O
33	kutscheri	O
34	from	O
35	13	O
36	additional	O
37	sites	O
38	.	O

1	The	O
2	strategy	O
3	has	O
4	been	O
5	used	O
6	to	O
7	determine	O
8	2	O
9	.	O
10	6	O
11	kilobases	O
12	of	O
13	nucleotide	O
14	sequence	O
15	in	O
16	the	O
17	Saccharomyces	B
18	cerevisiae	I
19	ADE	I
20	1	I
21	locus	I
22	.	O

1	Two	O
2	independent	O
3	promoters	O
4	as	O
5	well	O
6	as	O
7	5	O
8	'	O
9	untranslated	O
10	regions	O
11	regulate	O
12	Dd	B
13	ras	I
14	expression	O
15	in	O
16	Dictyostelium	O
17	.	O

1	The	O
2	results	O
3	suggested	O
4	that	O
5	,	O
6	depending	O
7	upon	O
8	the	O
9	cell	O
10	type	O
11	,	O
12	gene	O
13	cotransfer	O
14	using	O
15	aminoglycoside	O
16	resistance	O
17	as	O
18	a	O
19	selectable	O
20	marker	O
21	may	O
22	seriously	O
23	perturb	O
24	important	O
25	cellular	O
26	control	O
27	mechanisms	O
28	such	O
29	as	O
30	the	O
31	PKC	B
32	pathway	O
33	leading	O
34	to	O
35	activation	O
36	of	O
37	gene	O
38	expression	O
39	.	O

1	Transfer	O
2	RNA	O
3	genes	O
4	from	O
5	Dictyostelium	O
6	discoideum	O
7	are	O
8	frequently	O
9	associated	O
10	with	O
11	repetitive	O
12	elements	O
13	and	O
14	contain	O
15	consensus	O
16	boxes	O
17	in	O
18	their	O
19	5	O
20	'	O
21	and	O
22	3	O
23	'-	O
24	flanking	O
25	regions	O
26	.	O

1	Therefore	O
2	,	O
3	the	O
4	strD	B
5	and	O
6	strE	B
7	genes	I
8	could	O
9	serve	O
10	as	O
11	universal	O
12	probes	O
13	indicative	O
14	of	O
15	the	O
16	presence	O
17	of	O
18	biosynthetic	O
19	capacity	O
20	for	O
21	6	O
22	-	O
23	deoxyhexose	O
24	moieties	O
25	.	O

1	The	O
2	two	O
3	genes	O
4	code	O
5	for	O
6	polypeptides	B
7	of	I
8	420	I
9	amino	I
10	acids	I
11	(	I
12	M	I
13	.	I
14	HgiCI	I
15	)	I
16	and	O
17	345	O
18	amino	O
19	acids	O
20	(	O
21	R	O
22	.	O
23	HgiCI	O
24	).	O

1	Expression	O
2	of	O
3	the	O
4	wt1	B
5	gene	I
6	via	O
7	transient	O
8	transfection	O
9	in	O
10	COS	O
11	-	O
12	1	O
13	cells	O
14	revealed	O
15	a	O
16	52	O
17	kDa	O
18	protein	O
19	which	O
20	was	O
21	immunoprecipitated	O
22	by	O
23	both	O
24	the	O
25	N	O
26	-	O
27	terminal	O
28	-	O
29	and	O
30	C	O
31	-	O
32	terminal	O
33	-	O
34	specific	O
35	antisera	O
36	.	O

1	The	O
2	factor	O
3	which	O
4	binds	O
5	to	O
6	the	O
7	TR	B
8	promoter	I
9	co	O
10	-	O
11	sedimented	O
12	with	O
13	SV40	O
14	chromosomes	O
15	extracted	O
16	late	O
17	in	O
18	infection	O
19	.	O

1	Temafloxacin	O
2	400	O
3	mg	O
4	b	O
5	.	O
6	i	O
7	.	O
8	d	O
9	.	O
10	administered	O
11	orally	O
12	for	O
13	28	O
14	days	O
15	represents	O
16	a	O
17	safe	O
18	and	O
19	effective	O
20	treatment	O
21	for	O
22	chronic	O
23	bacterial	O
24	prostatitis	O
25	.	O

1	Its	O
2	neuromuscular	O
3	effects	O
4	are	O
5	similar	O
6	to	O
7	a	O
8	single	O
9	ED90	O
10	dose	O
11	of	O
12	vecuronium	O
13	.	O

1	The	O
2	patient	O
3	with	O
4	a	O
5	prolonged	O
6	fever	O
7	caused	O
8	by	O
9	dissecting	O
10	aneurysm	O
11	of	O
12	the	O
13	aorta	O
14	in	O
15	whom	O
16	pleuropneumonia	O
17	masked	O
18	the	O
19	real	O
20	diseases	O
21	has	O
22	been	O
23	presented	O
24	.	O

1	The	O
2	resulting	O
3	clone	O
4	pKB11	B
5	,	O
6	which	O
7	has	O
8	a	O
9	1369	O
10	-	O
11	base	O
12	pair	O
13	(	O
14	bp	O
15	)	O
16	cDNA	O
17	insert	O
18	,	O
19	overlapping	O
20	pCAD142	B
21	by	O
22	781	O
23	bp	O
24	,	O
25	was	O
26	identified	O
27	by	O
28	hybridization	O
29	methods	O
30	and	O
31	sequence	O
32	analysis	O
33	and	O
34	found	O
35	to	O
36	contain	O
37	the	O
38	entire	O
39	cDNA	O
40	sequence	O
41	for	O
42	the	O
43	amino	O
44	end	O
45	of	O
46	the	O
47	CAD	B
48	polypeptide	I
49	.	O

1	This	O
2	conclusion	O
3	was	O
4	confirmed	O
5	by	O
6	Northern	O
7	blotting	O
8	analysis	O
9	of	O
10	the	O
11	5	O
12	'-	O
13	flanking	O
14	region	O
15	of	O
16	CAD	B
17	gene	I
18	.	O

1	We	O
2	report	O
3	the	O
4	isolation	O
5	of	O
6	genomic	O
7	and	O
8	cDNA	O
9	clones	O
10	of	O
11	the	O
12	light	O
13	-	O
14	independent	O
15	Sn	B
16	:	I
17	bol3	I
18	allele	I
19	.	O

1	Histamine	O
2	-	O
3	2	O
4	blockade	O
5	in	O
6	psoriasis	O

1	Its	O
2	clearance	O
3	has	O
4	been	O
5	found	O
6	to	O
7	be	O
8	decreased	O
9	(	O
10	typically	O
11	by	O
12	around	O
13	25	O
14	%,	O
15	but	O
16	often	O
17	by	O
18	far	O
19	more	O
20	)	O
21	by	O
22	erythromycin	O
23	,	O
24	troleandomycin	O
25	(	O
26	triacetyloleandomycin	O
27	),	O
28	roxithromycin	O
29	,	O
30	enoxacin	O
31	,	O
32	ciprofloxacin	O
33	,	O
34	pefloxacin	O
35	,	O
36	norfloxacin	O
37	,	O
38	ofloxacin	O
39	,	O
40	fluoroquinolone	O
41	T	O
42	-	O
43	3262	O
44	,	O
45	pipemidic	O
46	acid	O
47	,	O
48	cimetidine	O
49	,	O
50	etintidine	O
51	,	O
52	propranolol	O
53	,	O
54	verapamil	O
55	,	O
56	diltiazem	O
57	,	O
58	nifedipine	O
59	,	O
60	furosemide	O
61	(	O
62	frusemide	O
63	),	O
64	at	O
65	least	O
66	some	O
67	anovulent	O
68	agents	O
69	,	O
70	viloxazine	O
71	,	O
72	allopurinol	O
73	,	O
74	ticlopidine	O
75	,	O
76	idrocilamide	O
77	,	O
78	thiabendazole	O
79	,	O
80	disulfiram	O
81	,	O
82	influenza	O
83	-	O
84	and	O
85	BCG	O
86	-	O
87	vaccination	O
88	,	O
89	interferon	B
90	,	O
91	and	O
92	caffeine	O
93	(	O
94	half	O
95	-	O
96	life	O
97	increase	O
98	).	O

1	A	O
2	third	O
3	is	O
4	a	O
5	partial	O
6	element	O
7	terminating	O
8	at	O
9	a	O
10	probable	O
11	internal	O
12	restriction	O
13	site	O
14	used	O
15	for	O
16	cloning	O
17	.	O

1	We	O
2	enrolled	O
3	253	O
4	HIV	B
5	-	I
6	antibody	I
7	positive	O
8	heroin	O
9	addicts	O
10	without	O
11	HIV	O
12	-	O
13	related	O
14	disease	O
15	(	O
16	n	O
17	=	O
18	81	O
19	)	O
20	or	O
21	with	O
22	persistent	O
23	generalized	O
24	lymphadenopathy	O
25	(	O
26	n	O
27	=	O
28	172	O
29	)	O
30	in	O
31	a	O
32	prospective	O
33	study	O
34	to	O
35	evaluate	O
36	clinical	O
37	progression	O
38	to	O
39	AIDS	O
40	related	O
41	complex	O
42	(	O
43	ARC	O
44	)	O
45	or	O
46	AIDS	O
47	and	O
48	to	O
49	identify	O
50	factors	O
51	of	O
52	possible	O
53	prognostic	O
54	relevance	O
55	.	O

1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	RNA14	B
7	and	O
8	RNA15	B
9	or	O
10	between	O
11	RNA14	B
12	and	O
13	other	O
14	proteins	O
15	contained	O
16	in	O
17	data	O
18	banks	O
19	.	O

1	Mutations	O
2	in	O
3	the	O
4	yeast	B
5	RNA14	I
6	and	O
7	RNA15	B
8	genes	I
9	result	O
10	in	O
11	an	O
12	abnormal	O
13	mRNA	O
14	decay	O
15	rate	O
16	;	O
17	sequence	O
18	analysis	O
19	reveals	O
20	an	O
21	RNA	O
22	-	O
23	binding	O
24	domain	O
25	in	O
26	the	O
27	RNA15	B
28	protein	I
29	.	O

1	Myocardial	O
2	infarction	O
3	in	O
4	patients	O
5	with	O
6	previous	O
7	bypass	O
8	surgery	O
9	.	O

1	The	O
2	most	O
3	striking	O
4	difference	O
5	in	O
6	the	O
7	birch	B
8	NAD	I
9	(	I
10	P	I
11	)	I
12	H	I
13	-	I
14	NR	I
15	sequence	I
16	in	O
17	comparison	O
18	to	O
19	NADH	B
20	-	I
21	NR	I
22	sequences	I
23	was	O
24	found	O
25	at	O
26	the	O
27	putative	O
28	pyridine	O
29	nucleotide	O
30	binding	O
31	site	O
32	.	O

1	A	O
2	single	O
3	amino	O
4	acid	O
5	difference	O
6	in	O
7	the	O
8	C	O
9	-	O
10	terminal	O
11	region	O
12	influences	O
13	dominant	O
14	negative	O
15	activity	O
16	and	O
17	receptor	O
18	dimer	O
19	formation	O
20	.	O

1	No	O
2	such	O
3	benefits	O
4	were	O
5	seen	O
6	for	O
7	children	O
8	with	O
9	CD4	B
10	+	I
11	counts	O
12	below	O
13	0	O
14	.	O
15	2	O
16	x	O
17	10	O
18	(	O
19	9	O
20	)	O
21	per	O
22	liter	O
23	at	O
24	entry	O
25	.	O

1	Because	O
2	the	O
3	human	B
4	Antp	I
5	TATAA	I
6	binding	I
7	protein	I
8	is	O
9	expressed	O
10	in	O
11	both	O
12	lymphoid	O
13	and	O
14	non	O
15	-	O
16	lymphoid	O
17	cells	O
18	,	O
19	we	O
20	suggest	O
21	that	O
22	this	O
23	homeobox	B
24	gene	I
25	has	O
26	evolved	O
27	a	O
28	more	O
29	general	O
30	transcriptional	O
31	regulatory	O
32	function	O
33	in	O
34	higher	O
35	eukaryotic	O
36	cells	O
37	.	O

1	The	O
2	95	O
3	%	O
4	confidence	O
5	values	O
6	(	O
7	2SD	O
8	)	O
9	for	O
10	the	O
11	change	O
12	in	O
13	Ros	O
14	required	O
15	to	O
16	exclude	O
17	natural	O
18	variability	O
19	were	O
20	0	O
21	.	O
22	39	O
23	,	O
24	0	O
25	.	O
26	50	O
27	and	O
28	0	O
29	.	O
30	53	O
31	cmH2O	O
32	l	O
33	-	O
34	1	O
35	s	O
36	,	O
37	respectively	O
38	.	O

1	Among	O
2	953	O
3	infants	O
4	in	O
5	22	O
6	neonatal	O
7	care	O
8	units	O
9	studied	O
10	,	O
11	23	O
12	%	O
13	(	O
14	median	O
15	value	O
16	,	O
17	range	O
18	0	O
19	-	O
20	78	O
21	)	O
22	were	O
23	found	O
24	to	O
25	be	O
26	faecally	O
27	colonized	O
28	with	O
29	one	O
30	of	O
31	21	O
32	distinct	O
33	nosocomial	O
34	strains	O
35	of	O
36	Escherichia	O
37	coli	O
38	,	O
39	Klebsiella	O
40	or	O
41	Enterobacter	O
42	spp	O
43	.	O

1	Biochemical	O
2	studies	O
3	revealed	O
4	the	O
5	expected	O
6	loss	O
7	of	O
8	ChAT	B
9	activity	O
10	in	O
11	the	O
12	dorsal	O
13	and	O
14	ventral	O
15	hippocampi	O
16	of	O
17	lesioned	O
18	animals	O
19	along	O
20	with	O
21	elevated	O
22	levels	O
23	of	O
24	norepinephrine	O
25	(	O
26	NE	O
27	)	O
28	in	O
29	the	O
30	dorsal	O
31	hippocampus	O
32	of	O
33	MS	O
34	/	O
35	HSI	O
36	animals	O
37	.(	O
38	ABSTRACT	O
39	TRUNCATED	O
40	AT	O
41	250	O
42	WORDS	O
43	)	O

1	The	O
2	localization	O
3	of	O
4	this	O
5	proteoglycan	O
6	locus	O
7	in	O
8	the	O
9	human	O
10	genome	O
11	and	O
12	the	O
13	availability	O
14	of	O
15	new	O
16	RFLPs	O
17	provide	O
18	the	O
19	tools	O
20	for	O
21	future	O
22	studies	O
23	of	O
24	human	O
25	diseases	O
26	where	O
27	the	O
28	HSPG2	B
29	proteoglycan	I
30	gene	I
31	is	O
32	suspected	O
33	to	O
34	be	O
35	involved	O
36	.	O

1	After	O
2	2	O
3	min	O
4	of	O
5	dobutamine	O
6	injection	O
7	,	O
8	or	O
9	after	O
10	20	O
11	min	O
12	of	O
13	pimobendan	O
14	injection	O
15	,	O
16	the	O
17	myocardium	O
18	was	O
19	removed	O
20	,	O
21	and	O
22	used	O
23	for	O
24	determination	O
25	of	O
26	the	O
27	tissue	O
28	levels	O
29	of	O
30	metabolites	O
31	of	O
32	energy	O
33	and	O
34	carbohydrate	O
35	metabolism	O
36	.	O

1	During	O
2	coronary	O
3	stenosis	O
4	,	O
5	on	O
6	the	O
7	contrary	O
8	,	O
9	intracoronary	O
10	procaterol	O
11	at	O
12	the	O
13	same	O
14	dose	O
15	significantly	O
16	deteriorated	O
17	regional	O
18	myocardial	O
19	dysfunction	O
20	without	O
21	changing	O
22	LCX	O
23	flow	O
24	,	O
25	global	O
26	hemodynamics	O
27	and	O
28	cardiac	O
29	lactate	O
30	metabolism	O
31	.	O

1	Here	O
2	we	O
3	present	O
4	evidence	O
5	that	O
6	major	B
7	IE	I
8	proteins	I
9	IE86	I
10	,	O
11	IE72	B
12	,	O
13	and	O
14	IE55	B
15	are	O
16	capable	O
17	of	O
18	trans	O
19	-	O
20	activating	O
21	the	O
22	HIV	B
23	LTR	I
24	in	O
25	a	O
26	T	O
27	-	O
28	cell	O
29	line	O
30	,	O
31	HUT	O
32	-	O
33	78	O
34	.	O

1	In	O
2	a	O
3	country	O
4	where	O
5	general	O
6	HIV	O
7	prevalence	O
8	is	O
9	low	O
10	,	O
11	the	O
12	strategy	O
13	is	O
14	cost	O
15	-	O
16	effective	O
17	for	O
18	location	O
19	and	O
20	counselling	O
21	of	O
22	unknowingly	O
23	seropositive	O
24	individuals	O
25	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	mediating	O
7	glucocorticoid	O
8	inducibility	O
9	of	O
10	the	O
11	chicken	B
12	glutamine	I
13	synthetase	I
14	gene	I
15	has	O
16	been	O
17	identified	O
18	.	O

1	However	O
2	,	O
3	the	O
4	increase	O
5	in	O
6	biliary	O
7	excretion	O
8	did	O
9	not	O
10	compensate	O
11	for	O
12	the	O
13	reduced	O
14	elimination	O
15	of	O
16	bretylium	O
17	and	O
18	hexylsalicylic	O
19	acid	O
20	via	O
21	the	O
22	kidney	O
23	.	O

1	Diagnostic	O
2	value	O
3	of	O
4	cerebrospinal	B
5	fluid	I
6	immunoglobulin	I
7	G	I
8	(	O
9	IgG	B
10	)	O
11	in	O
12	pediatric	O
13	neurological	O
14	diseases	O
15	.	O

1	Expression	O
2	of	O
3	six	O
4	genes	O
5	,	O
6	ipaB	B
7	,	O
8	ipaC	B
9	,	O
10	invE	B
11	,	O
12	invG	B
13	,	O
14	invJ	B
15	,	O
16	and	O
17	invK	B
18	,	O
19	was	O
20	apparently	O
21	regulated	O
22	by	O
23	the	O
24	positive	O
25	regulator	O
26	virF	B
27	.	O

1	Inducible	O
2	VT	O
3	was	O
4	suppressed	O
5	entirely	O
6	in	O
7	one	O
8	patient	O
9	.	O

1	Venkatesan	O
2	,	O
3	and	O
4	D	O
5	.	O

1	The	O
2	presence	O
3	of	O
4	the	O
5	corresponding	O
6	mature	O
7	mRNA	O
8	transcripts	O
9	(	O
10	3	O
11	.	O
12	2	O
13	-	O
14	3	O
15	.	O
16	5	O
17	kilobase	O
18	pairs	O
19	(	O
20	kb	O
21	]	O
22	in	O
23	human	O
24	fibroblasts	O
25	was	O
26	shown	O
27	by	O
28	Northern	O
29	blot	O
30	hybridization	O
31	,	O
32	S1	B
33	nuclease	I
34	protection	O
35	assay	O
36	,	O
37	and	O
38	the	O
39	polymerase	O
40	chain	O
41	reaction	O
42	.	O

1	Approximately	O
2	50	O
3	%	O
4	of	O
5	the	O
6	ribosomal	O
7	DNA	O
8	(	O
9	rDNA	O
10	)	O
11	units	O
12	of	O
13	Drosophila	O
14	melanogaster	O
15	are	O
16	inactivated	O
17	by	O
18	two	O
19	different	O
20	28	B
21	S	I
22	RNA	I
23	ribosomal	I
24	gene	I
25	insertions	O
26	(	O
27	type	O
28	I	O
29	and	O
30	type	O
31	II	O
32	).	O

1	Gap	B
2	b3	I
3	consists	O
4	of	O
5	two	O
6	polypeptide	O
7	chains	O
8	(	O
9	Mr	O
10	=	O
11	110	O
12	,	O
13	000	O
14	and	O
15	30	O
16	,	O
17	000	O
18	),	O
19	which	O
20	seem	O
21	to	O
22	be	O
23	proteolytic	O
24	cleavage	O
25	products	O
26	connected	O
27	by	O
28	disulfide	O
29	bonds	O
30	from	O
31	a	O
32	precursor	O
33	protein	O
34	.	O

1	However	O
2	,	O
3	the	O
4	rtFc	B
5	gamma	I
6	R	I
7	alpha	I
8	cDNA	I
9	clone	O
10	is	O
11	complementary	O
12	to	O
13	at	O
14	least	O
15	two	O
16	different	O
17	-	O
18	sized	O
19	mRNAs	O
20	expressed	O
21	by	O
22	CRNK	O
23	-	O
24	16	O
25	cells	O
26	,	O
27	contrasting	O
28	the	O
29	single	O
30	Fc	B
31	gamma	I
32	R	I
33	-	I
34	related	I
35	mRNA	I
36	species	O
37	expressed	O
38	by	O
39	human	O
40	and	O
41	mouse	O
42	natural	O
43	killer	O
44	cells	O
45	.	O

1	Both	O
2	genes	O
3	comprise	O
4	three	O
5	exons	O
6	,	O
7	two	O
8	introns	O
9	and	O
10	an	O
11	unusually	O
12	long	O
13	3	O
14	'-	O
15	untranslated	O
16	region	O
17	(	O
18	3	O
19	.	O
20	2	O
21	kilobase	O
22	pairs	O
23	),	O
24	specificying	O
25	a	O
26	mRNA	O
27	of	O
28	approximately	O
29	4	O
30	.	O
31	1	O
32	kilobases	O
33	.	O

1	Stable	O
2	expression	O
3	of	O
4	the	O
5	chimeric	O
6	alpha	B
7	i	I
8	(	I
9	54	I
10	)/	I
11	s	I
12	polypeptide	O
13	in	O
14	Chinese	O
15	hamster	O
16	ovary	O
17	(	O
18	CHO	O
19	)	O
20	cells	O
21	constitutively	O
22	increased	O
23	both	O
24	cAMP	O
25	synthesis	O
26	and	O
27	cAMP	B
28	-	I
29	dependent	I
30	protein	I
31	kinase	I
32	activity	O
33	.	O

1	This	O
2	exon	O
3	,	O
4	here	O
5	named	O
6	exon	O
7	0	O
8	,	O
9	contained	O
10	the	O
11	entire	O
12	5	O
13	'	O
14	untranslated	O
15	region	O
16	and	O
17	the	O
18	N	O
19	-	O
20	terminal	O
21	signal	O
22	sequence	O
23	of	O
24	the	O
25	polypeptide	O
26	.	O

1	Treatment	O
2	of	O
3	human	O
4	myeloid	O
5	cell	O
6	lines	O
7	HL	O
8	-	O
9	60	O
10	and	O
11	U937	O
12	with	O
13	phorbol	O
14	12	O
15	-	O
16	myristate	O
17	13	O
18	-	O
19	acetate	O
20	(	O
21	PMA	O
22	)	O
23	increased	O
24	within	O
25	2	O
26	h	O
27	cellular	O
28	levels	O
29	of	O
30	the	O
31	RNA	O
32	hybridizable	O
33	to	O
34	LD78	B
35	cDNA	I
36	.	O

1	A	O
2	new	O
3	,	O
4	flexible	O
5	fiberoptic	O
6	ventriculoscope	O
7	for	O
8	observation	O
9	of	O
10	the	O
11	ventricles	O
12	and	O
13	major	O
14	cisterns	O
15	is	O
16	reported	O
17	.	O

1	Isopenicillin	B
2	N	I
3	isomerase	I
4	(	O
5	epimerase	B
6	)	O
7	has	O
8	been	O
9	purified	O
10	from	O
11	Streptomyces	O
12	clavuligerus	O
13	,	O
14	and	O
15	the	O
16	amino	O
17	acid	O
18	sequence	O
19	of	O
20	the	O
21	N	O
22	-	O
23	terminus	O
24	has	O
25	been	O
26	determined	O
27	.	O

1	Serum	O
2	IgG	B
3	was	O
4	initially	O
5	elevated	O
6	in	O
7	6	O
8	patients	O
9	.	O

1	The	O
2	patient	O
3	initially	O
4	attained	O
5	complete	O
6	remission	O
7	(	O
8	CR1	O
9	)	O
10	with	O
11	conventional	O
12	chemotherapy	O
13	and	O
14	then	O
15	relapsed	O
16	14	O
17	months	O
18	later	O
19	.	O

1	157	O
2	+/-	O
3	16	O
4	mg	O
5	/	O
6	dl	O
7	;	O
8	NS	O
9	),	O
10	glucose	O
11	levels	O
12	,	O
13	and	O
14	basal	O
15	(	O
16	17	O
17	+/-	O
18	4	O
19	vs	O
20	.	O

1	Platelet	O
2	aggregation	O
3	and	O
4	metabolic	O
5	control	O
6	are	O
7	not	O
8	affected	O
9	by	O
10	calcium	O
11	antagonist	O
12	treatment	O
13	in	O
14	type	O
15	II	O
16	diabetes	O
17	mellitus	O
18	.	O

1	Wnt	B
2	-	I
3	1	I
4	(	O
5	int	B
6	-	I
7	1	I
8	)	O
9	is	O
10	a	O
11	cellular	O
12	oncogene	O
13	often	O
14	activated	O
15	by	O
16	insertion	O
17	of	O
18	proviral	O
19	DNA	O
20	of	O
21	the	O
22	mouse	O
23	mammary	O
24	tumor	O
25	virus	O
26	.	O

1	Induction	O
2	of	O
3	Jurkat	O
4	leukemic	O
5	T	O
6	cells	O
7	with	O
8	phorbol	O
9	12	O
10	-	O
11	myristate	O
12	13	O
13	-	O
14	acetate	O
15	and	O
16	ionomycin	O
17	did	O
18	not	O
19	affect	O
20	the	O
21	level	O
22	of	O
23	FKBP	B
24	mRNA	I
25	.	O

1	GLUT5	B
2	mRNA	I
3	is	O
4	expressed	O
5	at	O
6	highest	O
7	levels	O
8	in	O
9	small	O
10	intestine	O
11	and	O
12	at	O
13	much	O
14	lower	O
15	levels	O
16	in	O
17	kidney	O
18	,	O
19	skeletal	O
20	muscle	O
21	,	O
22	and	O
23	adipose	O
24	tissue	O
25	.	O

1	e	O
2	.	O

1	We	O
2	speculate	O
3	that	O
4	these	O
5	tumors	O
6	may	O
7	represent	O
8	congenital	O
9	hamartomatous	O
10	growths	O
11	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	the	O
6	promoter	O
7	for	O
8	the	O
9	cytotactin	B
10	gene	I
11	.	O

1	Surprisingly	O
2	,	O
3	there	O
4	is	O
5	no	O
6	sequence	O
7	homology	O
8	between	O
9	this	O
10	region	O
11	of	O
12	Ly	B
13	-	I
14	6E	I
15	and	O
16	the	O
17	established	O
18	consensus	O
19	for	O
20	the	O
21	interferon	B
22	-	I
23	stimulated	I
24	response	I
25	element	I
26	,	O
27	which	O
28	has	O
29	been	O
30	shown	O
31	functionally	O
32	important	O
33	to	O
34	all	O
35	previously	O
36	characterized	O
37	alpha	B
38	/	I
39	beta	I
40	interferon	I
41	-	O
42	inducible	O
43	promoters	O
44	.	O

1	Relatively	O
2	large	O
3	DNA	O
4	rearrangements	O
5	spanning	O
6	the	O
7	region	O
8	with	O
9	tandem	O
10	direct	O
11	repeats	O
12	encoding	O
13	the	O
14	carboxy	O
15	-	O
16	terminal	O
17	histone	B
18	H1	I
19	-	I
20	like	I
21	structure	O
22	of	O
23	AlgP	B
24	were	O
25	detected	O
26	in	O
27	several	O
28	strains	O
29	upon	O
30	conversion	O
31	from	O
32	the	O
33	mucoid	O
34	to	O
35	the	O
36	nonmucoid	O
37	phenotype	O
38	.	O

1	(	O
2	1988	O
3	)	O
4	J	O
5	.	O

1	These	O
2	results	O
3	strongly	O
4	suggested	O
5	that	O
6	similar	O
7	,	O
8	if	O
9	not	O
10	identical	O
11	,	O
12	the	O
13	CArG	B
14	box	I
15	binding	I
16	proteins	I
17	interact	O
18	with	O
19	the	O
20	functionally	O
21	different	O
22	promoter	O
23	element	O
24	in	O
25	the	O
26	VLC1	B
27	,	O
28	cardiac	B
29	alpha	I
30	-	I
31	actin	I
32	,	O
33	and	O
34	c	B
35	-	I
36	fos	I
37	genes	I
38	.	O

1	Polyadenylation	O
2	of	O
3	B4	B
4	RNA	I
5	,	O
6	which	O
7	occurs	O
8	very	O
9	early	O
10	during	O
11	maturation	O
12	,	O
13	is	O
14	limited	O
15	to	O
16	150	O
17	residues	O
18	,	O
19	and	O
20	it	O
21	is	O
22	this	O
23	number	O
24	that	O
25	is	O
26	required	O
27	for	O
28	polysomal	O
29	recruitment	O
30	.	O

1	Co	O
2	-	O
3	existence	O
4	of	O
5	these	O
6	regulatory	O
7	elements	O
8	with	O
9	other	O
10	elements	O
11	,	O
12	such	O
13	as	O
14	the	O
15	AP	B
16	-	I
17	2	I
18	element	I
19	or	O
20	CCAAT	O
21	box	O
22	,	O
23	was	O
24	also	O
25	found	O
26	.	O

1	Recently	O
2	,	O
3	studies	O
4	of	O
5	agents	O
6	that	O
7	disrupt	O
8	collagen	B
9	synthesis	O
10	and	O
11	deposition	O
12	have	O
13	yielded	O
14	several	O
15	new	O
16	angiogenesis	O
17	inhibitors	O
18	.	O

1	Since	O
2	the	O
3	5	O
4	'-	O
5	flanking	O
6	region	O
7	of	O
8	this	O
9	gene	O
10	is	O
11	likely	O
12	involved	O
13	in	O
14	hormonal	O
15	regulation	O
16	of	O
17	its	O
18	expression	O
19	,	O
20	we	O
21	have	O
22	isolated	O
23	and	O
24	partially	O
25	characterized	O
26	an	O
27	avian	O
28	fatty	B
29	acid	I
30	synthase	I
31	gene	O
32	.	O

1	A	O
2	new	O
3	set	O
4	of	O
5	cDNA	O
6	clones	O
7	spanning	O
8	approximately	O
9	3	O
10	.	O
11	2	O
12	kb	O
13	was	O
14	isolated	O
15	from	O
16	a	O
17	lambda	O
18	-	O
19	ZAP	O
20	goose	O
21	liver	O
22	cDNA	O
23	library	O
24	using	O
25	the	O
26	5	O
27	'-	O
28	most	O
29	exon	O
30	-	O
31	containing	O
32	fragment	O
33	of	O
34	the	O
35	5	O
36	'-	O
37	most	O
38	genomic	O
39	DNA	O
40	clone	O
41	.	O

1	Northern	O
2	blotting	O
3	analysis	O
4	indicates	O
5	that	O
6	expression	O
7	of	O
8	the	O
9	genes	O
10	corresponding	O
11	to	O
12	these	O
13	clones	O
14	is	O
15	confined	O
16	to	O
17	pollen	O
18	tissue	O
19	.	O

1	Whereas	O
2	cDNA	O
3	hybridization	O
4	to	O
5	genomic	O
6	DNA	O
7	blots	O
8	indicated	O
9	a	O
10	small	O
11	subfamily	O
12	of	O
13	G0S19	B
14	genes	I
15	,	O
16	simple	O
17	patterns	O
18	of	O
19	bands	O
20	indicated	O
21	that	O
22	most	O
23	cDNAs	O
24	,	O
25	including	O
26	G0S30	B
27	cDNA	I
28	,	O
29	corresponded	O
30	to	O
31	single	O
32	-	O
33	copy	O
34	genes	O
35	.	O

1	Lymphoproliferative	O
2	disorders	O
3	arising	O
4	under	O
5	immunosuppression	O
6	with	O
7	FK	O
8	506	O
9	:	O
10	initial	O
11	observations	O
12	in	O
13	a	O
14	large	O
15	transplant	O
16	population	O
17	.	O

1	The	O
2	Drosophila	B
3	suppressor	I
4	of	I
5	sable	I
6	gene	I
7	encodes	O
8	a	O
9	polypeptide	O
10	with	O
11	regions	O
12	similar	O
13	to	O
14	those	O
15	of	O
16	RNA	O
17	-	O
18	binding	O
19	proteins	O
20	.	O

1	2	O
2	:	O
3	121	O
4	-	O
5	133	O
6	,	O
7	1988	O
8	).	O

1	It	O
2	is	O
3	,	O
4	however	O
5	,	O
6	extremely	O
7	homologous	O
8	to	O
9	a	O
10	third	O
11	'	O
12	non	O
13	-	O
14	classical	O
15	'	O
16	gene	O
17	,	O
18	HLA	B
19	-	I
20	5	I
21	.	I
22	4	I
23	,	O
24	and	O
25	to	O
26	the	O
27	chimpanzee	O
28	gene	O
29	,	O
30	Ch28	B
31	.	O

1	Although	O
2	the	O
3	N13	O
4	-	O
5	N20	O
6	interpeak	O
7	interval	O
8	remained	O
9	stable	O
10	because	O
11	of	O
12	the	O
13	parallel	O
14	shift	O
15	of	O
16	the	O
17	2	O
18	peaks	O
19	,	O
20	the	O
21	central	O
22	conduction	O
23	time	O
24	measured	O
25	from	O
26	onset	O
27	latencies	O
28	of	O
29	N11	O
30	and	O
31	N20	O
32	significantly	O
33	increased	O
34	.	O

1	Using	O
2	avidin	B
3	-	I
4	biotin	I
5	complex	O
6	DNA	O
7	binding	O
8	assays	O
9	,	O
10	a	O
11	series	O
12	of	O
13	overlapping	O
14	alpha	B
15	promoter	I
16	DNA	I
17	sequences	I
18	between	O
19	-	O
20	170	O
21	to	O
22	29	O
23	basepairs	O
24	were	O
25	tested	O
26	,	O
27	but	O
28	each	O
29	failed	O
30	to	O
31	bind	O
32	GR	B
33	,	O
34	whereas	O
35	a	O
36	control	O
37	GRE	O
38	avidly	O
39	bound	O
40	receptor	O
41	.	O

1	Sequence	O
2	determination	O
3	of	O
4	isolated	O
5	peptides	O
6	suggested	O
7	that	O
8	Asn120	O
9	is	O
10	glycosylated	O
11	,	O
12	Asn65	O
13	and	O
14	Asn109	O
15	glycosylated	O
16	in	O
17	some	O
18	molecules	O
19	but	O
20	not	O
21	in	O
22	others	O
23	,	O
24	and	O
25	Asn72	O
26	not	O
27	glycosylated	O
28	.	O

1	The	O
2	DNA	O
3	sequence	O
4	conferring	O
5	AP	B
6	-	I
7	1	I
8	activity	O
9	was	O
10	located	O
11	in	O
12	the	O
13	proximal	O
14	promoter	O
15	region	O
16	.	O

1	The	O
2	murine	B
3	mutation	I
4	dominant	I
5	white	I
6	spotting	I
7	(	O
8	W	B
9	)	O
10	is	O
11	in	O
12	the	O
13	proto	O
14	-	O
15	oncogene	O
16	,	O
17	c	B
18	-	I
19	kit	I
20	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	the	O
6	rat	O
7	chromosomal	O
8	gene	O
9	for	O
10	a	O
11	polypeptide	O
12	(	O
13	pS1	B
14	)	O
15	antigenically	O
16	related	O
17	to	O
18	statin	B
19	.	O

1	The	O
2	proteins	O
3	differ	O
4	in	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	of	O
10	a	O
11	21	O
12	-	O
13	amino	O
14	-	O
15	acid	O
16	sequence	O
17	located	O
18	24	O
19	amino	O
20	acids	O
21	C	O
22	terminal	O
23	of	O
24	the	O
25	translational	O
26	initiation	O
27	codon	O
28	.	O

1	Our	O
2	results	O
3	also	O
4	indicate	O
5	the	O
6	existence	O
7	of	O
8	sequences	O
9	downstream	O
10	of	O
11	-	O
12	0	O
13	.	O
14	11	O
15	kb	O
16	which	O
17	can	O
18	influence	O
19	the	O
20	pattern	O
21	of	O
22	tissue	O
23	-	O
24	specific	O
25	expression	O
26	of	O
27	the	O
28	HLA	B
29	-	I
30	B7	I
31	gene	I
32	and	O
33	the	O
34	ability	O
35	of	O
36	this	O
37	gene	O
38	to	O
39	respond	O
40	to	O
41	gamma	B
42	interferon	I
43	.	O

1	The	O
2	SH2	B
3	and	O
4	SH3	B
5	domains	I
6	of	O
7	pp60src	B
8	direct	O
9	stable	O
10	association	O
11	with	O
12	tyrosine	O
13	phosphorylated	O
14	proteins	O
15	p130	B
16	and	O
17	p110	B
18	.	O

1	Chem	O
2	.	O

1	These	O
2	clones	O
3	overlapped	O
4	and	O
5	contained	O
6	the	O
7	structural	O
8	gene	O
9	encoding	O
10	the	O
11	complete	O
12	C5	B
13	alpha	I
14	-	I
15	chain	I
16	and	O
17	90	O
18	%	O
19	of	O
20	the	O
21	beta	O
22	-	O
23	chain	O
24	.	O

1	The	O
2	C5	B
3	alpha	I
4	-	I
5	chain	I
6	was	O
7	encoded	O
8	by	O
9	49	O
10	kilobases	O
11	containing	O
12	26	O
13	exons	O
14	;	O
15	the	O
16	beta	O
17	-	O
18	chain	O
19	was	O
20	encoded	O
21	by	O
22	29	O
23	kilobases	O
24	containing	O
25	16	O
26	exons	O
27	.	O

1	Heterozygous	O
2	mutation	O
3	in	O
4	the	O
5	G	O
6	+	O
7	5	O
8	position	O
9	of	O
10	intron	O
11	33	O
12	of	O
13	the	O
14	pro	B
15	-	I
16	alpha	I
17	2	I
18	(	I
19	I	I
20	)	I
21	gene	I
22	(	O
23	COL1A2	B
24	)	O
25	that	O
26	causes	O
27	aberrant	O
28	RNA	O
29	splicing	O
30	and	O
31	lethal	O
32	osteogenesis	O
33	imperfecta	O
34	.	O

1	The	O
2	nucleotide	O
3	sequences	O
4	of	O
5	these	O
6	genes	O
7	differ	O
8	at	O
9	only	O
10	nine	O
11	positions	O
12	,	O
13	resulting	O
14	in	O
15	three	O
16	amino	O
17	acid	O
18	differences	O
19	.	O

1	The	O
2	protein	O
3	predicted	O
4	by	O
5	the	O
6	sequence	O
7	of	O
8	the	O
9	human	B
10	pim	I
11	-	I
12	1	I
13	proto	I
14	-	I
15	oncogene	I
16	shares	O
17	extensive	O
18	homology	O
19	with	O
20	known	O
21	serine	B
22	/	I
23	threonine	I
24	protein	I
25	kinases	I
26	,	O
27	and	O
28	yet	O
29	the	O
30	human	B
31	Pim	I
32	-	I
33	1	I
34	enzyme	I
35	has	O
36	previously	O
37	been	O
38	reported	O
39	to	O
40	exhibit	O
41	protein	B
42	tyrosine	I
43	kinase	I
44	activity	O
45	both	O
46	in	O
47	vitro	O
48	and	O
49	in	O
50	vivo	O
51	.	O

1	A	O
2	full	B
3	-	I
4	length	I
5	human	I
6	pim	I
7	-	I
8	1	I
9	cDNA	I
10	was	O
11	subcloned	O
12	into	O
13	the	O
14	bacterial	O
15	vector	O
16	pGEX	O
17	-	O
18	2T	O
19	and	O
20	the	O
21	Pim	B
22	-	I
23	1	I
24	protein	I
25	expressed	O
26	as	O
27	a	O
28	fusion	O
29	product	O
30	with	O
31	bacterial	B
32	glutathione	I
33	S	I
34	-	I
35	transferase	I
36	(	O
37	GST	B
38	).	O

1	This	O
2	report	O
3	substantiates	O
4	that	O
5	at	O
6	least	O
7	two	O
8	of	O
9	the	O
10	18	O
11	kDa	O
12	hsps	B
13	in	O
14	maize	O
15	are	O
16	products	O
17	of	O
18	different	O
19	but	O
20	related	O
21	genes	O
22	.	O

1	The	O
2	10	O
3	kDa	O
4	polypeptide	O
5	was	O
6	phosphorylated	O
7	in	O
8	vitro	O
9	by	O
10	incubating	O
11	wheat	O
12	etioplast	O
13	membranes	O
14	with	O
15	[	O
16	gamma	O
17	32P	O
18	]	O
19	ATP	O
20	.	O

1	Homology	O
2	with	O
3	the	O
4	human	O
5	protein	O
6	is	O
7	only	O
8	34	O
9	%	O
10	in	O
11	the	O
12	tandem	O
13	repeat	O
14	domain	O
15	,	O
16	mainly	O
17	showing	O
18	conservation	O
19	of	O
20	serines	O
21	and	O
22	threonines	O
23	,	O
24	presumed	O
25	sites	O
26	of	O
27	O	O
28	-	O
29	linked	O
30	carbohydrate	O
31	attachment	O
32	.	O

1	In	O
2	addition	O
3	to	O
4	targeting	O
5	partially	O
6	assembled	O
7	Ti	B
8	alpha	I
9	-	I
10	beta	I
11	CD3	I
12	gamma	I
13	delta	I
14	epsilon	I
15	TCR	I
16	complexes	I
17	to	O
18	the	O
19	cell	O
20	surface	O
21	,	O
22	CD3	B
23	zeta	I
24	appears	O
25	to	O
26	be	O
27	essential	O
28	for	O
29	interleukin	B
30	-	I
31	2	I
32	production	O
33	after	O
34	TCR	B
35	stimulation	O
36	with	O
37	antigen	B
38	/	I
39	major	I
40	histocompatibility	I
41	complex	I
42	.	O

1	When	O
2	desipramine	O
3	was	O
4	injected	O
5	16	O
6	hrs	O
7	after	O
8	fluoxetine	O
9	injection	O
10	,	O
11	brain	O
12	levels	O
13	of	O
14	desipramine	O
15	were	O
16	no	O
17	longer	O
18	elevated	O
19	.	O

1	Opposite	O
2	effects	O
3	of	O
4	CYP1	B
5	are	O
6	observed	O
7	in	O
8	aerobic	O
9	,	O
10	heme	O
11	-	O
12	sufficient	O
13	cells	O
14	.	O

1	A	O
2	segmental	O
3	analysis	O
4	of	O
5	the	O
6	key	O
7	regions	O
8	of	O
9	HLA	B
10	-	I
11	DR1	I
12	that	O
13	control	O
14	T	O
15	cell	O
16	allorecognition	O
17	was	O
18	performed	O
19	by	O
20	using	O
21	a	O
22	series	O
23	of	O
24	transfected	O
25	cell	O
26	lines	O
27	expressing	O
28	the	O
29	products	O
30	of	O
31	recombinant	O
32	DRB	B
33	/	O
34	H	B
35	-	I
36	2Eb	I
37	genes	O
38	,	O
39	paired	O
40	with	O
41	either	O
42	DR	B
43	alpha	I
44	or	O
45	H	B
46	-	I
47	2E	I
48	alpha	I
49	.	O

1	We	O
2	characterized	O
3	cDNA	O
4	clones	O
5	specific	O
6	for	O
7	the	O
8	extracellular	O
9	matrix	O
10	glycoprotein	O
11	undulin	B
12	.	O

1	Finally	O
2	,	O
3	some	O
4	point	O
5	mutations	O
6	in	O
7	the	O
8	Gag	B
9	-	O
10	Pol	B
11	PR	O
12	domain	O
13	inhibited	O
14	activation	O
15	of	O
16	RT	B
17	in	O
18	trans	O
19	by	O
20	a	O
21	wild	O
22	-	O
23	type	O
24	PR	B
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	correct	O
30	conformation	O
31	of	O
32	the	O
33	PR	B
34	domain	O
35	in	O
36	Gag	B
37	-	O
38	Pol	B
39	is	O
40	prerequisite	O
41	for	O
42	activation	O
43	of	O
44	RT	B
45	.	O

1	The	O
2	alpha	B
3	inhibin	I
4	promoter	I
5	containing	O
6	a	O
7	mutated	O
8	CRE	O
9	was	O
10	not	O
11	regulated	O
12	by	O
13	forskolin	O
14	in	O
15	granulosa	O
16	cells	O
17	and	O
18	did	O
19	not	O
20	bind	O
21	the	O
22	CREB	B
23	protein	I
24	.	O

1	Regulation	O
2	of	O
3	the	O
4	alpha	B
5	inhibin	I
6	gene	I
7	by	O
8	cyclic	O
9	adenosine	O
10	3	O
11	',	O
12	5	O
13	'-	O
14	monophosphate	O
15	after	O
16	transfection	O
17	into	O
18	rat	O
19	granulosa	O
20	cells	O
21	.	O

1	Comparison	O
2	of	O
3	the	O
4	nucleotide	O
5	sequences	O
6	between	O
7	the	O
8	human	O
9	and	O
10	bovine	O
11	DNA	O
12	showed	O
13	that	O
14	the	O
15	sequence	O
16	similarity	O
17	extended	O
18	2400	O
19	bp	O
20	downstream	O
21	from	O
22	the	O
23	coding	O
24	region	O
25	.	O

1	Cloning	O
2	of	O
3	a	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	CDC2	B
9	-	I
10	related	I
11	kinase	I
12	by	O
13	complementation	O
14	of	O
15	a	O
16	budding	B
17	yeast	I
18	cdc28	I
19	mutation	O
20	.	O

1	In	O
2	patients	O
3	with	O
4	osteomyelitis	O
5	and	O
6	joint	O
7	empyema	O
8	(	O
9	n	O
10	=	O
11	48	O
12	)	O
13	PMN	B
14	elastase	I
15	had	O
16	a	O
17	sensitivity	O
18	of	O
19	77	O
20	%,	O
21	which	O
22	was	O
23	only	O
24	exceeded	O
25	by	O
26	that	O
27	of	O
28	the	O
29	unspecific	O
30	erythrocyte	O
31	sedimentation	O
32	rate	O
33	(	O
34	sensitivity	O
35	89	O
36	%).	O

1	E	O
2	.,	O
3	Hession	O
4	,	O
5	C	O
6	.,	O
7	Goff	O
8	,	O
9	D	O
10	.,	O
11	Griffiths	O
12	,	O
13	B	O
14	.,	O
15	Tizard	O
16	,	O
17	R	O
18	.,	O
19	Newman	O
20	,	O
21	B	O
22	.,	O
23	Chi	O
24	-	O
25	Rosso	O
26	,	O
27	G	O
28	.,	O
29	and	O
30	Lobb	O
31	,	O
32	R	O
33	.,	O
34	(	O
35	1990	O
36	)	O
37	Cell	O
38	63	O
39	,	O
40	1349	O
41	-	O
42	1356	O
43	).	O

1	The	O
2	above	O
3	results	O
4	mean	O
5	that	O
6	the	O
7	increase	O
8	in	O
9	alpha	B
10	-	I
11	adrenergic	I
12	receptors	I
13	makes	O
14	the	O
15	prostate	O
16	,	O
17	which	O
18	has	O
19	been	O
20	already	O
21	hypertrophied	O
22	,	O
23	less	O
24	elastic	O
25	,	O
26	inhibiting	O
27	external	O
28	urinary	O
29	sphincter	O
30	function	O
31	.	O

1	An	O
2	approximately	O
3	2	B
4	-	I
5	kilobase	I
6	B2	I
7	transcript	I
8	was	O
9	expressed	O
10	in	O
11	all	O
12	alfalfa	O
13	organs	O
14	tested	O
15	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	sulfhydryl	O
7	group	O
8	of	O
9	certain	O
10	angiotensin	B
11	converting	I
12	enzyme	I
13	inhibitors	O
14	can	O
15	potentiate	O
16	their	O
17	effect	O
18	on	O
19	the	O
20	endogenous	O
21	nitrovasodilator	O
22	EDRF	B
23	.	O

1	Pharmacokinetics	O
2	of	O
3	FK	O
4	506	O
5	in	O
6	transplant	O
7	patients	O
8	.	O

1	A	O
2	second	O
3	even	O
4	more	O
5	significant	O
6	match	O
7	to	O
8	this	O
9	E	O
10	.	O
11	coli	O
12	region	O
13	was	O
14	found	O
15	in	O
16	the	O
17	retroviral	B
18	ribonuclease	I
19	H	I
20	(	O
21	RNase	B
22	H	I
23	)	O
24	domain	O
25	,	O
26	and	O
27	corresponds	O
28	precisely	O
29	to	O
30	a	O
31	region	O
32	that	O
33	has	O
34	been	O
35	aligned	O
36	by	O
37	previous	O
38	investigators	O
39	with	O
40	the	O
41	E	B
42	.	I
43	coli	I
44	RNase	I
45	H	I
46	,	O
47	suggesting	O
48	that	O
49	Pol	B
50	I	I
51	helices	O
52	O	O
53	and	O
54	P	O
55	are	O
56	homologous	O
57	to	O
58	helices	O
59	A	O
60	and	O
61	D	O
62	of	O
63	the	O
64	RNase	B
65	H	I
66	crystal	O
67	structure	O
68	,	O
69	respectively	O
70	.	O

1	Analysis	O
2	of	O
3	the	O
4	deduced	O
5	amino	O
6	acid	O
7	sequence	O
8	suggests	O
9	that	O
10	CHIP28	B
11	protein	I
12	contains	O
13	six	O
14	bilayer	O
15	-	O
16	spanning	O
17	domains	O
18	,	O
19	two	O
20	exofacial	O
21	potential	O
22	N	O
23	-	O
24	glycosylation	O
25	sites	O
26	,	O
27	and	O
28	intracellular	O
29	N	O
30	and	O
31	C	O
32	termini	O
33	.	O

1	The	O
2	qualitative	O
3	concentrations	O
4	of	O
5	HCG	B
6	had	O
7	a	O
8	sensitivity	O
9	of	O
10	37	O
11	.	O
12	5	O
13	%	O
14	and	O
15	a	O
16	specificity	O
17	of	O
18	100	O
19	%.	O

1	The	O
2	reduced	O
3	rate	O
4	of	O
5	F	O
6	absorption	O
7	and	O
8	slower	O
9	rise	O
10	in	O
11	plasma	O
12	F	O
13	concentration	O
14	accompanying	O
15	delayed	O
16	gastric	O
17	emptying	O
18	indicate	O
19	that	O
20	passage	O
21	of	O
22	F	O
23	into	O
24	the	O
25	small	O
26	intestine	O
27	is	O
28	the	O
29	major	O
30	factor	O
31	in	O
32	rapid	O
33	F	O
34	absorption	O
35	.	O

1	The	O
2	activity	O
3	of	O
4	serum	B
5	lipase	I
6	and	O
7	amylase	B
8	distinctly	O
9	increased	O
10	at	O
11	3	O
12	h	O
13	and	O
14	went	O
15	up	O
16	to	O
17	the	O
18	maximum	O
19	at	O
20	12	O
21	h	O
22	after	O
23	injection	O
24	of	O
25	Na	O
26	-	O
27	Tc	O
28	.	O

1	They	O
2	were	O
3	checked	O
4	for	O
5	anti	B
6	-	I
7	HCV	I
8	(	O
9	anti	B
10	-	I
11	C100	I
12	-	I
13	3	I
14	)	O
15	with	O
16	HCV	O
17	EIA	O
18	kit	O
19	(	O
20	Abbott	O
21	Lab	O
22	.,	O
23	North	O
24	Chicago	O
25	,	O
26	IL	O
27	).	O

1	Diltiazem	O
2	resulted	O
3	in	O
4	a	O
5	significant	O
6	increase	O
7	in	O
8	epicardial	O
9	diameter	O
10	(+	O
11	10	O
12	%;	O
13	p	O
14	=	O
15	0	O
16	.	O
17	001	O
18	)	O
19	and	O
20	in	O
21	coronary	O
22	blood	O
23	flow	O
24	(	O
25	CBF	O
26	)	O
27	(+	O
28	30	O
29	%;	O
30	p	O
31	=	O
32	0	O
33	.	O
34	0001	O
35	).	O

1	The	O
2	first	O
3	transfusion	O
4	resulted	O
5	in	O
6	a	O
7	platelet	O
8	increment	O
9	to	O
10	32	O
11	Gpt	O
12	/	O
13	l	O
14	(	O
15	CCI	O
16	11	O
17	).	O

1	These	O
2	risk	O
3	factors	O
4	can	O
5	be	O
6	divided	O
7	into	O
8	2	O
9	groups	O
10	:	O
11	local	O
12	vessel	O
13	wall	O
14	-	O
15	related	O
16	factors	O
17	,	O
18	and	O
19	local	O
20	(	O
21	focal	O
22	action	O
23	)	O
24	systemic	O
25	factors	O
26	.	O

1	Epidemiology	O
2	and	O
3	prevention	O
4	of	O
5	hospital	O
6	infections	O
7	in	O
8	the	O
9	Local	O
10	Health	O
11	Unit	O
12	of	O
13	Sassari	O
14	:	O
15	profile	O
16	of	O
17	bacterial	O
18	resistance	O
19	and	O
20	antimicrobial	O
21	agents	O
22	of	O
23	large	O
24	usage	O
25	.	O

1	PRDII	B
2	-	I
3	BF1	I
4	-	I
5	derived	I
6	cDNAs	I
7	did	O
8	not	O
9	result	O
10	in	O
11	stimulation	O
12	of	O
13	either	O
14	basal	O
15	or	O
16	tat	B
17	-	O
18	induced	O
19	activated	O
20	gene	O
21	expression	O
22	.	O

1	Vaccinia	O
2	virus	O
3	(	O
4	VV	O
5	)	O
6	is	O
7	a	O
8	potent	O
9	immunogen	O
10	,	O
11	but	O
12	the	O
13	nature	O
14	of	O
15	VV	O
16	proteins	O
17	involved	O
18	in	O
19	the	O
20	activation	O
21	of	O
22	the	O
23	immune	O
24	response	O
25	of	O
26	the	O
27	host	O
28	is	O
29	not	O
30	yet	O
31	known	O
32	.	O

1	Max	B
2	:	O
3	functional	O
4	domains	O
5	and	O
6	interaction	O
7	with	O
8	c	B
9	-	I
10	Myc	I
11	.	O

1	86	O
2	:	O
3	3199	O
4	-	O
5	3203	O
6	)	O
7	or	O
8	G1	O
9	to	O
10	S	O
11	phase	O
12	(	O
13	Reilly	O
14	,	O
15	C	O
16	.	O

1	Substitutions	O
2	introduced	O
3	at	O
4	bases	O
5	surrounding	O
6	the	O
7	ICR2	B
8	motif	I
9	yielded	O
10	levels	O
11	of	O
12	pRNA	O
13	replication	O
14	that	O
15	differed	O
16	,	O
17	depending	O
18	on	O
19	the	O
20	maintenance	O
21	of	O
22	a	O
23	putative	O
24	5	O
25	'	O
26	stem	O
27	-	O
28	loop	O
29	structure	O
30	in	O
31	the	O
32	positive	O
33	strand	O
34	of	O
35	the	O
36	viral	O
37	genome	O
38	.	O

1	Zn	O
2	(	O
3	II	O
4	)	O
5	coordination	O
6	domain	O
7	mutants	O
8	of	O
9	T4	O
10	gene	B
11	32	I
12	protein	O
13	.	O

1	Zn	O
2	(	O
3	II	O
4	)	O
5	coordination	O
6	domain	O
7	mutants	O
8	of	O
9	T4	B
10	gene	I
11	32	I
12	protein	I
13	.	O

1	The	O
2	tissue	O
3	specificity	O
4	of	O
5	gene	O
6	expression	O
7	was	O
8	identical	O
9	to	O
10	that	O
11	described	O
12	previously	O
13	for	O
14	the	O
15	CaMV	B
16	35S	I
17	domain	I
18	B	I
19	enhancer	I
20	element	I
21	.	O

1	The	O
2	pathophysiology	O
3	and	O
4	clinical	O
5	management	O
6	of	O
7	acute	O
8	brain	O
9	injury	O
10	in	O
11	infancy	O
12	and	O
13	childhood	O
14	are	O
15	presented	O
16	using	O
17	acute	O
18	traumatic	O
19	brain	O
20	injury	O
21	as	O
22	a	O
23	model	O
24	.	O

1	Transcripts	O
2	from	O
3	a	O
4	second	O
5	POU	B
6	-	I
7	domain	I
8	gene	I
9	,	O
10	Oct	B
11	-	I
12	25	I
13	,	O
14	were	O
15	present	O
16	at	O
17	low	O
18	levels	O
19	in	O
20	oocytes	O
21	and	O
22	early	O
23	embryos	O
24	and	O
25	were	O
26	dramatically	O
27	upregulated	O
28	during	O
29	early	O
30	gastrulation	O
31	.	O

1	In	O
2	some	O
3	early	O
4	B	O
5	cells	O
6	and	O
7	Abelson	O
8	murine	O
9	leukemia	O
10	virus	O
11	-	O
12	transformed	O
13	pre	O
14	-	O
15	B	O
16	-	O
17	cell	O
18	lines	O
19	,	O
20	LT	B
21	mRNA	I
22	is	O
23	constitutively	O
24	expressed	O
25	.	O

1	The	O
2	genome	O
3	of	O
4	Thogoto	O
5	virus	O
6	comprises	O
7	six	O
8	segments	O
9	of	O
10	single	O
11	-	O
12	stranded	O
13	,	O
14	negative	O
15	sense	O
16	RNA	O
17	.	O

1	These	O
2	tumors	O
3	were	O
4	classified	O
5	into	O
6	three	O
7	broad	O
8	groups	O
9	:	O
10	I	O
11	,	O
12	cystadenoma	O
13	;	O
14	II	O
15	,	O
16	cystadenocarcinoma	O
17	;	O
18	and	O
19	III	O
20	,	O
21	adenocarcinoma	O
22	with	O
23	mucin	B
24	production	O
25	or	O
26	an	O
27	associated	O
28	cyst	O
29	.	O

1	Immunostaining	O
2	of	O
3	cells	O
4	transfected	O
5	with	O
6	these	O
7	constructs	O
8	revealed	O
9	that	O
10	both	O
11	the	O
12	myristoylated	O
13	and	O
14	nonmyristoylated	O
15	mutants	O
16	were	O
17	localized	O
18	in	O
19	nuclei	O
20	,	O
21	whereas	O
22	wild	B
23	-	I
24	type	I
25	PKC	I
26	alpha	I
27	was	O
28	primarily	O
29	cytoplasmic	O
30	and	O
31	perinuclear	O
32	.	O

1	We	O
2	have	O
3	partially	O
4	sequenced	O
5	the	O
6	RAP74	B
7	protein	I
8	from	O
9	purified	O
10	HeLa	O
11	cells	O
12	,	O
13	cloned	O
14	its	O
15	complementary	O
16	DNA	O
17	and	O
18	shown	O
19	that	O
20	its	O
21	translation	O
22	product	O
23	can	O
24	interact	O
25	with	O
26	RAP30	B
27	in	O
28	vitro	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vivo	O
34	.	O

1	Effects	O
2	of	O
3	thromboxane	B
4	synthetase	I
5	inhibition	O
6	on	O
7	postburn	O
8	mesenteric	O
9	vascular	O
10	resistance	O
11	and	O
12	the	O
13	rate	O
14	of	O
15	bacterial	O
16	translocation	O
17	in	O
18	a	O
19	chronic	O
20	porcine	O
21	model	O
22	.	O

1	The	O
2	primary	O
3	pancreatic	O
4	insult	O
5	seemed	O
6	to	O
7	be	O
8	unaffected	O
9	by	O
10	the	O
11	treatment	O
12	,	O
13	because	O
14	neither	O
15	the	O
16	rise	O
17	in	O
18	plasma	B
19	lipase	I
20	nor	O
21	the	O
22	development	O
23	of	O
24	ascites	O
25	or	O
26	the	O
27	extension	O
28	of	O
29	the	O
30	pancreatic	O
31	necrosis	O
32	were	O
33	diminished	O
34	.	O

1	The	O
2	size	O
3	of	O
4	the	O
5	mutant	O
6	molecule	O
7	corresponds	O
8	to	O
9	the	O
10	unprocessed	O
11	cytoplasmic	O
12	precursor	O
13	(	O
14	pre	B
15	-	I
16	super	I
17	-	I
18	pro	I
19	-	I
20	PrB	I
21	),	O
22	as	O
23	detected	O
24	in	O
25	sec61	B
26	mutants	I
27	,	O
28	when	O
29	translocation	O
30	into	O
31	the	O
32	endoplasmic	O
33	reticulum	O
34	is	O
35	blocked	O
36	.	O

1	Thus	O
2	,	O
3	the	O
4	active	O
5	-	O
6	site	O
7	mutation	O
8	prevents	O
9	the	O
10	wild	O
11	-	O
12	type	O
13	processing	O
14	of	O
15	the	O
16	N	O
17	-	O
18	glycosylated	O
19	73	O
20	-	O
21	kDa	O
22	precursor	O
23	of	O
24	PrB	B
25	to	O
26	the	O
27	41	B
28	.	I
29	5	I
30	kDa	I
31	pro	I
32	-	I
33	PrB	I
34	in	O
35	the	O
36	endoplasmic	O
37	reticulum	O
38	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	exhibited	O
7	70	O
8	%	O
9	identity	O
10	to	O
11	that	O
12	of	O
13	Bacillus	B
14	stearothermophilus	I
15	TyrTS	I
16	and	O
17	55	O
18	%	O
19	identity	O
20	to	O
21	that	O
22	of	O
23	E	B
24	.	I
25	coli	I
26	TyrTS	I
27	,	O
28	while	O
29	identity	O
30	to	O
31	a	O
32	second	O
33	cryptic	O
34	B	B
35	.	I
36	subtilis	I
37	TyrTS	I
38	gene	I
39	,	O
40	designated	O
41	tyrZ	B
42	,	O
43	was	O
44	only	O
45	27	O
46	%.	O

1	Heat	O
2	-	O
3	inducible	O
4	CAT	B
5	activity	O
6	was	O
7	detectable	O
8	when	O
9	additional	O
10	sequences	O
11	from	O
12	the	O
13	native	O
14	promoter	O
15	containing	O
16	three	O
17	CCAAT	O
18	boxes	O
19	and	O
20	a	O
21	single	O
22	HSE	O
23	were	O
24	present	O
25	in	O
26	the	O
27	constructions	O
28	.	O

1	SETTING	O
2	--	O
3	Women	O
4	,	O
5	Infants	O
6	,	O
7	and	O
8	Children	O
9	clinics	O
10	in	O
11	Minneapolis	O
12	,	O
13	Minn	O
14	.	O

1	Testosterone	O
2	,	O
3	free	O
4	testosterone	O
5	,	O
6	non	B
7	-	I
8	sex	I
9	hormone	I
10	-	I
11	binding	I
12	globulin	I
13	-	O
14	bound	O
15	testosterone	O
16	,	O
17	and	O
18	free	O
19	androgen	O
20	index	O
21	:	O
22	which	O
23	testosterone	O
24	measurement	O
25	is	O
26	most	O
27	relevant	O
28	to	O
29	reproductive	O
30	and	O
31	sexual	O
32	function	O
33	in	O
34	men	O
35	with	O
36	epilepsy	O
37	?	O

1	BACKGROUND	O
2	:	O
3	The	O
4	effectiveness	O
5	of	O
6	monoamine	B
7	oxidase	I
8	inhibitors	O
9	(	O
10	MAOIs	O
11	)	O
12	in	O
13	tricyclic	O
14	resistant	O
15	depression	O
16	has	O
17	received	O
18	surprisingly	O
19	little	O
20	systematic	O
21	study	O
22	.	O

1	The	O
2	upstream	O
3	delta	O
4	-	O
5	alpha	O
6	breakpoint	O
7	is	O
8	flanked	O
9	by	O
10	the	O
11	direct	O
12	repeats	O
13	of	O
14	the	O
15	acceptor	O
16	splice	O
17	site	O
18	,	O
19	whereas	O
20	the	O
21	down	O
22	-	O
23	stream	O
24	alpha	O
25	-	O
26	delta	O
27	breakpoint	O
28	is	O
29	located	O
30	in	O
31	the	O
32	adjacent	O
33	intron	O
34	.	O

1	Patients	O
2	with	O
3	moderate	O
4	PDDAT	O
5	were	O
6	impaired	O
7	on	O
8	all	O
9	serial	O
10	positions	O
11	for	O
12	both	O
13	spatial	O
14	order	O
15	and	O
16	spatial	O
17	recognition	O
18	memory	O
19	.	O

1	Bone	O
2	and	O
3	bones	O
4	.	O

1	One	O
2	patients	O
3	had	O
4	plasma	B
5	C	I
6	-	I
7	peptide	I
8	greater	O
9	than	O
10	3	O
11	pM	O
12	and	O
13	was	O
14	therefore	O
15	excluded	O
16	from	O
17	analysis	O
18	.	O

1	Complex	O
2	repetitive	O
3	discharges	O
4	were	O
5	observed	O
6	in	O
7	muscles	O
8	of	O
9	mdx	O
10	mice	O
11	but	O
12	no	O
13	complex	O
14	repetitive	O
15	discharges	O
16	or	O
17	other	O
18	abnormalities	O
19	were	O
20	observed	O
21	in	O
22	muscles	O
23	of	O
24	normal	O
25	control	O
26	mice	O
27	.	O

1	Management	O
2	often	O
3	involves	O
4	beta	O
5	-	O
6	and	O
7	calcium	O
8	channel	O
9	blocking	O
10	drugs	O
11	or	O
12	type	O
13	IC	O
14	antiarrhythmic	O
15	drugs	O
16	.	O

1	To	O
2	overcome	O
3	this	O
4	problem	O
5	,	O
6	we	O
7	have	O
8	overexpressed	O
9	Kex2p	B
10	using	O
11	the	O
12	baculovirus	O
13	/	O
14	insect	O
15	cell	O
16	expression	O
17	system	O
18	.	O

1	J	O
2	.	O

1	The	O
2	major	B
3	49	I
4	-	I
5	kDa	I
6	core	I
7	protein	I
8	in	O
9	the	O
10	liver	O
11	HSPG	B
12	preparation	O
13	was	O
14	found	O
15	to	O
16	be	O
17	reactive	O
18	to	O
19	an	O
20	antibody	O
21	that	O
22	specifically	O
23	recognizes	O
24	the	O
25	cytoplasmic	O
26	domain	O
27	of	O
28	fibroglycan	B
29	.	O

1	While	O
2	no	O
3	obvious	O
4	transmembrane	O
5	regions	O
6	were	O
7	identified	O
8	,	O
9	several	O
10	short	O
11	hydrophobic	O
12	amino	O
13	acid	O
14	stretches	O
15	were	O
16	found	O
17	to	O
18	be	O
19	localized	O
20	in	O
21	and	O
22	around	O
23	the	O
24	Pro	O
25	II	O
26	region	O
27	,	O
28	and	O
29	these	O
30	may	O
31	be	O
32	responsible	O
33	for	O
34	attachment	O
35	of	O
36	precursors	O
37	to	O
38	membranes	O
39	.	O

1	Toxicity	O
2	was	O
3	mild	O
4	,	O
5	mainly	O
6	consisting	O
7	of	O
8	emesis	O
9	(	O
10	81	O
11	%	O
12	of	O
13	the	O
14	patients	O
15	;	O
16	66	O
17	%	O
18	of	O
19	the	O
20	courses	O
21	),	O
22	leukopenia	O
23	of	O
24	World	O
25	Health	O
26	Organization	O
27	(	O
28	WHO	O
29	)	O
30	grade	O
31	1	O
32	to	O
33	2	O
34	(	O
35	47	O
36	%	O
37	of	O
38	the	O
39	patients	O
40	;	O
41	18	O
42	%	O
43	of	O
44	the	O
45	courses	O
46	),	O
47	and	O
48	thrombocytopenia	O
49	(	O
50	12	O
51	%	O
52	of	O
53	the	O
54	patients	O
55	;	O
56	3	O
57	%	O
58	of	O
59	the	O
60	courses	O
61	).	O

1	W	O
2	.	O
3	G	O
4	.	O

1	This	O
2	study	O
3	confirms	O
4	,	O
5	although	O
6	individual	O
7	reaction	O
8	is	O
9	remarkably	O
10	different	O
11	,	O
12	transportation	O
13	as	O
14	a	O
15	potent	O
16	stressor	O
17	for	O
18	Beagle	O
19	dogs	O
20	.	O

1	A	O
2	mouse	B
3	brain	I
4	beta	I
5	-	I
6	spectrin	I
7	of	O
8	cDNA	O
9	was	O
10	identified	O
11	within	O
12	a	O
13	lambda	O
14	Gt11	O
15	expression	O
16	library	O
17	using	O
18	an	O
19	antibody	O
20	which	O
21	specifically	O
22	binds	O
23	with	O
24	the	O
25	235	B
26	kDa	I
27	spectrin	I
28	beta	I
29	-	I
30	subunit	I
31	.	O

1	RESULTS	O
2	:	O
3	Plasma	B
4	AVP	I
5	responses	O
6	to	O
7	osmotic	O
8	stimulation	O
9	,	O
10	and	O
11	non	O
12	-	O
13	osmotic	O
14	inhibition	O
15	by	O
16	drinking	O
17	,	O
18	were	O
19	normal	O
20	in	O
21	patients	O
22	with	O
23	compulsive	O
24	water	O
25	drinking	O
26	.	O

1	The	O
2	fragments	O
3	of	O
4	each	O
5	region	O
6	were	O
7	amplified	O
8	by	O
9	polymerase	O
10	chain	O
11	reaction	O
12	and	O
13	analyzed	O
14	by	O
15	gel	O
16	electrophoresis	O
17	to	O
18	detect	O
19	single	O
20	-	O
21	strand	O
22	conformation	O
23	polymorphism	O
24	.	O

1	The	O
2	csbA	B
3	fusion	I
4	was	O
5	maximally	O
6	expressed	O
7	during	O
8	early	O
9	stationary	O
10	phase	O
11	in	O
12	cells	O
13	grown	O
14	in	O
15	Luria	O
16	broth	O
17	containing	O
18	5	O
19	%	O
20	glucose	O
21	and	O
22	0	O
23	.	O
24	2	O
25	%	O
26	glutamine	O
27	.	O

1	The	O
2	constraints	O
3	of	O
4	primase	B
5	recognition	I
6	sequences	I
7	,	O
8	nucleotide	O
9	substrate	O
10	requirements	O
11	,	O
12	and	O
13	the	O
14	effects	O
15	of	O
16	additional	O
17	proteins	O
18	on	O
19	oligoribonucleotide	O
20	synthesis	O
21	by	O
22	the	O
23	63	B
24	-	I
25	kDa	I
26	gene	I
27	4	I
28	protein	I
29	have	O
30	been	O
31	examined	O
32	using	O
33	templates	O
34	of	O
35	defined	O
36	sequence	O
37	.	O

1	Thrombolytic	O
2	therapy	O
3	in	O
4	spontaneous	O
5	coronary	O
6	artery	O
7	dissection	O
8	.	O

1	A	O
2	prospective	O
3	trial	O
4	was	O
5	carried	O
6	out	O
7	in	O
8	156	O
9	unselected	O
10	patients	O
11	(	O
12	41	O
13	men	O
14	,	O
15	mean	O
16	age	O
17	67	O
18	.	O
19	5	O
20	years	O
21	,	O
22	115	O
23	women	O
24	,	O
25	mean	O
26	age	O
27	71	O
28	.	O
29	4	O
30	years	O
31	)	O
32	who	O
33	had	O
34	undergone	O
35	total	O
36	hip	O
37	joint	O
38	replacement	O
39	because	O
40	of	O
41	degenerative	O
42	or	O
43	inflammatory	O
44	arthritis	O
45	or	O
46	fracture	O
47	of	O
48	the	O
49	neck	O
50	of	O
51	the	O
52	femur	O
53	.	O

1	When	O
2	both	O
3	lesions	O
4	were	O
5	complete	O
6	lateral	O
7	hemisections	O
8	in	O
9	weanling	O
10	operates	O
11	,	O
12	little	O
13	behavioral	O
14	recovery	O
15	was	O
16	observed	O
17	,	O
18	similar	O
19	to	O
20	complete	O
21	spinal	O
22	cord	O
23	transection	O
24	(	O
25	N	O
26	=	O
27	3	O
28	).	O

1	Human	O
2	SRF	B
3	-	I
4	related	I
5	proteins	I
6	:	O
7	DNA	O
8	-	O
9	binding	O
10	properties	O
11	and	O
12	potential	O
13	regulatory	O
14	targets	O
15	.	O

1	We	O
2	have	O
3	isolated	O
4	cDNAs	O
5	for	O
6	a	O
7	gene	O
8	coding	O
9	for	O
10	a	O
11	G	B
12	protein	I
13	alpha	I
14	subunit	I
15	from	I
16	tomato	I
17	(	O
18	Lycopersicon	O
19	esculentum	O
20	,	O
21	cv	O
22	.	O

1	Growth	O
2	factor	O
3	stimulation	O
4	of	O
5	cells	O
6	causes	O
7	the	O
8	phosphorylation	O
9	of	O
10	the	O
11	c	B
12	-	I
13	Myc	I
14	transcriptional	I
15	activation	I
16	domain	I
17	at	O
18	Ser62	O
19	within	O
20	a	O
21	proline	O
22	-	O
23	rich	O
24	region	O
25	that	O
26	is	O
27	highly	O
28	conserved	O
29	among	O
30	members	O
31	of	O
32	the	O
33	Myc	B
34	family	I
35	(	O
36	Alvarez	O
37	,	O
38	E	O
39	.,	O
40	Northwood	O
41	,	O
42	I	O
43	.	O
44	C	O
45	.,	O
46	Gonzalez	O
47	,	O
48	F	O
49	.	O

1	The	O
2	authors	O
3	evaluated	O
4	the	O
5	potential	O
6	for	O
7	thrombotic	O
8	complications	O
9	arising	O
10	from	O
11	implantation	O
12	of	O
13	a	O
14	ventricular	O
15	assist	O
16	device	O
17	(	O
18	Sarns	O
19	/	O
20	3M	O
21	-	O
22	VAD	O
23	)	O
24	in	O
25	four	O
26	calves	O
27	.	O

1	Cardiac	O
2	output	O
3	(	O
4	CO	O
5	)	O
6	was	O
7	significantly	O
8	higher	O
9	(	O
10	p	O
11	less	O
12	than	O
13	0	O
14	.	O
15	0005	O
16	)	O
17	in	O
18	the	O
19	MBBF	O
20	group	O
21	.	O

1	Amino	O
2	acid	O
3	residues	O
4	147	O
5	-	O
6	167	O
7	of	O
8	the	O
9	previously	O
10	reported	O
11	sequence	O
12	are	O
13	replaced	O
14	by	O
15	new	O
16	residues	O
17	147	O
18	to	O
19	150	O
20	.	O

1	Transcriptional	O
2	activation	O
3	by	O
4	the	O
5	HIV	B
6	-	I
7	1	I
8	Tat	I
9	protein	I
10	requires	O
11	specific	O
12	residues	O
13	in	O
14	the	O
15	hexanucleotide	O
16	loop	O
17	and	O
18	trinucleotide	O
19	bulge	O
20	of	O
21	the	O
22	TAR	B
23	RNA	O
24	stem	O
25	-	O
26	loop	O
27	structure	O
28	found	O
29	in	O
30	the	O
31	5	O
32	'-	O
33	untranslated	O
34	leader	O
35	of	O
36	all	O
37	viral	O
38	transcripts	O
39	.	O

1	We	O
2	obtained	O
3	quantitative	O
4	evidence	O
5	on	O
6	the	O
7	coding	O
8	of	O
9	interaural	O
10	time	O
11	differences	O
12	(	O
13	ITDs	O
14	)	O
15	of	O
16	click	O
17	stimuli	O
18	by	O
19	40	O
20	single	O
21	neurons	O
22	in	O
23	the	O
24	auditory	O
25	cortex	O
26	of	O
27	anesthetized	O
28	albino	O
29	rats	O
30	.	O

1	These	O
2	results	O
3	strongly	O
4	suggest	O
5	that	O
6	locally	O
7	-	O
8	applied	O
9	TTC	O
10	in	O
11	combination	O
12	with	O
13	FDBA	O
14	enhances	O
15	new	O
16	bone	O
17	formation	O
18	in	O
19	experimental	O
20	alveolar	O
21	bone	O
22	defects	O
23	.	O

1	As	O
2	an	O
3	initial	O
4	step	O
5	towards	O
6	the	O
7	characterization	O
8	of	O
9	replicative	O
10	DNA	B
11	polymerases	I
12	of	I
13	trypanosomes	I
14	,	O
15	we	O
16	have	O
17	cloned	O
18	,	O
19	sequenced	O
20	and	O
21	examined	O
22	the	O
23	expression	O
24	of	O
25	the	O
26	Trypanosoma	O
27	(	O
28	Trypanozoon	O
29	)	O
30	brucei	O
31	brucei	O
32	gene	O
33	that	O
34	encodes	O
35	the	O
36	DNA	B
37	polymerase	I
38	alpha	I
39	catalytic	I
40	core	I
41	(	O
42	pol	B
43	alpha	I
44	).	O

1	In	O
2	addition	O
3	,	O
4	there	O
5	was	O
6	a	O
7	significant	O
8	increase	O
9	in	O
10	postdexamethasone	O
11	cortical	O
12	concentrations	O
13	with	O
14	age	O
15	(	O
16	p	O
17	less	O
18	than	O
19	0	O
20	.	O
21	01	O
22	;	O
23	r	O
24	=	O
25	0	O
26	.	O
27	31	O
28	).	O

1	Pulmonary	O
2	hypertension	O
3	,	O
4	with	O
5	or	O
6	without	O
7	coronary	O
8	arterial	O
9	narrowing	O
10	,	O
11	is	O
12	the	O
13	major	O
14	condition	O
15	leading	O
16	to	O
17	isolated	O
18	atrial	O
19	infarction	O
20	.	O

1	The	O
2	volume	O
3	fraction	O
4	(	O
5	Vv	O
6	)	O
7	and	O
8	number	O
9	/	O
10	mm2	O
11	(	O
12	Na	O
13	)	O
14	of	O
15	all	O
16	capillaries	O
17	(	O
18	perfused	O
19	and	O
20	nonperfused	O
21	)	O
22	in	O
23	a	O
24	given	O
25	area	O
26	of	O
27	brain	O
28	were	O
29	determined	O
30	after	O
31	staining	O
32	for	O
33	alkaline	B
34	phosphatase	I
35	.	O

1	Airway	O
2	pressure	O
3	and	O
4	air	O
5	flow	O
6	were	O
7	measured	O
8	at	O
9	the	O
10	endotracheal	O
11	tube	O
12	in	O
13	13	O
14	children	O
15	on	O
16	a	O
17	variety	O
18	of	O
19	ventilators	O
20	.	O

1	Appl	O
2	.	O

1	Issues	O
2	of	O
3	distribution	O
4	of	O
5	kinetic	O
6	energy	O
7	of	O
8	traumatizing	O
9	object	O
10	in	O
11	direct	O
12	contact	O
13	interaction	O
14	with	O
15	head	O
16	during	O
17	impact	O
18	are	O
19	discussed	O
20	from	O
21	position	O
22	of	O
23	biomechanics	O
24	.	O

1	CONCLUSION	O
2	:	O
3	Monitoring	O
4	SpO2	O
5	at	O
6	the	O
7	nasal	O
8	septum	O
9	site	O
10	is	O
11	more	O
12	reliable	O
13	than	O
14	monitoring	O
15	it	O
16	at	O
17	the	O
18	finger	O
19	site	O
20	in	O
21	hypothermic	O
22	patients	O
23	.	O

1	Diltiazem	O
2	decreased	O
3	the	O
4	total	O
5	body	O
6	clearance	O
7	from	O
8	34	O
9	.	O
10	0	O
11	+/-	O
12	8	O
13	.	O
14	0	O
15	to	O
16	28	O
17	.	O
18	6	O
19	+/-	O
20	6	O
21	.	O
22	1	O
23	mL	O
24	/	O
25	min	O
26	(	O
27	P	O
28	less	O
29	than	O
30	.	O
31	01	O
32	),	O
33	and	O
34	prolonged	O
35	the	O
36	elimination	O
37	half	O
38	-	O
39	life	O
40	from	O
41	12	O
42	.	O
43	6	O
44	+/-	O
45	3	O
46	.	O
47	0	O
48	to	O
49	14	O
50	.	O
51	3	O
52	+/-	O
53	2	O
54	.	O
55	5	O
56	hours	O
57	(	O
58	P	O
59	less	O
60	than	O
61	.	O
62	01	O
63	)	O
64	of	O
65	antipyrine	O
66	without	O
67	any	O
68	changes	O
69	in	O
70	volume	O
71	of	O
72	distribution	O
73	.	O

1	The	O
2	granules	O
3	grew	O
4	as	O
5	the	O
6	melted	O
7	material	O
8	immersed	O
9	into	O
10	the	O
11	void	O
12	space	O
13	among	O
14	the	O
15	adhered	O
16	particles	O
17	.	O

1	Hence	O
2	,	O
3	the	O
4	uPA	B
5	promoter	I
6	contains	O
7	multiple	O
8	weak	O
9	cis	O
10	-	O
11	acting	O
12	elements	O
13	distributed	O
14	over	O
15	7	O
16	.	O
17	0	O
18	kb	O
19	5	O
20	'	O
21	to	O
22	the	O
23	translation	O
24	start	O
25	site	O
26	.	O

1	Substituting	O
2	a	O
3	Ser	O
4	for	O
5	Gly69	O
6	or	O
7	a	O
8	Glu	O
9	for	O
10	Lys	O
11	71	O
12	in	O
13	the	O
14	conserved	O
15	TGEK	B
16	tetrapeptide	I
17	in	O
18	finger	O
19	II	O
20	of	O
21	TFIIIA	B
22	resulted	O
23	in	O
24	the	O
25	loss	O
26	of	O
27	DNA	O
28	binding	O
29	.	O

1	P	O
2	.	O

1	In	O
2	one	O
3	,	O
4	exploratory	O
5	behavior	O
6	(	O
7	assessed	O
8	by	O
9	hole	O
10	pokes	O
11	)	O
12	and	O
13	locomotion	O
14	were	O
15	assessed	O
16	during	O
17	a	O
18	10	O
19	-	O
20	min	O
21	test	O
22	session	O
23	.	O

1	The	O
2	model	O
3	is	O
4	able	O
5	to	O
6	anticipate	O
7	why	O
8	the	O
9	effect	O
10	of	O
11	water	O
12	fluoridation	O
13	on	O
14	caries	O
15	prevalence	O
16	is	O
17	most	O
18	pronounced	O
19	when	O
20	caries	O
21	is	O
22	diagnosed	O
23	at	O
24	cavity	O
25	level	O
26	.	O

1	12	O
2	-	O
3	O	O
4	-	O
5	Tetradecanoylphorbol	O
6	13	O
7	-	O
8	acetate	O
9	was	O
10	found	O
11	to	O
12	inhibit	O
13	rapidly	O
14	and	O
15	potently	O
16	the	O
17	expression	O
18	of	O
19	mRNAs	O
20	coding	O
21	for	O
22	the	O
23	myogenic	O
24	regulators	O
25	CMD1	B
26	and	O
27	myogenin	B
28	.	O

1	In	O
2	Xenopus	O
3	laevis	O
4	,	O
5	the	O
6	gene	O
7	encoding	O
8	the	O
9	elongation	B
10	factor	I
11	1	I
12	-	I
13	alpha	I
14	variant	I
15	EF	I
16	-	I
17	1	I
18	alpha	I
19	O	I
20	,	O
21	where	O
22	O	O
23	stands	O
24	for	O
25	oocyte	O
26	,	O
27	is	O
28	expressed	O
29	in	O
30	oocytes	O
31	and	O
32	early	O
33	embryos	O
34	.	O

1	These	O
2	introns	O
3	belong	O
4	to	O
5	the	O
6	class	O
7	of	O
8	nuclear	O
9	pre	O
10	-	O
11	mRNA	O
12	introns	O
13	and	O
14	contain	O
15	typical	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	consensus	O
22	sequences	O
23	,	O
24	as	O
25	well	O
26	as	O
27	unique	O
28	features	O
29	.	O

1	The	O
2	mRNA	O
3	identified	O
4	in	O
5	both	O
6	human	O
7	and	O
8	rat	O
9	cells	O
10	with	O
11	the	O
12	human	B
13	clathrin	I
14	clone	O
15	revealed	O
16	transcripts	O
17	of	O
18	approximately	O
19	6	O
20	.	O
21	5	O
22	kb	O
23	,	O
24	which	O
25	is	O
26	consistent	O
27	with	O
28	the	O
29	predicted	O
30	180	O
31	kDa	O
32	molecular	O
33	weight	O
34	of	O
35	the	O
36	clathrin	B
37	heavy	I
38	chain	I
39	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	almost	O
6	6	O
7	kb	O
8	of	O
9	DNA	O
10	sequence	O
11	is	O
12	presented	O
13	,	O
14	including	O
15	1251	O
16	bp	O
17	5	O
18	'	O
19	to	O
20	the	O
21	gene	O
22	,	O
23	over	O
24	4	O
25	kb	O
26	of	O
27	exon	O
28	and	O
29	exon	O
30	-	O
31	intron	O
32	junctions	O
33	,	O
34	and	O
35	583	O
36	bp	O
37	3	O
38	'	O
39	to	O
40	the	O
41	gene	O
42	.	O

1	An	O
2	8	O
3	-	O
4	h	O
5	exposure	O
6	to	O
7	10	O
8	mg	O
9	DMEA	O
10	/	O
11	m3	O
12	corresponds	O
13	to	O
14	a	O
15	postexposure	O
16	plasma	O
17	concentration	O
18	and	O
19	2	O
20	-	O
21	h	O
22	postexposure	O
23	urinary	O
24	excretion	O
25	of	O
26	4	O
27	.	O
28	9	O
29	mumol	O
30	/	O
31	l	O
32	and	O
33	75	O
34	mmol	O
35	/	O
36	mol	O
37	creatinine	O
38	,	O
39	respectively	O
40	.	O

1	Antibodies	O
2	specific	O
3	to	O
4	rE12	B
5	and	O
6	rNFIL	B
7	-	I
8	6	I
9	disrupt	O
10	nucleoprotein	O
11	complexes	O
12	with	O
13	these	O
14	DNA	O
15	-	O
16	binding	O
17	sites	O
18	,	O
19	confirming	O
20	the	O
21	interaction	O
22	of	O
23	native	O
24	in	O
25	vivo	O
26	factors	O
27	.	O

1	A	O
2	method	O
3	is	O
4	described	O
5	for	O
6	detecting	O
7	targeted	O
8	events	O
9	at	O
10	the	O
11	mu	B
12	heavy	I
13	chain	I
14	gene	I
15	which	O
16	relies	O
17	on	O
18	co	O
19	-	O
20	conversion	O
21	(	O
22	or	O
23	co	O
24	-	O
25	exchange	O
26	)	O
27	of	O
28	a	O
29	point	O
30	mutation	O
31	with	O
32	a	O
33	selectable	O
34	marker	O
35	contained	O
36	on	O
37	a	O
38	replacement	O
39	vector	O
40	.	O

1	Allergenic	O
2	activity	O
3	of	O
4	allergen	O
5	extract	O
6	Ambrosia	O
7	elatior	O
8	(	O
9	AE	O
10	)	O
11	was	O
12	tested	O
13	in	O
14	fifteen	O
15	volunteers	O
16	extremely	O
17	sensitive	O
18	to	O
19	the	O
20	allergen	O
21	.	O

1	This	O
2	study	O
3	was	O
4	aimed	O
5	at	O
6	assessing	O
7	whether	O
8	c	O
9	-	O
10	DDP	O
11	administration	O
12	immediately	O
13	before	O
14	radiotherapy	O
15	could	O
16	increase	O
17	frequency	O
18	and	O
19	duration	O
20	of	O
21	objective	O
22	responses	O
23	,	O
24	as	O
25	well	O
26	as	O
27	survival	O
28	,	O
29	in	O
30	patients	O
31	affected	O
32	with	O
33	locally	O
34	advanced	O
35	stages	O
36	of	O
37	squamous	O
38	carcinomas	O
39	of	O
40	the	O
41	head	O
42	and	O
43	neck	O
44	.	O

1	Two	O
2	potential	O
3	regulatory	O
4	sequences	O
5	for	O
6	DNA	O
7	binding	O
8	proteins	O
9	were	O
10	found	O
11	in	O
12	the	O
13	non	O
14	-	O
15	coding	O
16	5	O
17	'	O
18	region	O
19	:	O
20	a	O
21	HAP2	B
22	/	O
23	HAP3	B
24	consensus	O
25	recognition	O
26	sequence	O
27	at	O
28	nucleotide	O
29	-	O
30	154	O
31	and	O
32	a	O
33	BAF1	B
34	consensus	I
35	recognition	I
36	sequence	I
37	at	O
38	nucleotide	O
39	-	O
40	136	O
41	.	O

1	Marked	O
2	thrombocytopenia	O
3	,	O
4	depletion	O
5	of	O
6	serum	B
7	fibrinogen	I
8	and	O
9	prolonged	O
10	prothrombin	B
11	and	O
12	activated	O
13	partial	O
14	thromboplastin	B
15	time	O
16	,	O
17	were	O
18	recorded	O
19	at	O
20	5	O
21	to	O
22	10	O
23	and	O
24	30	O
25	to	O
26	40	O
27	minutes	O
28	after	O
29	intravenous	O
30	envenomation	O
31	.	O

1	We	O
2	exploit	O
3	the	O
4	properties	O
5	of	O
6	LexA	B
7	fusion	I
8	proteins	I
9	to	O
10	study	O
11	the	O
12	dimerization	O
13	and	O
14	DNA	O
15	-	O
16	contacting	O
17	domains	O
18	of	O
19	cRel	B
20	.	O

1	Plasma	O
2	lipid	O
3	and	O
4	lipoprotein	O
5	profiles	O
6	were	O
7	compared	O
8	in	O
9	elderly	O
10	female	O
11	runners	O
12	(	O
13	RU	O
14	:	O
15	n	O
16	=	O
17	15	O
18	,	O
19	aged	O
20	66	O
21	+/-	O
22	5	O
23	years	O
24	,	O
25	body	O
26	fat	O
27	20	O
28	+/-	O
29	4	O
30	%,	O
31	training	O
32	distance	O
33	35	O
34	+/-	O
35	15	O
36	km	O
37	week	O
38	-	O
39	1	O
40	,	O
41	VO2max	O
42	36	O
43	+/-	O
44	4	O
45	ml	O
46	kg	O
47	-	O
48	1	O
49	min	O
50	-	O
51	1	O
52	,	O
53	mean	O
54	+/-	O
55	SD	O
56	)	O
57	and	O
58	age	O
59	-	O
60	matched	O
61	untrained	O
62	women	O
63	(	O
64	UT	O
65	:	O
66	n	O
67	=	O
68	28	O
69	,	O
70	66	O
71	+/-	O
72	4	O
73	years	O
74	,	O
75	body	O
76	fat	O
77	26	O
78	+/-	O
79	6	O
80	%,	O
81	VO2max	O
82	26	O
83	+/-	O
84	3	O
85	ml	O
86	kg	O
87	-	O
88	1	O
89	min	O
90	-	O
91	1	O
92	).	O

1	Auditory	O
2	threshold	O
3	shifts	O
4	,	O
5	as	O
6	measured	O
7	by	O
8	the	O
9	auditory	O
10	evoked	O
11	brainstem	O
12	response	O
13	,	O
14	were	O
15	measured	O
16	at	O
17	2	O
18	,	O
19	4	O
20	,	O
21	8	O
22	,	O
23	12	O
24	,	O
25	16	O
26	,	O
27	20	O
28	and	O
29	24	O
30	kHz	O
31	.	O

1	Fundamental	O
2	and	O
3	clinical	O
4	evaluation	O
5	of	O
6	equilibrium	O
7	dialysis	O
8	--	O
9	radioimmunoassay	O
10	system	O
11	for	O
12	measurement	O
13	of	O
14	serum	O
15	free	O
16	thyroxine	O

1	We	O
2	conclude	O
3	that	O
4	TA	O
5	caused	O
6	a	O
7	specific	O
8	decrease	O
9	in	O
10	AGD	O
11	on	O
12	GD	O
13	20	O
14	that	O
15	was	O
16	largely	O
17	reversed	O
18	by	O
19	PCD	O
20	23	O
21	.	O

1	When	O
2	examined	O
3	as	O
4	adults	O
5	(	O
6	8	O
7	weeks	O
8	old	O
9	),	O
10	the	O
11	external	O
12	genitalia	O
13	of	O
14	TA	O
15	-	O
16	exposed	O
17	offspring	O
18	were	O
19	normal	O
20	.	O

1	After	O
2	PTCA	O
3	,	O
4	ejection	O
5	fraction	O
6	increased	O
7	from	O
8	54	O
9	+/-	O
10	8	O
11	%	O
12	to	O
13	59	O
14	+/-	O
15	8	O
16	%	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	05	O
24	)	O
25	and	O
26	regional	O
27	function	O
28	improved	O
29	significantly	O
30	(	O
31	maximal	O
32	standard	O
33	deviation	O
34	before	O
35	PTCA	O
36	:	O
37	2	O
38	.	O
39	8	O
40	+/-	O
41	0	O
42	.	O
43	8	O
44	;	O
45	after	O
46	PTCA	O
47	:	O
48	1	O
49	.	O
50	9	O
51	+/-	O
52	0	O
53	.	O
54	9	O
55	-	O
56	segments	O
57	below	O
58	the	O
59	first	O
60	standard	O
61	deviation	O
62	before	O
63	PTCA	O
64	:	O
65	31	O
66	+/-	O
67	16	O
68	;	O
69	after	O
70	PTCA	O
71	:	O
72	19	O
73	+/-	O
74	17	O
75	).	O

1	The	O
2	alcoholic	O
3	patient	O
4	,	O
5	his	O
6	work	O
7	and	O
8	the	O
9	subjectivity	O
10	of	O
11	the	O
12	period	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	combined	O
7	treatment	O
8	with	O
9	a	O
10	thromboxane	B
11	synthetase	I
12	inhibitor	O
13	and	O
14	a	O
15	thromboxane	B
16	receptor	I
17	antagonist	O
18	provides	O
19	a	O
20	better	O
21	protection	O
22	against	O
23	digoxin	O
24	intoxication	O
25	than	O
26	with	O
27	either	O
28	agent	O
29	alone	O
30	.	O

1	A	O
2	330	O
3	-	O
4	kb	O
5	YAC	O
6	,	O
7	A148A7	O
8	,	O
9	spanned	O
10	from	O
11	the	O
12	HLA	B
13	-	O
14	DQA1	B
15	locus	O
16	through	O
17	the	O
18	Y3	B
19	/	O
20	Ring	B
21	4	I
22	locus	O
23	and	O
24	extended	O
25	at	O
26	least	O
27	130	O
28	kb	O
29	centromeric	O
30	of	O
31	YAC	O
32	B1D12	O
33	.	O

1	Interspecific	O
2	backcross	O
3	analysis	O
4	using	O
5	progeny	O
6	derived	O
7	from	O
8	matings	O
9	of	O
10	(	O
11	C57BL	O
12	/	O
13	6J	O
14	x	O
15	Mus	O
16	spretus	O
17	)	O
18	F1	O
19	x	O
20	C57BL	O
21	/	O
22	6J	O
23	mice	O
24	indicates	O
25	that	O
26	the	O
27	thrombospondin	B
28	gene	I
29	is	O
30	tightly	O
31	linked	O
32	to	O
33	the	O
34	Fshb	B
35	,	O
36	Actcl	B
37	,	O
38	Ltk	B
39	,	O
40	and	O
41	B2M	B
42	loci	I
43	on	O
44	murine	O
45	chromosome	O
46	2	O
47	.	O

1	Adverse	O
2	foetal	O
3	outcome	O
4	in	O
5	specific	O
6	IgM	B
7	positive	O
8	Chlamydia	O
9	trachomatis	O
10	infection	O
11	in	O
12	pregnancy	O
13	.	O

1	Using	O
2	an	O
3	image	O
4	-	O
5	processing	O
6	computer	O
7	,	O
8	regional	O
9	LV	O
10	time	O
11	-	O
12	density	O
13	curves	O
14	were	O
15	constructed	O
16	for	O
17	one	O
18	cardiac	O
19	cycle	O
20	.	O

1	In	O
2	a	O
3	second	O
4	patient	O
5	the	O
6	VT	O
7	became	O
8	nonsustained	O
9	.	O

1	If	O
2	delay	O
3	has	O
4	occurred	O
5	between	O
6	centrifugation	O
7	and	O
8	the	O
9	measurement	O
10	,	O
11	causing	O
12	substantial	O
13	loss	O
14	of	O
15	CO2	O
16	,	O
17	equilibration	O
18	of	O
19	the	O
20	sample	O
21	with	O
22	a	O
23	gas	O
24	mixture	O
25	corresponding	O
26	to	O
27	PCO2	O
28	=	O
29	5	O
30	.	O
31	3	O
32	kPa	O
33	prior	O
34	to	O
35	the	O
36	measurement	O
37	is	O
38	recommended	O
39	.	O

1	The	O
2	possible	O
3	mechanisms	O
4	underlying	O
5	differences	O
6	in	O
7	post	O
8	-	O
9	tetanic	O
10	effects	O
11	from	O
12	muscle	O
13	and	O
14	cutaneous	O
15	afferents	O
16	in	O
17	adults	O
18	and	O
19	neonates	O
20	are	O
21	discussed	O
22	.	O

1	We	O
2	examined	O
3	behavioral	O
4	alterations	O
5	in	O
6	the	O
7	brown	O
8	cockroach	O
9	,	O
10	Periplaneta	O
11	brunnea	O
12	,	O
13	infected	O
14	with	O
15	the	O
16	acanthocephalan	O
17	,	O
18	Moniliformis	O
19	moniliformis	O
20	.	O

1	First	O
2	,	O
3	the	O
4	finding	O
5	of	O
6	a	O
7	monomeric	O
8	Alu	B
9	family	O
10	repeat	O
11	at	O
12	the	O
13	junction	O
14	between	O
15	nonhomology	O
16	block	O
17	I	O
18	and	O
19	homology	O
20	block	O
21	Y	O
22	of	O
23	the	O
24	alpha	B
25	2	I
26	gene	I
27	-	I
28	containing	I
29	unit	I
30	in	I
31	rhesus	I
32	macaque	I
33	suggests	O
34	that	O
35	the	O
36	dimeric	O
37	Alu	B
38	family	O
39	repeat	O
40	,	O
41	Alu	B
42	3	I
43	,	O
44	at	O
45	the	O
46	orthologous	O
47	position	O
48	in	O
49	human	O
50	was	O
51	generated	O
52	by	O
53	insertion	O
54	of	O
55	a	O
56	monomeric	O
57	Alu	B
58	family	O
59	repeat	O
60	into	O
61	the	O
62	3	O
63	'	O
64	end	O
65	of	O
66	another	O
67	preexisting	O
68	Alu	B
69	family	O
70	repeat	O
71	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	repressor	O
6	locus	O
7	,	O
8	c	O
9	,	O
10	of	O
11	the	O
12	Streptomyces	O
13	temperate	O
14	phage	O
15	,	O
16	phi	O
17	C31	O
18	,	O
19	was	O
20	shown	O
21	previously	O
22	to	O
23	contain	O
24	an	O
25	open	O
26	reading	O
27	frame	O
28	encoding	O
29	a	O
30	74	O
31	kDa	O
32	protein	O
33	.	O

1	The	O
2	EPO	B
3	levels	O
4	were	O
5	distinctly	O
6	increased	O
7	before	O
8	transfusion	O
9	;	O
10	they	O
11	did	O
12	not	O
13	significantly	O
14	change	O
15	just	O
16	after	O
17	transfusion	O
18	,	O
19	but	O
20	subsequently	O
21	decreased	O
22	.	O

1	This	O
2	differential	O
3	sensitivity	O
4	to	O
5	DB	O
6	,	O
7	as	O
8	measured	O
9	by	O
10	a	O
11	lower	O
12	concentration	O
13	of	O
14	DB	O
15	which	O
16	caused	O
17	loss	O
18	of	O
19	righting	O
20	in	O
21	LS	O
22	,	O
23	was	O
24	accompanied	O
25	by	O
26	an	O
27	equal	O
28	rate	O
29	of	O
30	water	O
31	-	O
32	soluble	O
33	barbiturate	O
34	brain	O
35	distribution	O
36	and	O
37	elimination	O
38	in	O
39	the	O
40	two	O
41	lines	O
42	.	O

1	The	O
2	existence	O
3	of	O
4	threshold	O
5	concentrations	O
6	,	O
7	above	O
8	which	O
9	certain	O
10	phenomena	O
11	may	O
12	occur	O
13	,	O
14	strengthens	O
15	the	O
16	role	O
17	of	O
18	sentinels	O
19	.	O

1	However	O
2	,	O
3	it	O
4	was	O
5	synthesized	O
6	at	O
7	both	O
8	temperatures	O
9	after	O
10	addition	O
11	of	O
12	A23187	O
13	.	O

1	Felodipine	O
2	did	O
3	not	O
4	alter	O
5	the	O
6	baseline	O
7	FEV1	O
8	,	O
9	but	O
10	showed	O
11	a	O
12	small	O
13	significant	O
14	inhibitory	O
15	effect	O
16	upon	O
17	histamine	O
18	and	O
19	AMP	O
20	induced	O
21	bronchoconstriction	O
22	.	O

1	Ten	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	with	O
7	progressive	O
8	disease	O
9	had	O
10	mast	O
11	cells	O
12	greater	O
13	than	O
14	or	O
15	equal	O
16	to	O
17	0	O
18	.	O
19	5	O
20	%,	O
21	hyaluronan	O
22	greater	O
23	than	O
24	or	O
25	equal	O
26	to	O
27	50	O
28	micrograms	O
29	.	O
30	l	O
31	-	O
32	1	O
33	and	O
34	fibronectin	B
35	greater	O
36	than	O
37	or	O
38	equal	O
39	to	O
40	350	O
41	micrograms	O
42	.	O
43	l	O
44	-	O
45	1	O
46	compared	O
47	to	O
48	eight	O
49	out	O
50	of	O
51	41	O
52	patients	O
53	with	O
54	stable	O
55	or	O
56	regressive	O
57	disease	O
58	.(	O
59	ABSTRACT	O
60	TRUNCATED	O
61	AT	O
62	250	O
63	WORDS	O
64	)	O

1	Our	O
2	mapping	O
3	results	O
4	did	O
5	not	O
6	suggest	O
7	involvement	O
8	of	O
9	this	O
10	gene	O
11	in	O
12	previously	O
13	mapped	O
14	genetic	O
15	disorders	O
16	or	O
17	in	O
18	known	O
19	neoplasia	O
20	-	O
21	associated	O
22	translocation	O
23	breakpoints	O
24	.	O

1	Relatively	O
2	little	O
3	is	O
4	known	O
5	regarding	O
6	the	O
7	role	O
8	of	O
9	5	B
10	-	I
11	HT2	I
12	receptor	I
13	activity	O
14	in	O
15	male	O
16	rat	O
17	sexual	O
18	behavior	O
19	.	O

1	These	O
2	changes	O
3	weren	O
4	'	O
5	t	O
6	so	O
7	significant	O
8	in	O
9	the	O
10	group	O
11	of	O
12	obese	O
13	children	O
14	who	O
15	didn	O
16	'	O
17	t	O
18	lose	O
19	weight	O
20	.	O

1	Arsenic	O
2	contents	O
3	in	O
4	native	O
5	copper	O

1	In	O
2	ten	O
3	other	O
4	experiments	O
5	(	O
6	5	O
7	experimental	O
8	and	O
9	5	O
10	control	O
11	rats	O
12	)	O
13	99mTc	O
14	-	O
15	sulfur	O
16	colloid	O
17	was	O
18	injected	O
19	intravenously	O
20	.	O

1	Magnetotherapy	O
2	of	O
3	hepatitis	O
4	A	O
5	and	O
6	B	O
7	in	O
8	children	O

1	These	O
2	results	O
3	were	O
4	superior	O
5	to	O
6	those	O
7	in	O
8	24	O
9	patients	O
10	with	O
11	conventional	O
12	end	O
13	-	O
14	to	O
15	-	O
16	end	O
17	sutures	O
18	on	O
19	clinical	O
20	testing	O
21	.	O

1	Mutational	O
2	analysis	O
3	supports	O
4	a	O
5	role	O
6	for	O
7	multiple	O
8	structural	O
9	features	O
10	in	O
11	the	O
12	C	O
13	-	O
14	terminal	O
15	secretion	O
16	signal	O
17	of	O
18	Escherichia	B
19	coli	I
20	haemolysin	I
21	.	O

1	Among	O
2	blood	O
3	donors	O
4	in	O
5	the	O
6	Republic	O
7	of	O
8	Serbia	O
9	,	O
10	regardless	O
11	the	O
12	number	O
13	of	O
14	blood	O
15	donations	O
16	,	O
17	the	O
18	percentage	O
19	of	O
20	female	O
21	donors	O
22	is	O
23	significantly	O
24	lower	O
25	compared	O
26	to	O
27	the	O
28	percentage	O
29	of	O
30	male	O
31	blood	O
32	donors	O
33	.	O

1	Extramedullary	O
2	relapse	O
3	in	O
4	childhood	O
5	leukemia	O
6	.	O

1	Mycoplasma	O
2	pneumoniae	O
3	was	O
4	isolated	O
5	from	O
6	the	O
7	pleural	O
8	fluid	O
9	of	O
10	this	O
11	patient	O
12	.	O

1	RU486	O
2	and	O
3	ONO	O
4	802	O
5	in	O
6	combination	O
7	have	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	effective	O
13	in	O
14	early	O
15	termination	O
16	of	O
17	pregnancy	O
18	.	O

1	The	O
2	presence	O
3	of	O
4	local	O
5	abnormalities	O
6	in	O
7	both	O
8	patients	O
9	can	O
10	support	O
11	the	O
12	hypothesis	O
13	that	O
14	the	O
15	cortex	O
16	,	O
17	especially	O
18	of	O
19	the	O
20	temporal	O
21	anterior	O
22	lobe	O
23	,	O
24	is	O
25	involved	O
26	in	O
27	the	O
28	origin	O
29	of	O
30	the	O
31	laughing	O
32	seizures	O
33	.	O

1	In	O
2	line	O
3	with	O
4	the	O
5	small	O
6	values	O
7	for	O
8	QS	O
9	/	O
10	QC	O
11	,	O
12	our	O
13	results	O
14	further	O
15	indicate	O
16	that	O
17	even	O
18	large	O
19	,	O
20	well	O
21	-	O
22	perfused	O
23	,	O
24	occluded	O
25	air	O
26	spaces	O
27	in	O
28	the	O
29	lung	O
30	will	O
31	hardly	O
32	affect	O
33	the	O
34	recovered	O
35	ventilation	O
36	/	O
37	perfusion	O
38	distribution	O
39	obtained	O
40	from	O
41	inert	O
42	gas	O
43	data	O
44	when	O
45	CDCSF6	O
46	exceeds	O
47	0	O
48	.	O
49	1	O
50	ml	O
51	.	O
52	min	O
53	-	O
54	1	O
55	.	O
56	mmHg	O
57	-	O
58	1	O
59	.	O

1	Many	O
2	cells	O
3	were	O
4	negative	O
5	for	O
6	endothelial	O
7	-	O
8	cell	O
9	markers	O
10	,	O
11	and	O
12	they	O
13	reacted	O
14	with	O
15	a	O
16	monoclonal	O
17	antibody	O
18	against	O
19	muscle	O
20	actin	B
21	.	O

1	CT	O
2	abnormalities	O
3	noted	O
4	in	O
5	term	O
6	babies	O
7	included	O
8	hemorrhage	O
9	(	O
10	subarachnoid	O
11	5	O
12	.	O
13	8	O
14	%,	O
15	intracerebral	O
16	11	O
17	.	O
18	6	O
19	%),	O
20	hypodensity	O
21	(	O
22	mild	O
23	23	O
24	.	O
25	2	O
26	%,	O
27	moderate	O
28	11	O
29	.	O
30	6	O
31	%	O
32	severe	O
33	5	O
34	.	O
35	8	O
36	%);	O
37	hypodensity	O
38	with	O
39	hemorrhage	O
40	5	O
41	.	O
42	8	O
43	%	O
44	and	O
45	cerebral	O
46	atrophy	O
47	5	O
48	.	O
49	8	O
50	%.	O

1	The	O
2	effects	O
3	of	O
4	contrast	O
5	media	O
6	on	O
7	coagulation	B
8	factor	I
9	XII	I
10	.	O

1	Pigs	O
2	were	O
3	switched	O
4	from	O
5	the	O
6	growing	O
7	to	O
8	the	O
9	finishing	O
10	diet	O
11	at	O
12	57	O
13	and	O
14	61	O
15	kg	O
16	in	O
17	Exp	O
18	.	O

1	In	O
2	sixteen	O
3	patients	O
4	with	O
5	moderate	O
6	essential	O
7	hypertension	O
8	the	O
9	effects	O
10	of	O
11	10	O
12	-	O
13	day	O
14	nifedipine	O
15	treatment	O
16	on	O
17	serum	O
18	uric	O
19	acid	O
20	and	O
21	renal	O
22	excretion	O
23	of	O
24	uric	O
25	acid	O
26	were	O
27	evaluated	O
28	.	O

1	TPTA	O
2	produced	O
3	brain	O
4	congestion	O
5	,	O
6	and	O
7	hepatic	O
8	and	O
9	pulmonary	O
10	petechial	O
11	and	O
12	generalized	O
13	hemorrhages	O
14	.	O

1	Examples	O
2	are	O
3	using	O
4	more	O
5	subjects	O
6	or	O
7	an	O
8	improved	O
9	research	O
10	design	O
11	,	O
12	developing	O
13	consensus	O
14	statements	O
15	or	O
16	using	O
17	meta	O
18	-	O
19	analysis	O
20	.	O

1	A	O
2	two	O
3	phase	O
4	slug	O
5	flow	O
6	tubular	O
7	heat	O
8	exchanger	O
9	was	O
10	used	O
11	for	O
12	the	O
13	thermal	O
14	inactivation	O
15	of	O
16	Listeria	O
17	monocytogenes	O
18	in	O
19	natural	O
20	infected	O
21	milk	O
22	from	O
23	seven	O
24	cows	O
25	.	O

1	So	O
2	far	O
3	15	O
4	children	O
5	have	O
6	been	O
7	studied	O
8	.	O

1	Regional	O
2	cerebral	O
3	blood	O
4	flow	O
5	(	O
6	rCBF	O
7	)	O
8	measurements	O
9	and	O
10	psychiatric	O
11	ratings	O
12	were	O
13	performed	O
14	on	O
15	seven	O
16	schizophrenic	O
17	patients	O
18	(	O
19	mean	O
20	age	O
21	=	O
22	41	O
23	.	O
24	4	O
25	years	O
26	)	O
27	who	O
28	had	O
29	been	O
30	examined	O
31	18	O
32	years	O
33	previously	O
34	in	O
35	a	O
36	study	O
37	that	O
38	used	O
39	similar	O
40	psychiatric	O
41	ratings	O
42	and	O
43	a	O
44	comparable	O
45	rCBF	O
46	technique	O
47	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	identified	O
8	a	O
9	strong	O
10	positive	O
11	cis	O
12	-	O
13	regulatory	O
14	element	O
15	at	O
16	-	O
17	70	O
18	bp	O
19	to	O
20	-	O
21	75	O
22	bp	O
23	in	O
24	the	O
25	LpS1	B
26	beta	I
27	promoter	I
28	with	O
29	the	O
30	sequence	O
31	(	O
32	G	O
33	)	O
34	6	O
35	and	O
36	a	O
37	similar	O
38	,	O
39	more	O
40	distal	O
41	cis	O
42	-	O
43	element	O
44	at	O
45	-	O
46	721	O
47	bp	O
48	to	O
49	-	O
50	726	O
51	bp	O
52	.	O

1	The	O
2	present	O
3	study	O
4	reports	O
5	visual	O
6	evoked	O
7	potential	O
8	responses	O
9	to	O
10	pattern	O
11	reversal	O
12	(	O
13	VEP	O
14	-	O
15	P	O
16	)	O
17	in	O
18	ten	O
19	third	O
20	trimester	O
21	pregnant	O
22	women	O
23	and	O
24	changes	O
25	in	O
26	latency	O
27	of	O
28	NPN	O
29	complex	O
30	when	O
31	compared	O
32	with	O
33	these	O
34	responses	O
35	in	O
36	the	O
37	non	O
38	pregnant	O
39	state	O
40	.	O

1	No	O
2	case	O
3	of	O
4	SMF	O
5	demonstrated	O
6	expansive	O
7	tumorous	O
8	growth	O
9	.	O

1	Different	O
2	doses	O
3	of	O
4	15	O
5	-	O
6	methyl	O
7	-	O
8	PGF2	O
9	alpha	O
10	(	O
11	0	O
12	.	O
13	125	O
14	-	O
15	10	O
16	mg	O
17	)	O
18	were	O
19	used	O
20	to	O
21	induce	O
22	luteolysis	O
23	and	O
24	oestrus	O
25	in	O
26	7	O
27	heifers	O
28	with	O
29	28	O
30	treatments	O
31	on	O
32	day	O
33	8	O
34	-	O
35	12	O
36	of	O
37	the	O
38	oestrous	O
39	cycle	O
40	.	O

1	Review	O
2	of	O
3	the	O
4	literature	O
5	and	O
6	report	O
7	of	O
8	a	O
9	case	O
10	of	O
11	a	O
12	dermoid	O
13	cyst	O
14	.	O

1	Resolution	O
2	of	O
3	thermographic	O
4	asymmetry	O
5	and	O
6	/	O
7	or	O
8	decrease	O
9	in	O
10	Delta	O
11	T	O
12	was	O
13	demonstrated	O
14	in	O
15	approximately	O
16	81	O
17	%	O
18	of	O
19	the	O
20	post	O
21	-	O
22	treatment	O
23	population	O
24	.	O

1	In	O
2	all	O
3	instances	O
4	the	O
5	apparent	O
6	alcohol	O
7	responses	O
8	were	O
9	very	O
10	small	O
11	and	O
12	never	O
13	exceeded	O
14	a	O
15	reading	O
16	of	O
17	1	O
18	microgram	O
19	/	O
20	100ml	O
21	for	O
22	breath	O
23	samples	O
24	more	O
25	than	O
26	10min	O
27	post	O
28	-	O
29	exposure	O
30	.	O

1	Maize	B
2	rbcS	I
3	promoter	I
4	activity	O
5	depends	O
6	on	O
7	sequence	O
8	elements	O
9	not	O
10	found	O
11	in	O
12	dicot	B
13	rbcS	I
14	promoters	I
15	.	O

1	Measurements	O
2	were	O
3	done	O
4	with	O
5	a	O
6	commercial	O
7	haematofluorometer	O
8	Buchler	O
9	ZF	O
10	which	O
11	was	O
12	calibrated	O
13	to	O
14	the	O
15	average	O
16	haematocrit	O
17	value	O
18	of	O
19	0	O
20	.	O
21	42	O
22	.	O

1	The	O
2	relatively	O
3	scanty	O
4	number	O
5	of	O
6	examples	O
7	,	O
8	which	O
9	could	O
10	be	O
11	justified	O
12	by	O
13	the	O
14	variety	O
15	and	O
16	complexity	O
17	of	O
18	combined	O
19	exposure	O
20	,	O
21	allows	O
22	to	O
23	conclude	O
24	that	O
25	life	O
26	-	O
27	style	O
28	factors	O
29	have	O
30	considerable	O
31	influence	O
32	on	O
33	interindividual	O
34	differences	O
35	in	O
36	susceptibility	O
37	to	O
38	xenobiotics	O
39	toxicity	O
40	.	O

1	The	O
2	12S	B
3	E1A	I
4	product	I
5	does	O
6	not	O
7	activate	O
8	a	O
9	TRE	O
10	sequence	O
11	,	O
12	but	O
13	cotransfection	O
14	with	O
15	c	B
16	-	I
17	jun	I
18	circumvents	O
19	this	O
20	lack	O
21	of	O
22	stimulation	O
23	.	O

1	After	O
2	treatment	O
3	with	O
4	tunicamycin	O
5	,	O
6	the	O
7	transfectants	O
8	secreted	O
9	unglycosylated	O
10	18	O
11	-	O
12	kDa	O
13	polypeptides	O
14	which	O
15	could	O
16	also	O
17	bind	O
18	IgE	B
19	.	O

1	PAS1	B
2	,	O
3	a	O
4	yeast	O
5	gene	O
6	required	O
7	for	O
8	peroxisome	O
9	biogenesis	O
10	,	O
11	encodes	O
12	a	O
13	member	O
14	of	O
15	a	O
16	novel	O
17	family	O
18	of	O
19	putative	O
20	ATPases	B
21	.	O

1	The	O
2	gene	O
3	is	O
4	1	O
5	,	O
6	139	O
7	base	O
8	pairs	O
9	(	O
10	bp	O
11	)	O
12	long	O
13	,	O
14	and	O
15	,	O
16	like	O
17	other	O
18	members	O
19	of	O
20	the	O
21	SIG	B
22	family	I
23	,	O
24	the	O
25	beta	B
26	TG	I
27	gene	I
28	is	O
29	divided	O
30	into	O
31	3	O
32	exons	O
33	.	O

1	The	O
2	pp90rsk	B
3	-	I
4	protein	I
5	kinase	I
6	activity	O
7	(	O
8	referred	O
9	to	O
10	as	O
11	rsk	B
12	-	I
13	kinase	I
14	)	O
15	is	O
16	also	O
17	not	O
18	related	O
19	to	O
20	cofactor	O
21	-	O
22	dependent	O
23	signal	O
24	transducing	O
25	protein	O
26	kinases	O
27	such	O
28	as	O
29	the	O
30	cyclic	B
31	AMP	I
32	-	I
33	dependent	I
34	protein	I
35	kinases	I
36	,	O
37	members	O
38	of	O
39	the	O
40	protein	B
41	kinase	I
42	C	I
43	family	I
44	,	O
45	or	O
46	other	O
47	Ca2	B
48	(+)-	I
49	dependent	I
50	protein	I
51	kinases	I
52	.	O

1	Human	B
2	GATA	I
3	-	I
4	3	I
5	:	O
6	a	O
7	lineage	O
8	-	O
9	restricted	O
10	transcription	O
11	factor	O
12	that	O
13	regulates	O
14	the	O
15	expression	O
16	of	O
17	the	O
18	T	B
19	cell	I
20	receptor	I
21	alpha	I
22	gene	I
23	.	O

1	Like	O
2	many	O
3	eukaryotic	O
4	transcription	O
5	factors	O
6	,	O
7	these	O
8	proteins	O
9	bind	O
10	to	O
11	DNA	O
12	as	O
13	dimers	O
14	.	O

1	Furthermore	O
2	,	O
3	the	O
4	UvrA	B
5	protein	I
6	interacts	O
7	with	O
8	the	O
9	UvrB	B
10	protein	I
11	to	O
12	modulate	O
13	its	O
14	activities	O
15	,	O
16	both	O
17	in	O
18	solution	O
19	and	O
20	in	O
21	association	O
22	with	O
23	DNA	O
24	,	O
25	where	O
26	the	O
27	UvrAB	B
28	complex	I
29	possesses	O
30	a	O
31	helicase	B
32	activity	O
33	.	O

1	The	O
2	ED30	O
3	values	O
4	were	O
5	2	O
6	.	O
7	4	O
8	and	O
9	2	O
10	.	O
11	2	O
12	mg	O
13	/	O
14	kg	O
15	and	O
16	similar	O
17	to	O
18	the	O
19	respective	O
20	values	O
21	of	O
22	nifedipine	O
23	(	O
24	ED	O
25	30	O
26	:	O
27	2	O
28	.	O
29	4	O
30	,	O
31	2	O
32	.	O
33	1	O
34	mg	O
35	/	O
36	kg	O
37	).	O

1	Southwestern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	that	O
6	this	O
7	phosphoprotein	O
8	can	O
9	bind	O
10	the	O
11	kappa	B
12	B	I
13	element	I
14	directly	O
15	and	O
16	specifically	O
17	.	O

1	Thus	O
2	,	O
3	the	O
4	positive	O
5	effect	O
6	of	O
7	NS1	B
8	on	O
9	the	O
10	steady	O
11	-	O
12	state	O
13	levels	O
14	of	O
15	P4	B
16	transcripts	I
17	depends	O
18	on	O
19	the	O
20	amplification	O
21	of	O
22	gene	O
23	copy	O
24	number	O
25	and	O
26	the	O
27	integrity	O
28	of	O
29	the	O
30	terminal	O
31	repeats	O
32	.	O

1	The	O
2	minus	O
3	-	O
4	end	O
5	-	O
6	directed	O
7	microtubule	O
8	motors	O
9	,	O
10	the	O
11	dyneins	B
12	,	O
13	may	O
14	also	O
15	constitute	O
16	a	O
17	superfamily	O
18	of	O
19	force	O
20	-	O
21	generating	O
22	proteins	O
23	with	O
24	distinct	O
25	attachment	O
26	domains	O
27	.	O

1	It	O
2	is	O
3	transparent	O
4	,	O
5	cheap	O
6	to	O
7	be	O
8	made	O
9	,	O
10	and	O
11	easy	O
12	to	O
13	empty	O
14	and	O
15	was	O
16	tested	O
17	in	O
18	118	O
19	animals	O
20	for	O
21	two	O
22	and	O
23	four	O
24	weeks	O
25	.	O

1	The	O
2	incompatibility	O
3	group	O
4	W	O
5	plasmid	O
6	pSa	O
7	suppresses	O
8	Agrobacterium	O
9	tumefaciens	O
10	oncogenicity	O
11	(	O
12	J	O
13	.	O

1	Potential	O
2	translational	O
3	start	O
4	signals	O
5	are	O
6	upstream	O
7	of	O
8	ORF1	O
9	and	O
10	ORF2	O
11	.	O

1	Imaging	O
2	of	O
3	D2	B
4	dopamine	I
5	receptor	I

1	The	O
2	Thr161Val	O
3	mutation	O
4	causes	O
5	a	O
6	lethal	O
7	phenotype	O
8	in	O
9	the	O
10	fission	O
11	yeast	O
12	Schizosaccharomyces	O
13	pombe	O
14	,	O
15	while	O
16	replacement	O
17	of	O
18	Thr161	O
19	with	O
20	glutamic	O
21	acid	O
22	,	O
23	potentially	O
24	mimicking	O
25	phosphorylation	O
26	,	O
27	causes	O
28	uncoordination	O
29	of	O
30	mitosis	O
31	and	O
32	multiple	O
33	cytokinesis	O
34	.	O

1	The	O
2	abundance	O
3	of	O
4	transcripts	O
5	from	O
6	several	O
7	unrelated	O
8	genes	O
9	is	O
10	decreased	O
11	in	O
12	cdc68	B
13	-	I
14	1	I
15	mutant	I
16	cells	O
17	after	O
18	transfer	O
19	to	O
20	the	O
21	restrictive	O
22	temperature	O
23	,	O
24	while	O
25	at	O
26	least	O
27	one	O
28	transcript	O
29	,	O
30	from	O
31	the	O
32	HSP82	B
33	gene	I
34	,	O
35	persists	O
36	in	O
37	an	O
38	aberrant	O
39	fashion	O
40	.	O

1	Deregulation	O
2	of	O
3	their	O
4	expression	O
5	may	O
6	contribute	O
7	to	O
8	malignant	O
9	transformation	O
10	associated	O
11	with	O
12	HTLV	O
13	-	O
14	1	O
15	infection	O
16	.	O

1	The	O
2	murine	B
3	Mov	I
4	-	I
5	34	I
6	gene	I
7	:	O
8	full	O
9	-	O
10	length	O
11	cDNA	O
12	and	O
13	genomic	O
14	organization	O
15	.	O

1	CREB	B
2	was	O
3	identified	O
4	as	O
5	one	O
6	of	O
7	the	O
8	protein	O
9	components	O
10	in	O
11	several	O
12	of	O
13	the	O
14	gel	O
15	shift	O
16	complexes	O
17	formed	O
18	with	O
19	the	O
20	variant	O
21	CRE	O
22	.	O

1	The	O
2	spectrum	O
3	of	O
4	histologically	O
5	diagnosed	O
6	malignant	O
7	neoplasms	O
8	in	O
9	Sabah	O
10	,	O
11	1983	O
12	-	O
13	1988	O
14	.	O

1	When	O
2	transfected	O
3	into	O
4	Drosophila	O
5	SL	O
6	-	O
7	2	O
8	cells	O
9	,	O
10	pCAT	O
11	plasmid	O
12	containing	O
13	2	O
14	,	O
15	090	O
16	bp	O
17	of	O
18	5	O
19	'-	O
20	flanking	O
21	region	O
22	shows	O
23	a	O
24	3	O
25	.	O
26	0	O
27	-	O
28	to	O
29	3	O
30	.	O
31	5	O
32	-	O
33	fold	O
34	increase	O
35	in	O
36	chloramphenicol	B
37	acetyltransferase	I
38	activity	O
39	after	O
40	induction	O
41	with	O
42	retinoic	O
43	acid	O
44	and	O
45	/	O
46	or	O
47	8	O
48	-	O
49	bromo	O
50	-	O
51	cAMP	O
52	.	O

1	Two	O
2	alternatively	O
3	spliced	O
4	5	O
5	'	O
6	UTRs	O
7	,	O
8	designated	O
9	type	O
10	I	O
11	and	O
12	type	O
13	II	O
14	,	O
15	of	O
16	222	O
17	and	O
18	115	O
19	bp	O
20	,	O
21	respectively	O
22	,	O
23	were	O
24	found	O
25	associated	O
26	with	O
27	PFP	B
28	.	O

1	The	O
2	N	O
3	-	O
4	terminus	O
5	of	O
6	another	O
7	open	O
8	reading	O
9	frame	O
10	was	O
11	found	O
12	3	O
13	'	O
14	from	O
15	nifA	B
16	and	O
17	tentatively	O
18	identified	O
19	as	O
20	nifB	B
21	by	O
22	amino	O
23	acid	O
24	sequence	O
25	comparison	O
26	.	O

1	The	O
2	RNA	O
3	genome	O
4	of	O
5	rabbit	O
6	hemorrhagic	O
7	disease	O
8	virus	O
9	(	O
10	RHDV	O
11	)	O
12	was	O
13	molecularly	O
14	cloned	O
15	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	developed	O
6	a	O
7	system	O
8	to	O
9	study	O
10	nuclear	O
11	targeting	O
12	in	O
13	plants	O
14	and	O
15	have	O
16	established	O
17	that	O
18	the	O
19	nuclear	O
20	transport	O
21	machinery	O
22	is	O
23	similar	O
24	in	O
25	monocots	O
26	and	O
27	dicots	O
28	.	O

1	A	O
2	novel	O
3	cDNA	O
4	clone	O
5	termed	O
6	R2	O
7	was	O
8	isolated	O
9	by	O
10	subtractive	O
11	hybridization	O
12	of	O
13	a	O
14	cDNA	O
15	library	O
16	of	O
17	phytohemagglutinin	B
18	(	O
19	PHA	B
20	)/	O
21	phorbol	O
22	myristate	O
23	acetate	O
24	-	O
25	stimulated	O
26	Jurkat	O
27	cells	O
28	and	O
29	by	O
30	rescreening	O
31	a	O
32	cDNA	O
33	library	O
34	of	O
35	PHA	O
36	-	O
37	stimulated	O
38	peripheral	O
39	blood	O
40	lymphocytes	O
41	.	O

1	In	O
2	conclusion	O
3	,	O
4	we	O
5	observed	O
6	a	O
7	great	O
8	regeneration	O
9	ability	O
10	following	O
11	mechanical	O
12	injury	O
13	in	O
14	the	O
15	nasal	O
16	mucosa	O
17	.	O

1	There	O
2	occurred	O
3	a	O
4	linear	O
5	relationship	O
6	between	O
7	the	O
8	drop	O
9	in	O
10	glucose	B
11	-	I
12	6	I
13	-	I
14	phosphatase	I
15	dehydrogenase	I
16	activity	O
17	and	O
18	in	O
19	vitamin	O
20	E	O
21	level	O
22	,	O
23	on	O
24	one	O
25	hand	O
26	,	O
27	and	O
28	the	O
29	duration	O
30	of	O
31	poisoning	O
32	with	O
33	sodium	O
34	nitrite	O
35	.	O

1	A	O
2	vector	O
3	containing	O
4	a	O
5	transcriptionally	O
6	inactive	O
7	neomycin	B
8	phosphotransferase	I
9	II	I
10	gene	I
11	was	O
12	used	O
13	to	O
14	select	O
15	promoter	O
16	sequences	O
17	from	O
18	a	O
19	pool	O
20	of	O
21	random	O
22	genomic	O
23	DNA	O
24	fragments	O
25	.	O

1	Chagas	O
2	'	O
3	disease	O
4	,	O
5	visceral	O
6	leishmaniasis	O
7	,	O
8	anti	B
9	-	I
10	nuclear	I
11	factor	I
12	,	O
13	schistosomiasis	O
14	,	O
15	rheumatoid	B
16	factor	I
17	and	O
18	normal	O
19	controls	O
20	.	O

1	Previous	O
2	analysis	O
3	of	O
4	the	O
5	98	O
6	-	O
7	bp	O
8	sequence	O
9	has	O
10	delineated	O
11	several	O
12	protein	O
13	-	O
14	binding	O
15	domains	O
16	that	O
17	are	O
18	recognized	O
19	by	O
20	nuclear	O
21	factors	O
22	present	O
23	in	O
24	human	O
25	brain	O
26	cells	O
27	.	O

1	The	O
2	second	O
3	transcriptional	O
4	unit	O
5	,	O
6	designated	O
7	UL26	B
8	.	I
9	5	I
10	,	O
11	predicted	O
12	to	O
13	specify	O
14	a	O
15	protein	O
16	of	O
17	329	O
18	amino	O
19	acids	O
20	,	O
21	encodes	O
22	the	O
23	family	B
24	35	I
25	proteins	I
26	;	O
27	it	O
28	is	O
29	transcribed	O
30	by	O
31	an	O
32	mRNA	O
33	which	O
34	initiates	O
35	at	O
36	approximately	O
37	nucleotide	O
38	+	O
39	1000	O
40	of	O
41	the	O
42	UL26	B
43	transcription	O
44	initiation	O
45	site	O
46	and	O
47	is	O
48	translated	O
49	from	O
50	the	O
51	methionine	O
52	initiation	O
53	codon	O
54	located	O
55	at	O
56	position	O
57	+	O
58	1099	O
59	of	O
60	the	O
61	UL26	B
62	transcriptional	I
63	unit	I
64	.	O

1	The	O
2	adeno	B
3	-	I
4	associated	I
5	virus	I
6	(	I
7	AAV	I
8	)	I
9	rep	I
10	gene	I
11	encodes	O
12	four	O
13	proteins	O
14	(	O
15	Rep78	B
16	,	O
17	Rep68	B
18	,	O
19	Rep52	B
20	,	O
21	and	O
22	Rep40	B
23	)	O
24	required	O
25	for	O
26	AAV	O
27	DNA	O
28	replication	O
29	and	O
30	AAV	O
31	gene	O
32	regulation	O
33	.	O

1	A	O
2	larger	O
3	region	O
4	upstream	O
5	of	O
6	human	B
7	CMV	I
8	dbp	I
9	also	O
10	mediated	O
11	replication	O
12	in	O
13	transient	O
14	assays	O
15	.	O

1	It	O
2	also	O
3	contains	O
4	a	O
5	picornaviral	B
6	3C	I
7	-	I
8	like	I
9	protease	I
10	domain	I
11	and	O
12	two	O
13	papain	B
14	-	I
15	like	I
16	protease	I
17	domains	I
18	.	O

1	However	O
2	,	O
3	the	O
4	relative	O
5	positions	O
6	of	O
7	the	O
8	VV	O
9	genes	O
10	(	O
11	genus	O
12	Orthopoxvirus	O
13	)	O
14	are	O
15	different	O
16	than	O
17	those	O
18	of	O
19	the	O
20	corresponding	O
21	ORFs	O
22	in	O
23	SFV	O
24	(	O
25	genus	O
26	Leporipoxvirus	O
27	),	O
28	indicating	O
29	complex	O
30	rearrangements	O
31	of	O
32	DNA	O
33	in	O
34	the	O
35	genome	O
36	of	O
37	one	O
38	or	O
39	both	O
40	of	O
41	these	O
42	viruses	O
43	subsequent	O
44	to	O
45	their	O
46	divergence	O
47	from	O
48	a	O
49	common	O
50	ancestor	O
51	.	O

1	This	O
2	result	O
3	suggests	O
4	that	O
5	phosphorylation	O
6	of	O
7	Thr	O
8	14	O
9	and	O
10	/	O
11	or	O
12	Tyr	O
13	15	O
14	inhibits	O
15	p34cdc2	B
16	kinase	I
17	activity	O
18	,	O
19	in	O
20	line	O
21	with	O
22	the	O
23	location	O
24	of	O
25	these	O
26	residues	O
27	within	O
28	the	O
29	putative	O
30	ATP	O
31	binding	O
32	site	O
33	of	O
34	the	O
35	kinase	O
36	.	O

1	In	O
2	short	O
3	-	O
4	term	O
5	cotransfections	O
6	,	O
7	a	O
8	pFRTK	B
9	-	O
10	CAT	B
11	target	O
12	containing	O
13	EBNA	B
14	-	I
15	1	I
16	-	I
17	binding	I
18	sites	I
19	from	O
20	the	O
21	EBV	O
22	origin	O
23	of	O
24	plasmid	O
25	replication	O
26	,	O
27	ori	B
28	-	I
29	P	I
30	,	O
31	was	O
32	transactivated	O
33	by	O
34	a	O
35	carboxy	B
36	-	I
37	terminal	I
38	EBNA	I
39	-	I
40	1	I
41	construction	I
42	(	O
43	amino	O
44	acids	O
45	450	O
46	to	O
47	641	O
48	)	O
49	that	O
50	also	O
51	carried	O
52	a	O
53	c	B
54	-	I
55	myc	I
56	nuclear	I
57	localization	I
58	signal	I
59	.	O

1	The	O
2	findings	O
3	are	O
4	compatible	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	the	O
10	genes	O
11	encoding	O
12	PDGF	B
13	receptors	I
14	in	O
15	glioma	O
16	cells	O
17	are	O
18	regulated	O
19	in	O
20	concert	O
21	with	O
22	other	O
23	genes	O
24	,	O
25	the	O
26	expression	O
27	of	O
28	which	O
29	may	O
30	reflect	O
31	the	O
32	developmental	O
33	program	O
34	of	O
35	normal	O
36	glia	O
37	cell	O
38	lineages	O
39	.	O

1	Suggestive	O
2	evidence	O
3	was	O
4	obtained	O
5	that	O
6	cstA	B
7	is	O
8	involved	O
9	in	O
10	peptide	O
11	utilization	O
12	.	O

1	This	O
2	study	O
3	tested	O
4	the	O
5	hypothesis	O
6	that	O
7	sodium	O
8	channel	O
9	blocking	O
10	drugs	O
11	selectively	O
12	prolong	O
13	the	O
14	late	O
15	potential	O
16	,	O
17	or	O
18	terminal	O
19	low	O
20	amplitude	O
21	signal	O
22	,	O
23	portion	O
24	of	O
25	the	O
26	signal	O
27	-	O
28	averaged	O
29	QRS	O
30	complex	O
31	and	O
32	that	O
33	prolongation	O
34	of	O
35	the	O
36	late	O
37	potential	O
38	would	O
39	correlate	O
40	with	O
41	slowing	O
42	of	O
43	ventricular	O
44	tachycardia	O
45	.	O

1	Identification	O
2	and	O
3	nucleotide	O
4	sequence	O
5	of	O
6	Rhizobium	B
7	meliloti	I
8	insertion	I
9	sequence	I
10	ISRm3	I
11	:	O
12	similarity	O
13	between	O
14	the	O
15	putative	O
16	transposase	B
17	encoded	O
18	by	O
19	ISRm3	B
20	and	O
21	those	O
22	encoded	O
23	by	O
24	Staphylococcus	B
25	aureus	I
26	IS256	I
27	and	O
28	Thiobacillus	B
29	ferrooxidans	I
30	IST2	I
31	.	O

1	To	O
2	determine	O
3	the	O
4	relationship	O
5	of	O
6	these	O
7	viruses	O
8	,	O
9	the	O
10	complete	O
11	DNA	O
12	sequence	O
13	of	O
14	KV	O
15	consisting	O
16	of	O
17	4754	O
18	bp	O
19	was	O
20	determined	O
21	.	O

1	Whereas	O
2	a	O
3	PR55	B
4	beta	I
5	transcript	I
6	of	O
7	about	O
8	2	O
9	.	O
10	3	O
11	kb	O
12	was	O
13	detected	O
14	at	O
15	high	O
16	levels	O
17	in	O
18	the	O
19	neuroblastoma	O
20	derived	O
21	cell	O
22	line	O
23	LA	O
24	-	O
25	N	O
26	-	O
27	1	O
28	,	O
29	the	O
30	level	O
31	of	O
32	the	O
33	mRNA	O
34	was	O
35	very	O
36	low	O
37	in	O
38	the	O
39	other	O
40	human	O
41	cell	O
42	lines	O
43	analyzed	O
44	.	O

1	Heterodimers	O
2	of	O
3	myogenin	B
4	and	O
5	E12	B
6	(	O
7	or	O
8	MyoD	B
9	and	O
10	E12	B
11	)	O
12	specifically	O
13	bound	O
14	a	O
15	restriction	O
16	fragment	O
17	extending	O
18	from	O
19	-	O
20	200	O
21	to	O
22	-	O
23	103	O
24	relative	O
25	to	O
26	the	O
27	start	O
28	of	O
29	cardiac	B
30	alpha	I
31	-	I
32	actin	I
33	transcription	O
34	.	O

1	The	O
2	effects	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	were	O
8	further	O
9	dissected	O
10	by	O
11	showing	O
12	that	O
13	c	B
14	-	I
15	myc	I
16	can	O
17	inhibit	O
18	differentiation	O
19	independently	O
20	of	O
21	Id	B
22	,	O
23	a	O
24	negative	O
25	regulator	O
26	of	O
27	muscle	O
28	differentiation	O
29	.	O

1	Stable	O
2	association	O
3	of	O
4	U2	B
5	snRNP	I
6	with	O
7	the	O
8	branchpoint	O
9	sequence	O
10	of	O
11	mammalian	O
12	pre	O
13	-	O
14	mRNAs	O
15	requires	O
16	binding	O
17	of	O
18	a	O
19	non	O
20	-	O
21	snRNP	O
22	protein	O
23	to	O
24	the	O
25	polypyrimidine	O
26	tract	O
27	.	O

1	Naturally	O
2	acquired	O
3	antibodies	O
4	were	O
5	demonstrated	O
6	in	O
7	some	O
8	rabbits	O
9	kept	O
10	on	O
11	commercial	O
12	farms	O
13	.	O

1	The	O
2	Italian	O
3	Lung	O
4	Cancer	O
5	Task	O
6	Force	O
7	(	O
8	FONICAP	O
9	).	O

1	The	O
2	promoter	O
3	activity	O
4	of	O
5	the	O
6	gene	B
7	encoding	I
8	Alzheimer	I
9	beta	I
10	-	I
11	amyloid	I
12	precursor	I
13	protein	I
14	(	O
15	APP	B
16	)	O
17	is	O
18	regulated	O
19	by	O
20	two	O
21	blocks	O
22	of	O
23	upstream	O
24	sequences	O
25	.	O

1	Biol	O
2	.	O

1	Nucleotide	O
2	sequences	O
3	between	O
4	the	O
5	env	B
6	gene	I
7	and	O
8	the	O
9	LTR	B
10	of	I
11	SFV	I
12	-	I
13	1	I
14	were	O
15	determined	O
16	.	O

1	This	O
2	element	O
3	was	O
4	used	O
5	to	O
6	screen	O
7	an	O
8	EMBL3	O
9	mouse	O
10	genomic	O
11	library	O
12	.	O

1	The	O
2	MVV	O
3	-	O
4	value	O
5	is	O
6	under	O
7	the	O
8	predicted	O
9	level	O
10	in	O
11	the	O
12	case	O
13	of	O
14	67	O
15	-	O
16	76	O
17	percent	O
18	.	O

1	The	O
2	rad9	B
3	.	I
4	192	I
5	DNA	I
6	repair	I
7	mutant	I
8	from	I
9	the	I
10	fission	I
11	yeast	I
12	,	I
13	Schizosaccharomyces	I
14	pombe	I
15	,	O
16	is	O
17	sensitive	O
18	to	O
19	both	O
20	UV	O
21	and	O
22	ionising	O
23	radiation	O
24	.	O

1	Review	O
2	:	O
3	deterioration	O
4	of	O
5	glucose	O
6	tolerance	O
7	with	O
8	age	O
9	:	O
10	the	O
11	role	O
12	of	O
13	insulin	B
14	resistance	O
15	.	O

1	The	O
2	5	O
3	'	O
4	region	O
5	shows	O
6	strong	O
7	sequence	O
8	similarity	O
9	to	O
10	Escherichia	O
11	coli	O
12	consensus	O
13	promoters	O
14	and	O
15	ribosome	O
16	-	O
17	binding	O
18	sequences	O
19	and	O
20	allows	O
21	high	O
22	levels	O
23	of	O
24	expression	O
25	in	O
26	E	O
27	.	O
28	coli	O
29	.	O

1	Premature	O
2	initiation	O
3	of	O
4	mitosis	O
5	in	O
6	yeast	O
7	lacking	O
8	RCC1	B
9	or	O
10	an	O
11	interacting	O
12	GTPase	B
13	.	O

1	The	O
2	method	O
3	has	O
4	been	O
5	routinely	O
6	used	O
7	in	O
8	our	O
9	laboratory	O
10	for	O
11	1	O
12	year	O
13	and	O
14	has	O
15	proven	O
16	to	O
17	be	O
18	a	O
19	reliable	O
20	procedure	O
21	for	O
22	the	O
23	biological	O
24	control	O
25	of	O
26	occupational	O
27	exposure	O
28	to	O
29	toluene	O
30	and	O
31	/	O
32	or	O
33	xylene	O
34	.	O

1	The	O
2	patient	O
3	was	O
4	a	O
5	78	O
6	-	O
7	year	O
8	-	O
9	old	O
10	male	O
11	in	O
12	whom	O
13	skin	O
14	lesions	O
15	preceded	O
16	the	O
17	diagnosis	O
18	of	O
19	myelofibrosis	O
20	.	O

1	Oculus	O
2	-	O
3	500	O
4	is	O
5	a	O
6	group	O
7	of	O
8	high	O
9	resolution	O
10	imaging	O
11	boards	O
12	for	O
13	use	O
14	with	O
15	IBM	O
16	-	O
17	AT	O
18	and	O
19	compatible	O
20	computers	O
21	.	O

1	The	O
2	human	O
3	cDNA	O
4	was	O
5	used	O
6	to	O
7	demonstrate	O
8	that	O
9	tumor	B
10	necrosis	I
11	factor	I
12	-	I
13	alpha	I
14	could	O
15	rapidly	O
16	stimulate	O
17	MARCKS	B
18	gene	I
19	transcription	O
20	in	O
21	the	O
22	human	O
23	promyelocytic	O
24	leukemia	O
25	cell	O
26	line	O
27	HL60	O
28	.	O

1	After	O
2	resection	O
3	of	O
4	the	O
5	proximal	O
6	fragment	O
7	,	O
8	all	O
9	scaphoid	O
10	contact	O
11	area	O
12	and	O
13	pressure	O
14	was	O
15	born	O
16	by	O
17	the	O
18	distal	O
19	scaphoid	O
20	fragment	O
21	.	O

1	Plate	O
2	luting	O
3	,	O
4	a	O
5	technique	O
6	that	O
7	uses	O
8	polymethylmethacrylate	O
9	(	O
10	PMMA	O
11	)	O
12	interposed	O
13	between	O
14	the	O
15	plate	O
16	and	O
17	the	O
18	bone	O
19	,	O
20	as	O
21	well	O
22	as	O
23	between	O
24	the	O
25	screw	O
26	heads	O
27	and	O
28	the	O
29	plate	O
30	,	O
31	to	O
32	improve	O
33	the	O
34	stability	O
35	of	O
36	internal	O
37	fixation	O
38	was	O
39	tested	O
40	in	O
41	vitro	O
42	using	O
43	20	O
44	paired	O
45	equine	O
46	third	O
47	metacarpal	O
48	bones	O
49	with	O
50	mid	O
51	-	O
52	diaphyseal	O
53	osteotomies	O
54	plated	O
55	with	O
56	six	O
57	-	O
58	hole	O
59	broad	O
60	ASIF	O
61	compression	O
62	plates	O
63	.	O

1	These	O
2	features	O
3	were	O
4	considered	O
5	consistent	O
6	with	O
7	a	O
8	diagnosis	O
9	of	O
10	Rothmund	O
11	-	O
12	Thomson	O
13	syndrome	O
14	.	O

1	Thyroid	O
2	lymphoma	O
3	and	O
4	its	O
5	management	O
6	.	O

1	The	O
2	protein	O
3	encoded	O
4	by	O
5	ORF113	B
6	contains	O
7	a	O
8	transmembrane	O
9	domain	O
10	.	O

1	Space	O
2	limitations	O
3	prevent	O
4	an	O
5	exhaustive	O
6	review	O
7	of	O
8	all	O
9	biologic	O
10	pharmaceuticals	O
11	,	O
12	such	O
13	as	O
14	tissue	B
15	plasminogen	I
16	activating	I
17	substance	I
18	,	O
19	hormones	O
20	(	O
21	e	O
22	.	O
23	g	O
24	.,	O
25	thyroid	O
26	,	O
27	insulin	B
28	,	O
29	growth	B
30	hormone	I
31	,	O
32	erythropoietin	B
33	),	O
34	clotting	O
35	factors	O
36	,	O
37	and	O
38	blood	O
39	products	O
40	.	O

1	Dd	B
2	PK1	I
3	RNA	I
4	decreases	O
5	after	O
6	6	O
7	h	O
8	of	O
9	starvation	O
10	to	O
11	re	O
12	-	O
13	accumulate	O
14	once	O
15	the	O
16	cells	O
17	have	O
18	aggregated	O
19	.	O

1	The	O
2	various	O
3	forms	O
4	of	O
5	sickle	O
6	cell	O
7	disease	O
8	share	O
9	the	O
10	common	O
11	feature	O
12	of	O
13	an	O
14	abnormal	O
15	globin	B
16	chain	I
17	that	O
18	,	O
19	under	O
20	certain	O
21	conditions	O
22	such	O
23	as	O
24	hypoxia	O
25	,	O
26	results	O
27	in	O
28	the	O
29	sickling	O
30	of	O
31	red	O
32	blood	O
33	cells	O
34	and	O
35	obstruction	O
36	of	O
37	blood	O
38	vessels	O
39	.	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	each	O
6	of	O
7	the	O
8	three	O
9	proteins	O
10	has	O
11	about	O
12	70	O
13	%	O
14	homology	O
15	with	O
16	that	O
17	of	O
18	mouse	B
19	contrapsin	I
20	,	O
21	in	O
22	contrast	O
23	to	O
24	43	O
25	-	O
26	46	O
27	%	O
28	homology	O
29	with	O
30	that	O
31	of	O
32	rat	B
33	alpha	I
34	1	I
35	-	I
36	protease	I
37	inhibitor	O
38	.	O

1	Patterns	O
2	of	O
3	connections	O
4	underlying	O
5	cross	O
6	-	O
7	modality	O
8	integration	O
9	were	O
10	studied	O
11	by	O
12	injecting	O
13	distinguishable	O
14	,	O
15	retrograde	O
16	tracers	O
17	(	O
18	Fluoro	O
19	-	O
20	Gold	O
21	and	O
22	diamidino	O
23	yellow	O
24	)	O
25	in	O
26	pairwise	O
27	manner	O
28	into	O
29	different	O
30	sensory	O
31	representations	O
32	(	O
33	visual	O
34	,	O
35	somatosensory	O
36	,	O
37	and	O
38	auditory	O
39	)	O
40	in	O
41	the	O
42	cerebral	O
43	cortex	O
44	of	O
45	the	O
46	rat	O
47	.	O

1	Young	O
2	CD	O
3	-	O
4	1	O
5	mice	O
6	,	O
7	4	O
8	days	O
9	old	O
10	,	O
11	exposed	O
12	to	O
13	0	O
14	.	O
15	1	O
16	%	O
17	nicotine	O
18	sulfate	O
19	on	O
20	gestational	O
21	days	O
22	6	O
23	-	O
24	20	O
25	were	O
26	compared	O
27	with	O
28	untreated	O
29	pups	O
30	of	O
31	the	O
32	same	O
33	age	O
34	to	O
35	determine	O
36	its	O
37	effect	O
38	on	O
39	the	O
40	development	O
41	of	O
42	mandibular	O
43	first	O
44	molars	O
45	.	O

1	USF	B
2	synthesized	O
3	in	O
4	an	O
5	in	O
6	vitro	O
7	transcription	O
8	and	O
9	translation	O
10	system	O
11	also	O
12	binds	O
13	to	O
14	the	O
15	ADH	B
16	promoter	I
17	as	O
18	well	O
19	as	O
20	to	O
21	the	O
22	MLP	O
23	.	O

1	The	O
2	across	O
3	-	O
4	fiber	O
5	pattern	O
6	of	O
7	the	O
8	responses	O
9	to	O
10	hypotonic	O
11	NaCl	O
12	solutions	O
13	correlated	O
14	strongly	O
15	to	O
16	that	O
17	elicited	O
18	by	O
19	distilled	O
20	H2O	O
21	.(	O
22	ABSTRACT	O
23	TRUNCATED	O
24	AT	O
25	400	O
26	WORDS	O
27	)	O

1	Arterial	O
2	radioactivity	O
3	content	O
4	after	O
5	the	O
6	intravenous	O
7	administration	O
8	of	O
9	HMPAO	O
10	in	O
11	seven	O
12	human	O
13	subjects	O
14	was	O
15	analyzed	O
16	.	O

1	Linear	O
2	regression	O
3	analysis	O
4	was	O
5	performed	O
6	and	O
7	the	O
8	following	O
9	result	O
10	was	O
11	obtained	O
12	:	O
13	clearance	O
14	(	O
15	HMPAO	O
16	)	O
17	=	O
18	0	O
19	.	O
20	07	O
21	+	O
22	0	O
23	.	O
24	43	O
25	.	O
26	rCBF	O
27	with	O
28	a	O
29	high	O
30	significance	O
31	(	O
32	p	O
33	less	O
34	than	O
35	0	O
36	.	O
37	001	O
38	).	O

1	Human	B
2	immunodeficiency	I
3	virus	I
4	type	I
5	1	I
6	(	I
7	HIV	I
8	-	I
9	1	I
10	)	I
11	IN	I
12	,	O
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	,	O
18	was	O
19	purified	O
20	to	O
21	near	O
22	homogeneity	O
23	.	O

1	Thigh	O
2	girth	O
3	correlated	O
4	positively	O
5	with	O
6	HDL	B
7	and	O
8	HDL2	B
9	-	I
10	C	I
11	and	O
12	mass	O
13	,	O
14	and	O
15	with	O
16	LDL	B
17	particle	O
18	size	O
19	among	O
20	women	O
21	.	O

1	Contributions	O
2	from	O
3	pairs	O
4	of	O
5	source	O
6	and	O
7	target	O
8	volume	O
9	elements	O
10	are	O
11	summed	O
12	for	O
13	the	O
14	S	O
15	values	O
16	between	O
17	the	O
18	tumor	O
19	and	O
20	itself	O
21	,	O
22	between	O
23	the	O
24	remaining	O
25	healthy	O
26	host	O
27	organ	O
28	and	O
29	itself	O
30	,	O
31	and	O
32	between	O
33	the	O
34	tumor	O
35	and	O
36	the	O
37	remaining	O
38	healthy	O
39	host	O
40	organ	O
41	,	O
42	with	O
43	the	O
44	reciprocity	O
45	theorem	O
46	assumed	O
47	for	O
48	the	O
49	last	O
50	.	O

1	Tests	O
2	showed	O
3	that	O
4	an	O
5	overall	O
6	impression	O
7	of	O
8	the	O
9	force	O
10	applied	O
11	could	O
12	be	O
13	obtained	O
14	from	O
15	a	O
16	laboratory	O
17	simulation	O
18	,	O
19	but	O
20	that	O
21	clearing	O
22	cement	O
23	and	O
24	testing	O
25	cement	O
26	were	O
27	not	O
28	modelled	O
29	by	O
30	this	O
31	method	O
32	.	O

1	The	O
2	cDNA	O
3	contained	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	1392	O
10	bp	O
11	that	O
12	predicted	O
13	a	O
14	protein	O
15	of	O
16	464	O
17	amino	O
18	acids	O
19	and	O
20	a	O
21	molecular	O
22	mass	O
23	of	O
24	52	O
25	kDa	O
26	;	O
27	this	O
28	protein	O
29	has	O
30	97	O
31	%	O
32	identity	O
33	to	O
34	rat	B
35	liver	I
36	glucokinase	I
37	.	O

1	Analysis	O
2	of	O
3	viral	O
4	mutants	O
5	in	O
6	vivo	O
7	demonstrated	O
8	that	O
9	the	O
10	NFIII	B
11	/	O
12	OCT	B
13	-	I
14	1	I
15	binding	O
16	site	O
17	and	O
18	a	O
19	conserved	O
20	ATF	B
21	motif	I
22	were	O
23	important	O
24	for	O
25	efficient	O
26	viral	O
27	growth	O
28	.	O

1	Recovery	O
2	of	O
3	radiolabelled	O
4	BA	O
5	through	O
6	urine	O
7	(	O
8	28	O
9	%)	O
10	and	O
11	faeces	O
12	(	O
13	22	O
14	%)	O
15	up	O
16	to	O
17	96	O
18	hrs	O
19	averaged	O
20	50	O
21	%,	O
22	whereas	O
23	residual	O
24	radioactivity	O
25	in	O
26	liver	O
27	and	O
28	testis	O
29	experienced	O
30	a	O
31	recovery	O
32	of	O
33	29	O
34	%	O
35	in	O
36	scorbutic	O
37	animals	O
38	.	O

1	Saccharomyces	O
2	cerevisiae	O
3	has	O
4	been	O
5	used	O
6	widely	O
7	both	O
8	as	O
9	a	O
10	model	O
11	system	O
12	for	O
13	unraveling	O
14	the	O
15	biochemical	O
16	,	O
17	genetic	O
18	,	O
19	and	O
20	molecular	O
21	details	O
22	of	O
23	gene	O
24	expression	O
25	and	O
26	the	O
27	secretion	O
28	process	O
29	,	O
30	and	O
31	as	O
32	a	O
33	host	O
34	for	O
35	the	O
36	production	O
37	of	O
38	heterologous	O
39	proteins	O
40	of	O
41	biotechnological	O
42	interest	O
43	.	O

1	Paradoxically	O
2	,	O
3	however	O
4	,	O
5	the	O
6	GH	B
7	receptor	I
8	cloned	O
9	from	O
10	liver	O
11	exhibits	O
12	no	O
13	sequence	O
14	similarity	O
15	to	O
16	receptors	O
17	with	O
18	known	O
19	signal	O
20	transduction	O
21	mechanisms	O
22	,	O
23	including	O
24	those	O
25	exhibiting	O
26	ligand	O
27	-	O
28	activated	O
29	tyrosine	B
30	kinase	I
31	activity	O
32	.	O

1	This	O
2	indicates	O
3	that	O
4	under	O
5	certain	O
6	experimental	O
7	conditions	O
8	cdc2	B
9	/	O
10	p58	B
11	and	O
12	cdc2	B
13	/	O
14	p62	B
15	may	O
16	express	O
17	some	O
18	differences	O
19	in	O
20	their	O
21	catalytic	O
22	activity	O
23	.	O

1	Mutation	O
2	analysis	O
3	implicated	O
4	multiple	O
5	segments	O
6	of	O
7	the	O
8	5	O
9	'	O
10	untranslated	O
11	region	O
12	as	O
13	contributing	O
14	to	O
15	the	O
16	inhibitory	O
17	effect	O
18	.	O

1	Identification	O
2	of	O
3	Ets	B
4	-	O
5	and	O
6	notch	B
7	-	O
8	related	O
9	subunits	O
10	in	O
11	GA	B
12	binding	I
13	protein	I
14	.	O

1	The	O
2	enzymatic	O
3	response	O
4	of	O
5	neutrophils	O
6	and	O
7	monocytes	O
8	was	O
9	similar	O
10	although	O
11	the	O
12	magnitude	O
13	of	O
14	the	O
15	NADPH	B
16	oxidase	I
17	activity	O
18	was	O
19	significantly	O
20	higher	O
21	in	O
22	neutrophils	O
23	than	O
24	in	O
25	monocytes	O
26	.	O

1	In	O
2	the	O
3	ileum	O
4	,	O
5	enterotoxin	O
6	increased	O
7	the	O
8	luminal	O
9	disappearance	O
10	(	O
11	P	O
12	less	O
13	than	O
14	0	O
15	.	O
16	05	O
17	)	O
18	and	O
19	peripheral	O
20	blood	O
21	appearance	O
22	(	O
23	P	O
24	less	O
25	than	O
26	0	O
27	.	O
28	001	O
29	)	O
30	of	O
31	chloroquine	O
32	.	O

1	Formalin	O
2	activated	O
3	both	O
4	SNO	O
5	NS	O
6	and	O
7	NnS	O
8	neurones	O
9	,	O
10	but	O
11	,	O
12	when	O
13	they	O
14	responded	O
15	,	O
16	NS	O
17	neurones	O
18	(	O
19	n	O
20	=	O
21	5	O
22	)	O
23	showed	O
24	only	O
25	the	O
26	first	O
27	phase	O
28	of	O
29	activity	O
30	while	O
31	NnS	O
32	neurones	O
33	showed	O
34	either	O
35	one	O
36	(	O
37	n	O
38	=	O
39	13	O
40	)	O
41	or	O
42	two	O
43	phases	O
44	(	O
45	n	O
46	=	O
47	6	O
48	).	O

1	Uptake	O
2	of	O
3	ofloxacin	O
4	by	O
5	Escherichia	O
6	coli	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	attention	O
6	to	O
7	these	O
8	issues	O
9	can	O
10	substantially	O
11	improve	O
12	the	O
13	quality	O
14	of	O
15	research	O
16	on	O
17	AIDS	O
18	related	O
19	behaviors	O
20	on	O
21	Black	O
22	communities	O
23	.	O

1	The	O
2	effectiveness	O
3	of	O
4	alpha	O
5	-	O
6	mercapto	O
7	-	O
8	beta	O
9	-(	O
10	2	O
11	-	O
12	furyl	O
13	)	O
14	acrylic	O
15	acid	O
16	(	O
17	MFA	O
18	)	O
19	and	O
20	N	O
21	-	O
22	benzyl	O
23	-	O
24	N	O
25	-	O
26	dithiocarboxy	O
27	-	O
28	D	O
29	-	O
30	glucamine	O
31	(	O
32	NaB	O
33	),	O
34	used	O
35	in	O
36	combination	O
37	,	O
38	in	O
39	the	O
40	mobilization	O
41	and	O
42	excretion	O
43	of	O
44	lead	O
45	was	O
46	investigated	O
47	in	O
48	rats	O
49	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	beta	B
6	-	I
7	1	I
8	may	O
9	act	O
10	as	O
11	a	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	trans	O
17	-	O
18	acting	O
19	regulator	O
20	of	O
21	the	O
22	expression	O
23	of	O
24	the	O
25	beta	B
26	-	I
27	zein	I
28	gene	I
29	in	O
30	developing	O
31	maize	O
32	endosperm	O
33	.	O

1	This	O
2	study	O
3	examines	O
4	the	O
5	effects	O
6	of	O
7	hypovolemia	O
8	on	O
9	the	O
10	extracellular	O
11	ptO2	O
12	and	O
13	ptH	O
14	distributions	O
15	at	O
16	multiple	O
17	tissue	O
18	sites	O
19	using	O
20	a	O
21	recently	O
22	developed	O
23	multipoint	O
24	microelectrode	O
25	,	O
26	that	O
27	provides	O
28	simultaneous	O
29	measurements	O
30	of	O
31	ptO2	O
32	and	O
33	ptH	O
34	.	O

1	All	O
2	members	O
3	are	O
4	also	O
5	capable	O
6	of	O
7	activating	O
8	in	O
9	vivo	O
10	transcription	O
11	from	O
12	promoters	O
13	that	O
14	contain	O
15	a	O
16	C	B
17	/	I
18	EBP	I
19	-	I
20	binding	I
21	site	I
22	.	O

1	The	O
2	domains	O
3	involved	O
4	in	O
5	superactivation	O
6	appear	O
7	to	O
8	be	O
9	a	O
10	subset	O
11	of	O
12	those	O
13	necessary	O
14	to	O
15	achieve	O
16	synergistic	O
17	activation	O
18	.	O

1	Information	O
2	on	O
3	conserved	O
4	noncoding	O
5	sequences	O
6	will	O
7	help	O
8	in	O
9	studies	O
10	on	O
11	the	O
12	regulation	O
13	of	O
14	the	O
15	pro	B
16	alpha	I
17	1	I
18	(	I
19	II	I
20	)	I
21	collagen	I
22	gene	I
23	.	O

1	Chlamydia	O
2	trachomatis	O
3	and	O
4	Chlamydia	O
5	psittaci	O
6	were	O
7	not	O
8	affected	O
9	by	O
10	methanol	O
11	fixation	O
12	.	O

1	Although	O
2	human	O
3	infections	O
4	with	O
5	bacteraemia	O
6	due	O
7	to	O
8	Pasteurella	O
9	multocida	O
10	are	O
11	not	O
12	uncommon	O
13	,	O
14	endocarditis	O
15	associated	O
16	with	O
17	P	O
18	.	O
19	haemolytica	O
20	is	O
21	rare	O
22	.	O

1	For	O
2	SMX	O
3	at	O
4	pH	O
5	7	O
6	.	O
7	0	O
8	,	O
9	a	O
10	1	O
11	:	O
12	1	O
13	complex	O
14	is	O
15	formed	O
16	,	O
17	but	O
18	at	O
19	pH	O
20	7	O
21	.	O
22	5	O
23	HPCD	O
24	has	O
25	little	O
26	effect	O
27	on	O
28	the	O
29	solubility	O
30	of	O
31	the	O
32	highly	O
33	ionized	O
34	SMX	O
35	,	O
36	presumably	O
37	since	O
38	only	O
39	un	O
40	-	O
41	ionized	O
42	molecules	O
43	can	O
44	form	O
45	inclusion	O
46	complexes	O
47	with	O
48	the	O
49	HPCD	O
50	.	O

1	PO2	O
2	measurements	O
3	using	O
4	a	O
5	double	O
6	barrelled	O
7	recess	O
8	type	O
9	microelectrodes	O
10	were	O
11	measured	O
12	in	O
13	the	O
14	optic	O
15	nerve	O
16	head	O
17	of	O
18	miniature	O
19	pigs	O
20	in	O
21	normoxia	O
22	and	O
23	hyperoxia	O
24	.	O

1	POU	B
2	-	O
3	specific	O
4	and	O
5	POU	B
6	-	O
7	homeo	O
8	domains	O
9	of	O
10	Oct3	B
11	were	O
12	produced	O
13	in	O
14	Echerichia	O
15	coli	O
16	for	O
17	characterization	O
18	of	O
19	DNA	O
20	binding	O
21	to	O
22	the	O
23	octamer	O
24	sequence	O
25	.	O

1	A	O
2	deletion	O
3	series	O
4	of	O
5	the	O
6	5	O
7	'	O
8	flanking	O
9	region	O
10	was	O
11	created	O
12	from	O
13	position	O
14	-	O
15	1329	O
16	to	O
17	-	O
18	74	O
19	relative	O
20	to	O
21	the	O
22	transcriptional	O
23	initiation	O
24	site	O
25	and	O
26	similarly	O
27	examined	O
28	in	O
29	transgenic	O
30	tobacco	O
31	.	O

1	The	O
2	nucleotide	O
3	(	O
4	nt	O
5	)	O
6	sequences	O
7	of	O
8	the	O
9	exons	O
10	,	O
11	exon	O
12	/	O
13	intron	O
14	boundaries	O
15	and	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	untranslated	O
22	regions	O
23	were	O
24	determined	O
25	.	O

1	Out	O
2	of	O
3	40	O
4	patients	O
5	,	O
6	who	O
7	initially	O
8	did	O
9	not	O
10	show	O
11	eye	O
12	complications	O
13	due	O
14	to	O
15	leprosy	O
16	,	O
17	37	O
18	patients	O
19	were	O
20	essentially	O
21	the	O
22	same	O
23	10	O
24	years	O
25	later	O
26	.	O

1	Thus	O
2	,	O
3	two	O
4	very	O
5	different	O
6	regulatory	O
7	elements	O
8	are	O
9	used	O
10	to	O
11	mediate	O
12	estrogen	O
13	induction	O
14	of	O
15	related	O
16	genes	O
17	in	O
18	chickens	O
19	and	O
20	amphibians	O
21	.	O

1	Toxicity	O
2	was	O
3	very	O
4	mild	O
5	with	O
6	both	O
7	regimens	O
8	,	O
9	although	O
10	sedation	O
11	was	O
12	significantly	O
13	higher	O
14	in	O
15	arm	O
16	B	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	001	O
24	).	O

1	Experimentally	O
2	in	O
3	green	O
4	monkeys	O
5	,	O
6	Syrian	O
7	hamsters	O
8	and	O
9	white	O
10	mice	O
11	the	O
12	authors	O
13	studied	O
14	the	O
15	pathogenic	O
16	properties	O
17	of	O
18	a	O
19	new	O
20	virus	O
21	Issyk	O
22	-	O
23	Kul	O
24	.	O

1	Increasing	O
2	mean	O
3	arterial	O
4	pressure	O
5	by	O
6	phenylephrine	O
7	infusion	O
8	to	O
9	levels	O
10	much	O
11	greater	O
12	than	O
13	produced	O
14	by	O
15	NMA	O
16	and	O
17	NNA	O
18	caused	O
19	only	O
20	small	O
21	reductions	O
22	in	O
23	cardiac	O
24	output	O
25	.	O

1	J	O
2	.	O

1	Limits	O
2	of	O
3	energy	O
4	turnover	O
5	in	O
6	relation	O
7	to	O
8	physical	O
9	performance	O
10	were	O
11	addressed	O
12	in	O
13	terms	O
14	of	O
15	upper	O
16	and	O
17	lower	O
18	limit	O
19	,	O
20	changes	O
21	during	O
22	a	O
23	training	O
24	programme	O
25	and	O
26	how	O
27	to	O
28	regulate	O
29	energy	O
30	balance	O
31	at	O
32	a	O
33	changing	O
34	energy	O
35	turnover	O
36	.	O

1	With	O
2	stepwise	O
3	reductions	O
4	in	O
5	flow	O
6	,	O
7	the	O
8	peak	O
9	(	O
10	S	O
11	)	O
12	and	O
13	trough	O
14	(	O
15	D	O
16	)	O
17	points	O
18	of	O
19	the	O
20	maximum	O
21	shifted	O
22	-	O
23	frequency	O
24	envelope	O
25	fell	O
26	in	O
27	parallel	O
28	in	O
29	a	O
30	linear	O
31	fashion	O
32	until	O
33	D	O
34	reached	O
35	zero	O
36	.	O

1	The	O
2	IE0	B
3	gene	I
4	product	O
5	also	O
6	transactivated	O
7	the	O
8	IE1	B
9	promoter	I
10	but	O
11	did	O
12	not	O
13	affect	O
14	expression	O
15	from	O
16	its	O
17	own	O
18	promoter	O
19	.	O

1	Moreover	O
2	,	O
3	promoters	O
4	containing	O
5	a	O
6	TATA	O
7	box	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	Sp1	B
13	sites	I
14	or	O
15	Sp1	B
16	sites	I
17	in	O
18	the	O
19	absence	O
20	of	O
21	a	O
22	TATA	O
23	box	O
24	were	O
25	equally	O
26	inducible	O
27	in	O
28	vitro	O
29	,	O
30	as	O
31	was	O
32	an	O
33	RNA	B
34	polymerase	I
35	III	I
36	promoter	I
37	.	O

1	Evaluation	O
2	of	O
3	left	O
4	ventricular	O
5	function	O
6	using	O
7	gated	O
8	planar	O
9	myocardial	O
10	imaging	O
11	with	O
12	Tc	O
13	-	O
14	99m	O
15	-	O
16	MIBI	O

1	Ivermectin	O
2	uptake	O
3	and	O
4	distribution	O
5	in	O
6	the	O
7	plasma	O
8	and	O
9	tissue	O
10	of	O
11	Sudanese	O
12	and	O
13	Mexican	O
14	patients	O
15	infected	O
16	with	O
17	Onchocerca	O
18	volvulus	O
19	.	O

1	Bone	O
2	marrow	O
3	abnormalities	O
4	in	O
5	Hodgkin	O
6	'	O
7	s	O
8	disease	O
9	are	O
10	reviewed	O
11	and	O
12	the	O
13	current	O
14	understanding	O
15	of	O
16	the	O
17	pathological	O
18	mechanisms	O
19	leading	O
20	to	O
21	aplastic	O
22	anemia	O
23	is	O
24	discussed	O
25	.	O

1	The	O
2	smaller	O
3	uptake	O
4	rate	O
5	and	O
6	faster	O
7	clearance	O
8	rate	O
9	resulted	O
10	in	O
11	the	O
12	lower	O
13	BCF	O
14	for	O
15	SWA	O
16	killifish	O
17	.	O

1	The	O
2	currently	O
3	proposed	O
4	extended	O
5	arch	O
6	repair	O
7	should	O
8	be	O
9	reserved	O
10	for	O
11	the	O
12	small	O
13	group	O
14	of	O
15	infants	O
16	with	O
17	transverse	O
18	aortic	O
19	arch	O
20	to	O
21	ascending	O
22	aorta	O
23	diameter	O
24	ratios	O
25	(	O
26	arch	O
27	indices	O
28	)	O
29	of	O
30	less	O
31	than	O
32	0	O
33	.	O
34	25	O
35	.	O

1	DNA	O
2	hybridization	O
3	analysis	O
4	revealed	O
5	that	O
6	both	O
7	pigmented	O
8	and	O
9	nonpigmented	O
10	cells	O
11	of	O
12	Y	O
13	.	O
14	pestis	O
15	possess	O
16	a	O
17	DNA	O
18	locus	O
19	homologous	O
20	to	O
21	the	O
22	Escherichia	B
23	coli	I
24	fur	I
25	gene	I
26	.	O

1	Increases	O
2	in	O
3	the	O
4	perfusate	O
5	PCO2	O
6	but	O
7	not	O
8	in	O
9	the	O
10	perfusate	O
11	H	O
12	+	O
13	were	O
14	highly	O
15	correlated	O
16	with	O
17	decreases	O
18	in	O
19	both	O
20	myocardial	O
21	contractility	O
22	and	O
23	oxygen	O
24	consumption	O
25	(	O
26	r2	O
27	=	O
28	.	O
29	88	O
30	).	O

1	Expression	O
2	was	O
3	cell	O
4	cycle	O
5	controlled	O
6	,	O
7	with	O
8	steady	O
9	-	O
10	state	O
11	RNA	O
12	levels	O
13	significantly	O
14	higher	O
15	in	O
16	growth	O
17	-	O
18	arrested	O
19	than	O
20	in	O
21	growth	O
22	-	O
23	stimulated	O
24	cells	O
25	.	O

1	Determinants	O
2	of	O
3	recurrent	O
4	ischaemia	O
5	and	O
6	revascularisation	O
7	procedures	O
8	after	O
9	thrombolysis	O
10	with	O
11	recombinant	O
12	tissue	B
13	plasminogen	I
14	activator	I
15	in	O
16	primary	O
17	coronary	O
18	occlusion	O
19	.	O

1	Therefore	O
2	,	O
3	the	O
4	rbcL	B
5	-	O
6	rbcS	B
7	locus	O
8	seems	O
9	to	O
10	be	O
11	barely	O
12	expressed	O
13	under	O
14	a	O
15	standard	O
16	condition	O
17	for	O
18	photoautotrophic	O
19	growth	O
20	.	O

1	Relationship	O
2	between	O
3	mitochondrial	B
4	NADH	I
5	-	I
6	ubiquinone	I
7	reductase	I
8	and	O
9	a	O
10	bacterial	B
11	NAD	I
12	-	I
13	reducing	I
14	hydrogenase	I
15	.	O

1	Analysis	O
2	of	O
3	mRNA	O
4	expression	O
5	shows	O
6	that	O
7	AT	B
8	-	I
9	BP1	I
10	and	O
11	AT	B
12	-	I
13	BP2	I
14	are	O
15	expressed	O
16	in	O
17	all	O
18	the	O
19	tissues	O
20	examined	O
21	.	O

1	We	O
2	report	O
3	two	O
4	patients	O
5	receiving	O
6	maintenance	O
7	valproate	O
8	,	O
9	one	O
10	with	O
11	resolving	O
12	acute	O
13	hepatitis	O
14	C	O
15	and	O
16	the	O
17	other	O
18	with	O
19	chronic	O
20	persistent	O
21	hepatitis	O
22	C	O
23	,	O
24	with	O
25	incidental	O
26	microvesicular	O
27	steatosis	O
28	demonstrated	O
29	on	O
30	oil	O
31	-	O
32	red	O
33	O	O
34	stains	O
35	.	O

1	3	O
2	cases	O

1	UDP	B
2	-	I
3	Gal	I
4	:	I
5	Gal	I
6	beta	I
7	1	I
8	----	I
9	4GlcNAc	I
10	alpha	I
11	1	I
12	----	I
13	3	I
14	-	I
15	galactosyltransferase	I
16	is	O
17	a	O
18	terminal	B
19	glycosyltransferase	I
20	that	O
21	is	O
22	widely	O
23	expressed	O
24	in	O
25	a	O
26	variety	O
27	of	O
28	mammalian	O
29	species	O
30	,	O
31	with	O
32	the	O
33	notable	O
34	exception	O
35	of	O
36	man	O
37	,	O
38	apes	O
39	,	O
40	and	O
41	Old	O
42	World	O
43	monkeys	O
44	.	O

1	A	O
2	synthetic	O
3	oligonucleotide	O
4	containing	O
5	the	O
6	SRE	O
7	sequence	O
8	from	O
9	the	O
10	mouse	B
11	c	I
12	-	I
13	fos	I
14	gene	I
15	promoter	I
16	(-	O
17	299	O
18	to	O
19	-	O
20	322	O
21	)	O
22	was	O
23	radioactively	O
24	labeled	O
25	,	O
26	used	O
27	as	O
28	a	O
29	probe	O
30	for	O
31	the	O
32	mobility	O
33	shift	O
34	assay	O
35	and	O
36	Southwestern	O
37	(	O
38	DNA	O
39	-	O
40	protein	O
41	)	O
42	blotting	O
43	,	O
44	and	O
45	also	O
46	used	O
47	for	O
48	sequence	O
49	-	O
50	specific	O
51	affinity	O
52	chromatography	O
53	.	O

1	Sequence	O
2	requirements	O
3	for	O
4	premature	O
5	transcription	O
6	arrest	O
7	within	O
8	the	O
9	first	O
10	intron	O
11	of	O
12	the	O
13	mouse	B
14	c	I
15	-	I
16	fos	I
17	gene	I
18	.	O

1	Infarct	O
2	regional	O
3	ejection	O
4	fraction	O
5	improved	O
6	by	O
7	10	O
8	.	O
9	1	O
10	+/-	O
11	2	O
12	.	O
13	1	O
14	%	O
15	between	O
16	early	O
17	and	O
18	late	O
19	studies	O
20	when	O
21	the	O
22	infarct	O
23	-	O
24	related	O
25	artery	O
26	was	O
27	patent	O
28	and	O
29	by	O
30	4	O
31	.	O
32	8	O
33	+/-	O
34	1	O
35	.	O
36	4	O
37	%	O
38	if	O
39	it	O
40	was	O
41	occluded	O
42	(	O
43	p	O
44	=	O
45	0	O
46	.	O
47	048	O
48	);	O
49	changes	O
50	in	O
51	global	O
52	and	O
53	noninfarct	O
54	regional	O
55	ejection	O
56	fraction	O
57	were	O
58	similar	O
59	irrespective	O
60	of	O
61	perfusion	O
62	status	O
63	.	O

1	One	O
2	of	O
3	its	O
4	lysine	O
5	residues	O
6	is	O
7	modified	O
8	by	O
9	spermidine	O
10	to	O
11	form	O
12	hypusine	O
13	,	O
14	a	O
15	posttranslational	O
16	modification	O
17	unique	O
18	to	O
19	eIF	B
20	-	I
21	5A	I
22	.	O

1	The	O
2	plasmid	O
3	shuffle	O
4	technique	O
5	was	O
6	used	O
7	to	O
8	replace	O
9	the	O
10	wild	O
11	-	O
12	type	O
13	gene	O
14	with	O
15	the	O
16	mutant	O
17	form	O
18	,	O
19	resulting	O
20	in	O
21	failure	O
22	of	O
23	the	O
24	yeast	O
25	cells	O
26	to	O
27	grow	O
28	.	O

1	If	O
2	this	O
3	is	O
4	the	O
5	case	O
6	,	O
7	identification	O
8	and	O
9	characterization	O
10	of	O
11	transcripts	O
12	from	O
13	the	O
14	Ig	B
15	loci	I
16	should	O
17	permit	O
18	a	O
19	better	O
20	understanding	O
21	of	O
22	the	O
23	gene	O
24	rearrangement	O
25	process	O
26	.	O

1	Transcription	O
2	of	O
3	the	O
4	metH	B
5	gene	I
6	in	I
7	Salmonella	I
8	typhimurium	I
9	and	I
10	Escherichia	I
11	coli	I
12	is	O
13	positively	O
14	regulated	O
15	by	O
16	the	O
17	metR	B
18	gene	I
19	product	I
20	,	O
21	a	O
22	DNA	O
23	binding	O
24	protein	O
25	.	O

1	Disruption	O
2	of	O
3	the	O
4	chromosomal	B
5	AAR1	I
6	gene	I
7	in	O
8	alpha	O
9	and	O
10	a	O
11	/	O
12	alpha	O
13	cells	O
14	conferred	O
15	the	O
16	nonmating	O
17	phenotype	O
18	,	O
19	and	O
20	the	O
21	a	O
22	/	O
23	alpha	O
24	diploids	O
25	could	O
26	not	O
27	sporulate	O
28	.	O

1	The	O
2	effect	O
3	of	O
4	ICRF	O
5	-	O
6	187	O
7	on	O
8	the	O
9	antitumor	O
10	response	O
11	induced	O
12	by	O
13	the	O
14	combination	O
15	of	O
16	ADR	O
17	and	O
18	WBH	O
19	was	O
20	also	O
21	investigated	O
22	in	O
23	order	O
24	to	O
25	assess	O
26	alterations	O
27	in	O
28	the	O
29	therapeutic	O
30	index	O
31	of	O
32	this	O
33	combined	O
34	therapeutic	O
35	modality	O
36	treatment	O
37	.	O

1	The	O
2	ORF	O
3	was	O
4	analyzed	O
5	for	O
6	secondary	O
7	structural	O
8	features	O
9	,	O
10	and	O
11	the	O
12	sequence	O
13	data	O
14	bases	O
15	were	O
16	searched	O
17	for	O
18	homologies	O
19	.	O

1	This	O
2	study	O
3	indicates	O
4	that	O
5	this	O
6	dose	O
7	-	O
8	intense	O
9	regimen	O
10	can	O
11	be	O
12	safely	O
13	administered	O
14	,	O
15	even	O
16	with	O
17	the	O
18	use	O
19	of	O
20	purged	O
21	marrow	O
22	,	O
23	with	O
24	an	O
25	acceptable	O
26	toxicity	O
27	profile	O
28	.	O

1	Mitomycin	O
2	-	O
3	C	O
4	can	O
5	cause	O
6	severe	O
7	necrosis	O
8	and	O
9	ulceration	O
10	when	O
11	extravasated	O
12	inadvertently	O
13	into	O
14	skin	O
15	and	O
16	soft	O
17	tissues	O
18	following	O
19	IV	O
20	drug	O
21	administration	O
22	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	human	B
16	nidogen	I
17	gene	I
18	.	O

1	INTERVENTIONS	O
2	:	O
3	Patients	O
4	received	O
5	rt	B
6	-	I
7	PA	I
8	,	O
9	heparin	O
10	,	O
11	and	O
12	aspirin	O
13	.	O

1	Consistent	O
2	with	O
3	the	O
4	in	O
5	vivo	O
6	result	O
7	,	O
8	the	O
9	pseudorevertant	O
10	endonucleases	O
11	in	O
12	the	O
13	crude	O
14	cell	O
15	extract	O
16	display	O
17	site	O
18	-	O
19	specific	O
20	partial	O
21	DNA	O
22	cleavage	O
23	activity	O
24	.	O

1	Additionally	O
2	,	O
3	I	B
4	kappa	I
5	B	I
6	beta	I
7	,	O
8	but	O
9	not	O
10	I	B
11	kappa	I
12	B	I
13	alpha	I
14	,	O
15	also	O
16	prevented	O
17	the	O
18	binding	O
19	of	O
20	Rel	B
21	to	O
22	the	O
23	kappa	B
24	B	I
25	site	I
26	.	O

1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	DNA	O
7	binding	O
8	domain	O
9	of	O
10	ILF	B
11	has	O
12	strong	O
13	homology	O
14	to	O
15	the	O
16	recently	O
17	described	O
18	fork	B
19	head	I
20	DNA	I
21	binding	I
22	domain	I
23	found	O
24	in	O
25	the	O
26	Drosophila	B
27	homeotic	I
28	protein	I
29	fork	I
30	head	I
31	and	O
32	a	O
33	family	O
34	of	O
35	hepatocyte	B
36	nuclear	I
37	factors	I
38	,	O
39	HNF	B
40	-	I
41	3	I
42	.	O

1	Lengthy	O
2	and	O
3	repeated	O
4	hemodialyses	O
5	were	O
6	required	O
7	to	O
8	lower	O
9	lithemia	O
10	to	O
11	nontoxic	O
12	ranges	O
13	.	O

1	A	O
2	single	O
3	i	O
4	.	O
5	p	O
6	.	O
7	injection	O
8	of	O
9	d	O
10	,	O
11	l	O
12	-	O
13	baclofen	O
14	10	O
15	mg	O
16	/	O
17	kg	O
18	both	O
19	reduced	O
20	noradrenaline	O
21	(	O
22	NA	O
23	)	O
24	biosynthesis	O
25	in	O
26	vivo	O
27	(	O
28	31	O
29	%)	O
30	and	O
31	the	O
32	endogenous	O
33	concentration	O
34	of	O
35	normetanephrine	O
36	(	O
37	NMN	O
38	)	O
39	(	O
40	32	O
41	%)	O
42	and	O
43	increased	O
44	NA	O
45	levels	O
46	(	O
47	28	O
48	%).	O

1	Fufang	O
2	wuzi	O
3	yanzong	O
4	pills	O
5	have	O
6	strong	O
7	leukogenic	O
8	effect	O
9	on	O
10	cyclophosphamide	O
11	induced	O
12	leukopenia	O
13	in	O
14	mice	O
15	.	O

1	Mutations	O
2	in	O
3	the	O
4	small	O
5	subunit	O
6	of	O
7	ribulosebisphosphate	B
8	carboxylase	I
9	affect	O
10	subunit	O
11	binding	O
12	and	O
13	catalysis	O
14	.	O

1	The	O
2	structural	O
3	changes	O
4	in	O
5	intra	O
6	-	O
7	acinar	O
8	artery	O
9	manifested	O
10	mainly	O
11	by	O
12	an	O
13	increase	O
14	in	O
15	number	O
16	of	O
17	muscular	O
18	artery	O
19	resulting	O
20	from	O
21	muscularization	O
22	of	O
23	precursor	O
24	cells	O
25	(	O
26	pericytes	O
27	and	O
28	intermediate	O
29	cells	O
30	)	O
31	located	O
32	within	O
33	partially	O
34	muscular	O
35	and	O
36	nonmuscular	O
37	arterial	O
38	wall	O
39	to	O
40	smooth	O
41	muscle	O
42	cell	O
43	,	O
44	and	O
45	by	O
46	the	O
47	medial	O
48	wall	O
49	thickened	O
50	due	O
51	to	O
52	hypertrophy	O
53	and	O
54	hyperplasia	O
55	of	O
56	smooth	O
57	muscle	O
58	cells	O
59	as	O
60	well	O
61	as	O
62	accumulation	O
63	of	O
64	a	O
65	large	O
66	amount	O
67	of	O
68	collagen	B
69	,	O
70	especially	O
71	the	O
72	type	B
73	1	I
74	collagen	I
75	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	NZ	O
6	-	O
7	107	O
8	may	O
9	be	O
10	a	O
11	useful	O
12	drug	O
13	for	O
14	the	O
15	treatment	O
16	of	O
17	bronchial	O
18	asthma	O
19	by	O
20	reducing	O
21	late	O
22	-	O
23	phase	O
24	airway	O
25	responses	O
26	and	O
27	airway	O
28	hyperreactivity	O
29	.	O

1	In	O
2	study	O
3	2	O
4	,	O
5	the	O
6	correlation	O
7	coefficients	O
8	between	O
9	the	O
10	ISO2	O
11	measurements	O
12	obtained	O
13	at	O
14	the	O
15	ulcer	O
16	margin	O
17	and	O
18	at	O
19	the	O
20	adjacent	O
21	normal	O
22	mucosa	O
23	,	O
24	and	O
25	delta	O
26	ISO2	O
27	obtained	O
28	by	O
29	the	O
30	experienced	O
31	observer	O
32	and	O
33	one	O
34	of	O
35	the	O
36	three	O
37	learners	O
38	were	O
39	0	O
40	.	O
41	94	O
42	,	O
43	0	O
44	.	O
45	97	O
46	,	O
47	and	O
48	0	O
49	.	O
50	94	O
51	,	O
52	respectively	O
53	.	O

1	Bronchial	O
2	mucosa	O
3	tattooing	O
4	in	O
5	persons	O
6	exposed	O
7	to	O
8	different	O
9	industrial	O
10	aerosols	O
11	did	O
12	not	O
13	depend	O
14	on	O
15	the	O
16	forms	O
17	of	O
18	PC	O
19	,	O
20	DB	O
21	and	O
22	the	O
23	diseases	O
24	'	O
25	stages	O
26	.	O

1	Anti	B
2	-	I
3	HBc	I
4	production	O
5	of	O
6	PBMC	O
7	was	O
8	enhanced	O
9	remarkably	O
10	in	O
11	this	O
12	case	O
13	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	sMtCK	B
6	genomic	I
7	upstream	I
8	sequences	I
9	reveals	O
10	a	O
11	typical	O
12	TATAA	O
13	box	O
14	within	O
15	the	O
16	80	O
17	base	O
18	pairs	O
19	(	O
20	bp	O
21	)	O
22	that	O
23	,	O
24	by	O
25	transfection	O
26	experiments	O
27	,	O
28	are	O
29	sufficient	O
30	to	O
31	promote	O
32	expression	O
33	of	O
34	chimeric	O
35	plasmids	O
36	with	O
37	the	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	I
41	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	sMtCK	B
6	genomic	I
7	upstream	I
8	sequences	I
9	reveals	O
10	a	O
11	typical	O
12	TATAA	O
13	box	O
14	within	O
15	the	O
16	80	O
17	base	O
18	pairs	O
19	(	O
20	bp	O
21	)	O
22	that	O
23	,	O
24	by	O
25	transfection	O
26	experiments	O
27	,	O
28	are	O
29	sufficient	O
30	to	O
31	promote	O
32	expression	O
33	of	O
34	chimeric	O
35	plasmids	O
36	with	O
37	the	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	I
41	.	O

1	The	O
2	cDNA	O
3	segment	O
4	is	O
5	flanked	O
6	by	O
7	the	O
8	immunoglobulin	B
9	gene	I
10	recombination	I
11	signal	I
12	sequences	I
13	so	O
14	that	O
15	the	O
16	cDNA	O
17	segment	O
18	can	O
19	invert	O
20	and	O
21	the	O
22	human	B
23	IL	I
24	-	I
25	2R	I
26	L	I
27	chain	I
28	is	O
29	subsequently	O
30	expressed	O
31	under	O
32	the	O
33	control	O
34	of	O
35	the	O
36	SV40	B
37	promoter	I
38	.	O

1	Lipoprotein	B
2	lipase	I
3	(	O
4	LPL	B
5	),	O
6	a	O
7	key	O
8	enzyme	O
9	in	O
10	normal	O
11	lipoprotein	O
12	metabolism	O
13	,	O
14	has	O
15	a	O
16	complex	O
17	pattern	O
18	of	O
19	regulation	O
20	and	O
21	tissue	O
22	-	O
23	specific	O
24	expression	O
25	.	O

1	Deletion	O
2	of	O
3	the	O
4	proximal	O
5	octanucleotide	O
6	motif	O
7	from	O
8	the	O
9	plasmid	O
10	containing	O
11	the	O
12	-	O
13	461	O
14	fragment	O
15	of	O
16	the	O
17	LPL	B
18	promoter	I
19	,	O
20	resulted	O
21	in	O
22	a	O
23	79	O
24	and	O
25	76	O
26	%	O
27	decrease	O
28	in	O
29	the	O
30	level	O
31	of	O
32	expression	O
33	in	O
34	transfected	O
35	3T3	O
36	-	O
37	L1	O
38	adipocytes	O
39	and	O
40	HepG2	O
41	hepatocytes	O
42	,	O
43	respectively	O
44	.	O

1	We	O
2	examined	O
3	the	O
4	binding	O
5	of	O
6	purified	O
7	T3	B
8	receptor	I
9	alpha	I
10	(	O
11	T3R	B
12	alpha	I
13	),	O
14	overexpressed	O
15	in	O
16	Escherichia	O
17	coli	O
18	,	O
19	to	O
20	wild	O
21	-	O
22	type	O
23	and	O
24	up	O
25	and	O
26	down	O
27	mutations	O
28	of	O
29	the	O
30	rGH	B
31	T3RE	I
32	to	O
33	evaluate	O
34	whether	O
35	transcriptional	O
36	potency	O
37	correlates	O
38	with	O
39	changes	O
40	in	O
41	T3R	B
42	binding	O
43	.	O

1	Comparison	O
2	of	O
3	the	O
4	cDNA	O
5	-	O
6	predicted	O
7	avian	B
8	TnIcardiac	I
9	amino	I
10	acid	I
11	sequences	I
12	with	O
13	known	O
14	TnI	B
15	sequences	I
16	indicated	O
17	1	O
18	)	O
19	that	O
20	the	O
21	presence	O
22	of	O
23	an	O
24	N	O
25	-	O
26	terminal	O
27	extension	O
28	sequence	O
29	carrying	O
30	a	O
31	dual	O
32	protein	B
33	kinase	I
34	A	I
35	phosphorylation	O
36	target	O
37	site	O
38	and	O
39	an	O
40	adjacent	O
41	proline	O
42	-	O
43	rich	O
44	segment	O
45	is	O
46	an	O
47	ancient	O
48	cardiac	O
49	-	O
50	specific	O
51	feature	O
52	of	O
53	TnI	B
54	which	O
55	has	O
56	been	O
57	conserved	O
58	since	O
59	the	O
60	bird	O
61	/	O
62	mammal	O
63	divergence	O
64	,	O
65	2	O
66	)	O
67	that	O
68	features	O
69	of	O
70	the	O
71	near	O
72	-	O
73	N	O
74	-	O
75	terminal	O
76	troponin	B
77	C	I
78	(	O
79	TnC	B
80	)-	O
81	binding	O
82	site	O
83	sequence	O
84	suggest	O
85	isoform	O
86	-	O
87	specific	O
88	adaptation	O
89	of	O
90	TnI	B
91	and	O
92	TnC	B
93	,	O
94	and	O
95	3	O
96	)	O
97	that	O
98	the	O
99	avian	O
100	TnIcardiac	B
101	internal	O
102	actin	B
103	/	I
104	TnC	I
105	-	I
106	binding	I
107	,	I
108	actomyosin	I
109	-	I
110	inhibitory	I
111	,	I
112	domain	I
113	shows	O
114	significant	O
115	sequence	O
116	divergence	O
117	from	O
118	mammalian	B
119	TnIcardiac	I
120	sequences	I
121	,	O
122	including	O
123	the	O
124	absence	O
125	of	O
126	a	O
127	protein	B
128	kinase	I
129	C	I
130	target	O
131	site	O
132	which	O
133	is	O
134	a	O
135	cardiac	O
136	-	O
137	specific	O
138	feature	O
139	of	O
140	TnI	B
141	in	O
142	mammals	O
143	.	O

1	Ventilatory	O
2	management	O
3	casebook	O
4	.	O

1	An	O
2	ASSEMBLER	O
3	routine	O
4	for	O
5	on	O
6	-	O
7	line	O
8	graphic	O
9	display	O
10	and	O
11	averaging	O
12	of	O
13	data	O
14	acquired	O
15	on	O
16	a	O
17	personal	O
18	microcomputer	O
19	.	O

1	Expression	O
2	of	O
3	the	O
4	mouse	B
5	TSH	I
6	beta	I
7	gene	I
8	,	O
9	therefore	O
10	,	O
11	gives	O
12	rise	O
13	to	O
14	multiple	O
15	mRNAs	O
16	,	O
17	each	O
18	with	O
19	a	O
20	unique	O
21	5	O
22	'-	O
23	untranslated	O
24	region	O
25	.	O

1	Habituation	O
2	of	O
3	completely	O
4	isolated	O
5	neurons	O
6	of	O
7	the	O
8	edible	O
9	snail	O
10	to	O
11	electrical	O
12	stimulation	O
13	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	the	O
6	ROSP	O
7	undergoes	O
8	a	O
9	number	O
10	of	O
11	fluctuations	O
12	in	O
13	the	O
14	negative	O
15	and	O
16	positive	O
17	directions	O
18	with	O
19	a	O
20	gradually	O
21	decreasing	O
22	amplitude	O
23	in	O
24	the	O
25	course	O
26	of	O
27	5	O
28	-	O
29	25	O
30	days	O
31	following	O
32	the	O
33	operation	O
34	,	O
35	after	O
36	which	O
37	relatively	O
38	stable	O
39	negative	O
40	values	O
41	of	O
42	the	O
43	ROSP	O
44	are	O
45	established	O
46	on	O
47	the	O
48	average	O
49	in	O
50	electrodes	O
51	implanted	O
52	to	O
53	the	O
54	level	O
55	of	O
56	the	O
57	dura	O
58	mater	O
59	,	O
60	and	O
61	positive	O
62	values	O
63	in	O
64	electrodes	O
65	implanted	O
66	to	O
67	the	O
68	level	O
69	of	O
70	the	O
71	pia	O
72	mater	O
73	.	O

1	Blood	O
2	flow	O
3	velocity	O
4	waveforms	O
5	were	O
6	recorded	O
7	by	O
8	pulsed	O
9	Doppler	O
10	examination	O
11	of	O
12	the	O
13	fetal	O
14	internal	O
15	carotid	O
16	and	O
17	middle	O
18	cerebral	O
19	arteries	O
20	using	O
21	the	O
22	established	O
23	transabdominal	O
24	route	O
25	as	O
26	well	O
27	as	O
28	a	O
29	new	O
30	transvaginal	O
31	approach	O
32	.	O

1	Quantitative	O
2	analysis	O
3	of	O
4	DNA	O
5	using	O
6	flow	O
7	cytometry	O
8	and	O
9	immunocytochemical	O
10	findings	O
11	in	O
12	16	O
13	cases	O
14	of	O
15	cardiac	O
16	myxomas	O

1	Sequence	O
2	analysis	O
3	revealed	O
4	that	O
5	in	O
6	addition	O
7	to	O
8	the	O
9	non	O
10	-	O
11	spliced	O
12	variant	O
13	,	O
14	multiple	O
15	mRNA	O
16	species	O
17	were	O
18	generated	O
19	by	O
20	alternative	O
21	splicing	O
22	resulting	O
23	in	O
24	the	O
25	exclusion	O
26	of	O
27	92	O
28	,	O
29	166	O
30	,	O
31	170	O
32	,	O
33	174	O
34	and	O
35	263	O
36	nucleotides	O
37	(	O
38	nt	O
39	),	O
40	respectively	O
41	,	O
42	from	O
43	exon	O
44	1	O
45	.	O

1	Position	O
2	22	O
3	is	O
4	an	O
5	isoleucine	O
6	in	O
7	the	O
8	complete	B
9	SsoL12	I
10	protein	I
11	sequence	I
12	,	O
13	coded	O
14	by	O
15	an	O
16	AUA	O
17	codon	O
18	.	O

1	Symptoms	O
2	due	O
3	to	O
4	the	O
5	action	O
6	of	O
7	mastocyte	O
8	mediators	O
9	were	O
10	observed	O
11	.	O

1	In	O
2	the	O
3	yeast	O
4	Saccharomyces	O
5	cerevisiae	O
6	,	O
7	copper	O
8	levels	O
9	exert	O
10	some	O
11	control	O
12	over	O
13	the	O
14	level	O
15	of	O
16	SOD1	B
17	expression	O
18	.	O

1	Of	O
2	these	O
3	179	O
4	samples	O
5	,	O
6	Mobiluncus	O
7	SP	O
8	was	O
9	observed	O
10	in	O
11	35	O
12	(	O
13	19	O
14	.	O
15	6	O
16	%)	O
17	using	O
18	Gram	O
19	staining	O
20	and	O
21	in	O
22	18	O
23	(	O
24	10	O
25	.	O
26	1	O
27	%)	O
28	this	O
29	microorganism	O
30	was	O
31	isolated	O
32	in	O
33	agar	O
34	RLK	O
35	and	O
36	anaerobic	O
37	atmosphere	O
38	.	O

1	Previous	O
2	investigators	O
3	have	O
4	suggested	O
5	that	O
6	subretinal	O
7	blood	O
8	damages	O
9	the	O
10	retina	O
11	in	O
12	part	O
13	because	O
14	of	O
15	its	O
16	solid	O
17	fibrin	B
18	meshwork	O
19	.	O

1	Twenty	O
2	-	O
3	four	O
4	hours	O
5	later	O
6	,	O
7	the	O
8	animals	O
9	were	O
10	randomized	O
11	to	O
12	subretinal	O
13	treatment	O
14	with	O
15	2	O
16	.	O
17	5	O
18	micrograms	O
19	of	O
20	tissue	B
21	plasminogen	I
22	activator	I
23	or	O
24	a	O
25	similar	O
26	volume	O
27	of	O
28	physiologic	O
29	saline	O
30	.	O

1	Neuro	O
2	-	O
3	otological	O
4	examinations	O
5	revealed	O
6	spontaneous	O
7	downbeat	O
8	nystagmus	O
9	,	O
10	bilateral	O
11	gaze	O
12	nystagmus	O
13	and	O
14	rebound	O
15	nystagmus	O
16	.	O

1	Since	O
2	the	O
3	morphology	O
4	of	O
5	the	O
6	lesions	O
7	can	O
8	mimic	O
9	that	O
10	of	O
11	other	O
12	cutaneous	O
13	disorders	O
14	,	O
15	Bowen	O
16	'	O
17	s	O
18	disease	O
19	is	O
20	often	O
21	not	O
22	recognized	O
23	initially	O
24	.	O

1	Equine	O
2	amnion	O
3	and	O
4	live	O
5	yeast	O
6	cell	O
7	derivative	O
8	were	O
9	evaluated	O
10	as	O
11	a	O
12	biological	O
13	dressing	O
14	and	O
15	as	O
16	a	O
17	topical	O
18	wound	O
19	medicament	O
20	respectively	O
21	,	O
22	in	O
23	the	O
24	treatment	O
25	of	O
26	granulating	O
27	wounds	O
28	of	O
29	the	O
30	distal	O
31	portion	O
32	of	O
33	the	O
34	limbs	O
35	of	O
36	horses	O
37	.	O

1	To	O
2	lower	O
3	the	O
4	current	O
5	high	O
6	incidence	O
7	of	O
8	NANB	O
9	-	O
10	induced	O
11	PTH	O
12	,	O
13	in	O
14	1986	O
15	,	O
16	the	O
17	American	O
18	Association	O
19	of	O
20	Blood	O
21	Banks	O
22	(	O
23	AABB	O
24	)	O
25	recommended	O
26	testing	O
27	for	O
28	these	O
29	PTH	O
30	-	O
31	associated	O
32	"	O
33	surrogate	O
34	"	O
35	markers	O
36	on	O
37	all	O
38	donated	O
39	units	O
40	of	O
41	blood	O
42	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	1	I
7	(	O
8	IGF	B
9	-	I
10	1	I
11	)	O
12	in	O
13	burn	O
14	patients	O
15	.	O

1	Fusion	O
2	of	O
3	ubiquitin	B
4	to	O
5	pADPRP	B
6	increased	O
7	the	O
8	yield	O
9	of	O
10	pADPRP	B
11	approximately	O
12	10	O
13	-	O
14	fold	O
15	compared	O
16	to	O
17	that	O
18	of	O
19	the	O
20	unfused	O
21	enzyme	O
22	.	O

1	In	O
2	group	O
3	III	O
4	,	O
5	patients	O
6	also	O
7	received	O
8	their	O
9	own	O
10	mediastinal	O
11	drainage	O
12	blood	O
13	,	O
14	shed	O
15	for	O
16	6	O
17	hours	O
18	after	O
19	operation	O
20	,	O
21	after	O
22	concentration	O
23	and	O
24	washing	O
25	in	O
26	a	O
27	MBRS	O
28	.	O

1	The	O
2	suppression	O
3	was	O
4	also	O
5	demonstrated	O
6	in	O
7	a	O
8	transient	O
9	expression	O
10	assay	O
11	in	O
12	vivo	O
13	using	O
14	isolated	O
15	barley	O
16	endosperms	O
17	.	O

1	The	O
2	effect	O
3	of	O
4	salmon	B
5	calcitonin	I
6	nasal	O
7	spray	O
8	in	O
9	women	O
10	with	O
11	established	O
12	osteoporosis	O
13	has	O
14	also	O
15	been	O
16	studied	O
17	.	O

1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	responses	O
5	are	O
6	impaired	O
7	in	O
8	heart	O
9	failure	O
10	.	O

1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	exercise	O
5	responses	O
6	are	O
7	attenuated	O
8	in	O
9	heart	O
10	failure	O
11	.	O

1	Evaluation	O
2	of	O
3	antiepileptic	O
4	drug	O
5	effect	O
6	on	O
7	membrane	O
8	fluidity	O
9	.	O

1	The	O
2	examinations	O
3	were	O
4	performed	O
5	on	O
6	two	O
7	groups	O
8	of	O
9	20	O
10	(	O
11	using	O
12	AmF	O
13	/	O
14	SnF2	O
15	)-,	O
16	resp	O
17	.	O

1	RNA	O
2	gel	O
3	retardation	O
4	and	O
5	competition	O
6	analyses	O
7	indicate	O
8	that	O
9	TRP	B
10	-	I
11	185	I
12	binding	O
13	is	O
14	strongly	O
15	dependent	O
16	on	O
17	the	O
18	TAR	O
19	RNA	O
20	loop	O
21	sequences	O
22	.	O

1	The	O
2	vaccine	O
3	used	O
4	was	O
5	known	O
6	to	O
7	be	O
8	immunogenic	O
9	for	O
10	older	O
11	children	O
12	and	O
13	adults	O
14	.	O

1	Both	O
2	groups	O
3	then	O
4	underwent	O
5	hypnotic	O
6	induction	O
7	,	O
8	and	O
9	completed	O
10	the	O
11	test	O
12	again	O
13	(	O
14	R2	O
15	).	O

1	Applications	O
2	of	O
3	three	O
4	-	O
5	dimensional	O
6	analysis	O
7	to	O
8	the	O
9	auditory	O
10	P300	O
11	.	O

1	The	O
2	construct	O
3	was	O
4	introduced	O
5	into	O
6	BW2001	O
7	(	O
8	xth	O
9	-	O
10	11	O
11	,	O
12	nfo	O
13	-	O
14	2	O
15	)	O
16	strain	O
17	cells	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O

1	Recombinant	B
2	human	I
3	TFIID	I
4	supported	O
5	weak	O
6	basal	O
7	transcription	O
8	in	O
9	heat	O
10	-	O
11	treated	O
12	nuclear	O
13	extracts	O
14	whereas	O
15	a	O
16	partially	O
17	purified	O
18	TFIID	B
19	fraction	O
20	from	O
21	HeLa	O
22	cells	O
23	reconstituted	O
24	a	O
25	maximal	O
26	level	O
27	of	O
28	transcription	O
29	.	O

1	Only	O
2	after	O
3	a	O
4	pretreatment	O
5	aimed	O
6	at	O
7	increasing	O
8	its	O
9	oxide	O
10	surface	O
11	layer	O
12	was	O
13	titanium	O
14	powder	O
15	found	O
16	to	O
17	accelerate	O
18	the	O
19	precipitation	O
20	from	O
21	solutions	O
22	containing	O
23	2	O
24	mmol	O
25	/	O
26	L	O
27	CaCl2	O
28	,	O
29	2	O
30	mmol	O
31	/	O
32	L	O
33	KH2PO4	O
34	,	O
35	50	O
36	mmol	O
37	/	O
38	L	O
39	Hepes	O
40	,	O
41	pH	O
42	7	O
43	.	O
44	2	O
45	,	O
46	and	O
47	to	O
48	induce	O
49	precipitation	O
50	from	O
51	metastable	O
52	solutions	O
53	containing	O
54	1	O
55	.	O
56	2	O
57	mmol	O
58	/	O
59	L	O
60	CaCl2	O
61	,	O
62	1	O
63	.	O
64	2	O
65	mmol	O
66	/	O
67	L	O
68	KH2PO4	O
69	,	O
70	50	O
71	mmol	O
72	/	O
73	L	O
74	Hepes	O
75	,	O
76	pH	O
77	7	O
78	.	O
79	2	O
80	,	O
81	at	O
82	37	O
83	degrees	O
84	C	O
85	.	O

1	We	O
2	conclude	O
3	that	O
4	solidification	O
5	could	O
6	occur	O
7	in	O
8	all	O
9	feeds	O
10	containing	O
11	casein	B
12	and	O
13	that	O
14	alternative	O
15	feeds	O
16	should	O
17	be	O
18	considered	O
19	in	O
20	patients	O
21	with	O
22	increased	O
23	gastric	O
24	acidity	O
25	.	O

1	Neither	O
2	model	O
3	,	O
4	as	O
5	applied	O
6	,	O
7	provided	O
8	a	O
9	satisfactory	O
10	account	O
11	of	O
12	the	O
13	effects	O
14	of	O
15	the	O
16	main	O
17	variables	O
18	of	O
19	number	O
20	of	O
21	tones	O
22	and	O
23	amount	O
24	of	O
25	perturbation	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	400	O
31	WORDS	O
32	)	O

1	This	O
2	generalization	O
3	of	O
4	MFP	O
5	involves	O
6	defining	O
7	an	O
8	appropriate	O
9	high	O
10	-	O
11	resolution	O
12	cost	O
13	function	O
14	,	O
15	parametrizing	O
16	the	O
17	search	O
18	space	O
19	of	O
20	the	O
21	environment	O
22	and	O
23	source	O
24	,	O
25	constructing	O
26	solutions	O
27	of	O
28	the	O
29	wave	O
30	equation	O
31	,	O
32	and	O
33	utilizing	O
34	a	O
35	nonlinear	O
36	optimization	O
37	method	O
38	to	O
39	search	O
40	the	O
41	parameter	O
42	landscape	O
43	for	O
44	the	O
45	global	O
46	minimum	O
47	of	O
48	the	O
49	cost	O
50	function	O
51	.	O

1	Determination	O
2	of	O
3	an	O
4	RNA	O
5	structure	O
6	involved	O
7	in	O
8	splicing	O
9	inhibition	O
10	of	O
11	a	O
12	muscle	O
13	-	O
14	specific	O
15	exon	O
16	.	O

1	Endothelial	O
2	cells	O
3	stored	O
4	with	O
5	University	O
6	of	O
7	Wisconsin	O
8	solution	O
9	excluded	O
10	trypan	O
11	blue	O
12	better	O
13	(	O
14	1	O
15	.	O
16	0	O
17	%	O
18	+/-	O
19	0	O
20	.	O
21	5	O
22	%	O
23	cells	O
24	stained	O
25	,	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	.	O

1	The	O
2	original	O
3	technique	O
4	was	O
5	developed	O
6	in	O
7	the	O
8	1960	O
9	'	O
10	s	O
11	to	O
12	analyze	O
13	the	O
14	inner	O
15	ear	O
16	fluid	O
17	as	O
18	a	O
19	diagnostic	O
20	procedure	O
21	(	O
22	i	O
23	.	O
24	e	O
25	.,	O
26	diagnostic	O
27	labyrinthotomy	O
28	)	O
29	in	O
30	acoustic	O
31	neuroma	O
32	suspects	O
33	.	O

1	The	O
2	effect	O
3	of	O
4	diffusion	O
5	limitation	O
6	was	O
7	quantified	O
8	in	O
9	terms	O
10	of	O
11	the	O
12	ratio	O
13	O2	O
14	uptake	O
15	/	O
16	O2	O
17	requirement	O
18	(=	O
19	fraction	O
20	of	O
21	cross	O
22	-	O
23	sectional	O
24	area	O
25	supplied	O
26	with	O
27	O2	O
28	),	O
29	assuming	O
30	local	O
31	O2	O
32	requirement	O
33	per	O
34	unit	O
35	volume	O
36	to	O
37	be	O
38	constant	O
39	and	O
40	independent	O
41	of	O
42	PO2	O
43	at	O
44	PO2	O
45	greater	O
46	than	O
47	0	O
48	.	O

1	(	O
2	2	O
3	)	O
4	Diffusion	O
5	limitation	O
6	in	O
7	the	O
8	heterogeneous	O
9	model	O
10	sets	O
11	in	O
12	at	O
13	a	O
14	lower	O
15	O2	O
16	requirement	O
17	value	O
18	,	O
19	and	O
20	increases	O
21	more	O
22	gradually	O
23	with	O
24	increasing	O
25	O2	O
26	requirement	O
27	,	O
28	than	O
29	in	O
30	the	O
31	corresponding	O
32	homogeneous	O
33	models	O
34	with	O
35	the	O
36	same	O
37	average	O
38	cylinder	O
39	diameter	O
40	.	O

1	The	O
2	antihypertensive	O
3	effect	O
4	of	O
5	Estulic	O
6	has	O
7	been	O
8	examined	O
9	over	O
10	a	O
11	12	O
12	-	O
13	month	O
14	period	O
15	in	O
16	101	O
17	hypertensive	O
18	patients	O
19	.	O

1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	seizure	O
7	,	O
8	the	O
9	patient	O
10	was	O
11	asked	O
12	to	O
13	read	O
14	a	O
15	test	O
16	phrase	O
17	aloud	O
18	until	O
19	it	O
20	was	O
21	read	O
22	correctly	O
23	and	O
24	clearly	O
25	.	O

1	Monitoring	O
2	patients	O
3	with	O
4	acute	O
5	leukemia	O
6	for	O
7	IL	B
8	-	I
9	1	I
10	and	O
11	TNF	B
12	levels	O
13	throughout	O
14	the	O
15	clinical	O
16	course	O
17	of	O
18	disease	O
19	may	O
20	help	O
21	clarify	O
22	the	O
23	causes	O
24	of	O
25	febrile	O
26	episodes	O
27	.	O

1	Echinococcus	O
2	granulosus	O
3	was	O
4	diagnosed	O
5	by	O
6	fine	O
7	-	O
8	needle	O
9	aspiration	O
10	cytology	O
11	of	O
12	a	O
13	lung	O
14	cyst	O
15	in	O
16	a	O
17	6	O
18	-	O
19	yr	O
20	-	O
21	old	O
22	white	O
23	female	O
24	in	O
25	central	O
26	Missouri	O
27	.	O

1	The	O
2	sequence	O
3	was	O
4	determined	O
5	of	O
6	6493	O
7	nucleotides	O
8	encompassing	O
9	the	O
10	bet	B
11	genes	I
12	of	I
13	Escherichia	I
14	coli	I
15	which	O
16	encode	O
17	the	O
18	osmoregulatory	O
19	choline	O
20	-	O
21	glycine	O
22	betaine	O
23	pathway	O
24	.	O

1	A	O
2	7	O
3	-	O
4	day	O
5	treatment	O
6	of	O
7	amphotericin	O
8	B	O
9	(	O
10	5	O
11	mg	O
12	/	O
13	kg	O
14	/	O
15	day	O
16	i	O
17	.	O
18	p	O
19	.)	O
20	significantly	O
21	reduced	O
22	the	O
23	glomerular	O
24	filtration	O
25	rate	O
26	(	O
27	GFR	O
28	)	O
29	measured	O
30	as	O
31	inuline	O
32	clearance	O
33	and	O
34	creatinine	O
35	clearance	O
36	(	O
37	0	O
38	.	O
39	74	O
40	+/-	O
41	0	O
42	.	O
43	29	O
44	and	O
45	0	O
46	.	O
47	16	O
48	+/-	O
49	0	O
50	.	O
51	04	O
52	ml	O
53	/	O
54	min	O
55	,	O
56	respectively	O
57	)	O
58	in	O
59	comparison	O
60	to	O
61	vehicle	O
62	-	O
63	treated	O
64	rats	O
65	(	O
66	2	O
67	.	O
68	04	O
69	+/-	O
70	0	O
71	.	O
72	23	O
73	and	O
74	1	O
75	.	O
76	29	O
77	+/-	O
78	0	O
79	.	O
80	19	O
81	ml	O
82	/	O
83	min	O
84	,	O
85	respectively	O
86	).	O

1	Evolution	O
2	of	O
3	lesions	O
4	did	O
5	not	O
6	necessarily	O
7	follow	O
8	a	O
9	regular	O
10	progression	O
11	through	O
12	the	O
13	later	O
14	stages	O
15	of	O
16	the	O
17	vitelliform	O
18	classification	O
19	.	O

1	Confocal	O
2	fluorescence	O
3	microscopy	O
4	in	O
5	modern	O
6	cell	O
7	biology	O
8	.	O

1	Toluene	O
2	is	O
3	the	O
4	chemical	O
5	most	O
6	frequently	O
7	present	O
8	in	O
9	cases	O
10	involving	O
11	volatile	O
12	solvents	O
13	.	O

1	Fortunately	O
2	DDT	O
3	-,	O
4	HCH	O
5	-	O
6	and	O
7	HCB	O
8	-	O
9	levels	O
10	decreased	O
11	in	O
12	breast	O
13	milk	O
14	during	O
15	the	O
16	last	O
17	years	O
18	.	O

1	A	O
2	herpesvirus	O
3	proteinase	O
4	activity	O
5	has	O
6	been	O
7	identified	O
8	and	O
9	partially	O
10	characterized	O
11	by	O
12	using	O
13	the	O
14	cloned	O
15	enzyme	O
16	and	O
17	substrate	O
18	genes	O
19	in	O
20	transient	O
21	transfection	O
22	assays	O
23	.	O

1	Adult	O
2	H	O
3	,	O
4	but	O
5	not	O
6	R	O
7	,	O
8	manifested	O
9	the	O
10	burrowing	O
11	preference	O
12	whenever	O
13	offered	O
14	the	O
15	opportunity	O
16	.	O

1	The	O
2	rear	O
3	silver	O
4	liquid	O
5	chamber	O
6	was	O
7	threefold	O
8	thick	O
9	to	O
10	17	O
11	MeV	O
12	protons	O
13	in	O
14	water	O
15	and	O
16	it	O
17	efficiently	O
18	produced	O
19	either	O
20	13N	O
21	by	O
22	the	O
23	16O	O
24	(	O
25	p	O
26	,	O
27	alpha	O
28	)	O
29	13N	O
30	reaction	O
31	or	O
32	[	O
33	18F	O
34	]	O
35	fluoride	O
36	ion	O
37	by	O
38	the	O
39	18O	O
40	(	O
41	p	O
42	,	O
43	n	O
44	)	O
45	18F	O
46	reaction	O
47	.	O

1	Heterogeneous	O
2	electron	O
3	transfer	O
4	of	O
5	cytochrome	B
6	c	I
7	facilitated	O
8	by	O
9	polypyrrole	O
10	and	O
11	methylene	O
12	blue	O
13	polypyrrole	O
14	film	O
15	modified	O
16	electrodes	O
17	.	O

1	Selective	O
2	activation	O
3	of	O
4	adrenaline	O
5	secretion	O
6	by	O
7	the	O
8	rat	O
9	adrenal	O
10	in	O
11	neuroglycopenia	O
12	detected	O
13	via	O
14	microdialysis	O

1	Urine	O
2	specimens	O
3	containing	O
4	either	O
5	phencyclidine	O
6	(	O
7	PCP	O
8	)	O
9	or	O
10	11	O
11	-	O
12	nor	O
13	-	O
14	delta	O
15	9	O
16	-	O
17	tetrahydrocannabinol	O
18	-	O
19	9	O
20	-	O
21	carboxylic	O
22	acid	O
23	(	O
24	9	O
25	-	O
26	THC	O
27	-	O
28	COOH	O
29	)	O
30	were	O
31	adulterated	O
32	with	O
33	sodium	O
34	chloride	O
35	,	O
36	bleach	O
37	,	O
38	vinegar	O
39	,	O
40	potassium	O
41	hydroxide	O
42	,	O
43	liquid	O
44	soap	O
45	,	O
46	2	O
47	-	O
48	propanol	O
49	,	O
50	and	O
51	ammonia	O
52	.	O

1	The	O
2	1489	O
3	-	O
4	base	O
5	pair	O
6	EFIA	B
7	cDNA	O
8	encodes	O
9	a	O
10	322	O
11	-	O
12	amino	O
13	acid	O
14	protein	O
15	which	O
16	is	O
17	nearly	O
18	identical	O
19	to	O
20	two	O
21	previously	O
22	described	O
23	human	O
24	DNA	O
25	binding	O
26	proteins	O
27	.	O

1	Four	O
2	putative	O
3	positive	O
4	cDNA	O
5	clones	O
6	were	O
7	isolated	O
8	,	O
9	and	O
10	the	O
11	largest	O
12	insert	O
13	(	O
14	pASB	B
15	-	I
16	1	I
17	)	O
18	was	O
19	sequenced	O
20	in	O
21	both	O
22	orientations	O
23	.	O

1	Sci	O
2	.	O

1	Dose	O
2	standardisation	O
3	of	O
4	botulinum	B
5	toxin	I
6	.	O

1	The	O
2	coding	O
3	sequence	O
4	for	O
5	a	O
6	260	O
7	-	O
8	amino	O
9	-	O
10	acid	O
11	residue	O
12	polypeptide	O
13	was	O
14	interrupted	O
15	by	O
16	a	O
17	single	O
18	short	O
19	intron	O
20	of	O
21	60	O
22	base	O
23	pairs	O
24	(	O
25	bp	O
26	),	O
27	and	O
28	about	O
29	70	O
30	%	O
31	of	O
32	the	O
33	deduced	O
34	amino	O
35	acid	O
36	sequence	O
37	of	O
38	the	O
39	Drosophila	B
40	PCNA	I
41	was	O
42	identical	O
43	to	O
44	the	O
45	rat	O
46	and	O
47	human	B
48	PCNA	I
49	polypeptides	I
50	,	O
51	with	O
52	conserved	O
53	unique	O
54	repeats	O
55	of	O
56	leucine	O
57	in	O
58	the	O
59	C	O
60	-	O
61	terminal	O
62	region	O
63	.	O

1	Translational	O
2	fusions	O
3	of	O
4	the	O
5	aroF	B
6	regulatory	I
7	regions	I
8	to	O
9	lacZ	B
10	were	O
11	constructed	O
12	and	O
13	then	O
14	introduced	O
15	in	O
16	single	O
17	copy	O
18	into	O
19	the	O
20	E	O
21	.	O
22	coli	O
23	chromosome	O
24	.	O
25	beta	B
26	-	I
27	Galactosidase	I
28	assays	O
29	for	O
30	tyrR	O
31	-	O
32	mediated	O
33	regulation	O
34	of	O
35	aroF	B
36	-	O
37	lacZ	B
38	expression	O
39	revealed	O
40	that	O
41	the	O
42	E	B
43	.	I
44	coli	I
45	TyrR	I
46	repressor	I
47	apparently	O
48	recognizes	O
49	the	O
50	operators	O
51	of	O
52	both	O
53	organisms	O
54	with	O
55	about	O
56	equal	O
57	efficiency	O
58	.	O

1	Along	O
2	with	O
3	previously	O
4	mapped	O
5	genes	O
6	including	O
7	Ly	B
8	-	I
9	1	I
10	and	O
11	CD20	B
12	,	O
13	OSBP	B
14	defines	O
15	a	O
16	new	O
17	conserved	O
18	syntenic	O
19	group	O
20	on	O
21	the	O
22	long	O
23	arm	O
24	of	O
25	chromosome	O
26	11	O
27	in	O
28	the	O
29	human	O
30	and	O
31	the	O
32	proximal	O
33	end	O
34	of	O
35	chromosome	O
36	19	O
37	in	O
38	the	O
39	mouse	O
40	.	O

1	During	O
2	exercise	O
3	K	O
4	+	O
5	is	O
6	released	O
7	from	O
8	contracting	O
9	muscle	O
10	and	O
11	plasma	O
12	K	O
13	+	O
14	concentration	O
15	rises	O
16	.	O

1	Following	O
2	treatment	O
3	,	O
4	serum	O
5	estradiol	O
6	levels	O
7	were	O
8	higher	O
9	in	O
10	groups	O
11	E	O
12	+	O
13	T	O
14	and	O
15	E	O
16	than	O
17	in	O
18	group	O
19	C	O
20	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	beta	O
6	-	O
7	adrenergic	O
8	agonist	O
9	,	O
10	isoproterenol	O
11	,	O
12	has	O
13	little	O
14	influence	O
15	on	O
16	vascular	O
17	capacitance	O
18	or	O
19	liver	O
20	volume	O
21	of	O
22	dogs	O
23	,	O
24	unless	O
25	the	O
26	hepatic	O
27	outflow	O
28	resistance	O
29	is	O
30	elevated	O
31	by	O
32	agents	O
33	such	O
34	as	O
35	histamine	O
36	.	O

1	DNA	O
2	sequence	O
3	and	O
4	evolution	O
5	of	O
6	the	O
7	CPS	B
8	domain	I
9	of	O
10	the	O
11	Syrian	B
12	hamster	I
13	multifunctional	I
14	protein	I
15	CAD	I
16	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	these	O
6	synthetic	O
7	binding	O
8	sites	O
9	have	O
10	a	O
11	more	O
12	restricted	O
13	and	O
14	specific	O
15	ability	O
16	to	O
17	enhance	O
18	transcription	O
19	when	O
20	assayed	O
21	in	O
22	transformed	O
23	embryos	O
24	.	O

1	After	O
2	base	O
3	-	O
4	line	O
5	CBF	O
6	was	O
7	established	O
8	,	O
9	hexamethonium	O
10	bromide	O
11	(	O
12	2	O
13	mg	O
14	/	O
15	kg	O
16	iv	O
17	),	O
18	ipratropium	O
19	bromide	O
20	(	O
21	0	O
22	.	O
23	5	O
24	microgram	O
25	/	O
26	kg	O
27	iv	O
28	),	O
29	indomethacin	O
30	(	O
31	2	O
32	mg	O
33	/	O
34	kg	O
35	iv	O
36	),	O
37	or	O
38	intravenous	O
39	0	O
40	.	O
41	9	O
42	%	O
43	saline	O
44	was	O
45	administered	O
46	.	O

1	A	O
2	high	O
3	-	O
4	frequency	O
5	restriction	O
6	fragment	O
7	length	O
8	polymorphism	O
9	was	O
10	evident	O
11	in	O
12	the	O
13	DNA	O
14	from	O
15	29	O
16	unrelated	O
17	individuals	O
18	using	O
19	the	O
20	enzyme	O
21	BglII	B
22	.	O

1	The	O
2	antilog	O
3	transformation	O
4	of	O
5	pH	O
6	did	O
7	not	O
8	improve	O
9	the	O
10	results	O
11	.	O

1	Telomeres	O
2	prevent	O
3	end	O
4	-	O
5	to	O
6	-	O
7	end	O
8	fusions	O
9	and	O
10	exonucleolytic	O
11	degradation	O
12	,	O
13	enable	O
14	the	O
15	end	O
16	of	O
17	the	O
18	linear	O
19	DNA	O
20	molecule	O
21	to	O
22	replicate	O
23	,	O
24	and	O
25	function	O
26	in	O
27	cell	O
28	division	O
29	.	O

1	One	O
2	of	O
3	these	O
4	is	O
5	located	O
6	in	O
7	the	O
8	5	O
9	'-	O
10	untranslated	O
11	region	O
12	,	O
13	and	O
14	may	O
15	encode	O
16	regulatory	O
17	sequences	O
18	.	O

1	The	O
2	native	O
3	enzyme	O
4	purified	O
5	from	O
6	protease	B
7	-	I
8	B	I
9	-	O
10	deficient	O
11	URA2	B
12	-	O
13	transformed	O
14	cells	O
15	,	O
16	was	O
17	phosphorylated	O
18	in	O
19	vitro	O
20	using	O
21	catalytic	O
22	subunits	O
23	of	O
24	pure	O
25	cAMP	B
26	-	I
27	dependent	I
28	protein	I
29	kinase	I
30	.	O

1	This	O
2	study	O
3	suggests	O
4	that	O
5	BSPMs	O
6	are	O
7	useful	O
8	in	O
9	the	O
10	assessment	O
11	of	O
12	AMI	O
13	in	O
14	terms	O
15	of	O
16	diagnosis	O
17	,	O
18	location	O
19	and	O
20	extent	O
21	of	O
22	myocardial	O
23	infarct	O
24	.	O

1	A	O
2	bovine	O
3	abomasum	O
4	lambda	O
5	gt11	O
6	cDNA	O
7	library	O
8	was	O
9	screened	O
10	with	O
11	a	O
12	monoclonal	O
13	antibody	O
14	raised	O
15	against	O
16	the	O
17	rabbit	B
18	H	I
19	,	I
20	K	I
21	-	I
22	ATPase	I
23	beta	I
24	subunit	I
25	.	O

1	Judicious	O
2	use	O
3	of	O
4	laboratory	O
5	testing	O
6	,	O
7	including	O
8	monitoring	O
9	of	O
10	CD4	B
11	cell	O
12	counts	O
13	,	O
14	is	O
15	recommended	O
16	.	O

1	There	O
2	is	O
3	no	O
4	TATA	O
5	box	O
6	appropriately	O
7	spaced	O
8	upstream	O
9	from	O
10	the	O
11	transcription	O
12	initiation	O
13	site	O
14	.	O

1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'	O
6	end	O
7	of	O
8	the	O
9	growth	O
10	-	O
11	regulated	O
12	Syrian	B
13	hamster	I
14	CAD	I
15	gene	I
16	.	O

1	Early	O
2	cirrhosis	O
3	,	O
4	an	O
5	early	O
6	modality	O
7	of	O
8	the	O
9	evolution	O
10	of	O
11	acute	O
12	hepatitis	O
13	.	O

1	Examination	O
2	of	O
3	immediate	B
4	-	I
5	early	I
6	transcription	I
7	factor	I
8	expression	O
9	during	O
10	the	O
11	MDI	O
12	regimen	O
13	revealed	O
14	that	O
15	RA	O
16	mediated	O
17	an	O
18	elevated	O
19	,	O
20	prolonged	O
21	expression	O
22	of	O
23	c	B
24	-	I
25	Jun	I
26	mRNA	I
27	accompanied	O
28	by	O
29	diminished	O
30	expression	O
31	of	O
32	c	B
33	-	I
34	Fos	I
35	and	O
36	Jun	B
37	-	I
38	B	I
39	mRNAs	I
40	.	O

1	Although	O
2	heart	O
3	rate	O
4	and	O
5	diastolic	O
6	pressure	O
7	rose	O
8	in	O
9	some	O
10	degree	O
11	1	O
12	min	O
13	after	O
14	intubation	O
15	,	O
16	free	O
17	and	O
18	total	O
19	CA	O
20	concentrations	O
21	did	O
22	not	O
23	increase	O
24	during	O
25	study	O
26	period	O
27	.	O

1	Processing	O
2	,	O
3	secretion	O
4	,	O
5	and	O
6	immunoreactivity	O
7	of	O
8	carboxy	B
9	terminally	I
10	truncated	I
11	dengue	I
12	-	I
13	2	I
14	virus	I
15	envelope	I
16	proteins	I
17	expressed	O
18	in	O
19	insect	O
20	cells	O
21	by	O
22	recombinant	O
23	baculoviruses	O
24	.	O

1	Combined	O
2	therapy	O
3	with	O
4	MK	O
5	-	O
6	801	O
7	and	O
8	nimodipine	O
9	for	O
10	protection	O
11	of	O
12	ischemic	O
13	brain	O
14	damage	O
15	.	O

1	Initial	O
2	screening	O
3	of	O
4	a	O
5	rat	O
6	liver	O
7	cDNA	O
8	library	O
9	with	O
10	an	O
11	oligonucleotide	O
12	probe	O
13	derived	O
14	from	O
15	the	O
16	rat	O
17	SCP2	B
18	protein	O
19	sequence	O
20	revealed	O
21	an	O
22	825	O
23	-	O
24	base	O
25	pair	O
26	cDNA	O
27	clone	O
28	coding	O
29	for	O
30	the	O
31	complete	O
32	SCP2	B
33	protein	O
34	sequence	O
35	.	O

1	Cloning	O
2	,	O
3	expression	O
4	,	O
5	and	O
6	nucleotide	O
7	sequence	O
8	of	O
9	rat	B
10	liver	I
11	sterol	I
12	carrier	I
13	protein	I
14	2	I
15	cDNAs	I
16	.	O

1	The	O
2	addition	O
3	of	O
4	an	O
5	equimolar	O
6	complex	O
7	of	O
8	the	O
9	fourth	O
10	and	O
11	seventh	O
12	largest	O
13	subunits	O
14	,	O
15	purified	O
16	from	O
17	pol	B
18	II	I
19	holoenzyme	I
20	by	O
21	ion	O
22	-	O
23	exchange	O
24	chromatography	O
25	in	O
26	the	O
27	presence	O
28	of	O
29	urea	O
30	,	O
31	restored	O
32	promoter	O
33	-	O
34	directed	O
35	initiation	O
36	activity	O
37	to	O
38	pol	B
39	II	I
40	delta	I
41	4	I
42	/	I
43	7	I
44	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	identification	O
6	of	O
7	HSF	B
8	in	O
9	the	O
10	fission	O
11	yeast	O
12	Schizosaccharomyces	O
13	pombe	O
14	.	O

1	Induction	O
2	requires	O
3	the	O
4	ACE1	B
5	gene	I
6	product	I
7	,	O
8	which	O
9	binds	O
10	to	O
11	specific	O
12	sites	O
13	in	O
14	the	O
15	promoter	O
16	region	O
17	of	O
18	the	O
19	CUP1	B
20	gene	I
21	.	O

1	Gel	O
2	mobility	O
3	shift	O
4	assays	O
5	using	O
6	a	O
7	synthetic	O
8	E6	B
9	motif	I
10	detected	O
11	a	O
12	B	O
13	-	O
14	cell	O
15	-	O
16	specific	O
17	complex	O
18	in	O
19	addition	O
20	to	O
21	a	O
22	ubiquitous	O
23	band	O
24	found	O
25	also	O
26	in	O
27	T	O
28	cells	O
29	and	O
30	HeLa	O
31	cells	O
32	.	O

1	Seven	O
2	clones	O
3	encoding	O
4	interferon	B
5	response	I
6	element	I
7	binding	I
8	factors	I
9	have	O
10	been	O
11	isolated	O
12	from	O
13	a	O
14	mouse	O
15	fibroblast	O
16	lambda	O
17	gt11	O
18	cDNA	O
19	library	O
20	by	O
21	using	O
22	a	O
23	32P	O
24	end	O
25	-	O
26	labeled	O
27	tandem	O
28	trimer	O
29	of	O
30	the	O
31	mouse	B
32	(	I
33	2	I
34	'-	I
35	5	I
36	')	I
37	oligoadenylate	I
38	synthetase	I
39	gene	I
40	interferon	O
41	response	O
42	element	O
43	as	O
44	a	O
45	probe	O
46	.	O

1	The	O
2	sequence	O
3	of	O
4	four	O
5	clones	O
6	was	O
7	sufficient	O
8	to	O
9	construct	O
10	a	O
11	3018	B
12	-	I
13	bp	I
14	BAL	I
15	cDNA	I
16	structure	O
17	.	O

1	The	O
2	application	O
3	of	O
4	these	O
5	instruments	O
6	allows	O
7	occlusion	O
8	of	O
9	the	O
10	ascending	O
11	aorta	O
12	traversed	O
13	by	O
14	the	O
15	perfusion	O
16	cannula	O
17	inserted	O
18	directly	O
19	or	O
20	through	O
21	the	O
22	apex	O
23	of	O
24	the	O
25	heart	O
26	as	O
27	well	O
28	as	O
29	simultaneous	O
30	left	O
31	ventricular	O
32	venting	O
33	.	O

1	Adenylosuccinate	B
2	synthetase	I
3	(	O
4	IMP	O
5	:	O
6	L	B
7	-	I
8	aspartate	I
9	ligase	I
10	(	O
11	GDP	O
12	),	O
13	EC	B
14	6	I
15	.	I
16	3	I
17	.	I
18	4	I
19	.	I
20	4	I
21	)	O
22	plays	O
23	an	O
24	important	O
25	role	O
26	in	O
27	purine	O
28	biosynthesis	O
29	catalyzing	O
30	the	O
31	GTP	O
32	-	O
33	dependent	O
34	conversion	O
35	of	O
36	IMP	O
37	to	O
38	AMP	O
39	.	O

1	Immunophenotyping	O
2	in	O
3	four	O
4	cases	O
5	,	O
6	demonstrated	O
7	non	O
8	-	O
9	B	O
10	,	O
11	non	O
12	-	O
13	T	O
14	cell	O
15	origin	O
16	in	O
17	three	O
18	and	O
19	pre	O
20	-	O
21	B	O
22	cell	O
23	origin	O
24	in	O
25	one	O
26	.	O

1	DNA	O
2	-	O
3	protein	O
4	UV	O
5	cross	O
6	-	O
7	linking	O
8	studies	O
9	indicated	O
10	that	O
11	UHF	B
12	-	I
13	1	I
14	has	O
15	an	O
16	electrophoretic	O
17	mobility	O
18	on	O
19	sodium	O
20	dodecyl	O
21	sulfate	O
22	-	O
23	acrylamide	O
24	gels	O
25	of	O
26	approximately	O
27	85	O
28	kDa	O
29	and	O
30	suggested	O
31	that	O
32	additional	O
33	proteins	O
34	,	O
35	specific	O
36	to	O
37	each	O
38	promoter	O
39	,	O
40	bind	O
41	to	O
42	each	O
43	site	O
44	.	O

1	The	O
2	results	O
3	strengthen	O
4	the	O
5	conclusion	O
6	that	O
7	predominantly	O
8	dynamic	O
9	activity	O
10	increases	O
11	the	O
12	G4	B
13	content	O
14	of	O
15	mature	O
16	innervated	O
17	fast	O
18	muscles	O
19	.	O

1	The	O
2	specific	O
3	interaction	O
4	between	O
5	a	O
6	defined	O
7	structural	O
8	element	O
9	of	O
10	the	O
11	human	O
12	immunodeficiency	O
13	virus	O
14	mRNA	O
15	(	O
16	RRE	B
17	,	O
18	the	O
19	Rev	B
20	response	I
21	element	I
22	)	O
23	and	O
24	the	O
25	virus	B
26	-	I
27	encoded	I
28	protein	I
29	Rev	I
30	has	O
31	been	O
32	implicated	O
33	in	O
34	the	O
35	regulation	O
36	of	O
37	the	O
38	export	O
39	of	O
40	unspliced	O
41	or	O
42	singly	O
43	spliced	O
44	mRNA	O
45	from	O
46	the	O
47	nucleus	O
48	to	O
49	the	O
50	cytoplasm	O
51	.	O

1	We	O
2	reviewed	O
3	the	O
4	records	O
5	of	O
6	151	O
7	patients	O
8	with	O
9	optic	O
10	neuritis	O
11	examined	O
12	over	O
13	an	O
14	eight	O
15	-	O
16	year	O
17	period	O
18	.	O

1	Cut	O
2	-	O
3	off	O
4	levels	O
5	that	O
6	define	O
7	abnormality	O
8	are	O
9	rather	O
10	arbitrary	O
11	and	O
12	this	O
13	decreases	O
14	the	O
15	specificity	O
16	of	O
17	the	O
18	test	O
19	in	O
20	apparently	O
21	healthy	O
22	patients	O
23	.	O

1	Alanine	B
2	aminotransferase	I
3	in	O
4	clinical	O
5	practice	O
6	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	Pseudomonas	B
7	putida	I
8	PpG7	I
9	salicylate	I
10	hydroxylase	I
11	gene	I
12	(	O
13	nahG	B
14	)	O
15	and	O
16	its	O
17	3	O
18	'-	O
19	flanking	O
20	region	O
21	.	O

1	All	O
2	six	O
3	ARF	B
4	cDNAs	I
5	are	O
6	more	O
7	similar	O
8	to	O
9	each	O
10	other	O
11	than	O
12	to	O
13	other	O
14	approximately	O
15	20	B
16	-	I
17	kDa	I
18	guanine	I
19	nucleotide	I
20	-	I
21	binding	I
22	proteins	I
23	.	O

1	The	O
2	long	O
3	terminal	O
4	repeat	O
5	(	O
6	LTR	O
7	)	O
8	of	O
9	the	O
10	human	O
11	immunodeficiency	O
12	virus	O
13	(	O
14	HIV	O
15	)	O
16	contains	O
17	three	O
18	binding	O
19	sites	O
20	for	O
21	the	O
22	transcriptional	O
23	factor	O
24	Sp1	B
25	.	O

1	DNA	O
2	from	O
3	PCR	O
4	was	O
5	labeled	O
6	and	O
7	used	O
8	to	O
9	isolate	O
10	several	O
11	lambda	O
12	gt11	O
13	cDNA	O
14	clones	O
15	,	O
16	including	O
17	one	O
18	full	O
19	-	O
20	length	O
21	one	O
22	(	O
23	Dd	B
24	kinase	I
25	-	I
26	2	I
27	).	O

1	Radiation	O
2	-	O
3	induced	O
4	changes	O
5	in	O
6	the	O
7	area	O
8	of	O
9	alveoli	O
10	and	O
11	septa	O
12	as	O
13	well	O
14	as	O
15	collagen	B
16	content	O
17	were	O
18	seen	O
19	11	O
20	weeks	O
21	after	O
22	irradiation	O
23	.	O

1	The	O
2	first	O
3	follow	O
4	-	O
5	up	O
6	was	O
7	at	O
8	a	O
9	nearly	O
10	constant	O
11	interval	O
12	of	O
13	5	O
14	.	O
15	1	O
16	years	O
17	in	O
18	Caerphilly	O
19	and	O
20	3	O
21	.	O
22	2	O
23	years	O
24	in	O
25	Speedwell	O
26	;	O
27	251	O
28	major	O
29	IHD	O
30	events	O
31	had	O
32	occurred	O
33	.	O

1	A	O
2	.	O

1	Perilunar	O
2	luxation	O
3	--	O
4	an	O
5	unusual	O
6	injury	O
7	demanding	O
8	immediate	O
9	and	O
10	correct	O
11	treatment	O

1	Landsberg	O
2	(	O
3	La	O
4	-	O
5	O	O
6	)	O
7	and	O
8	cv	O
9	.	O

1	In	O
2	summary	O
3	,	O
4	at	O
5	equianesthetic	O
6	concentrations	O
7	,	O
8	desflurane	O
9	and	O
10	isoflurane	O
11	produced	O
12	similar	O
13	hemodynamic	O
14	effects	O
15	;	O
16	however	O
17	,	O
18	in	O
19	the	O
20	absence	O
21	of	O
22	drugs	O
23	that	O
24	inhibit	O
25	autonomic	O
26	reflexes	O
27	,	O
28	desflurane	O
29	had	O
30	less	O
31	negative	O
32	inotropic	O
33	activity	O
34	and	O
35	produced	O
36	less	O
37	decrease	O
38	in	O
39	arterial	O
40	pressure	O
41	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	isolation	O
6	of	O
7	a	O
8	full	O
9	-	O
10	length	O
11	cDNA	O
12	clone	O
13	coding	O
14	for	O
15	a	O
16	hitherto	O
17	undiscovered	O
18	isoform	O
19	of	O
20	the	O
21	bovine	B
22	C	I
23	-	I
24	subunit	I
25	.	O

1	Isoform	B
2	C	I
3	beta	I
4	2	I
5	,	O
6	an	O
7	unusual	O
8	form	O
9	of	O
10	the	O
11	bovine	O
12	catalytic	O
13	subunit	O
14	of	O
15	cAMP	B
16	-	I
17	dependent	I
18	protein	I
19	kinase	I
20	.	O

1	Salient	O
2	applications	O
3	of	O
4	PB	O
5	-	O
6	PK	O
7	modeling	O
8	to	O
9	toxicological	O
10	problems	O
11	are	O
12	illustrated	O
13	with	O
14	examples	O
15	.	O

1	Patients	O
2	with	O
3	apparently	O
4	minor	O
5	CT	O
6	abnormalities	O
7	may	O
8	have	O
9	significant	O
10	epidural	O
11	disease	O
12	.	O

1	The	O
2	cdr1	B
3	sequence	I
4	includes	O
5	an	O
6	additional	O
7	237	O
8	amino	O
9	acids	O
10	of	O
11	the	O
12	contiguous	O
13	fragment	O
14	and	O
15	encodes	O
16	a	O
17	product	O
18	of	O
19	predicted	O
20	Mr	O
21	67	O
22	,	O
23	000	O
24	.	O

1	Armed	O
2	with	O
3	a	O
4	clear	O
5	understanding	O
6	of	O
7	the	O
8	pathophysiologic	O
9	pathways	O
10	that	O
11	may	O
12	cause	O
13	and	O
14	/	O
15	or	O
16	contribute	O
17	to	O
18	the	O
19	development	O
20	of	O
21	unconjugated	O
22	hyperbilirubinemia	O
23	and	O
24	the	O
25	associated	O
26	jaundice	O
27	,	O
28	the	O
29	practitioner	O
30	will	O
31	be	O
32	successful	O
33	in	O
34	helping	O
35	the	O
36	family	O
37	understand	O
38	their	O
39	child	O
40	'	O
41	s	O
42	illness	O
43	.	O

1	Displacement	O
2	thresholds	O
3	of	O
4	peripheral	O
5	sites	O
6	in	O
7	monocular	O
8	human	O
9	vision	O
10	were	O
11	obtained	O
12	.	O

1	The	O
2	authors	O
3	report	O
4	a	O
5	case	O
6	in	O
7	which	O
8	stereotactic	O
9	irrigation	O
10	of	O
11	a	O
12	brain	O
13	cyst	O
14	was	O
15	temporally	O
16	associated	O
17	with	O
18	respiratory	O
19	distress	O
20	.	O

1	ELISA	O
2	was	O
3	found	O
4	to	O
5	make	O
6	a	O
7	contribution	O
8	to	O
9	the	O
10	diagnosis	O
11	of	O
12	tuberculosis	O
13	similar	O
14	to	O
15	that	O
16	of	O
17	sputum	O
18	smear	O
19	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	report	O
7	a	O
8	detailed	O
9	study	O
10	of	O
11	the	O
12	structure	O
13	and	O
14	the	O
15	functional	O
16	role	O
17	of	O
18	the	O
19	MalT	B
20	binding	I
21	sites	I
22	located	O
23	in	O
24	the	O
25	adjacent	O
26	and	O
27	divergent	O
28	pulAp	B
29	and	O
30	pulCp	B
31	promoters	I
32	.	O

1	Despite	O
2	the	O
3	small	O
4	number	O
5	of	O
6	patients	O
7	,	O
8	on	O
9	the	O
10	basis	O
11	of	O
12	this	O
13	report	O
14	,	O
15	we	O
16	can	O
17	confirm	O
18	that	O
19	1	O
20	.	O
21	5	O
22	MU	O
23	/	O
24	day	O
25	of	O
26	alpha	B
27	-	I
28	IFN	I
29	is	O
30	an	O
31	adequate	O
32	treatment	O
33	for	O
34	patients	O
35	with	O
36	hairy	O
37	cell	O
38	leukemia	O
39	.	O

1	Paroxysmal	O
2	fluctuations	O
3	in	O
4	observed	O
5	parasitemia	O
6	in	O
7	Plasmodium	O
8	falciparum	O
9	malaria	O
10	.	O

1	No	O
2	positive	O
3	family	O
4	history	O
5	was	O
6	obtained	O
7	.	O

1	Occupational	O
2	asthma	O
3	and	O
4	rhinoconjunctivitis	O
5	from	O
6	inhalation	O
7	of	O
8	crystalline	O
9	bovine	B
10	serum	I
11	albumin	I
12	powder	O
13	.	O

1	A	O
2	further	O
3	subdivision	O
4	of	O
5	Category	O
6	pN1	O
7	into	O
8	pN1a	O
9	(	O
10	metastasis	O
11	in	O
12	single	O
13	node	O
14	)	O
15	and	O
16	pN1b	O
17	(	O
18	two	O
19	or	O
20	more	O
21	nodes	O
22	)	O
23	is	O
24	recommended	O
25	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	comparisons	O
5	of	O
6	the	O
7	E74A	B
8	protein	I
9	reveal	O
10	a	O
11	highly	O
12	conserved	O
13	C	O
14	-	O
15	terminal	O
16	region	O
17	that	O
18	is	O
19	rich	O
20	in	O
21	basic	O
22	amino	O
23	acid	O
24	residues	O
25	and	O
26	which	O
27	has	O
28	been	O
29	proposed	O
30	to	O
31	possess	O
32	sequence	O
33	-	O
34	specific	O
35	DNA	O
36	binding	O
37	activity	O
38	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	relative	O
6	strengths	O
7	of	O
8	the	O
9	promoters	O
10	were	O
11	similar	O
12	in	O
13	different	O
14	contexts	O
15	.	O

1	Grasso	O
2	,	O
3	and	O
4	A	O
5	.	O

1	After	O
2	6	O
3	months	O
4	,	O
5	definite	O
6	improvement	O
7	in	O
8	strength	O
9	occurred	O
10	in	O
11	4	O
12	of	O
13	7	O
14	carnitine	O
15	-	O
16	treated	O
17	patients	O
18	and	O
19	in	O
20	none	O
21	of	O
22	7	O
23	controls	O
24	.	O

1	Age	O
2	at	O
3	POI	O
4	and	O
5	asymptote	O
6	were	O
7	achieved	O
8	later	O
9	for	O
10	Line	O
11	RBC2	O
12	than	O
13	for	O
14	Line	O
15	F	O
16	.	O

1	To	O
2	identify	O
3	the	O
4	DNA	O
5	sequences	O
6	that	O
7	cis	O
8	-	O
9	regulate	O
10	the	O
11	expression	O
12	of	O
13	the	O
14	rat	B
15	liver	I
16	pyruvate	I
17	kinase	I
18	(	O
19	L	B
20	-	I
21	PK	I
22	)	O
23	genes	O
24	,	O
25	a	O
26	series	O
27	of	O
28	constructs	O
29	in	O
30	which	O
31	the	O
32	chloramphenicol	B
33	acetyltransferase	I
34	reporter	I
35	genes	I
36	is	O
37	driven	O
38	by	O
39	various	O
40	deleted	O
41	fragments	O
42	of	O
43	the	O
44	3200	O
45	base	O
46	pairs	O
47	(	O
48	bp	O
49	)	O
50	upstream	O
51	of	O
52	the	O
53	L	B
54	-	I
55	PK	I
56	gene	I
57	cap	I
58	site	I
59	have	O
60	been	O
61	assayed	O
62	for	O
63	transient	O
64	expression	O
65	after	O
66	introduction	O
67	into	O
68	hepatoma	O
69	HepG2	O
70	cells	O
71	,	O
72	rat	O
73	hepatocytes	O
74	in	O
75	primary	O
76	culture	O
77	,	O
78	fibroblast	O
79	LTK	O
80	-	O
81	cells	O
82	,	O
83	myogenic	O
84	C2C12	O
85	cells	O
86	,	O
87	and	O
88	CHO	O
89	cells	O
90	.	O

1	The	O
2	disturbance	O
3	of	O
4	pulmonary	O
5	gas	O
6	exchange	O
7	,	O
8	as	O
9	revealed	O
10	by	O
11	the	O
12	high	O
13	value	O
14	of	O
15	AaDO2	O
16	,	O
17	existed	O
18	without	O
19	left	O
20	ventricular	O
21	dysfunction	O
22	,	O
23	and	O
24	AaDO2	O
25	had	O
26	no	O
27	significant	O
28	relationship	O
29	with	O
30	any	O
31	of	O
32	the	O
33	hemodynamic	O
34	parameters	O
35	including	O
36	the	O
37	difference	O
38	between	O
39	plasma	O
40	colloid	O
41	osmotic	O
42	pressure	O
43	and	O
44	PCW	O
45	.	O

1	A	O
2	dose	O
3	of	O
4	3	O
5	and	O
6	6	O
7	micrograms	O
8	/	O
9	kg	O
10	/	O
11	day	O
12	GM	B
13	-	I
14	CSF	I
15	reduces	O
16	the	O
17	severity	O
18	of	O
19	neutropenia	O
20	and	O
21	thrombocytopenia	O
22	after	O
23	carboplatin	O
24	-	O
25	cyclophosphamide	O
26	chemotherapy	O
27	,	O
28	which	O
29	may	O
30	lead	O
31	to	O
32	more	O
33	effective	O
34	chemotherapy	O
35	for	O
36	ovarian	O
37	cancer	O
38	in	O
39	the	O
40	future	O
41	.	O